<?xml version="1.0" standalone="yes"?>
<REMINDER_EXCHANGE_FILE_ENTRY>
<PACKAGE_VERSION>2.0P65</PACKAGE_VERSION>
<INDEX_AT>15884</INDEX_AT>
<SOURCE>
<NAME>UPDATE_2_0_578 VA-ONC KIDNEY AND PROSTATE CANCER PATHWAY UPDATE</NAME>
<USER>PACKER,REMINDER</USER>
<SITE>FOIA</SITE>
<ENV>NATREM^NATREM^oitausdhctlexb.r02.domain.ext^NATREM:LEXR0TSVR</ENV>
<DATE_PACKED>06/09/2026@10:30:56</DATE_PACKED>
</SOURCE>
<DESCRIPTION><![CDATA[
The following Clinical Reminder items were selected for packing:
REMINDER DIALOG
  VA-ONCOLOGY KIDNEY CANCER PATHWAYS
  VA-ONC PRCA UPDATE 2026
 
REMINDER TERM
  VA-REMINDER UPDATE_2_0_578
]]></DESCRIPTION>
<KEYWORDS>
</KEYWORDS>
<PACKING ATTRIBUTES><![CDATA[
<ATTRIBUTE>GROUPING DIALOG COMPONENTS</ATTRIBUTE>
]]></PACKING ATTRIBUTES>
<FILEMAN_FILE>
<FILE_NAME>REMINDER GENERAL FINDINGS</FILE_NAME>
<FILE_NUMBER>801.46</FILE_NUMBER>
<POINT_01>VIEW PROGRESS NOTE TEXT</POINT_01>
<INTERNAL_ENTRY_NUMBER>454</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1980651110</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.46;+454,;.01~VIEW PROGRESS NOTE TEXT
801.46;+454,;2~CLINICAL REMINDERS^PXRM
801.46;+454,;3~801.41
801.46;+454,;10~GF_VIEW
801.46;+454,;11~VIEW PROGRESS NOTE TEXT
801.46;+454,;20~SINGLE VALUE
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC PRESUMPTIVE CONDITIONS</POINT_01>
<INTERNAL_ENTRY_NUMBER>11598</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2232043786</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+11598,;.01~VA-ONC PRESUMPTIVE CONDITIONS
8927.1;+11598,;.02~Hyperlink
8927.1;+11598,;.03~NO
8927.1;+11598,;.04~0
8927.1;+11598,;.05~Presumptive Disability Benefits
8927.1;+11598,;.07~0
8927.1;+11598,;.08~NO
8927.1;+11598,;.09~YES
8927.1;+11598,;.1~0
8927.1;+11598,;.11~2
8927.1;+11598,;.12~0
8927.1;+11598,;.13~0
8927.1;+11598,;.14~0
8927.1;+11598,;.15~0
8927.1;+11598,;3~https://www.benefits.domain.ext/BENEFITS/factsheets/serviceconnected/presumption.pdf
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC OFF REASON TXT</POINT_01>
<INTERNAL_ENTRY_NUMBER>7551</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3060976492</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+7551,;.01~VA-ONC OFF REASON TXT
8927.1;+7551,;.02~Text
8927.1;+7551,;.03~NO
8927.1;+7551,;.04~0
8927.1;+7551,;.07~0
8927.1;+7551,;.08~NO
8927.1;+7551,;.09~NO
8927.1;+7551,;.1~0
8927.1;+7551,;.11~0
8927.1;+7551,;.12~0
8927.1;+7551,;.13~0
8927.1;+7551,;.14~0
8927.1;+7551,;.15~0
8927.1;+7551,;10~WP-start~1
REASON OFF PATHWAY:
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC TREATMENT REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>7550</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1969443347</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+7550,;.01~VA-ONC TREATMENT REASON
8927.1;+7550,;.02~Text
8927.1;+7550,;.03~NO
8927.1;+7550,;.04~0
8927.1;+7550,;.07~0
8927.1;+7550,;.08~NO
8927.1;+7550,;.09~YES
8927.1;+7550,;.1~0
8927.1;+7550,;.11~0
8927.1;+7550,;.12~0
8927.1;+7550,;.13~0
8927.1;+7550,;.14~0
8927.1;+7550,;.15~0
8927.1;+7550,;10~WP-start~1
(specify treatment Veteran will receive)
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>20438</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1857125923</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+20438,;.01~VA-ONC CLINICAL TRIAL
8927.1;+20438,;.02~Text
8927.1;+20438,;.03~NO
8927.1;+20438,;.04~0
8927.1;+20438,;.07~0
8927.1;+20438,;.08~NO
8927.1;+20438,;.09~YES
8927.1;+20438,;.1~0
8927.1;+20438,;.11~0
8927.1;+20438,;.12~0
8927.1;+20438,;.13~0
8927.1;+20438,;.14~0
8927.1;+20438,;.15~0
8927.1;+20438,;10~WP-start~1
Clinical trial (specify name of study and NCT number):
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC INSTRUCTIONS ON/OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>11980</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2785771400</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+11980,;.01~VA-ONC INSTRUCTIONS ON/OFF PATHWAY
8927.1;+11980,;.02~Text
8927.1;+11980,;.03~NO
8927.1;+11980,;.04~0
8927.1;+11980,;.07~0
8927.1;+11980,;.08~NO
8927.1;+11980,;.09~YES
8927.1;+11980,;.1~0
8927.1;+11980,;.11~0
8927.1;+11980,;.12~0
8927.1;+11980,;.13~0
8927.1;+11980,;.14~0
8927.1;+11980,;.15~0
8927.1;+11980,;10~WP-start~2
++ Selections for each treatment decision are listed with the recommended treatment 
   in order of preference and are considered On Pathway, unless stated Off Pathway. ++
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC PATHWAYS SHAREPOINT</POINT_01>
<INTERNAL_ENTRY_NUMBER>18139</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1384808292</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+18139,;.01~VA-ONC PATHWAYS SHAREPOINT
8927.1;+18139,;.02~Hyperlink
8927.1;+18139,;.03~NO
8927.1;+18139,;.04~0
8927.1;+18139,;.05~Clinical Pathways SharePoint
8927.1;+18139,;.07~0
8927.1;+18139,;.08~NO
8927.1;+18139,;.09~YES
8927.1;+18139,;.1~0
8927.1;+18139,;.11~2
8927.1;+18139,;.12~0
8927.1;+18139,;.13~0
8927.1;+18139,;.14~0
8927.1;+18139,;.15~0
8927.1;+18139,;3~https://dvagov.sharepoint.com/sites/VHACP
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU TEMPLATE FIELD</FILE_NAME>
<FILE_NUMBER>8927.1</FILE_NUMBER>
<POINT_01>VA-ONC CT RN NAV</POINT_01>
<INTERNAL_ENTRY_NUMBER>17561</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3884540967</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8927.1;+17561,;.01~VA-ONC CT RN NAV
8927.1;+17561,;.02~Hyperlink
8927.1;+17561,;.03~NO
8927.1;+17561,;.04~0
8927.1;+17561,;.05~VA Cancer Clinical Trial Nurse Navigator
8927.1;+17561,;.07~0
8927.1;+17561,;.08~NO
8927.1;+17561,;.09~YES
8927.1;+17561,;.1~0
8927.1;+17561,;.11~0
8927.1;+17561,;.12~0
8927.1;+17561,;.13~0
8927.1;+17561,;.14~0
8927.1;+17561,;.15~0
8927.1;+17561,;3~mailto:CancerClinicalTrialsNavigation@domain.ext
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-REMINDER UPDATES [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>8722</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>981639263</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+8722,;.01~VA-REMINDER UPDATES [C]
9999999.64;+8722,;.1~CATEGORY
9999999.64;+8722,;100~LOCAL
9999999.64;+8722,;200~Reminder Updates
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-UPDATE_2_0_578</POINT_01>
<INTERNAL_ENTRY_NUMBER>46528</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3682996213</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46528,;.01~VA-UPDATE_2_0_578
9999999.64;+46528,;.03~VA-REMINDER UPDATES [C]
9999999.64;+46528,;.08~YES
9999999.64;+46528,;.1~FACTOR
9999999.64;+46528,;100~NATIONAL
9999999.64;+46528,;200~Update_2_0_578
9999999.64;+46528,;201~WP-start~2
 
VA-UPDATE_2_0_567
9999999.65;+46529,+46528,;.01~MAY 15, 2026@05:17:53
9999999.65;+46529,+46528,;2~WP-start~1
Copied from VA-UPDATE_2_0_577
9999999.65;+46530,+46528,;.01~MAY 15, 2026@05:18:03
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46529^1
46530^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 PATHWAY [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>20204</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3014695805</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20204,;.01~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+20204,;.08~YES
9999999.64;+20204,;.1~CATEGORY
9999999.64;+20204,;100~NATIONAL
9999999.64;+20204,;101~VHA ONCOLOGY
9999999.64;+20204,;200~Castrate Resistant Prostate Cancer M1 Pathway
9999999.64;+20204,;201~WP-start~1
Category for Castrate Resistant Prostate Cancer M1 health factors
9999999.65;+20205,+20204,;.01~NOV 10, 2021@08:18:08
9999999.65;+20206,+20204,;.01~JUN 01, 2023@08:51:09
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20205^1
20206^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST NEUROENDOCRINE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>23900</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3744815968</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+23900,;.01~VA-ONC PRCA CRPC M1 1ST NEUROENDOCRINE OFF PATH RSN
9999999.64;+23900,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+23900,;.08~YES
9999999.64;+23900,;.1~FACTOR
9999999.64;+23900,;100~NATIONAL
9999999.64;+23900,;101~VHA ONCOLOGY
9999999.64;+23900,;200~CRPC M1 1st Line Neuroendocrine Component Off Path Rsn
9999999.64;+23900,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, neuroendocrine
component; off pathway reason
9999999.65;+23901,+23900,;.01~NOV 10, 2021@08:37:07
9999999.65;+23901,+23900,;2~WP-start~1
 Creation.
9999999.65;+23902,+23900,;.01~NOV 10, 2021@12:03:04
9999999.65;+23903,+23900,;.01~JAN 24, 2022@11:32:11
9999999.65;+23904,+23900,;.01~MAR 10, 2022@06:49:08
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
23901^1
23902^2
23903^3
23904^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST NEUROENDOCRINE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>20379</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4209575219</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20379,;.01~VA-ONC PRCA CRPC M1 1ST NEUROENDOCRINE OFF PATH TX
9999999.64;+20379,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+20379,;.08~YES
9999999.64;+20379,;.1~FACTOR
9999999.64;+20379,;100~NATIONAL
9999999.64;+20379,;101~VHA ONCOLOGY
9999999.64;+20379,;200~CRPC M1 1st Line Neuroendocrine Component Off Path Tx
9999999.64;+20379,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, neuroendocrine
component; off pathway treatment
9999999.65;+20380,+20379,;.01~NOV 10, 2021@08:36:27
9999999.65;+20381,+20379,;.01~NOV 10, 2021@12:03:21
9999999.65;+20382,+20379,;.01~JAN 24, 2022@11:33:01
9999999.65;+20383,+20379,;.01~MAR 10, 2022@06:49:34
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20380^1
20381^2
20382^3
20383^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST NEUROENDOCRINE PLATINUM</POINT_01>
<INTERNAL_ENTRY_NUMBER>20378</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>634291139</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20378,;.01~VA-ONC PRCA CRPC M1 1ST NEUROENDOCRINE PLATINUM
9999999.64;+20378,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+20378,;.08~YES
9999999.64;+20378,;.1~FACTOR
9999999.64;+20378,;100~NATIONAL
9999999.64;+20378,;101~VHA ONCOLOGY
9999999.64;+20378,;200~CRPC M1 1st Line Neuroendocrine Component Platinum Combination
9999999.64;+20378,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, neuroendocrine
component; on pathway platinum-based combination
9999999.65;+20379,+20378,;.01~NOV 10, 2021@08:35:46
9999999.65;+20380,+20378,;.01~NOV 10, 2021@12:03:37
9999999.65;+20381,+20378,;.01~JAN 24, 2022@11:33:24
9999999.65;+20382,+20378,;.01~MAR 10, 2022@06:50
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20379^1
20380^2
20381^3
20382^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST NEUROENDOCRINE CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>20434</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1283789656</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20434,;.01~VA-ONC PRCA CRPC M1 1ST NEUROENDOCRINE CLINICAL TRIAL
9999999.64;+20434,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+20434,;.08~YES
9999999.64;+20434,;.1~FACTOR
9999999.64;+20434,;100~NATIONAL
9999999.64;+20434,;101~VHA ONCOLOGY
9999999.64;+20434,;200~CRPC M1 1st Line Neuroendocrine Component Clinical Trial
9999999.64;+20434,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, neuroendocrine
component; on pathway clinical trial
9999999.65;+20435,+20434,;.01~NOV 10, 2021@08:34:21
9999999.65;+20436,+20434,;.01~NOV 10, 2021@12:02:13
9999999.65;+20437,+20434,;.01~JAN 24, 2022@11:32:32
9999999.65;+20438,+20434,;.01~MAR 10, 2022@06:48:37
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20435^1
20436^2
20437^3
20438^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &gt;2 CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>23898</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>263777534</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+23898,;.01~VA-ONC PRCA CRPC M1 1ST ECOG >2 CLINICAL TRIAL
9999999.64;+23898,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+23898,;.08~YES
9999999.64;+23898,;.1~FACTOR
9999999.64;+23898,;100~NATIONAL
9999999.64;+23898,;101~VHA ONCOLOGY
9999999.64;+23898,;200~CRPC M1 1st Line ECOG >2 Clinical Trial
9999999.64;+23898,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG >2; on 
pathway clinical trial
9999999.65;+23899,+23898,;.01~NOV 10, 2021@08:30:07
9999999.65;+23899,+23898,;2~WP-start~1
 Creation.
9999999.65;+23900,+23898,;.01~NOV 10, 2021@08:50:13
9999999.65;+23901,+23898,;.01~MAR 10, 2022@06:46:33
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
23899^1
23900^2
23901^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &gt;2 REFER PALLIATIVE CARE</POINT_01>
<INTERNAL_ENTRY_NUMBER>20376</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2068115417</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20376,;.01~VA-ONC PRCA CRPC M1 1ST ECOG >2 REFER PALLIATIVE CARE
9999999.64;+20376,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+20376,;.08~YES
9999999.64;+20376,;.1~FACTOR
9999999.64;+20376,;100~NATIONAL
9999999.64;+20376,;101~VHA ONCOLOGY
9999999.64;+20376,;200~CRPC M1 1st Line ECOG >2 Refer to Palliative Care
9999999.64;+20376,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG >2; on 
pathway palliative care
9999999.65;+20377,+20376,;.01~NOV 10, 2021@08:31:12
9999999.65;+20378,+20376,;.01~NOV 10, 2021@08:50:50
9999999.65;+20379,+20376,;.01~MAR 10, 2022@06:47:50
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20377^1
20378^2
20379^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &gt;2 OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>23899</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2917375505</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+23899,;.01~VA-ONC PRCA CRPC M1 1ST ECOG >2 OFF PATH RSN
9999999.64;+23899,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+23899,;.08~YES
9999999.64;+23899,;.1~FACTOR
9999999.64;+23899,;100~NATIONAL
9999999.64;+23899,;101~VHA ONCOLOGY
9999999.64;+23899,;200~CRPC M1 1st Line ECOG >2 Off Path Reason
9999999.64;+23899,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG >2; off 
pathway reason
9999999.65;+23900,+23899,;.01~NOV 10, 2021@08:32:42
9999999.65;+23900,+23899,;2~WP-start~1
 Creation.
9999999.65;+23901,+23899,;.01~NOV 10, 2021@08:50:26
9999999.65;+23902,+23899,;.01~NOV 10, 2021@12:00:44
9999999.65;+23903,+23899,;.01~MAR 10, 2022@06:47:04
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
23900^1
23901^2
23902^3
23903^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &gt;2 OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>20377</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1634614854</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20377,;.01~VA-ONC PRCA CRPC M1 1ST ECOG >2 OFF PATH TX
9999999.64;+20377,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+20377,;.08~YES
9999999.64;+20377,;.1~FACTOR
9999999.64;+20377,;100~NATIONAL
9999999.64;+20377,;101~VHA ONCOLOGY
9999999.64;+20377,;200~CRPC M1 1st Line ECOG >2 Off Path Treatment
9999999.64;+20377,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG >2; off 
pathway treatment
9999999.65;+20378,+20377,;.01~NOV 10, 2021@08:31:53
9999999.65;+20379,+20377,;.01~NOV 10, 2021@08:50:38
9999999.65;+20380,+20377,;.01~NOV 10, 2021@12:01:09
9999999.65;+20381,+20377,;.01~MAR 10, 2022@06:47:24
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20378^1
20379^2
20380^3
20381^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 BRCA - ABIRATERONE</POINT_01>
<INTERNAL_ENTRY_NUMBER>29289</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2913296342</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+29289,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA - ABIRATERONE
9999999.64;+29289,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+29289,;.08~YES
9999999.64;+29289,;.1~FACTOR
9999999.64;+29289,;100~NATIONAL
9999999.64;+29289,;101~VHA ONCOLOGY
9999999.64;+29289,;200~CRPC M1 1st Line ECOG <=2 BRCA Mutation - Abiraterone
9999999.64;+29289,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2, no 
contraindications to abiraterone; BRCA mutation -, abiraterone
9999999.65;+29290,+29289,;.01~JUN 28, 2023@09:29:36
9999999.65;+29290,+29289,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
29290^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 BRCA - OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>29291</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3282151390</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+29291,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA - OFF PATH RSN
9999999.64;+29291,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+29291,;.08~YES
9999999.64;+29291,;.1~FACTOR
9999999.64;+29291,;100~NATIONAL
9999999.64;+29291,;101~VHA ONCOLOGY
9999999.64;+29291,;200~CRPC M1 1st Line ECOG <=2 BRCA Mutation -  Off Path Reason
9999999.64;+29291,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2, no 
contraindications to abiraterone; BRCA mutation -, off pathway reason
9999999.65;+29292,+29291,;.01~JUN 28, 2023@09:39:51
9999999.65;+29292,+29291,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
29292^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 BRCA - OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>29290</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3071069356</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+29290,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA - OFF PATH TX
9999999.64;+29290,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+29290,;.08~YES
9999999.64;+29290,;.1~FACTOR
9999999.64;+29290,;100~NATIONAL
9999999.64;+29290,;101~VHA ONCOLOGY
9999999.64;+29290,;200~CRPC M1 1st Line ECOG <=2 BRCA Mutation - Off Path Treatment
9999999.64;+29290,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2, no 
contraindications to abiraterone; BRCA mutation -, off pathway treatment
9999999.65;+29291,+29290,;.01~JUN 28, 2023@09:38:22
9999999.65;+29291,+29290,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
29291^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 BRCA - CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>29288</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1401510404</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+29288,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA - CLIN TRIAL
9999999.64;+29288,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+29288,;.08~YES
9999999.64;+29288,;.1~FACTOR
9999999.64;+29288,;100~NATIONAL
9999999.64;+29288,;101~VHA ONCOLOGY
9999999.64;+29288,;200~CRPC M1 1st Line ECOG <=2 BRCA Mutation - Clinical Trial
9999999.64;+29288,;201~WP-start~3
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2, no 
contraindications to abiraterone; BRCA mutation -, on pathway clinical 
trial
9999999.65;+29289,+29288,;.01~JUN 28, 2023@08:59:10
9999999.65;+29289,+29288,;2~WP-start~1
 Creation.
9999999.65;+29290,+29288,;.01~JUN 28, 2023@09:21:48
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
29289^1
29290^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 BRCA + OLAPARIB/ABIRATERONE</POINT_01>
<INTERNAL_ENTRY_NUMBER>29283</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3020812090</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+29283,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA + OLAPARIB/ABIRATERONE
9999999.64;+29283,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+29283,;.08~YES
9999999.64;+29283,;.1~FACTOR
9999999.64;+29283,;100~NATIONAL
9999999.64;+29283,;101~VHA ONCOLOGY
9999999.64;+29283,;200~CRPC M1 1st Line ECOG <=2 BRCA Mutation + Olaparib/Abiraterone
9999999.64;+29283,;201~WP-start~3
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2, no 
contraindications to abiraterone; BRCA mutation +, olaparib and
abiraterone
9999999.65;+29284,+29283,;.01~JUN 27, 2023@14:00:14
9999999.65;+29284,+29283,;2~WP-start~1
 Creation.
9999999.65;+29285,+29283,;.01~JUN 28, 2023@07:56:01
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
29284^1
29285^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 BRCA + OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>29285</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3113464153</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+29285,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA + OFF PATH TX
9999999.64;+29285,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+29285,;.08~YES
9999999.64;+29285,;.1~FACTOR
9999999.64;+29285,;100~NATIONAL
9999999.64;+29285,;101~VHA ONCOLOGY
9999999.64;+29285,;200~CRPC M1 1st Line ECOG <=2 BRCA Mutation + Off Path Treatment
9999999.64;+29285,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2, no
contraindications to abiraterone; BRCA mutation +, off pathway treatment
9999999.65;+29286,+29285,;.01~JUN 28, 2023@08:49:30
9999999.65;+29286,+29285,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
29286^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 BRCA + OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>29286</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3033484231</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+29286,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA + OFF PATH RSN
9999999.64;+29286,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+29286,;.08~YES
9999999.64;+29286,;.1~FACTOR
9999999.64;+29286,;100~NATIONAL
9999999.64;+29286,;101~VHA ONCOLOGY
9999999.64;+29286,;200~CRPC M1 1st Line ECOG <=2 BRCA Mutation + Off Path Reason
9999999.64;+29286,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2, no 
contraindications to abiraterone; BRCA mutation +, off pathway reason
9999999.65;+29287,+29286,;.01~JUN 28, 2023@08:53:29
9999999.65;+29287,+29286,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
29287^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 BRCA + CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>29282</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3213410204</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+29282,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA + CLIN TRIAL
9999999.64;+29282,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+29282,;.08~YES
9999999.64;+29282,;.1~FACTOR
9999999.64;+29282,;100~NATIONAL
9999999.64;+29282,;101~VHA ONCOLOGY
9999999.64;+29282,;200~CRPC M1 1st Line ECOG <=2 BRCA Mutation + Clinical Trial
9999999.64;+29282,;201~WP-start~3
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2, no 
contraindications to abiraterone; BRCA mutation +, on pathway clinical
trial
9999999.65;+29283,+29282,;.01~JUN 27, 2023@13:51:13
9999999.65;+29283,+29282,;2~WP-start~1
 Creation.
9999999.65;+29284,+29282,;.01~JUN 28, 2023@07:55:16
9999999.65;+29285,+29282,;.01~JUN 28, 2023@09:50:11
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
29283^1
29284^2
29285^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 ARPI+ NO DOCE RAD223+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>36348</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3136695969</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+36348,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE RAD223+ADT
9999999.64;+36348,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+36348,;.08~YES
9999999.64;+36348,;.1~FACTOR
9999999.64;+36348,;100~NATIONAL
9999999.64;+36348,;101~VHA ONCOLOGY
9999999.64;+36348,;200~CRPC M1 1st Line ECOG <=2 No Prior ARPI, Not Doce Rad223+ADT
9999999.64;+36348,;201~WP-start~3
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2 no 
prior ARPI therapy, not a candidate for docetaxel; on pathway radium 223
and ADT
9999999.65;+36349,+36348,;.01~JUL 01, 2024@06:31:35
9999999.65;+36349,+36348,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE CABA+ADT
9999999.65;+36350,+36348,;.01~JUL 01, 2024@06:32:45
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
36349^1
36350^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 ARPI+ NO DOCE PEMB+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>36346</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1583032376</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+36346,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE PEMB+ADT
9999999.64;+36346,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+36346,;.08~YES
9999999.64;+36346,;.1~FACTOR
9999999.64;+36346,;100~NATIONAL
9999999.64;+36346,;101~VHA ONCOLOGY
9999999.64;+36346,;200~CRPC M1 1st Line ECOG <=2 No Prior ARPI, Not Doce Pemb+ADT
9999999.64;+36346,;201~WP-start~3
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2 no 
prior ARPI therapy, not a candidate for docetaxel; on pathway 
pembrolizumab and ADT
9999999.65;+36347,+36346,;.01~JUL 01, 2024@06:24:43
9999999.65;+36347,+36346,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE CLIN TRIAL   
9999999.65;+36348,+36346,;.01~JUL 01, 2024@06:26:27
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
36347^1
36348^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 ARPI+ NO DOCE OLAP+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>36349</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3858441703</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+36349,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE OLAP+ADT
9999999.64;+36349,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+36349,;.08~YES
9999999.64;+36349,;.1~FACTOR
9999999.64;+36349,;100~NATIONAL
9999999.64;+36349,;101~VHA ONCOLOGY
9999999.64;+36349,;200~CRPC M1 1st Line ECOG <=2 No Prior ARPI, Not Doce Olap+ADT
9999999.64;+36349,;201~WP-start~3
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2 no 
prior ARPI therapy, not a candidate for docetaxel; on pathway olaparib
and ADT
9999999.65;+36350,+36349,;.01~JUL 01, 2024@06:33:50
9999999.65;+36350,+36349,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE RAD223+ADT
9999999.65;+36351,+36349,;.01~JUL 01, 2024@06:35:15
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
36350^1
36351^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 ARPI+ NO DOCE LU177+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>36350</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2716113265</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+36350,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE LU177+ADT
9999999.64;+36350,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+36350,;.08~YES
9999999.64;+36350,;.1~FACTOR
9999999.64;+36350,;100~NATIONAL
9999999.64;+36350,;101~VHA ONCOLOGY
9999999.64;+36350,;200~CRPC M1 1st Line ECOG <=2 No Prior ARPI, Not Doce Lu177+ADT
9999999.64;+36350,;201~WP-start~3
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2 no 
prior ARPI therapy, not a candidate for docetaxel; on pathway lutetium 
177 and ADT
9999999.65;+36351,+36350,;.01~JUL 01, 2024@06:35:59
9999999.65;+36351,+36350,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE RAD223+ADT
9999999.65;+36352,+36350,;.01~JUL 01, 2024@06:38:37
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
36351^1
36352^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 ARPI+ NO DOCE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>36345</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3404187160</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+36345,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE CLIN TRIAL
9999999.64;+36345,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+36345,;.08~YES
9999999.64;+36345,;.1~FACTOR
9999999.64;+36345,;100~NATIONAL
9999999.64;+36345,;101~VHA ONCOLOGY
9999999.64;+36345,;200~CRPC M1 1st Line ECOG <=2 No Prior ARPI, Not Doce Clin Trial
9999999.64;+36345,;201~WP-start~3
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2 no 
prior ARPI therapy, not a candidate for docetaxel; on pathway clinical 
trial
9999999.65;+36346,+36345,;.01~JUL 01, 2024@06:22:42
9999999.65;+36346,+36345,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ DOCE CLIN TRIAL
9999999.65;+36347,+36345,;.01~JUL 01, 2024@06:23:38
9999999.65;+36348,+36345,;.01~JUL 01, 2024@06:27
9999999.65;+36349,+36345,;.01~JUL 09, 2024@07:31:24
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
36346^1
36347^2
36348^3
36349^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 ARPI+ NO DOCE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>36352</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2901781589</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+36352,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE OFF PATH RSN
9999999.64;+36352,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+36352,;.08~YES
9999999.64;+36352,;.1~FACTOR
9999999.64;+36352,;100~NATIONAL
9999999.64;+36352,;101~VHA ONCOLOGY
9999999.64;+36352,;200~CRPC M1 1st Line ECOG <=2 Prior ARPI, Doce Cand Off Path RSN
9999999.64;+36352,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2 
prior ARPI therapy, candidate for docetaxel; off pathway reason
9999999.65;+36353,+36352,;.01~JUL 01, 2024@06:41:03
9999999.65;+36353,+36352,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE OFF PATH TX
9999999.65;+36354,+36352,;.01~JUL 01, 2024@06:42:03
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
36353^1
36354^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 ARPI+ NO DOCE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>36351</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>999585649</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+36351,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE OFF PATH TX
9999999.64;+36351,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+36351,;.08~YES
9999999.64;+36351,;.1~FACTOR
9999999.64;+36351,;100~NATIONAL
9999999.64;+36351,;101~VHA ONCOLOGY
9999999.64;+36351,;200~CRPC M1 1st Line ECOG <=2 Prior ARPI, Doce Cand Off Path TX
9999999.64;+36351,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2 
prior ARPI therapy, candidate for docetaxel; off pathway treatment
9999999.65;+36352,+36351,;.01~JUL 01, 2024@06:39:05
9999999.65;+36352,+36351,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ DOCE CLIN TRIAL
9999999.65;+36353,+36351,;.01~JUL 01, 2024@06:40:02
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
36352^1
36353^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 ARPI+ DOCE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>36344</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3488394192</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+36344,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ DOCE OFF PATH RSN
9999999.64;+36344,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+36344,;.08~YES
9999999.64;+36344,;.1~FACTOR
9999999.64;+36344,;100~NATIONAL
9999999.64;+36344,;101~VHA ONCOLOGY
9999999.64;+36344,;200~CRPC M1 1st Line ECOG <=2 Prior ARPI, Doce Cand Off Path RSN
9999999.64;+36344,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2 
prior ARPI therapy, candidate for docetaxel; off pathway reason
9999999.65;+36345,+36344,;.01~JUN 28, 2024@13:39:40
9999999.65;+36345,+36344,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ DOCE OFF PATH TX
9999999.65;+36346,+36344,;.01~JUN 28, 2024@13:40:06
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
36345^1
36346^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 ARPI+ DOCE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>36343</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3307720019</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+36343,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ DOCE OFF PATH TX
9999999.64;+36343,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+36343,;.08~YES
9999999.64;+36343,;.1~FACTOR
9999999.64;+36343,;100~NATIONAL
9999999.64;+36343,;101~VHA ONCOLOGY
9999999.64;+36343,;200~CRPC M1 1st Line ECOG <=2 Prior ARPI, Doce Cand Off Path TX
9999999.64;+36343,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2 
prior ARPI therapy, candidate for docetaxel; off pathway treatment
9999999.65;+36344,+36343,;.01~JUN 28, 2024@13:36:41
9999999.65;+36344,+36343,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ DOCE CLIN TRIAL
9999999.65;+36345,+36343,;.01~JUN 28, 2024@13:39:25
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
36344^1
36345^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 ARPI+ DOCE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>36341</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1007050380</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+36341,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ DOCE CLIN TRIAL
9999999.64;+36341,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+36341,;.08~YES
9999999.64;+36341,;.1~FACTOR
9999999.64;+36341,;100~NATIONAL
9999999.64;+36341,;101~VHA ONCOLOGY
9999999.64;+36341,;200~CRPC M1 1st Line ECOG <=2 Prior ARPI, Doce Cand Clin Trial
9999999.64;+36341,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2 
prior ARPI therapy, candidate for docetaxel; on pathway clinical trial
9999999.65;+36342,+36341,;.01~JUN 28, 2024@13:29:13
9999999.65;+36342,+36341,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 1ST ECOG <=2 CLINICAL TRIAL
9999999.65;+36343,+36341,;.01~JUN 28, 2024@13:30:33
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
36342^1
36343^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 1ST ECOG &lt;=2 ARPI+ DOCE DOCETAXEL+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>36342</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4152779471</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+36342,;.01~VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ DOCE DOCETAXEL+ADT
9999999.64;+36342,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+36342,;.08~YES
9999999.64;+36342,;.1~FACTOR
9999999.64;+36342,;100~NATIONAL
9999999.64;+36342,;101~VHA ONCOLOGY
9999999.64;+36342,;200~CRPC M1 1st Line ECOG <=2 Prior ARPI, Doce Cand Docetaxel+ADT
9999999.64;+36342,;201~WP-start~2
Castrate resistant prostate cancer M1 first line treatment, ECOG <=2 
prior ARPI therapy, candidate for docetaxel; on pathway docetaxel and ADT
9999999.65;+36343,+36342,;.01~JUN 28, 2024@13:33:06
9999999.65;+36343,+36342,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ DOCE CLIN TRIAL
9999999.65;+36344,+36342,;.01~JUN 28, 2024@13:34:17
9999999.65;+36345,+36342,;.01~JUL 01, 2024@08:47:34
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
36343^1
36344^2
36345^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX-/LU177- OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>46407</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1342370609</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46407,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- OFF PATH RSN
9999999.64;+46407,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46407,;.08~YES
9999999.64;+46407,;.1~FACTOR
9999999.64;+46407,;100~NATIONAL
9999999.64;+46407,;101~VHA ONCOLOGY
9999999.64;+46407,;200~CRPC M1 3rd line ECOG <=2 Tax-/Lu177- Off Path RSN
9999999.64;+46407,;201~WP-start~2
Castrate resistant prostate cancer M1 third line treatment ECOG <=2; 
contraindication to taxane and lutetium-177; off pathway reason
9999999.65;+46408,+46407,;.01~APR 27, 2026@12:48:17
9999999.65;+46408,+46407,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- OFF PATH TX
9999999.65;+46409,+46407,;.01~APR 27, 2026@12:49:27
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46408^1
46409^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX-/LU177- OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>46406</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3280127614</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46406,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- OFF PATH TX
9999999.64;+46406,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46406,;.08~YES
9999999.64;+46406,;.1~FACTOR
9999999.64;+46406,;100~NATIONAL
9999999.64;+46406,;101~VHA ONCOLOGY
9999999.64;+46406,;200~CRPC M1 3rd line ECOG <=2 Tax-/Lu177- Off Path TX
9999999.64;+46406,;201~WP-start~2
Castrate resistant prostate cancer M1 third line treatment ECOG <=2; 
contraindication to taxane and lutetium-177; off pathway treatment
9999999.65;+46407,+46406,;.01~APR 27, 2026@12:41:27
9999999.65;+46407,+46406,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- CLIN TRIAL
9999999.65;+46408,+46406,;.01~APR 27, 2026@12:41:59
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46407^1
46408^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX-/LU177- RADIUM+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>46405</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3027799389</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46405,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- RADIUM+ADT
9999999.64;+46405,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46405,;.08~YES
9999999.64;+46405,;.1~FACTOR
9999999.64;+46405,;100~NATIONAL
9999999.64;+46405,;101~VHA ONCOLOGY
9999999.64;+46405,;200~CRPC M1 3rd line ECOG <=2 Tax-/Lu177- Radium 223+ADT
9999999.64;+46405,;201~WP-start~3
Castrate resistant prostate cancer M1 third line treatment ECOG <=2; 
contraindication to taxane and lutetium-177; on pathway radium 223 with
ADT
9999999.65;+46406,+46405,;.01~APR 27, 2026@12:38:52
9999999.65;+46406,+46405,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- PEMBRO+ADT
9999999.65;+46407,+46405,;.01~APR 27, 2026@12:40:57
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46406^1
46407^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX-/LU177- PEMBRO+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>46404</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2579025255</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46404,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- PEMBRO+ADT
9999999.64;+46404,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46404,;.08~YES
9999999.64;+46404,;.1~FACTOR
9999999.64;+46404,;100~NATIONAL
9999999.64;+46404,;101~VHA ONCOLOGY
9999999.64;+46404,;200~CRPC M1 3rd line ECOG <=2 Tax-/Lu177- Pembrolizumab+ADT
9999999.64;+46404,;201~WP-start~3
Castrate resistant prostate cancer M1 third line treatment ECOG <=2; 
contraindication to taxane and lutetium-177; on pathway pembrolizumab with
ADT
9999999.65;+46405,+46404,;.01~APR 27, 2026@12:37:51
9999999.65;+46405,+46404,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- OLAP+ADT
9999999.65;+46406,+46404,;.01~APR 27, 2026@12:38:34
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46405^1
46406^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX-/LU177- OLAP+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>46403</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3981534216</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46403,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- OLAP+ADT
9999999.64;+46403,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46403,;.08~YES
9999999.64;+46403,;.1~FACTOR
9999999.64;+46403,;100~NATIONAL
9999999.64;+46403,;101~VHA ONCOLOGY
9999999.64;+46403,;200~CRPC M1 3rd line ECOG <=2 Tax-/Lu177- Olaparib+ADT
9999999.64;+46403,;201~WP-start~2
Castrate resistant prostate cancer M1 third line treatment ECOG <=2; 
contraindication to taxane and lutetium-177; on pathway olaparib with ADT
9999999.65;+46404,+46403,;.01~APR 27, 2026@12:36:52
9999999.65;+46404,+46403,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- CLIN TRIAL
9999999.65;+46405,+46403,;.01~APR 27, 2026@12:37:32
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46404^1
46405^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX-/LU177- ENZA+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>46402</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3929891316</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46402,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- ENZA+ADT
9999999.64;+46402,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46402,;.08~YES
9999999.64;+46402,;.1~FACTOR
9999999.64;+46402,;100~NATIONAL
9999999.64;+46402,;101~VHA ONCOLOGY
9999999.64;+46402,;200~CRPC M1 3rd line ECOG <=2 Tax-/Lu177- Enzalutamide+ADT
9999999.64;+46402,;201~WP-start~3
Castrate resistant prostate cancer M1 third line treatment ECOG <=2; 
contraindication to taxane and lutetium-177; on pathway enzalutamide 
with ADT
9999999.65;+46403,+46402,;.01~APR 27, 2026@12:35:16
9999999.65;+46403,+46402,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- ABI+PRED+ADT
9999999.65;+46404,+46402,;.01~APR 27, 2026@12:36:20
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46403^1
46404^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX-/LU177- ABI+PRED+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>46401</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2784795229</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46401,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- ABI+PRED+ADT
9999999.64;+46401,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46401,;.08~YES
9999999.64;+46401,;.1~FACTOR
9999999.64;+46401,;100~NATIONAL
9999999.64;+46401,;101~VHA ONCOLOGY
9999999.64;+46401,;200~CRPC M1 3rd line ECOG <=2 Tax-/Lu177- Abiraterone+Prednisone+ADT
9999999.64;+46401,;201~WP-start~3
Castrate resistant prostate cancer M1 third line treatment ECOG <=2; 
contraindication to taxane and lutetium-177; on pathway abiraterone and 
prednisone with ADT
9999999.65;+46402,+46401,;.01~APR 27, 2026@12:33:44
9999999.65;+46402,+46401,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- CLIN TRIAL
9999999.65;+46403,+46401,;.01~APR 27, 2026@12:34:40
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46402^1
46403^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX-/LU177- CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>46400</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2143536029</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46400,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- CLIN TRIAL
9999999.64;+46400,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46400,;.08~YES
9999999.64;+46400,;.1~FACTOR
9999999.64;+46400,;100~NATIONAL
9999999.64;+46400,;101~VHA ONCOLOGY
9999999.64;+46400,;200~CRPC M1 3rd line ECOG <=2 Tax-/Lu177- Clin Trial
9999999.64;+46400,;201~WP-start~2
Castrate resistant prostate cancer M1 third line treatment ECOG <=2; 
contraindication to taxane and lutetium-177; on pathway clinical trial
9999999.65;+46401,+46400,;.01~APR 27, 2026@12:31:43
9999999.65;+46401,+46400,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177+ CLIN TRIAL
9999999.65;+46402,+46400,;.01~APR 27, 2026@12:32:37
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46401^1
46402^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX-/LU177+ OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>46399</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3367319854</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46399,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177+ OFF PATH RSN
9999999.64;+46399,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46399,;.08~YES
9999999.64;+46399,;.1~FACTOR
9999999.64;+46399,;100~NATIONAL
9999999.64;+46399,;101~VHA ONCOLOGY
9999999.64;+46399,;200~CRPC M1 3rd line ECOG <=2 Tax-/Lu177+ Off Path RSN
9999999.64;+46399,;201~WP-start~3
Castrate resistant prostate cancer M1 third line treatment ECOG <=2; 
contraindication to taxane, no contraindications to lutetium-177; off 
pathway reason
9999999.65;+46400,+46399,;.01~APR 27, 2026@12:26:15
9999999.65;+46400,+46399,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177+ OFF PATH TX
9999999.65;+46401,+46399,;.01~APR 27, 2026@12:26:50
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46400^1
46401^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX-/LU177+ OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>46398</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1323929521</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46398,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177+ OFF PATH TX
9999999.64;+46398,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46398,;.08~YES
9999999.64;+46398,;.1~FACTOR
9999999.64;+46398,;100~NATIONAL
9999999.64;+46398,;101~VHA ONCOLOGY
9999999.64;+46398,;200~CRPC M1 3rd line ECOG <=2 Tax-/Lu177+ Off Path TX
9999999.64;+46398,;201~WP-start~3
Castrate resistant prostate cancer M1 third line treatment ECOG <=2; 
contraindication to taxane, no contraindications to lutetium-177; off 
pathway treatment
9999999.65;+46399,+46398,;.01~APR 27, 2026@12:20:56
9999999.65;+46399,+46398,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177+ CLIN TRIAL
9999999.65;+46400,+46398,;.01~APR 27, 2026@12:23:03
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46399^1
46400^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX-/LU177+ LU177-PSMA+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>46397</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3226695190</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46397,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177+ LU177-PSMA+ADT
9999999.64;+46397,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46397,;.08~YES
9999999.64;+46397,;.1~FACTOR
9999999.64;+46397,;100~NATIONAL
9999999.64;+46397,;101~VHA ONCOLOGY
9999999.64;+46397,;200~CRPC M1 3rd line ECOG <=2 Tax-/Lu177+ Lu177-PSMA+ADT
9999999.64;+46397,;201~WP-start~3
Castrate resistant prostate cancer M1 third line treatment ECOG <=2; 
contraindication to taxane, no contraindications to lutetium-177; on 
pathway lutetium-177 PSMA with ADT
9999999.65;+46398,+46397,;.01~APR 27, 2026@12:17:31
9999999.65;+46398,+46397,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177+ CLIN TRIAL
9999999.65;+46399,+46397,;.01~APR 27, 2026@12:20:11
9999999.65;+46400,+46397,;.01~MAY 20, 2026@10:12:49
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46398^1
46399^2
46400^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX-/LU177+ CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>46396</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2298133731</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46396,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177+ CLIN TRIAL
9999999.64;+46396,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46396,;.08~YES
9999999.64;+46396,;.1~FACTOR
9999999.64;+46396,;100~NATIONAL
9999999.64;+46396,;101~VHA ONCOLOGY
9999999.64;+46396,;200~CRPC M1 3rd line ECOG <=2 Tax-/Lu177+ Clin Trial
9999999.64;+46396,;201~WP-start~3
Castrate resistant prostate cancer M1 third line treatment ECOG <=2; 
contraindication to taxane, no contraindications to lutetium-177; on 
pathway clinical trial
9999999.65;+46397,+46396,;.01~APR 27, 2026@12:14:32
9999999.65;+46397,+46396,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX CLIN TRIAL
9999999.65;+46398,+46396,;.01~APR 27, 2026@12:15:58
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46397^1
46398^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX CABAZITAXEL+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>46393</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3866264342</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46393,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX CABAZITAXEL+ADT
9999999.64;+46393,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46393,;.08~YES
9999999.64;+46393,;.1~FACTOR
9999999.64;+46393,;100~NATIONAL
9999999.64;+46393,;101~VHA ONCOLOGY
9999999.64;+46393,;200~CRPC M1 3rd line ECOG <=2 Taxane Cabazitaxel+ADT
9999999.64;+46393,;201~WP-start~2
Castrate resistant prostate cancer M1 third line treatment ECOG <=2 no 
contraindications to taxane; on pathway cabazitaxel with ADT
9999999.65;+46394,+46393,;.01~APR 27, 2026@12:10:24
9999999.65;+46394,+46393,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX CLIN TRIAL
9999999.65;+46395,+46393,;.01~APR 27, 2026@12:11:02
9999999.65;+46396,+46393,;.01~MAY 20, 2026@10:11:08
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46394^1
46395^2
46396^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>46395</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4033255955</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46395,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX OFF PATH RSN
9999999.64;+46395,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46395,;.08~YES
9999999.64;+46395,;.1~FACTOR
9999999.64;+46395,;100~NATIONAL
9999999.64;+46395,;101~VHA ONCOLOGY
9999999.64;+46395,;200~CRPC M1 3rd line ECOG <=2 Taxane Off Path RSN
9999999.64;+46395,;201~WP-start~2
Castrate resistant prostate cancer M1 third line treatment ECOG <=2 no 
contraindications to taxane; off pathway reason
9999999.65;+46396,+46395,;.01~APR 27, 2026@12:13:25
9999999.65;+46396,+46395,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX OFF PATH TX
9999999.65;+46397,+46395,;.01~APR 27, 2026@12:13:51
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46396^1
46397^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>46394</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1101528767</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46394,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX OFF PATH TX
9999999.64;+46394,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46394,;.08~YES
9999999.64;+46394,;.1~FACTOR
9999999.64;+46394,;100~NATIONAL
9999999.64;+46394,;101~VHA ONCOLOGY
9999999.64;+46394,;200~CRPC M1 3rd line ECOG <=2 Taxane Off Path TX
9999999.64;+46394,;201~WP-start~2
Castrate resistant prostate cancer M1 third line treatment ECOG <=2 no 
contraindications to taxane; off pathway taxane
9999999.65;+46395,+46394,;.01~APR 27, 2026@12:11:20
9999999.65;+46395,+46394,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX CABAZITAXEL
9999999.65;+46396,+46394,;.01~APR 27, 2026@12:12:40
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46395^1
46396^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX DOCETAXEL+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>46392</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1193167245</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46392,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX DOCETAXEL+ADT
9999999.64;+46392,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46392,;.08~YES
9999999.64;+46392,;.1~FACTOR
9999999.64;+46392,;100~NATIONAL
9999999.64;+46392,;101~VHA ONCOLOGY
9999999.64;+46392,;200~CRPC M1 3rd line ECOG <=2 Taxane Docetaxel+ADT
9999999.64;+46392,;201~WP-start~2
Castrate resistant prostate cancer M1 third line treatment ECOG <=2 no 
contraindications to taxane; on pathway docetaxel with ADT
9999999.65;+46393,+46392,;.01~APR 27, 2026@12:09:34
9999999.65;+46393,+46392,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX CLIN TRIAL
9999999.65;+46394,+46392,;.01~APR 27, 2026@12:10:05
9999999.65;+46395,+46392,;.01~MAY 20, 2026@10:11:48
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46393^1
46394^2
46395^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 3RD ECOG &lt;=2 TAX CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>46391</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1054482742</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46391,;.01~VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX CLIN TRIAL
9999999.64;+46391,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+46391,;.08~YES
9999999.64;+46391,;.1~FACTOR
9999999.64;+46391,;100~NATIONAL
9999999.64;+46391,;101~VHA ONCOLOGY
9999999.64;+46391,;200~CRPC M1 3rd line ECOG <=2 Taxane Clinical Trial
9999999.64;+46391,;201~WP-start~2
Castrate resistant prostate cancer M1 third line treatment ECOG <=2 no 
contraindications to taxane; on pathway clinical trial
9999999.65;+46392,+46391,;.01~APR 27, 2026@11:55:41
9999999.65;+46392,+46391,;2~WP-start~1
Copied from VA-ONC PRCA CRPC M1 3RD ECOG <=2 LU177 CLIN TRIAL
9999999.65;+46393,+46391,;.01~APR 27, 2026@11:57:22
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46392^1
46393^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 2ND ECOG &lt;=2 CONTRA DOCE ENZALUT+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>20363</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2531807795</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20363,;.01~VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE ENZALUT+ADT
9999999.64;+20363,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+20363,;.08~YES
9999999.64;+20363,;.1~FACTOR
9999999.64;+20363,;100~NATIONAL
9999999.64;+20363,;101~VHA ONCOLOGY
9999999.64;+20363,;200~CRPC M1 2nd line ECOG <=2 Contra Doce Enzalutamide+ADT
9999999.64;+20363,;201~WP-start~2
Castrate resistant prostate cancer M1 second line treatment ECOG <=2,  
contraindications to docetaxel; on pathway enzalutamide+ADT
9999999.65;+20364,+20363,;.01~NOV 10, 2021@08:42:45
9999999.65;+20365,+20363,;.01~NOV 10, 2021@12:17:39
9999999.65;+20366,+20363,;.01~NOV 10, 2021@12:20:07
9999999.65;+20367,+20363,;.01~JAN 08, 2025@08:23:41
9999999.65;+20368,+20363,;.01~MAY 13, 2026@07:57:57
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20364^1
20365^2
20366^3
20367^4
20368^5
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 2ND ECOG &lt;=2 CONTRA DOCE RADIUM 223+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>20366</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1326175837</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20366,;.01~VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE RADIUM 223+ADT
9999999.64;+20366,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+20366,;.08~YES
9999999.64;+20366,;.1~FACTOR
9999999.64;+20366,;100~NATIONAL
9999999.64;+20366,;101~VHA ONCOLOGY
9999999.64;+20366,;200~CRPC M1 2nd line ECOG <=2 Contra Doce Radium 223+ADT
9999999.64;+20366,;201~WP-start~2
Castrate resistant prostate cancer M1 second line treatment ECOG <=2,  
contraindications to docetaxel; on pathway Radium 223+ADT
9999999.65;+20367,+20366,;.01~NOV 10, 2021@08:45:41
9999999.65;+20368,+20366,;.01~NOV 10, 2021@12:19:12
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20367^1
20368^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 2ND ECOG &lt;=2 CONTRA DOCE PEMBRO+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>20362</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3901463402</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20362,;.01~VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE PEMBRO+ADT
9999999.64;+20362,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+20362,;.08~YES
9999999.64;+20362,;.1~FACTOR
9999999.64;+20362,;100~NATIONAL
9999999.64;+20362,;101~VHA ONCOLOGY
9999999.64;+20362,;200~CRPC M1 2nd line ECOG <=2 Contra Doce Pembrolizumab+ADT
9999999.64;+20362,;201~WP-start~2
Castrate resistant prostate cancer M1 second line treatment ECOG <=2,  
contraindications to docetaxel; on pathway pembrolizumab+ADT
9999999.65;+20363,+20362,;.01~NOV 10, 2021@08:42:15
9999999.65;+20364,+20362,;.01~NOV 10, 2021@12:18:53
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20363^1
20364^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 2ND ECOG &lt;=2 CONTRA DOCE OLAPARIB+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>20367</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1807040599</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20367,;.01~VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE OLAPARIB+ADT
9999999.64;+20367,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+20367,;.08~YES
9999999.64;+20367,;.1~FACTOR
9999999.64;+20367,;100~NATIONAL
9999999.64;+20367,;101~VHA ONCOLOGY
9999999.64;+20367,;200~CRPC M1 2nd line ECOG <=2 Contra Doce Olaparib+ ADT
9999999.64;+20367,;201~WP-start~2
Castrate resistant prostate cancer M1 second line treatment ECOG <=2,  
contraindications to docetaxel; on pathway olaparib+ADT
9999999.65;+20368,+20367,;.01~NOV 10, 2021@08:46:25
9999999.65;+20369,+20367,;.01~NOV 10, 2021@12:18:38
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20368^1
20369^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 2ND ECOG &lt;=2 CONTRA DOCE LU177+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>31365</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2754302789</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+31365,;.01~VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE LU177+ADT
9999999.64;+31365,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+31365,;.08~YES
9999999.64;+31365,;.1~FACTOR
9999999.64;+31365,;100~NATIONAL
9999999.64;+31365,;101~VHA ONCOLOGY
9999999.64;+31365,;200~CRPC M1 2nd line ECOG <=2 Contra Doce Lu177-PSMA+ ADT
9999999.64;+31365,;201~WP-start~2
Castrate resistant prostate cancer M1 second line treatment ECOG <=2,  
contraindications to docetaxel; on pathway Lu177-PSMA+ADT.
9999999.65;+31366,+31365,;.01~SEP 19, 2023@11:36:43
9999999.65;+31366,+31365,;2~WP-start~1
 Creation.
9999999.65;+31367,+31365,;.01~SEP 19, 2023@12:06:06
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
31366^1
31367^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 2ND ECOG &lt;=2 CONTRA DOCE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>23904</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1416172372</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+23904,;.01~VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE OFF PATH RSN
9999999.64;+23904,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+23904,;.08~YES
9999999.64;+23904,;.1~FACTOR
9999999.64;+23904,;100~NATIONAL
9999999.64;+23904,;101~VHA ONCOLOGY
9999999.64;+23904,;200~CRPC M1 2nd line ECOG <=2 Contra Doce Off Path Reason
9999999.64;+23904,;201~WP-start~2
Castrate resistant prostate cancer M1 second line treatment ECOG <=2,  
contraindications to docetaxel; off pathway reason
9999999.65;+23905,+23904,;.01~NOV 10, 2021@08:48:22
9999999.65;+23905,+23904,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
23905^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 2ND ECOG &lt;=2 CONTRA DOCE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>23903</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3292628525</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+23903,;.01~VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE OFF PATH TX
9999999.64;+23903,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+23903,;.08~YES
9999999.64;+23903,;.1~FACTOR
9999999.64;+23903,;100~NATIONAL
9999999.64;+23903,;101~VHA ONCOLOGY
9999999.64;+23903,;200~CRPC M1 2nd line ECOG <=2 Contra Doce Off Path Treatment
9999999.64;+23903,;201~WP-start~2
Castrate resistant prostate cancer M1 second line treatment ECOG <=2,  
contraindications to docetaxel; off pathway treatment
9999999.65;+23904,+23903,;.01~NOV 10, 2021@08:47:37
9999999.65;+23904,+23903,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
23904^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 2ND ECOG &lt;=2 CONTRA DOCE CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>23902</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3521888056</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+23902,;.01~VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE CLINICAL TRIAL
9999999.64;+23902,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+23902,;.08~YES
9999999.64;+23902,;.1~FACTOR
9999999.64;+23902,;100~NATIONAL
9999999.64;+23902,;101~VHA ONCOLOGY
9999999.64;+23902,;200~CRPC M1 2nd line ECOG <=2 Contra Doce Clinical Trial
9999999.64;+23902,;201~WP-start~2
Castrate resistant prostate cancer M1 second line treatment ECOG <=2,  
contraindications to docetaxel; on pathway clinical trial
9999999.65;+23903,+23902,;.01~NOV 10, 2021@08:41:16
9999999.65;+23903,+23902,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
23903^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 2ND ECOG &lt;=2 OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>23901</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1059058983</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+23901,;.01~VA-ONC PRCA CRPC M1 2ND ECOG <=2 OFF PATH RSN
9999999.64;+23901,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+23901,;.08~YES
9999999.64;+23901,;.1~FACTOR
9999999.64;+23901,;100~NATIONAL
9999999.64;+23901,;101~VHA ONCOLOGY
9999999.64;+23901,;200~CRPC M1 2nd line ECOG <=2 Off Path Rsn
9999999.64;+23901,;201~WP-start~2
Castrate resistant prostate cancer M1 second line treatment ECOG <=2, no 
contraindications to docetaxel; off pathway reason
9999999.65;+23902,+23901,;.01~NOV 10, 2021@08:40:29
9999999.65;+23902,+23901,;2~WP-start~1
 Creation.
9999999.65;+23903,+23901,;.01~APR 06, 2022@11:41:35
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
23902^1
23903^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 2ND ECOG &lt;=2 OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>20368</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1822244624</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20368,;.01~VA-ONC PRCA CRPC M1 2ND ECOG <=2 OFF PATH TX
9999999.64;+20368,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+20368,;.08~YES
9999999.64;+20368,;.1~FACTOR
9999999.64;+20368,;100~NATIONAL
9999999.64;+20368,;101~VHA ONCOLOGY
9999999.64;+20368,;200~CRPC M1 2nd line ECOG <=2 Off Path Tx
9999999.64;+20368,;201~WP-start~2
Castrate resistant prostate cancer M1 second line treatment ECOG <=2, no 
contraindications to docetaxel; off pathway treatment
9999999.65;+20369,+20368,;.01~NOV 10, 2021@08:39:38
9999999.65;+20370,+20368,;.01~APR 06, 2022@11:41:59
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20369^1
20370^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 2ND ECOG &lt;=2 CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>20430</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1607586812</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20430,;.01~VA-ONC PRCA CRPC M1 2ND ECOG <=2 CLIN TRIAL
9999999.64;+20430,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+20430,;.08~YES
9999999.64;+20430,;.1~FACTOR
9999999.64;+20430,;100~NATIONAL
9999999.64;+20430,;101~VHA ONCOLOGY
9999999.64;+20430,;200~CRPC M1 2nd line ECOG <=2 Clinical Trial
9999999.64;+20430,;201~WP-start~2
Castrate resistant prostate cancer M1 second line treatment ECOG <=2, no 
contraindications to docetaxel; on pathway clinical trial
9999999.65;+20431,+20430,;.01~NOV 10, 2021@08:38:28
9999999.65;+20432,+20430,;.01~NOV 10, 2021@12:04:48
9999999.65;+20433,+20430,;.01~APR 06, 2022@11:39:37
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20431^1
20432^2
20433^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 2ND ECOG &lt;=2 DOCETAXEL+ADT</POINT_01>
<INTERNAL_ENTRY_NUMBER>20361</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3703935515</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20361,;.01~VA-ONC PRCA CRPC M1 2ND ECOG <=2 DOCETAXEL+ADT
9999999.64;+20361,;.03~VA-ONC PRCA CRPC M1 PATHWAY [C]
9999999.64;+20361,;.08~YES
9999999.64;+20361,;.1~FACTOR
9999999.64;+20361,;100~NATIONAL
9999999.64;+20361,;101~VHA ONCOLOGY
9999999.64;+20361,;200~CRPC M1 2nd line ECOG <=2 Docetaxel + ADT
9999999.64;+20361,;201~WP-start~2
Castrate resistant prostate cancer M1 second line treatment ECOG <=2, no 
contraindications to docetaxel; on pathway docetaxel+ADT
9999999.65;+20362,+20361,;.01~NOV 10, 2021@08:39:03
9999999.65;+20363,+20361,;.01~NOV 10, 2021@12:05:07
9999999.65;+20364,+20361,;.01~APR 06, 2022@11:40:50
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20362^1
20363^2
20364^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONCOLOGY PATHWAYS [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>23018</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1432377665</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+23018,;.01~VA-ONCOLOGY PATHWAYS [C]
9999999.64;+23018,;.08~YES
9999999.64;+23018,;.1~CATEGORY
9999999.64;+23018,;100~NATIONAL
9999999.64;+23018,;101~VHA ONCOLOGY
9999999.64;+23018,;200~Oncology Pathways
9999999.64;+23018,;201~WP-start~2
For all pathways; the health factor that designates that the template was 
opened.
9999999.65;+23019,+23018,;.01~AUG 24, 2021@09:05:11
9999999.65;+23019,+23018,;2~WP-start~1
 Creation.
9999999.65;+23020,+23018,;.01~SEP 03, 2024@07:46:45
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
23019^1
23020^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>20205</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3868955004</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+20205,;.01~VA-ONC PRCA CRPC M1 PATHWAY
9999999.64;+20205,;.03~VA-ONCOLOGY PATHWAYS [C]
9999999.64;+20205,;.08~YES
9999999.64;+20205,;.1~FACTOR
9999999.64;+20205,;100~NATIONAL
9999999.64;+20205,;101~VHA ONCOLOGY
9999999.64;+20205,;200~Castrate Resistant Prostate Cancer M1 Pathway
9999999.64;+20205,;201~WP-start~2
Designates that the Castrate Resistant Prostate Cancer M1 pathway was 
opened
9999999.65;+20206,+20205,;.01~OCT 06, 2021@09:09:20
9999999.65;+20207,+20205,;.01~NOV 10, 2021@08:17:01
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
20206^1
20207^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV CLINICAL PATHWAY [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>25038</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>700749012</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25038,;.01~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25038,;.08~YES
9999999.64;+25038,;.1~CATEGORY
9999999.64;+25038,;100~NATIONAL
9999999.64;+25038,;101~VHA ONCOLOGY
9999999.64;+25038,;200~Kidney Cancer-Stage IV Clinical Pathway
9999999.64;+25038,;201~WP-start~2
Category for all health factors in Kidney Cancer - Stage IV Clinical 
Pathway
9999999.65;+25039,+25038,;.01~JUN 17, 2022@08:56:45
9999999.65;+25039,+25038,;2~WP-start~1
 Creation.
9999999.65;+25040,+25038,;.01~JUN 21, 2022@07:39:38
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25039^1
25040^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER NO OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>46375</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1994024735</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46375,;.01~VA-ONC KID STG IV NCC INTER NO OFF PATH RSN
9999999.64;+46375,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46375,;.08~YES
9999999.64;+46375,;.1~FACTOR
9999999.64;+46375,;100~NATIONAL
9999999.64;+46375,;101~VHA ONCOLOGY
9999999.64;+46375,;200~Kidney CA-Stage IV Non-CC Cand Inter No Off Path RSN
9999999.64;+46375,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, not a candidate for an
intervention (cytoreductive nephrectomy or metastasis directed therapy);
off pathway reason
9999999.65;+46376,+46375,;.01~APR 24, 2026@06:34:03
9999999.65;+46376,+46375,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC INTER NO OFF PATH TX
9999999.65;+46377,+46375,;.01~APR 24, 2026@06:34:38
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46376^1
46377^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER NO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>46374</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1970789945</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46374,;.01~VA-ONC KID STG IV NCC INTER NO OFF PATH TX
9999999.64;+46374,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46374,;.08~YES
9999999.64;+46374,;.1~FACTOR
9999999.64;+46374,;100~NATIONAL
9999999.64;+46374,;101~VHA ONCOLOGY
9999999.64;+46374,;200~Kidney CA-Stage IV Non-CC Cand Inter No Off Path TX
9999999.64;+46374,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, not a candidate for an
intervention (cytoreductive nephrectomy or metastasis directed therapy);
off pathway treatment
9999999.65;+46375,+46374,;.01~APR 24, 2026@06:33:15
9999999.65;+46375,+46374,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC INTER NO CLIN TRIAL
9999999.65;+46376,+46374,;.01~APR 24, 2026@06:33:45
9999999.65;+46377,+46374,;.01~APR 24, 2026@06:35:09
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46375^1
46376^2
46377^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER NO PEMB+LEN</POINT_01>
<INTERNAL_ENTRY_NUMBER>46373</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3140820890</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46373,;.01~VA-ONC KID STG IV NCC INTER NO PEMB+LEN
9999999.64;+46373,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46373,;.08~YES
9999999.64;+46373,;.1~FACTOR
9999999.64;+46373,;100~NATIONAL
9999999.64;+46373,;101~VHA ONCOLOGY
9999999.64;+46373,;200~Kidney CA-Stage IV Non-CC Cand Inter No Pemb+Len
9999999.64;+46373,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, not a candidate for an
intervention (cytoreductive nephrectomy or metastasis directed therapy);
on pathway pembrolizumab and lenvatinib
9999999.65;+46374,+46373,;.01~APR 24, 2026@06:31:32
9999999.65;+46374,+46373,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC INTER NO CLIN TRIAL
9999999.65;+46375,+46373,;.01~APR 24, 2026@06:32:16
9999999.65;+46376,+46373,;.01~APR 24, 2026@08:10:01
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46374^1
46375^2
46376^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER NO CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>46372</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>812188123</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46372,;.01~VA-ONC KID STG IV NCC INTER NO CLIN TRIAL
9999999.64;+46372,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46372,;.08~YES
9999999.64;+46372,;.1~FACTOR
9999999.64;+46372,;100~NATIONAL
9999999.64;+46372,;101~VHA ONCOLOGY
9999999.64;+46372,;200~Kidney CA-Stage IV Non-CC Cand Inter No Clin Trial
9999999.64;+46372,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, not a candidate for an
intervention (cytoreductive nephrectomy or metastasis directed therapy);
on pathway clinical trial
9999999.65;+46373,+46372,;.01~APR 24, 2026@06:29:30
9999999.65;+46373,+46372,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC INTER CLIN TRIAL
9999999.65;+46374,+46372,;.01~APR 24, 2026@06:30:54
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46373^1
46374^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC NO PERSIST S/P INTER SURVEILLANCE</POINT_01>
<INTERNAL_ENTRY_NUMBER>46381</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>832813754</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46381,;.01~VA-ONC KID STG IV NCC NO PERSIST S/P INTER SURVEILLANCE
9999999.64;+46381,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46381,;.08~YES
9999999.64;+46381,;.1~FACTOR
9999999.64;+46381,;100~NATIONAL
9999999.64;+46381,;101~VHA ONCOLOGY
9999999.64;+46381,;200~Kidney CA-Stage IV Non-CC No Persist Dz After Inter Surveillance
9999999.64;+46381,;201~WP-start~9
Kidney Cancer-Stage IV Relapse Non-Clear Cell, candidate for an 
intervention (cytoreductive nephrectomy or metastasis directed therapy) 
with no persistent disease; on pathway active surveillance;
Follow up every 6-16 weeks for 5 years if receiving systemic therapy:
         -history and physical 
         -comprehensive metabolic panel (based on therapy used) 
Follow up at baseline, then every 12 weeks for 5 years:
         -abdominal CT/MRI with contrast
         -chest x-ray/CT
9999999.65;+46382,+46381,;.01~APR 24, 2026@06:50:08
9999999.65;+46382,+46381,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC NO PERSIST S/P INTER CLIN TRIAL
9999999.65;+46383,+46381,;.01~APR 24, 2026@06:52:16
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46382^1
46383^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC NO PERSIST S/P INTER OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>46383</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2172101865</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46383,;.01~VA-ONC KID STG IV NCC NO PERSIST S/P INTER OFF PATH RSN
9999999.64;+46383,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46383,;.08~YES
9999999.64;+46383,;.1~FACTOR
9999999.64;+46383,;100~NATIONAL
9999999.64;+46383,;101~VHA ONCOLOGY
9999999.64;+46383,;200~Kidney CA-Stage IV Non-CC No Persist Dz After Inter Off Path RSN
9999999.64;+46383,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, candidate for an 
intervention (cytoreductive nephrectomy or metastasis directed therapy) 
with no persistent disease; off pathway reason
9999999.65;+46384,+46383,;.01~APR 24, 2026@06:54:21
9999999.65;+46384,+46383,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC NO PERSIST S/P INTER OFF PATH TX
9999999.65;+46385,+46383,;.01~APR 24, 2026@06:54:48
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46384^1
46385^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC NO PERSIST S/P INTER OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>46382</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>878844353</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46382,;.01~VA-ONC KID STG IV NCC NO PERSIST S/P INTER OFF PATH TX
9999999.64;+46382,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46382,;.08~YES
9999999.64;+46382,;.1~FACTOR
9999999.64;+46382,;100~NATIONAL
9999999.64;+46382,;101~VHA ONCOLOGY
9999999.64;+46382,;200~Kidney CA-Stage IV Non-CC No Persist Dz After Inter Off Path TX
9999999.64;+46382,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, candidate for an 
intervention (cytoreductive nephrectomy or metastasis directed therapy) 
with no persistent disease; off pathway treatment
9999999.65;+46383,+46382,;.01~APR 24, 2026@06:53:28
9999999.65;+46383,+46382,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC NO PERSIST S/P INTER CLIN TRIAL
9999999.65;+46384,+46382,;.01~APR 24, 2026@06:54:02
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46383^1
46384^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC NO PERSIST S/P INTER CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>46380</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2679488942</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46380,;.01~VA-ONC KID STG IV NCC NO PERSIST S/P INTER CLIN TRIAL
9999999.64;+46380,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46380,;.08~YES
9999999.64;+46380,;.1~FACTOR
9999999.64;+46380,;100~NATIONAL
9999999.64;+46380,;101~VHA ONCOLOGY
9999999.64;+46380,;200~Kidney CA-Stage IV Non-CC No Persist Dz After Inter Clin Trial
9999999.64;+46380,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, candidate for an 
intervention (cytoreductive nephrectomy or metastasis directed therapy) 
with no persistent disease; on pathway clinical trial
9999999.65;+46381,+46380,;.01~APR 24, 2026@06:49:15
9999999.65;+46381,+46380,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC PERSIST S/P INTER CLIN TRIAL
9999999.65;+46382,+46380,;.01~APR 24, 2026@06:49:53
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46381^1
46382^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC PERSIST S/P INTER OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>46379</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1680579930</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46379,;.01~VA-ONC KID STG IV NCC PERSIST S/P INTER OFF PATH RSN
9999999.64;+46379,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46379,;.08~YES
9999999.64;+46379,;.1~FACTOR
9999999.64;+46379,;100~NATIONAL
9999999.64;+46379,;101~VHA ONCOLOGY
9999999.64;+46379,;200~Kidney CA-Stage IV Non-CC Persist Dz After Inter Off Path RSN
9999999.64;+46379,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, candidate for an 
intervention (cytoreductive nephrectomy or metastasis directed therapy) 
with persistent disease; off pathway reason
9999999.65;+46380,+46379,;.01~APR 24, 2026@06:41:08
9999999.65;+46380,+46379,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC PERSIST S/P INTER OFF PATH TX
9999999.65;+46381,+46379,;.01~APR 24, 2026@06:41:34
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46380^1
46381^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC PERSIST S/P INTER OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>46378</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2699488455</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46378,;.01~VA-ONC KID STG IV NCC PERSIST S/P INTER OFF PATH TX
9999999.64;+46378,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46378,;.08~YES
9999999.64;+46378,;.1~FACTOR
9999999.64;+46378,;100~NATIONAL
9999999.64;+46378,;101~VHA ONCOLOGY
9999999.64;+46378,;200~Kidney CA-Stage IV Non-CC Persist Dz After Inter Off Path TX
9999999.64;+46378,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, candidate for an 
intervention (cytoreductive nephrectomy or metastasis directed therapy) 
with persistent disease; off pathway treatment
9999999.65;+46379,+46378,;.01~APR 24, 2026@06:40:13
9999999.65;+46379,+46378,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC PERSIST S/P INTER PEMB+LEN
9999999.65;+46380,+46378,;.01~APR 24, 2026@06:40:48
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46379^1
46380^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC PERSIST S/P INTER PEMB+LEN</POINT_01>
<INTERNAL_ENTRY_NUMBER>46377</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3714223207</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46377,;.01~VA-ONC KID STG IV NCC PERSIST S/P INTER PEMB+LEN
9999999.64;+46377,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46377,;.08~YES
9999999.64;+46377,;.1~FACTOR
9999999.64;+46377,;100~NATIONAL
9999999.64;+46377,;101~VHA ONCOLOGY
9999999.64;+46377,;200~Kidney CA-Stage IV Non-CC Persist Dz After Inter Pemb+Len
9999999.64;+46377,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, candidate for an 
intervention (cytoreductive nephrectomy or metastasis directed therapy) 
with persistent disease; on pathway pembrolizumab and lenvatinib
9999999.65;+46378,+46377,;.01~APR 24, 2026@06:39:07
9999999.65;+46378,+46377,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC PERSIST S/P INTER CLIN TRIAL
9999999.65;+46379,+46377,;.01~APR 24, 2026@06:39:54
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46378^1
46379^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC PERSIST S/P INTER CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>46376</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1129167374</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46376,;.01~VA-ONC KID STG IV NCC PERSIST S/P INTER CLIN TRIAL
9999999.64;+46376,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46376,;.08~YES
9999999.64;+46376,;.1~FACTOR
9999999.64;+46376,;100~NATIONAL
9999999.64;+46376,;101~VHA ONCOLOGY
9999999.64;+46376,;200~Kidney CA-Stage IV Non-CC Persist Dz After Inter Clin Trial
9999999.64;+46376,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, candidate for an 
intervention (cytoreductive nephrectomy or metastasis directed therapy) 
with persistent disease; on pathway clinical trial
9999999.65;+46377,+46376,;.01~APR 24, 2026@06:36:38
9999999.65;+46377,+46376,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC INTER NO CLIN TRIAL
9999999.65;+46378,+46376,;.01~APR 24, 2026@06:38:42
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46377^1
46378^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>46371</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3233282941</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46371,;.01~VA-ONC KID STG IV NCC INTER OFF PATH RSN
9999999.64;+46371,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46371,;.08~YES
9999999.64;+46371,;.1~FACTOR
9999999.64;+46371,;100~NATIONAL
9999999.64;+46371,;101~VHA ONCOLOGY
9999999.64;+46371,;200~Kidney CA-Stage IV Non-CC Cand Inter Off Path RSN
9999999.64;+46371,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, candidate for an
intervention (cytoreductive nephrectomy or metastasis directed therapy);
off pathway reason
9999999.65;+46372,+46371,;.01~APR 24, 2026@06:22:01
9999999.65;+46372,+46371,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC INTER OFF PATH TX
9999999.65;+46373,+46371,;.01~APR 24, 2026@06:22:28
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46372^1
46373^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>46370</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2750251700</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46370,;.01~VA-ONC KID STG IV NCC INTER OFF PATH TX
9999999.64;+46370,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46370,;.08~YES
9999999.64;+46370,;.1~FACTOR
9999999.64;+46370,;100~NATIONAL
9999999.64;+46370,;101~VHA ONCOLOGY
9999999.64;+46370,;200~Kidney CA-Stage IV Non-CC Cand Inter Off Path TX
9999999.64;+46370,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, candidate for an
intervention (cytoreductive nephrectomy or metastasis directed therapy);
off pathway treatment
9999999.65;+46371,+46370,;.01~APR 24, 2026@06:21:01
9999999.65;+46371,+46370,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC INTER CLIN TRIAL
9999999.65;+46372,+46370,;.01~APR 24, 2026@06:21:40
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46371^1
46372^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER METS DIRECTED TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>46369</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1711149571</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46369,;.01~VA-ONC KID STG IV NCC INTER METS DIRECTED TX
9999999.64;+46369,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46369,;.08~YES
9999999.64;+46369,;.1~FACTOR
9999999.64;+46369,;100~NATIONAL
9999999.64;+46369,;101~VHA ONCOLOGY
9999999.64;+46369,;200~Kidney CA-Stage IV Non-CC Cand Inter Mets Directed TX
9999999.64;+46369,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, candidate for an
intervention (cytoreductive nephrectomy or metastasis directed therapy);
on pathway metastasis directed therapy
9999999.65;+46370,+46369,;.01~APR 24, 2026@06:19:48
9999999.65;+46370,+46369,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC INTER CYTO NEPHRECTOMY
9999999.65;+46371,+46369,;.01~APR 24, 2026@06:20:45
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46370^1
46371^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER CYTO NEPHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>46368</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>859241983</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46368,;.01~VA-ONC KID STG IV NCC INTER CYTO NEPHRECTOMY
9999999.64;+46368,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46368,;.08~YES
9999999.64;+46368,;.1~FACTOR
9999999.64;+46368,;100~NATIONAL
9999999.64;+46368,;101~VHA ONCOLOGY
9999999.64;+46368,;200~Kidney CA-Stage IV Non-CC Cand Inter Cyto Nephrectomy
9999999.64;+46368,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, candidate for an
intervention (cytoreductive nephrectomy or metastasis directed therapy);
on pathway cytoreductive nephrectomy
9999999.65;+46369,+46368,;.01~APR 24, 2026@06:17:34
9999999.65;+46369,+46368,;2~WP-start~1
Copied from VA-ONC KID STG IV NCC INTER CLIN TRIAL
9999999.65;+46370,+46368,;.01~APR 24, 2026@06:19:28
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46369^1
46370^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>46367</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2190538783</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46367,;.01~VA-ONC KID STG IV NCC INTER CLIN TRIAL
9999999.64;+46367,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46367,;.08~YES
9999999.64;+46367,;.1~FACTOR
9999999.64;+46367,;100~NATIONAL
9999999.64;+46367,;101~VHA ONCOLOGY
9999999.64;+46367,;200~Kidney CA-Stage IV Non-CC Cand Inter Clin Trial
9999999.64;+46367,;201~WP-start~3
Kidney Cancer-Stage IV Relapse Non-Clear Cell, candidate for an
intervention (cytoreductive nephrectomy or metastasis directed therapy);
on pathway clinical trial
9999999.65;+46368,+46367,;.01~APR 24, 2026@06:11:45
9999999.65;+46368,+46367,;2~WP-start~1
Copied from VA-ONC KID STAGE IV CAND INTER CLINICAL TRIAL
9999999.65;+46369,+46367,;.01~APR 24, 2026@06:15:51
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46368^1
46369^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROGRESS AFTER 1ST LINE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25150</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4080019920</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25150,;.01~VA-ONC KID STAGE IV PROGRESS AFTER 1ST LINE OFF PATH RSN
9999999.64;+25150,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25150,;.08~YES
9999999.64;+25150,;.1~FACTOR
9999999.64;+25150,;100~NATIONAL
9999999.64;+25150,;101~VHA ONCOLOGY
9999999.64;+25150,;200~Kidney CA-Stage IV Progress After 1st Line Tx Off Path Rsn
9999999.64;+25150,;201~WP-start~2
Kidney Cancer-Stage IV with progression after first line systemic therapy;
off pathway reason
9999999.65;+25151,+25150,;.01~JUL 11, 2022@10:48:38
9999999.65;+25151,+25150,;2~WP-start~1
 Creation.
9999999.65;+25152,+25150,;.01~JUL 13, 2022@07:42:21
9999999.65;+25153,+25150,;.01~OCT 12, 2022@08:31:07
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25151^1
25152^2
25153^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROGRESS AFTER 1ST LINE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25149</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>635562116</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25149,;.01~VA-ONC KID STAGE IV PROGRESS AFTER 1ST LINE OFF PATH TX
9999999.64;+25149,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25149,;.08~YES
9999999.64;+25149,;.1~FACTOR
9999999.64;+25149,;100~NATIONAL
9999999.64;+25149,;101~VHA ONCOLOGY
9999999.64;+25149,;200~Kidney CA-Stage IV Progress After 1st Line Tx Off Path Tx
9999999.64;+25149,;201~WP-start~2
Kidney Cancer-Stage IV with progression after first line systemic therapy;
off pathway treatment
9999999.65;+25150,+25149,;.01~JUL 11, 2022@10:48:08
9999999.65;+25150,+25149,;2~WP-start~1
 Creation.
9999999.65;+25151,+25149,;.01~JUL 13, 2022@07:42:39
9999999.65;+25152,+25149,;.01~OCT 12, 2022@08:32:31
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25150^1
25151^2
25152^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROGRESS AFTER 1ST LINE CABOZANTINIB</POINT_01>
<INTERNAL_ENTRY_NUMBER>25148</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>482018277</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25148,;.01~VA-ONC KID STAGE IV PROGRESS AFTER 1ST LINE CABOZANTINIB
9999999.64;+25148,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25148,;.08~YES
9999999.64;+25148,;.1~FACTOR
9999999.64;+25148,;100~NATIONAL
9999999.64;+25148,;101~VHA ONCOLOGY
9999999.64;+25148,;200~Kidney CA-Stage IV Progress After 1st Line Tx Cabozantinib
9999999.64;+25148,;201~WP-start~2
Kidney Cancer-Stage IV with progression after first line systemic therapy;
on pathway cabozantinib
9999999.65;+25149,+25148,;.01~JUL 11, 2022@10:47:03
9999999.65;+25149,+25148,;2~WP-start~1
 Creation.
9999999.65;+25150,+25148,;.01~JUL 13, 2022@07:41:39
9999999.65;+25151,+25148,;.01~OCT 12, 2022@08:25:21
9999999.65;+25152,+25148,;.01~OCT 12, 2022@08:33:08
9999999.65;+25153,+25148,;.01~OCT 12, 2022@08:33:49
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25149^1
25150^2
25151^3
25152^4
25153^5
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROGRESS AFTER 1ST LINE CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25147</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>729124140</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25147,;.01~VA-ONC KID STAGE IV PROGRESS AFTER 1ST LINE CLINICAL TRIAL
9999999.64;+25147,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25147,;.08~YES
9999999.64;+25147,;.1~FACTOR
9999999.64;+25147,;100~NATIONAL
9999999.64;+25147,;101~VHA ONCOLOGY
9999999.64;+25147,;200~Kidney CA-Stage IV Progress After 1st Line Clinical Trial
9999999.64;+25147,;201~WP-start~2
Kidney Cancer-Stage IV with progression after 1st line systemic therapy;
on pathway clinical trial
9999999.65;+25148,+25147,;.01~JUL 11, 2022@10:46:07
9999999.65;+25148,+25147,;2~WP-start~1
 Creation.
9999999.65;+25149,+25147,;.01~JUL 13, 2022@07:42:04
9999999.65;+25150,+25147,;.01~OCT 12, 2022@08:29:45
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25148^1
25149^2
25150^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER FAVOR OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25131</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>345368602</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25131,;.01~VA-ONC KID STAGE IV NOT CAND INTER FAVOR OFF PATH RSN
9999999.64;+25131,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25131,;.08~YES
9999999.64;+25131,;.1~FACTOR
9999999.64;+25131,;100~NATIONAL
9999999.64;+25131,;101~VHA ONCOLOGY
9999999.64;+25131,;200~Kidney CA-Stage IV Not Cand Inter Favor Risk Off Path Rsn
9999999.64;+25131,;201~WP-start~3
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be a favorable 
risk group; off pathway reason
9999999.65;+25132,+25131,;.01~JUL 11, 2022@10:19:07
9999999.65;+25132,+25131,;2~WP-start~1
 Creation.
9999999.65;+25133,+25131,;.01~JUL 13, 2022@07:39:24
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25132^1
25133^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER FAVOR OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25130</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2936685136</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25130,;.01~VA-ONC KID STAGE IV NOT CAND INTER FAVOR OFF PATH TX
9999999.64;+25130,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25130,;.08~YES
9999999.64;+25130,;.1~FACTOR
9999999.64;+25130,;100~NATIONAL
9999999.64;+25130,;101~VHA ONCOLOGY
9999999.64;+25130,;200~Kidney CA-Stage IV Not Cand Inter Favor Risk Off Path Tx
9999999.64;+25130,;201~WP-start~3
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be a favorable 
risk group; off pathway treatment
9999999.65;+25131,+25130,;.01~JUL 11, 2022@10:17:53
9999999.65;+25131,+25130,;2~WP-start~1
 Creation.
9999999.65;+25132,+25130,;.01~JUL 13, 2022@07:39:42
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25131^1
25132^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER FAVOR PEMBRO+AXIT</POINT_01>
<INTERNAL_ENTRY_NUMBER>25129</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3775422562</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25129,;.01~VA-ONC KID STAGE IV NOT CAND INTER FAVOR PEMBRO+AXIT
9999999.64;+25129,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25129,;.08~YES
9999999.64;+25129,;.1~FACTOR
9999999.64;+25129,;100~NATIONAL
9999999.64;+25129,;101~VHA ONCOLOGY
9999999.64;+25129,;200~Kidney CA-Stage IV Not Cand Inter Favor Risk Pembro+Axit
9999999.64;+25129,;201~WP-start~3
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be a favorable 
risk group; on pathway pembrolizubam and axitinib
9999999.65;+25130,+25129,;.01~JUL 11, 2022@10:16:57
9999999.65;+25130,+25129,;2~WP-start~1
 Creation.
9999999.65;+25131,+25129,;.01~JUL 13, 2022@07:39:57
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25130^1
25131^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER FAVOR CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25128</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>672492017</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25128,;.01~VA-ONC KID STAGE IV NOT CAND INTER FAVOR CLINICAL TRIAL
9999999.64;+25128,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25128,;.08~YES
9999999.64;+25128,;.1~FACTOR
9999999.64;+25128,;100~NATIONAL
9999999.64;+25128,;101~VHA ONCOLOGY
9999999.64;+25128,;200~Kidney CA-Stage IV Not Cand Inter Favor Risk Clinical Trial
9999999.64;+25128,;201~WP-start~3
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be a favorable 
risk group; on pathway clinical trial
9999999.65;+25129,+25128,;.01~JUL 11, 2022@10:14:23
9999999.65;+25129,+25128,;2~WP-start~1
 Creation.
9999999.65;+25130,+25128,;.01~JUL 13, 2022@07:39:10
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25129^1
25130^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39643</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3257052447</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39643,;.01~VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX OFF PATH RSN
9999999.64;+39643,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39643,;.08~YES
9999999.64;+39643,;.1~FACTOR
9999999.64;+39643,;100~NATIONAL
9999999.64;+39643,;101~VHA ONCOLOGY
9999999.64;+39643,;200~Kidney CA-Stage IV Not Cand Inter No Threat/Sx, Off Path RSN
9999999.64;+39643,;201~WP-start~4
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group, with no life threatening or symptomatic 
tumor; off pathway reason
9999999.65;+39644,+39643,;.01~FEB 24, 2025@09:05:11
9999999.65;+39644,+39643,;2~WP-start~1
Copied from VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX OFF PATH TX
9999999.65;+39645,+39643,;.01~FEB 24, 2025@09:05:43
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39644^1
39645^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39642</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1010120521</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39642,;.01~VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX OFF PATH TX
9999999.64;+39642,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39642,;.08~YES
9999999.64;+39642,;.1~FACTOR
9999999.64;+39642,;100~NATIONAL
9999999.64;+39642,;101~VHA ONCOLOGY
9999999.64;+39642,;200~Kidney CA-Stage IV Not Cand Inter No Threat/Sx, Off Path TX
9999999.64;+39642,;201~WP-start~4
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group, with no life threatening or symptomatic 
tumor; off pathway treatment
9999999.65;+39643,+39642,;.01~FEB 24, 2025@09:03:56
9999999.65;+39643,+39642,;2~WP-start~1
Copied from VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX CLIN TRIAL
9999999.65;+39644,+39642,;.01~FEB 24, 2025@09:04:36
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39643^1
39644^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX IPI+NIVO</POINT_01>
<INTERNAL_ENTRY_NUMBER>39641</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3166987999</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39641,;.01~VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX IPI+NIVO
9999999.64;+39641,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39641,;.08~YES
9999999.64;+39641,;.1~FACTOR
9999999.64;+39641,;100~NATIONAL
9999999.64;+39641,;101~VHA ONCOLOGY
9999999.64;+39641,;200~Kidney CA-Stage IV Not Cand Inter No Threat/Sx, IPI+Nivo
9999999.64;+39641,;201~WP-start~4
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group, with no life threatening or symptomatic 
tumor; on pathway ipilimumab and nivolumab
9999999.65;+39642,+39641,;.01~FEB 24, 2025@09:01:38
9999999.65;+39642,+39641,;2~WP-start~1
Copied from VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX CLIN TRIAL
9999999.65;+39643,+39641,;.01~FEB 24, 2025@09:02:30
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39642^1
39643^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>39640</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3599896616</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39640,;.01~VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX CLIN TRIAL
9999999.64;+39640,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39640,;.08~YES
9999999.64;+39640,;.1~FACTOR
9999999.64;+39640,;100~NATIONAL
9999999.64;+39640,;101~VHA ONCOLOGY
9999999.64;+39640,;200~Kidney CA-Stage IV Not Cand Inter No Threat/Sx, Clin Trial
9999999.64;+39640,;201~WP-start~4
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group, with no life threatening or symptomatic 
tumor; on pathway clinical trial
9999999.65;+39641,+39640,;.01~FEB 24, 2025@08:45:22
9999999.65;+39641,+39640,;2~WP-start~1
Copied from VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX CLIN TRIAL
9999999.65;+39642,+39640,;.01~FEB 24, 2025@08:50:08
9999999.65;+39643,+39640,;.01~FEB 24, 2025@08:59:42
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39641^1
39642^2
39643^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39548</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1857615233</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39548,;.01~VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX OFF PATH RSN
9999999.64;+39548,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39548,;.08~YES
9999999.64;+39548,;.1~FACTOR
9999999.64;+39548,;100~NATIONAL
9999999.64;+39548,;101~VHA ONCOLOGY
9999999.64;+39548,;200~Kidney CA-Stage IV Not Cand Inter Threat/Sx, Off Path RSN
9999999.64;+39548,;201~WP-start~4
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group, with life threatening or symptomatic 
tumor; off pathway reason
9999999.65;+39549,+39548,;.01~FEB 12, 2025@12:25:35
9999999.65;+39549,+39548,;2~WP-start~1
Copied from VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX OFF PATH TX
9999999.65;+39550,+39548,;.01~FEB 12, 2025@12:26:36
9999999.65;+39551,+39548,;.01~FEB 24, 2025@08:54:24
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39549^1
39550^2
39551^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39547</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>914291234</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39547,;.01~VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX OFF PATH TX
9999999.64;+39547,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39547,;.08~YES
9999999.64;+39547,;.1~FACTOR
9999999.64;+39547,;100~NATIONAL
9999999.64;+39547,;101~VHA ONCOLOGY
9999999.64;+39547,;200~Kidney CA-Stage IV Not Cand Inter Threat/Sx, Off Path TX
9999999.64;+39547,;201~WP-start~4
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group, with life threatening or symptomatic 
tumor; off pathway treatment
9999999.65;+39548,+39547,;.01~FEB 12, 2025@12:20:20
9999999.65;+39548,+39547,;2~WP-start~1
Copied from VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX PEMB+AXIT
9999999.65;+39549,+39547,;.01~FEB 12, 2025@12:22:43
9999999.65;+39550,+39547,;.01~FEB 24, 2025@08:55:29
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39548^1
39549^2
39550^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX PEMB+AXIT</POINT_01>
<INTERNAL_ENTRY_NUMBER>39545</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>791224793</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39545,;.01~VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX PEMB+AXIT
9999999.64;+39545,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39545,;.08~YES
9999999.64;+39545,;.1~FACTOR
9999999.64;+39545,;100~NATIONAL
9999999.64;+39545,;101~VHA ONCOLOGY
9999999.64;+39545,;200~Kidney CA-Stage IV Not Cand Inter Threat/Sx, Pemb+Axit
9999999.64;+39545,;201~WP-start~4
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group, with life threatening or symptomatic 
tumor; on pathway pembrolizumab and axitinib
9999999.65;+39546,+39545,;.01~FEB 12, 2025@12:18:44
9999999.65;+39546,+39545,;2~WP-start~1
Copied from VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX CLIN TRIAL
9999999.65;+39547,+39545,;.01~FEB 12, 2025@12:19:43
9999999.65;+39548,+39545,;.01~FEB 12, 2025@12:23:40
9999999.65;+39549,+39545,;.01~FEB 24, 2025@08:57:09
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39546^1
39547^2
39548^3
39549^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>39544</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1304174483</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39544,;.01~VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX CLIN TRIAL
9999999.64;+39544,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39544,;.08~YES
9999999.64;+39544,;.1~FACTOR
9999999.64;+39544,;100~NATIONAL
9999999.64;+39544,;101~VHA ONCOLOGY
9999999.64;+39544,;200~Kidney CA-Stage IV Not Cand Inter Threat/Sx, Clin Trial
9999999.64;+39544,;201~WP-start~4
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group, with life threatening or symptomatic 
tumor; on pathway clinical trial
9999999.65;+39545,+39544,;.01~FEB 12, 2025@12:13:02
9999999.65;+39545,+39544,;2~WP-start~1
Copied from VA-ONC KID STAGE IV NOT CAND INTER IN/POOR CLINICAL TRIAL
9999999.65;+39546,+39544,;.01~FEB 12, 2025@12:18:21
9999999.65;+39547,+39544,;.01~FEB 24, 2025@08:52:50
9999999.65;+39548,+39544,;.01~FEB 24, 2025@09:01:16
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39545^1
39546^2
39547^3
39548^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NO PROG AFTER INTER PEMBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>46040</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3153341214</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+46040,;.01~VA-ONC KID STAGE IV NO PROG AFTER INTER PEMBRO
9999999.64;+46040,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+46040,;.08~YES
9999999.64;+46040,;.1~FACTOR
9999999.64;+46040,;100~NATIONAL
9999999.64;+46040,;101~VHA ONCOLOGY
9999999.64;+46040,;200~Kidney CA-Stage IV No Progress After Inter Pembrolizumab
9999999.64;+46040,;201~WP-start~3
Kidney Cancer-Stage IV candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) with no persistent disease; 
on pathway pembrolizumab
9999999.65;+46041,+46040,;.01~APR 23, 2026@11:57:22
9999999.65;+46041,+46040,;2~WP-start~1
Copied from VA-ONC KID STAGE IV NO PROG AFTER INTER CLINICAL TRIAL
9999999.65;+46042,+46040,;.01~APR 23, 2026@11:58:08
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46041^1
46042^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NO PROG AFTER INTER SURVEILLANCE</POINT_01>
<INTERNAL_ENTRY_NUMBER>25144</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1871466188</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25144,;.01~VA-ONC KID STAGE IV NO PROG AFTER INTER SURVEILLANCE
9999999.64;+25144,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25144,;.08~YES
9999999.64;+25144,;.1~FACTOR
9999999.64;+25144,;100~NATIONAL
9999999.64;+25144,;101~VHA ONCOLOGY
9999999.64;+25144,;200~Kidney CA-Stage IV No Progress After Inter Surveillance
9999999.64;+25144,;201~WP-start~7
"Kidney Cancer-Stage IV candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) with no persistent disease; 
on pathway surveillance;       Follow up every 6-16 weeks for 5 years if 
receiving systemic therapy:          -history and physical          
-comprehensive metabolic panel (based on therapy used)       Follow up at 
baseline, then every 12 weeks for 5 years:         -abdominal CT/MRI with 
contrast         -chest x-ray/CT"
9999999.65;+25145,+25144,;.01~JUL 11, 2022@10:43:40
9999999.65;+25145,+25144,;2~WP-start~1
 Creation.
9999999.65;+25146,+25144,;.01~JUL 13, 2022@07:38:52
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25145^1
25146^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NO PROG AFTER INTER OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25146</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>193155820</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25146,;.01~VA-ONC KID STAGE IV NO PROG AFTER INTER OFF PATH RSN
9999999.64;+25146,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25146,;.08~YES
9999999.64;+25146,;.1~FACTOR
9999999.64;+25146,;100~NATIONAL
9999999.64;+25146,;101~VHA ONCOLOGY
9999999.64;+25146,;200~Kidney CA-Stage IV No Progress After Inter Off Path Reason
9999999.64;+25146,;201~WP-start~3
Kidney Cancer-Stage IV candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) with no persistent disease; 
off pathway reason
9999999.65;+25147,+25146,;.01~JUL 11, 2022@10:45
9999999.65;+25147,+25146,;2~WP-start~1
 Creation.
9999999.65;+25148,+25146,;.01~JUL 13, 2022@07:37:26
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25147^1
25148^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NO PROG AFTER INTER OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25145</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>154798586</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25145,;.01~VA-ONC KID STAGE IV NO PROG AFTER INTER OFF PATH TX
9999999.64;+25145,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25145,;.08~YES
9999999.64;+25145,;.1~FACTOR
9999999.64;+25145,;100~NATIONAL
9999999.64;+25145,;101~VHA ONCOLOGY
9999999.64;+25145,;200~Kidney CA-Stage IV No Progress After Inter Off Path Treatment
9999999.64;+25145,;201~WP-start~3
Kidney Cancer-Stage IV candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) with no persistent disease; 
off pathway treatment
9999999.65;+25146,+25145,;.01~JUL 11, 2022@10:44:15
9999999.65;+25146,+25145,;2~WP-start~1
 Creation.
9999999.65;+25147,+25145,;.01~JUL 13, 2022@07:37:45
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25146^1
25147^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NO PROG AFTER INTER CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25143</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1666393078</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25143,;.01~VA-ONC KID STAGE IV NO PROG AFTER INTER CLINICAL TRIAL
9999999.64;+25143,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25143,;.08~YES
9999999.64;+25143,;.1~FACTOR
9999999.64;+25143,;100~NATIONAL
9999999.64;+25143,;101~VHA ONCOLOGY
9999999.64;+25143,;200~Kidney CA-Stage IV No Progress After Inter Clinical Trial
9999999.64;+25143,;201~WP-start~3
Kidney Cancer-Stage IV candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) with no persistent disease; 
on pathway clinical trial
9999999.65;+25144,+25143,;.01~JUL 11, 2022@10:42:50
9999999.65;+25144,+25143,;2~WP-start~1
 Creation.
9999999.65;+25145,+25143,;.01~JUL 13, 2022@07:37:02
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25144^1
25145^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER FAVOR OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25139</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>589051654</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25139,;.01~VA-ONC KID STAGE IV PROG AFTER INTER FAVOR OFF PATH RSN
9999999.64;+25139,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25139,;.08~YES
9999999.64;+25139,;.1~FACTOR
9999999.64;+25139,;100~NATIONAL
9999999.64;+25139,;101~VHA ONCOLOGY
9999999.64;+25139,;200~Kidney CA-Stage IV Prog After Inter Favor Risk Off Path Rsn
9999999.64;+25139,;201~WP-start~3
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be a favorable 
risk group; off pathway reason
9999999.65;+25140,+25139,;.01~JUL 11, 2022@10:32:48
9999999.65;+25140,+25139,;2~WP-start~1
 Creation.
9999999.65;+25141,+25139,;.01~JUL 13, 2022@07:43:33
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25140^1
25141^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER FAVOR OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25138</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3666985113</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25138,;.01~VA-ONC KID STAGE IV PROG AFTER INTER FAVOR OFF PATH TX
9999999.64;+25138,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25138,;.08~YES
9999999.64;+25138,;.1~FACTOR
9999999.64;+25138,;100~NATIONAL
9999999.64;+25138,;101~VHA ONCOLOGY
9999999.64;+25138,;200~Kidney CA-Stage IV Prog After Inter Favor Risk Off Path Tx
9999999.64;+25138,;201~WP-start~3
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be a favorable 
risk group; off pathway treatment
9999999.65;+25139,+25138,;.01~JUL 11, 2022@10:32:13
9999999.65;+25139,+25138,;2~WP-start~1
 Creation.
9999999.65;+25140,+25138,;.01~JUL 13, 2022@07:43:59
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25139^1
25140^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER FAVOR PEMBRO+AXIT</POINT_01>
<INTERNAL_ENTRY_NUMBER>25156</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4024009455</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25156,;.01~VA-ONC KID STAGE IV PROG AFTER INTER FAVOR PEMBRO+AXIT
9999999.64;+25156,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25156,;.08~YES
9999999.64;+25156,;.1~FACTOR
9999999.64;+25156,;100~NATIONAL
9999999.64;+25156,;101~VHA ONCOLOGY
9999999.64;+25156,;200~Kidney CA-Stage IV Prog After Inter Favor Risk Pembro+Axit
9999999.64;+25156,;201~WP-start~3
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be a favorable 
risk group; on pathway pembrolizubam and axitinib
9999999.65;+25157,+25156,;.01~JUL 13, 2022@07:32:53
9999999.65;+25157,+25156,;2~WP-start~1
 Creation.
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25157^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER FAVOR CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25136</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>842589825</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25136,;.01~VA-ONC KID STAGE IV PROG AFTER INTER FAVOR CLINICAL TRIAL
9999999.64;+25136,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25136,;.08~YES
9999999.64;+25136,;.1~FACTOR
9999999.64;+25136,;100~NATIONAL
9999999.64;+25136,;101~VHA ONCOLOGY
9999999.64;+25136,;200~Kidney CA-Stage IV Prog After Inter Favor Risk Clinical Trial
9999999.64;+25136,;201~WP-start~3
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be a favorable 
risk group; on pathway clinical trial
9999999.65;+25137,+25136,;.01~JUL 11, 2022@10:30:43
9999999.65;+25137,+25136,;2~WP-start~1
 Creation.
9999999.65;+25138,+25136,;.01~JUL 13, 2022@07:43:08
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25137^1
25138^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39639</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>853875828</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39639,;.01~VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX OFF PATH RSN
9999999.64;+39639,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39639,;.08~YES
9999999.64;+39639,;.1~FACTOR
9999999.64;+39639,;100~NATIONAL
9999999.64;+39639,;101~VHA ONCOLOGY
9999999.64;+39639,;200~Kidney CA-Stage IV Prog After Inter No Threat/Sx, Off Path RSN
9999999.64;+39639,;201~WP-start~4
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an
intermediate or poor risk group, with no life threatening or symptomatic
tumor; off pathway reason
9999999.65;+39640,+39639,;.01~FEB 24, 2025@08:38:48
9999999.65;+39640,+39639,;2~WP-start~1
Copied from VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX OFF PATH TX
9999999.65;+39641,+39639,;.01~FEB 24, 2025@08:39:53
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39640^1
39641^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39638</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1449902724</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39638,;.01~VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX OFF PATH TX
9999999.64;+39638,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39638,;.08~YES
9999999.64;+39638,;.1~FACTOR
9999999.64;+39638,;100~NATIONAL
9999999.64;+39638,;101~VHA ONCOLOGY
9999999.64;+39638,;200~Kidney CA-Stage IV Prog After Inter No Threat/Sx, Off Path TX
9999999.64;+39638,;201~WP-start~4
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an
intermediate or poor risk group, with no life threatening or symptomatic
tumor; off pathway treatment 
9999999.65;+39639,+39638,;.01~FEB 24, 2025@08:35:28
9999999.65;+39639,+39638,;2~WP-start~1
Copied from VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX CLIN TRIAL
9999999.65;+39640,+39638,;.01~FEB 24, 2025@08:37:09
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39639^1
39640^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX IPI+NIVO</POINT_01>
<INTERNAL_ENTRY_NUMBER>39637</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3804477929</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39637,;.01~VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX IPI+NIVO
9999999.64;+39637,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39637,;.08~YES
9999999.64;+39637,;.1~FACTOR
9999999.64;+39637,;100~NATIONAL
9999999.64;+39637,;101~VHA ONCOLOGY
9999999.64;+39637,;200~Kidney CA-Stage IV Prog After Inter No Threat/Sx, IPI+Nivo
9999999.64;+39637,;201~WP-start~4
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an
intermediate or poor risk group, with no life threatening or symptomatic
tumor; on pathway ipilimumab and nivolumab
9999999.65;+39638,+39637,;.01~FEB 24, 2025@08:20:14
9999999.65;+39638,+39637,;2~WP-start~1
Copied from VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX CLIN TRIAL
9999999.65;+39639,+39637,;.01~FEB 24, 2025@08:28:53
9999999.65;+39640,+39637,;.01~FEB 24, 2025@08:38:06
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39638^1
39639^2
39640^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>39636</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>848325850</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39636,;.01~VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX CLIN TRIAL
9999999.64;+39636,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39636,;.08~YES
9999999.64;+39636,;.1~FACTOR
9999999.64;+39636,;100~NATIONAL
9999999.64;+39636,;101~VHA ONCOLOGY
9999999.64;+39636,;200~Kidney CA-Stage IV Prog After Inter No Threat/Sx, Clin Trial
9999999.64;+39636,;201~WP-start~4
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an
intermediate or poor risk group, with no life threatening or symptomatic
tumor; on pathway clinical trial
9999999.65;+39637,+39636,;.01~FEB 24, 2025@08:17:15
9999999.65;+39637,+39636,;2~WP-start~1
Copied from VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX CLIN TRIAL
9999999.65;+39638,+39636,;.01~FEB 24, 2025@08:19:49
9999999.65;+39639,+39636,;.01~FEB 24, 2025@08:31:04
9999999.65;+39640,+39636,;.01~FEB 24, 2025@08:37:40
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39637^1
39638^2
39639^3
39640^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>39543</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2361943108</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39543,;.01~VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX OFF PATH RSN
9999999.64;+39543,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39543,;.08~YES
9999999.64;+39543,;.1~FACTOR
9999999.64;+39543,;100~NATIONAL
9999999.64;+39543,;101~VHA ONCOLOGY
9999999.64;+39543,;200~Kidney CA-Stage IV Prog After Inter Threat/Sx, Off Path RSN
9999999.64;+39543,;201~WP-start~4
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an
intermediate or poor risk group, with life threatening or symptomatic
tumor; off pathway reason
9999999.65;+39544,+39543,;.01~FEB 12, 2025@12:10:57
9999999.65;+39544,+39543,;2~WP-start~1
Copied from VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX OFF PATH TX
9999999.65;+39545,+39543,;.01~FEB 12, 2025@12:11:41
9999999.65;+39546,+39543,;.01~FEB 24, 2025@08:33:19
9999999.65;+39547,+39543,;.01~FEB 24, 2025@08:42:17
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39544^1
39545^2
39546^3
39547^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>39541</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2973882481</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39541,;.01~VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX OFF PATH TX
9999999.64;+39541,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39541,;.08~YES
9999999.64;+39541,;.1~FACTOR
9999999.64;+39541,;100~NATIONAL
9999999.64;+39541,;101~VHA ONCOLOGY
9999999.64;+39541,;200~Kidney CA-Stage IV Prog After Inter Threat/Sx, Off Path TX
9999999.64;+39541,;201~WP-start~4
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an
intermediate or poor risk group, with life threatening or symptomatic
tumor; off pathway treatment
9999999.65;+39542,+39541,;.01~FEB 12, 2025@12:07:45
9999999.65;+39542,+39541,;2~WP-start~1
Copied from VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX CLIN TRIAL
9999999.65;+39543,+39541,;.01~FEB 12, 2025@12:08:50
9999999.65;+39544,+39541,;.01~FEB 24, 2025@08:33:58
9999999.65;+39545,+39541,;.01~FEB 24, 2025@08:43:16
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39542^1
39543^2
39544^3
39545^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX PEMB+AXIT</POINT_01>
<INTERNAL_ENTRY_NUMBER>39540</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3670669771</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39540,;.01~VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX PEMB+AXIT
9999999.64;+39540,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39540,;.08~YES
9999999.64;+39540,;.1~FACTOR
9999999.64;+39540,;100~NATIONAL
9999999.64;+39540,;101~VHA ONCOLOGY
9999999.64;+39540,;200~Kidney CA-Stage IV Prog After Inter Threat/Sx, Pembro+Axit
9999999.64;+39540,;201~WP-start~4
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an
intermediate or poor risk group, with life threatening or symptomatic
tumor; on pathway pembrolizumab and axitinib
9999999.65;+39541,+39540,;.01~FEB 12, 2025@12:06:06
9999999.65;+39541,+39540,;2~WP-start~1
Copied from VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX CLIN TRIAL
9999999.65;+39542,+39540,;.01~FEB 12, 2025@12:07:24
9999999.65;+39543,+39540,;.01~FEB 24, 2025@08:34:57
9999999.65;+39544,+39540,;.01~FEB 24, 2025@08:43:47
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39541^1
39542^2
39543^3
39544^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>39539</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3831916510</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+39539,;.01~VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX CLIN TRIAL
9999999.64;+39539,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+39539,;.08~YES
9999999.64;+39539,;.1~FACTOR
9999999.64;+39539,;100~NATIONAL
9999999.64;+39539,;101~VHA ONCOLOGY
9999999.64;+39539,;200~Kidney CA-Stage IV Prog After Inter Threat/Sx, Clin Trial
9999999.64;+39539,;201~WP-start~4
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an
intermediate or poor risk group, with life threatening or symptomatic
tumor; on pathway clinical trial
9999999.65;+39540,+39539,;.01~FEB 12, 2025@12:04:17
9999999.65;+39540,+39539,;2~WP-start~1
Copied from VA-ONC KID STAGE IV PROG AFTER INTER IN/POOR CLINICAL TRIAL
9999999.65;+39541,+39539,;.01~FEB 12, 2025@12:05:42
9999999.65;+39542,+39539,;.01~FEB 12, 2025@12:09:08
9999999.65;+39543,+39539,;.01~FEB 24, 2025@08:32:25
9999999.65;+39544,+39539,;.01~FEB 24, 2025@08:41:38
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
39540^1
39541^2
39542^3
39543^4
39544^5
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV CAND INTER METASTASIS DIRECTED TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25125</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1720387078</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25125,;.01~VA-ONC KID STAGE IV CAND INTER METASTASIS DIRECTED TX
9999999.64;+25125,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25125,;.08~YES
9999999.64;+25125,;.1~FACTOR
9999999.64;+25125,;100~NATIONAL
9999999.64;+25125,;101~VHA ONCOLOGY
9999999.64;+25125,;200~Kidney CA-Stage IV Cand Inter Metatstasis Directed Therapy
9999999.64;+25125,;201~WP-start~3
Kidney Cancer-Stage IV candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy); on pathway metastasis 
directed therapy
9999999.65;+25126,+25125,;.01~JUL 11, 2022@10:10:33
9999999.65;+25126,+25125,;2~WP-start~1
 Creation.
9999999.65;+25127,+25125,;.01~JUL 11, 2022@10:11:23
9999999.65;+25128,+25125,;.01~JUL 13, 2022@08:18:08
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25126^1
25127^2
25128^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV CAND INTER CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25123</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4090230648</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25123,;.01~VA-ONC KID STAGE IV CAND INTER CLINICAL TRIAL
9999999.64;+25123,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25123,;.08~YES
9999999.64;+25123,;.1~FACTOR
9999999.64;+25123,;100~NATIONAL
9999999.64;+25123,;101~VHA ONCOLOGY
9999999.64;+25123,;200~Kidney CA-Stage IV Cand Inter Clinical Trial
9999999.64;+25123,;201~WP-start~2
Kidney Cancer-Stage IV candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy); on pathway clinical trial
9999999.65;+25124,+25123,;.01~JUL 11, 2022@10:07:56
9999999.65;+25124,+25123,;2~WP-start~1
 Creation.
9999999.65;+25125,+25123,;.01~JUL 13, 2022@08:16
9999999.65;+25126,+25123,;.01~JUL 13, 2022@08:17:28
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25124^1
25125^2
25126^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV CAND INTER OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25127</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>124126081</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25127,;.01~VA-ONC KID STAGE IV CAND INTER OFF PATH RSN
9999999.64;+25127,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25127,;.08~YES
9999999.64;+25127,;.1~FACTOR
9999999.64;+25127,;100~NATIONAL
9999999.64;+25127,;101~VHA ONCOLOGY
9999999.64;+25127,;200~Kidney CA-Stage IV Cand Inter Off Path Reason
9999999.64;+25127,;201~WP-start~2
Kidney Cancer-Stage IV candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy); off pathway reason
9999999.65;+25128,+25127,;.01~JUL 11, 2022@10:12:32
9999999.65;+25128,+25127,;2~WP-start~1
 Creation.
9999999.65;+25129,+25127,;.01~JUL 13, 2022@08:18:27
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25128^1
25129^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV CAND INTER OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25126</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>996972783</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25126,;.01~VA-ONC KID STAGE IV CAND INTER OFF PATH TX
9999999.64;+25126,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25126,;.08~YES
9999999.64;+25126,;.1~FACTOR
9999999.64;+25126,;100~NATIONAL
9999999.64;+25126,;101~VHA ONCOLOGY
9999999.64;+25126,;200~Kidney CA-Stage IV Cand Inter Off Path Treatment
9999999.64;+25126,;201~WP-start~2
Kidney Cancer-Stage IV candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy); off pathway treatment
9999999.65;+25127,+25126,;.01~JUL 11, 2022@10:11:57
9999999.65;+25127,+25126,;2~WP-start~1
 Creation.
9999999.65;+25128,+25126,;.01~JUL 13, 2022@08:18:43
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25127^1
25128^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV CAND INTER CYTO NEPHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>25124</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2765098310</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25124,;.01~VA-ONC KID STAGE IV CAND INTER CYTO NEPHRECTOMY
9999999.64;+25124,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25124,;.08~YES
9999999.64;+25124,;.1~FACTOR
9999999.64;+25124,;100~NATIONAL
9999999.64;+25124,;101~VHA ONCOLOGY
9999999.64;+25124,;200~Kidney CA-Stage IV Cand Inter Cytoreductive Nephrectomy
9999999.64;+25124,;201~WP-start~3
Kidney Cancer-Stage IV candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy); on pathway cytoreductive 
nephrectomy
9999999.65;+25125,+25124,;.01~JUL 11, 2022@10:09:16
9999999.65;+25125,+25124,;2~WP-start~1
 Creation.
9999999.65;+25126,+25124,;.01~JUL 13, 2022@08:17:13
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25125^1
25126^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV CLINICAL PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>25039</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>862091674</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25039,;.01~VA-ONC KID STAGE IV CLINICAL PATHWAY
9999999.64;+25039,;.03~VA-ONCOLOGY PATHWAYS [C]
9999999.64;+25039,;.08~YES
9999999.64;+25039,;.1~FACTOR
9999999.64;+25039,;100~NATIONAL
9999999.64;+25039,;101~VHA ONCOLOGY
9999999.64;+25039,;200~Kidney Cancer-Stage IV Clinical Pathway
9999999.64;+25039,;201~WP-start~1
Designates that the Kidney Cancer Stage IV Clinical Pathway was opened.
9999999.65;+25040,+25039,;.01~JUN 17, 2022@08:57:27
9999999.65;+25040,+25039,;2~WP-start~1
 Creation.
9999999.65;+25041,+25039,;.01~JUN 21, 2022@07:39:26
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25040^1
25041^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III CLINICAL PATHWAY [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>25010</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1613951794</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25010,;.01~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+25010,;.08~YES
9999999.64;+25010,;.1~CATEGORY
9999999.64;+25010,;100~NATIONAL
9999999.64;+25010,;101~VHA ONCOLOGY
9999999.64;+25010,;200~Kidney Cancer-Stage III Clinical Pathway
9999999.64;+25010,;201~WP-start~2
Category for all health factors in Kidney Cancer - Stage III Clinical 
Pathway
9999999.65;+25011,+25010,;.01~JUN 17, 2022@06:52:02
9999999.65;+25011,+25010,;2~WP-start~1
 Creation.
9999999.65;+25012,+25010,;.01~JUN 21, 2022@07:38:02
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25011^1
25012^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III S/P SURG PEM NO OFF PTH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>45798</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>413432164</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45798,;.01~VA-ONC KID STAGE III S/P SURG PEM NO OFF PTH TX
9999999.64;+45798,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+45798,;.08~YES
9999999.64;+45798,;.1~FACTOR
9999999.64;+45798,;100~NATIONAL
9999999.64;+45798,;101~VHA ONCOLOGY
9999999.64;+45798,;200~Kidney CA-Stage III S/P Surgery Pembro No Off Path TX
9999999.64;+45798,;201~WP-start~2
Kidney Cancer-Stage III after radical nephrectomy, not a candidate for 
adjuvant pembrolizumab; off pathway treatment
9999999.65;+45799,+45798,;.01~FEB 27, 2026@12:41:56
9999999.65;+45799,+45798,;2~WP-start~1
Copied from VA-ONC KID STAGE III S/P SURG PEM NO CLIN TRIAL
9999999.65;+45800,+45798,;.01~FEB 27, 2026@12:42:30
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45799^1
45800^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III S/P SURG PEM NO OFF PTH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>45799</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2675737805</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45799,;.01~VA-ONC KID STAGE III S/P SURG PEM NO OFF PTH RSN
9999999.64;+45799,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+45799,;.08~YES
9999999.64;+45799,;.1~FACTOR
9999999.64;+45799,;100~NATIONAL
9999999.64;+45799,;101~VHA ONCOLOGY
9999999.64;+45799,;200~Kidney CA-Stage III S/P Surgery Pembro No Off Path RSN
9999999.64;+45799,;201~WP-start~2
Kidney Cancer-Stage III after radical nephrectomy, not a candidate for 
adjuvant pembrolizumab; off pathway reason
9999999.65;+45800,+45799,;.01~FEB 27, 2026@12:42:48
9999999.65;+45800,+45799,;2~WP-start~1
Copied from VA-ONC KID STAGE III S/P SURG PEM NO OFF PTH TX
9999999.65;+45801,+45799,;.01~FEB 27, 2026@12:43:43
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45800^1
45801^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III S/P SURG PEM NO SURVEILLANCE</POINT_01>
<INTERNAL_ENTRY_NUMBER>45797</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3724847817</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45797,;.01~VA-ONC KID STAGE III S/P SURG PEM NO SURVEILLANCE
9999999.64;+45797,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+45797,;.08~YES
9999999.64;+45797,;.1~FACTOR
9999999.64;+45797,;100~NATIONAL
9999999.64;+45797,;101~VHA ONCOLOGY
9999999.64;+45797,;200~Kidney CA-Stage III S/P Surgery Pembro No Active Surveillance
9999999.64;+45797,;201~WP-start~7
Kidney Cancer-Stage III after radical nephrectomy, not an adjuvant
pembroluzimab candidate; on pathway active surveillance Follow up every
3-6 months for 3 Years, then annually for 2 years: 
       -history and physical
       -comprehensive metabolic panel 
       -abdominal CT/MRI with contrast
       -chest x-ray/CT
9999999.65;+45798,+45797,;.01~FEB 27, 2026@12:38:37
9999999.65;+45798,+45797,;2~WP-start~1
Copied from VA-ONC KID STAGE III S/P SURG ADJ PEMB SURVEILLANCE
9999999.65;+45799,+45797,;.01~FEB 27, 2026@12:41:42
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45798^1
45799^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III S/P SURG PEM NO CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>45796</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1133382277</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45796,;.01~VA-ONC KID STAGE III S/P SURG PEM NO CLIN TRIAL
9999999.64;+45796,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+45796,;.08~YES
9999999.64;+45796,;.1~FACTOR
9999999.64;+45796,;100~NATIONAL
9999999.64;+45796,;101~VHA ONCOLOGY
9999999.64;+45796,;200~Kidney CA-Stage III S/P Surgery Pembro No Clin Trial
9999999.64;+45796,;201~WP-start~2
Kidney Cancer-Stage III after radical nephrectomy, not a candidate for 
adjuvant pembrolizumab; on pathway clinical trial
9999999.65;+45797,+45796,;.01~FEB 27, 2026@12:36:19
9999999.65;+45797,+45796,;2~WP-start~1
Copied from VA-ONC KID STAGE III S/P SURG ADJ PEMBRO W SURV
9999999.65;+45798,+45796,;.01~FEB 27, 2026@12:37:55
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45797^1
45798^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III S/P SURG OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25019</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3645721918</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25019,;.01~VA-ONC KID STAGE III S/P SURG OFF PATH RSN
9999999.64;+25019,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+25019,;.08~YES
9999999.64;+25019,;.1~FACTOR
9999999.64;+25019,;100~NATIONAL
9999999.64;+25019,;101~VHA ONCOLOGY
9999999.64;+25019,;200~Kidney CA-Stage III S/P Surgery Off Pathway Reason
9999999.64;+25019,;201~WP-start~1
Kidney Cancer - Stage III after radical nephrectomy; off pathway reason
9999999.65;+25020,+25019,;.01~JUN 17, 2022@07:08:11
9999999.65;+25020,+25019,;2~WP-start~1
 Creation.
9999999.65;+25021,+25019,;.01~JUN 21, 2022@07:36:34
9999999.65;+25022,+25019,;.01~JUL 13, 2022@09:12:18
9999999.65;+25023,+25019,;.01~AUG 25, 2022@06:36:28
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25020^1
25021^2
25022^3
25023^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III S/P SURG OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25018</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2552974853</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25018,;.01~VA-ONC KID STAGE III S/P SURG OFF PATH TX
9999999.64;+25018,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+25018,;.08~YES
9999999.64;+25018,;.1~FACTOR
9999999.64;+25018,;100~NATIONAL
9999999.64;+25018,;101~VHA ONCOLOGY
9999999.64;+25018,;200~Kidney CA-Stage III S/P Surgery Off Pathway Treatment
9999999.64;+25018,;201~WP-start~1
Kidney Cancer - Stage III after radical nephrectomy; off pathway treatment
9999999.65;+25019,+25018,;.01~JUN 17, 2022@07:07:36
9999999.65;+25019,+25018,;2~WP-start~1
 Creation.
9999999.65;+25020,+25018,;.01~JUN 21, 2022@07:23:56
9999999.65;+25021,+25018,;.01~JUL 13, 2022@09:12:30
9999999.65;+25022,+25018,;.01~AUG 25, 2022@06:37:42
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25019^1
25020^2
25021^3
25022^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III S/P SURG ADJ PEMB SURVEILLANCE</POINT_01>
<INTERNAL_ENTRY_NUMBER>45232</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1915523739</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45232,;.01~VA-ONC KID STAGE III S/P SURG ADJ PEMB SURVEILLANCE
9999999.64;+45232,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+45232,;.08~YES
9999999.64;+45232,;.1~FACTOR
9999999.64;+45232,;100~NATIONAL
9999999.64;+45232,;101~VHA ONCOLOGY
9999999.64;+45232,;200~Kidney CA-Stage III S/P Surgery Adjuvant Pembro Surveillance
9999999.64;+45232,;201~WP-start~7
Kidney Cancer-Stage III after radical nephrectomy, adjuvant pembroluzimab 
candidate; on pathway active surveillance
Follow up every 3-6 months for 3 Years, then annually for 2 years: 
       -history and physical
       -comprehensive metabolic panel 
       -abdominal CT/MRI with contrast
       -chest x-ray/CT
9999999.65;+45233,+45232,;.01~NOV 20, 2025@11:06:32
9999999.65;+45233,+45232,;2~WP-start~1
Copied from VA-ONC KID STAGE III S/P SURG ADJ PEMBRO W SURV
9999999.65;+45234,+45232,;.01~NOV 20, 2025@11:07:49
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45233^1
45234^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III S/P SURG ADJ PEMBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>45231</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3225547129</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45231,;.01~VA-ONC KID STAGE III S/P SURG ADJ PEMBRO
9999999.64;+45231,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+45231,;.08~YES
9999999.64;+45231,;.1~FACTOR
9999999.64;+45231,;.11~INACTIVE
9999999.64;+45231,;100~NATIONAL
9999999.64;+45231,;101~VHA ONCOLOGY
9999999.64;+45231,;200~Kidney CA-Stage III S/P Surgery Adjuvant Pembro 
9999999.64;+45231,;201~WP-start~2
Kidney Cancer - Stage III after radical nephrectomy; on pathway adjuvant 
pembrolizumab for one year.
9999999.65;+45232,+45231,;.01~NOV 20, 2025@10:58:35
9999999.65;+45232,+45231,;2~WP-start~1
Copied from VA-ONC KID STAGE III S/P SURG ADJ PEMBRO W SURV
9999999.65;+45233,+45231,;.01~NOV 20, 2025@11:06:08
9999999.65;+45234,+45231,;.01~FEB 27, 2026@12:34:17
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45232^1
45233^2
45234^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III S/P SURG CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25016</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>108613943</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25016,;.01~VA-ONC KID STAGE III S/P SURG CLINICAL TRIAL
9999999.64;+25016,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+25016,;.08~YES
9999999.64;+25016,;.1~FACTOR
9999999.64;+25016,;100~NATIONAL
9999999.64;+25016,;101~VHA ONCOLOGY
9999999.64;+25016,;200~Kidney CA-Stage III S/P Surgery Clinical Trial
9999999.64;+25016,;201~WP-start~2
Kidney Cancer - Stage III after radical nephrectomy, on pathway
clinical trial
9999999.65;+25017,+25016,;.01~JUN 17, 2022@07:05:59
9999999.65;+25017,+25016,;2~WP-start~1
 Creation.
9999999.65;+25018,+25016,;.01~JUN 21, 2022@07:36:06
9999999.65;+25019,+25016,;.01~JUL 13, 2022@09:12
9999999.65;+25020,+25016,;.01~AUG 25, 2022@06:34:26
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25017^1
25018^2
25019^3
25020^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III SURG CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25012</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3804028740</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25012,;.01~VA-ONC KID STAGE III SURG CLINICAL TRIAL
9999999.64;+25012,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+25012,;.08~YES
9999999.64;+25012,;.1~FACTOR
9999999.64;+25012,;100~NATIONAL
9999999.64;+25012,;101~VHA ONCOLOGY
9999999.64;+25012,;200~Kidney CA-Stage III Surgery Clinical Trial
9999999.64;+25012,;201~WP-start~1
Kidney Cancer - Stage III surgery; on pathway clinical trial
9999999.65;+25013,+25012,;.01~JUN 17, 2022@06:53:48
9999999.65;+25013,+25012,;2~WP-start~1
 Creation.
9999999.65;+25014,+25012,;.01~JUN 21, 2022@07:38:25
9999999.65;+25015,+25012,;.01~JUL 13, 2022@09:13:42
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25013^1
25014^2
25015^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III SURG OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25015</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3010115716</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25015,;.01~VA-ONC KID STAGE III SURG OFF PATH RSN
9999999.64;+25015,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+25015,;.08~YES
9999999.64;+25015,;.1~FACTOR
9999999.64;+25015,;100~NATIONAL
9999999.64;+25015,;101~VHA ONCOLOGY
9999999.64;+25015,;200~Kidney CA-Stage III Surgery Off Pathway Reason
9999999.64;+25015,;201~WP-start~1
Kidney Cancer - Stage III surgery; off pathway reason
9999999.65;+25016,+25015,;.01~JUN 17, 2022@07:04:25
9999999.65;+25016,+25015,;2~WP-start~1
 Creation.
9999999.65;+25017,+25015,;.01~JUN 21, 2022@07:38:38
9999999.65;+25018,+25015,;.01~JUL 13, 2022@09:14:05
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25016^1
25017^2
25018^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III SURG OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25014</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2273484813</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25014,;.01~VA-ONC KID STAGE III SURG OFF PATH TX
9999999.64;+25014,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+25014,;.08~YES
9999999.64;+25014,;.1~FACTOR
9999999.64;+25014,;100~NATIONAL
9999999.64;+25014,;101~VHA ONCOLOGY
9999999.64;+25014,;200~Kidney CA-Stage III Surgery Off Pathway Treatment
9999999.64;+25014,;201~WP-start~1
Kidney Cancer - Stage III surgery; off pathway treatment
9999999.65;+25015,+25014,;.01~JUN 17, 2022@07:03:38
9999999.65;+25015,+25014,;2~WP-start~1
 Creation.
9999999.65;+25016,+25014,;.01~JUN 21, 2022@07:38:49
9999999.65;+25017,+25014,;.01~JUL 13, 2022@09:14:20
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25015^1
25016^2
25017^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III SURG RADICAL NEPHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>25013</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1670318221</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25013,;.01~VA-ONC KID STAGE III SURG RADICAL NEPHRECTOMY
9999999.64;+25013,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+25013,;.08~YES
9999999.64;+25013,;.1~FACTOR
9999999.64;+25013,;100~NATIONAL
9999999.64;+25013,;101~VHA ONCOLOGY
9999999.64;+25013,;200~Kidney CA-Stage III Surgery Radical Nephrectomy
9999999.64;+25013,;201~WP-start~1
Kidney Cancer - Stage III surgery; on pathway radical nephrectomy
9999999.65;+25014,+25013,;.01~JUN 17, 2022@07:02:56
9999999.65;+25014,+25013,;2~WP-start~1
 Creation.
9999999.65;+25015,+25013,;.01~JUN 21, 2022@07:39:03
9999999.65;+25016,+25013,;.01~JUL 13, 2022@09:14:34
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25014^1
25015^2
25016^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III CLINICAL PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>25011</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3838019405</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25011,;.01~VA-ONC KID STAGE III CLINICAL PATHWAY
9999999.64;+25011,;.03~VA-ONCOLOGY PATHWAYS [C]
9999999.64;+25011,;.08~YES
9999999.64;+25011,;.1~FACTOR
9999999.64;+25011,;100~NATIONAL
9999999.64;+25011,;101~VHA ONCOLOGY
9999999.64;+25011,;200~Kidney Cancer-Stage III Clinical Pathway
9999999.64;+25011,;201~WP-start~1
Designates that the Kidney Cancer Stage III Clinical Pathway was opened.
9999999.65;+25012,+25011,;.01~JUN 17, 2022@06:52:52
9999999.65;+25012,+25011,;2~WP-start~1
 Creation.
9999999.65;+25013,+25011,;.01~JUN 21, 2022@07:37:48
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25012^1
25013^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II CLINICAL PATHWAY [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>25040</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3639059899</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25040,;.01~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25040,;.08~YES
9999999.64;+25040,;.1~CATEGORY
9999999.64;+25040,;100~NATIONAL
9999999.64;+25040,;101~VHA ONCOLOGY
9999999.64;+25040,;200~Kidney Cancer-Stage II Clinical Pathway
9999999.64;+25040,;201~WP-start~2
Category for all health factors in Kidney Cancer - Stage II Clinical 
Pathway
9999999.65;+25041,+25040,;.01~JUN 17, 2022@09:13:19
9999999.65;+25041,+25040,;2~WP-start~1
 Creation.
9999999.65;+25042,+25040,;.01~JUN 21, 2022@07:33:02
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25041^1
25042^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II SURGERY OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25046</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2663219326</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25046,;.01~VA-ONC KID STAGE II SURGERY OFF PATH RSN
9999999.64;+25046,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25046,;.08~YES
9999999.64;+25046,;.1~FACTOR
9999999.64;+25046,;100~NATIONAL
9999999.64;+25046,;101~VHA ONCOLOGY
9999999.64;+25046,;200~Kidney CA-Stage II Surgery Off Path Reason
9999999.64;+25046,;201~WP-start~1
Kidney Cancer - Stage II surgery; off pathway reason
9999999.65;+25047,+25046,;.01~JUN 17, 2022@09:17:51
9999999.65;+25047,+25046,;2~WP-start~1
 Creation.
9999999.65;+25048,+25046,;.01~JUN 21, 2022@07:35:10
9999999.65;+25049,+25046,;.01~JUL 13, 2022@08:49:33
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25047^1
25048^2
25049^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II SURGERY OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25045</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2377527697</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25045,;.01~VA-ONC KID STAGE II SURGERY OFF PATH TX
9999999.64;+25045,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25045,;.08~YES
9999999.64;+25045,;.1~FACTOR
9999999.64;+25045,;100~NATIONAL
9999999.64;+25045,;101~VHA ONCOLOGY
9999999.64;+25045,;200~Kidney CA-Stage II Surgery Off Path Treatment
9999999.64;+25045,;201~WP-start~1
Kidney Cancer - Stage II surgery; off pathway treatment
9999999.65;+25046,+25045,;.01~JUN 17, 2022@09:17:11
9999999.65;+25046,+25045,;2~WP-start~1
 Creation.
9999999.65;+25047,+25045,;.01~JUN 21, 2022@07:35:26
9999999.65;+25048,+25045,;.01~JUL 13, 2022@08:49:45
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25046^1
25047^2
25048^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II SURGERY RADICAL NEPHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>25044</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3428235149</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25044,;.01~VA-ONC KID STAGE II SURGERY RADICAL NEPHRECTOMY
9999999.64;+25044,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25044,;.08~YES
9999999.64;+25044,;.1~FACTOR
9999999.64;+25044,;100~NATIONAL
9999999.64;+25044,;101~VHA ONCOLOGY
9999999.64;+25044,;200~Kidney CA-Stage II Surgery Radical Nephrectomy
9999999.64;+25044,;201~WP-start~1
Kidney Cancer - Stage II surgery; on pathway radical nephrectomy
9999999.65;+25045,+25044,;.01~JUN 17, 2022@09:16:37
9999999.65;+25045,+25044,;2~WP-start~1
 Creation.
9999999.65;+25046,+25044,;.01~JUN 21, 2022@07:35:54
9999999.65;+25047,+25044,;.01~JUL 13, 2022@08:50:10
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25045^1
25046^2
25047^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II SURGERY PARTIAL NEPHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>25043</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>29945213</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25043,;.01~VA-ONC KID STAGE II SURGERY PARTIAL NEPHRECTOMY
9999999.64;+25043,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25043,;.08~YES
9999999.64;+25043,;.1~FACTOR
9999999.64;+25043,;100~NATIONAL
9999999.64;+25043,;101~VHA ONCOLOGY
9999999.64;+25043,;200~Kidney CA-Stage II Surgery Partial Nephrectomy
9999999.64;+25043,;201~WP-start~1
Kidney Cancer - Stage II surgery; on pathway partial nephrectomy
9999999.65;+25044,+25043,;.01~JUN 17, 2022@09:15:24
9999999.65;+25044,+25043,;2~WP-start~1
 Creation.
9999999.65;+25045,+25043,;.01~JUN 21, 2022@07:35:40
9999999.65;+25046,+25043,;.01~JUL 13, 2022@08:49:58
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25044^1
25045^2
25046^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II SURGERY CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25042</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2828469572</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25042,;.01~VA-ONC KID STAGE II SURGERY CLINICAL TRIAL
9999999.64;+25042,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25042,;.08~YES
9999999.64;+25042,;.1~FACTOR
9999999.64;+25042,;100~NATIONAL
9999999.64;+25042,;101~VHA ONCOLOGY
9999999.64;+25042,;200~Kidney CA-Stage II Surgery Clinical Trial
9999999.64;+25042,;201~WP-start~1
Kidney Cancer - Stage II surgery; on pathway clinical trial
9999999.65;+25043,+25042,;.01~JUN 17, 2022@09:14:43
9999999.65;+25043,+25042,;2~WP-start~1
 Creation.
9999999.65;+25044,+25042,;.01~JUN 21, 2022@07:34:55
9999999.65;+25045,+25042,;.01~JUL 13, 2022@08:49:18
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25043^1
25044^2
25045^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II NO ADJ PEMBRO SURVEILLANCE</POINT_01>
<INTERNAL_ENTRY_NUMBER>25052</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3285714615</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25052,;.01~VA-ONC KID STAGE II NO ADJ PEMBRO SURVEILLANCE
9999999.64;+25052,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25052,;.08~YES
9999999.64;+25052,;.1~FACTOR
9999999.64;+25052,;100~NATIONAL
9999999.64;+25052,;101~VHA ONCOLOGY
9999999.64;+25052,;200~Kidney CA-Stage II No Adjuvant Pembro Surveillance
9999999.64;+25052,;201~WP-start~7
Kidney Cancer - Stage II not a candidate for adjuvant pembrolizumab; on 
pathway surveillance;              
Follow up every 3-6 months for 3 Years, then annually for 2 years:
-history and physical
-comprehensive metabolic panel            
-abdominal CT/MRI with contrast           
-chest x-ray/CT
9999999.65;+25053,+25052,;.01~JUN 17, 2022@09:26:39
9999999.65;+25053,+25052,;2~WP-start~1
 Creation.
9999999.65;+25054,+25052,;.01~JUN 21, 2022@07:34:35
9999999.65;+25055,+25052,;.01~JUL 13, 2022@08:53:57
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25053^1
25054^2
25055^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II NO ADJ PEMBRO OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25054</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>924877369</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25054,;.01~VA-ONC KID STAGE II NO ADJ PEMBRO OFF PATH RSN
9999999.64;+25054,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25054,;.08~YES
9999999.64;+25054,;.1~FACTOR
9999999.64;+25054,;100~NATIONAL
9999999.64;+25054,;101~VHA ONCOLOGY
9999999.64;+25054,;200~Kidney CA-Stage II No Adjuvant Pembro Off Path Reason
9999999.64;+25054,;201~WP-start~2
Kidney Cancer - Stage II not a candidate for adjuvant pembrolizumab; off 
pathway reason
9999999.65;+25055,+25054,;.01~JUN 17, 2022@09:27:46
9999999.65;+25055,+25054,;2~WP-start~1
 Creation.
9999999.65;+25056,+25054,;.01~JUN 21, 2022@07:33:53
9999999.65;+25057,+25054,;.01~JUL 13, 2022@08:53:05
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25055^1
25056^2
25057^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II NO ADJ PEMBRO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25053</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2274613013</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25053,;.01~VA-ONC KID STAGE II NO ADJ PEMBRO OFF PATH TX
9999999.64;+25053,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25053,;.08~YES
9999999.64;+25053,;.1~FACTOR
9999999.64;+25053,;100~NATIONAL
9999999.64;+25053,;101~VHA ONCOLOGY
9999999.64;+25053,;200~Kidney CA-Stage II No Adjuvant Pembro Off Path Treatment
9999999.64;+25053,;201~WP-start~2
Kidney Cancer - Stage II not a candidate for adjuvant pembrolizumab; off 
pathway treatment
9999999.65;+25054,+25053,;.01~JUN 17, 2022@09:27:12
9999999.65;+25054,+25053,;2~WP-start~1
 Creation.
9999999.65;+25055,+25053,;.01~JUN 21, 2022@07:34:21
9999999.65;+25056,+25053,;.01~JUL 13, 2022@08:53:33
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25054^1
25055^2
25056^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II NO ADJ PEMBRO CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25051</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1155291329</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25051,;.01~VA-ONC KID STAGE II NO ADJ PEMBRO CLINICAL TRIAL
9999999.64;+25051,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25051,;.08~YES
9999999.64;+25051,;.1~FACTOR
9999999.64;+25051,;100~NATIONAL
9999999.64;+25051,;101~VHA ONCOLOGY
9999999.64;+25051,;200~Kidney CA-Stage II No Adjuvant Pembro Clinical Trial
9999999.64;+25051,;201~WP-start~2
Kidney Cancer - Stage II not a candidate for adjuvant pembrolizumab; on 
pathway clinical trial
9999999.65;+25052,+25051,;.01~JUN 17, 2022@09:24:51
9999999.65;+25052,+25051,;2~WP-start~1
 Creation.
9999999.65;+25053,+25051,;.01~JUN 21, 2022@07:33:31
9999999.65;+25054,+25051,;.01~JUL 13, 2022@08:52:31
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25052^1
25053^2
25054^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II ADJ PEMBRO SURVEILLANCE</POINT_01>
<INTERNAL_ENTRY_NUMBER>45230</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1984308059</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+45230,;.01~VA-ONC KID STAGE II ADJ PEMBRO SURVEILLANCE
9999999.64;+45230,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+45230,;.08~YES
9999999.64;+45230,;.1~FACTOR
9999999.64;+45230,;100~NATIONAL
9999999.64;+45230,;101~VHA ONCOLOGY
9999999.64;+45230,;200~Kidney CA-Stage II Adjuvant Pembro Surveillance
9999999.64;+45230,;201~WP-start~7
Kidney Cancer - Stage II candidate for adjuvant pembrolizumab; on 
pathway surveillance;              
Follow up every 3-6 months for 3 Years, then annually for 2 years:
-history and physical
-comprehensive metabolic panel            
-abdominal CT/MRI with contrast           
-chest x-ray/CT
9999999.65;+45231,+45230,;.01~NOV 20, 2025@10:49:57
9999999.65;+45231,+45230,;2~WP-start~1
Copied from VA-ONC KID STAGE II NO ADJ PEMBRO SURVEILLANCE
9999999.65;+45232,+45230,;.01~NOV 20, 2025@10:50:30
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45231^1
45232^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II CAND ADJ PEMBRO OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25050</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>966681870</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25050,;.01~VA-ONC KID STAGE II CAND ADJ PEMBRO OFF PATH RSN
9999999.64;+25050,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25050,;.08~YES
9999999.64;+25050,;.1~FACTOR
9999999.64;+25050,;100~NATIONAL
9999999.64;+25050,;101~VHA ONCOLOGY
9999999.64;+25050,;200~Kidney CA-Stage II Cand Adjuvant Pembro Off Path Reason
9999999.64;+25050,;201~WP-start~2
Kidney Cancer - Stage II candidate for adjuvant pembrolizumab; off 
pathway reason
9999999.65;+25051,+25050,;.01~JUN 17, 2022@09:20:32
9999999.65;+25051,+25050,;2~WP-start~1
 Creation.
9999999.65;+25052,+25050,;.01~JUN 21, 2022@07:32:14
9999999.65;+25053,+25050,;.01~JUL 13, 2022@08:52:07
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25051^1
25052^2
25053^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II CAND ADJ PEMBRO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25049</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>171174542</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25049,;.01~VA-ONC KID STAGE II CAND ADJ PEMBRO OFF PATH TX
9999999.64;+25049,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25049,;.08~YES
9999999.64;+25049,;.1~FACTOR
9999999.64;+25049,;100~NATIONAL
9999999.64;+25049,;101~VHA ONCOLOGY
9999999.64;+25049,;200~Kidney CA-Stage II Cand Adjuvant Pembro Off Path Treatment
9999999.64;+25049,;201~WP-start~2
Kidney Cancer - Stage II candidate for adjuvant pembrolizumab; off 
pathway treatment
9999999.65;+25050,+25049,;.01~JUN 17, 2022@09:19:42
9999999.65;+25050,+25049,;2~WP-start~1
 Creation.
9999999.65;+25051,+25049,;.01~JUN 21, 2022@07:32:32
9999999.65;+25052,+25049,;.01~JUL 13, 2022@08:51:35
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25050^1
25051^2
25052^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II CAND ADJ PEMBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>25048</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2522040567</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25048,;.01~VA-ONC KID STAGE II CAND ADJ PEMBRO
9999999.64;+25048,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25048,;.08~YES
9999999.64;+25048,;.1~FACTOR
9999999.64;+25048,;100~NATIONAL
9999999.64;+25048,;101~VHA ONCOLOGY
9999999.64;+25048,;200~Kidney CA-Stage II Cand Adjuvant Pembro
9999999.64;+25048,;201~WP-start~2
Kidney Cancer - Stage II candidate for adjuvant pembrolizumab; on pathway 
adjuvant pembrolizumab for 1 year.
9999999.65;+25049,+25048,;.01~JUN 17, 2022@09:18:55
9999999.65;+25049,+25048,;2~WP-start~1
 Creation.
9999999.65;+25050,+25048,;.01~JUN 21, 2022@07:30:45
9999999.65;+25051,+25048,;.01~JUN 21, 2022@07:31:56
9999999.65;+25052,+25048,;.01~JUL 13, 2022@08:50:54
9999999.65;+25053,+25048,;.01~JUL 13, 2022@08:51:51
9999999.65;+25054,+25048,;.01~NOV 20, 2025@10:45:45
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25049^1
25050^2
25051^3
25052^4
25053^5
25054^6
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II CAND ADJ PEMBRO CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25047</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2017339901</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25047,;.01~VA-ONC KID STAGE II CAND ADJ PEMBRO CLINICAL TRIAL
9999999.64;+25047,;.03~VA-ONC KID STAGE II CLINICAL PATHWAY [C]
9999999.64;+25047,;.08~YES
9999999.64;+25047,;.1~FACTOR
9999999.64;+25047,;100~NATIONAL
9999999.64;+25047,;101~VHA ONCOLOGY
9999999.64;+25047,;200~Kidney Ca-Stage II Cand Adjuvant Pembro Clinical Trial
9999999.64;+25047,;201~WP-start~2
Kidney Cancer - Stage II candidate for adjuvant pembrolizumab; on pathway 
clinical trial
9999999.65;+25048,+25047,;.01~JUN 17, 2022@09:18:23
9999999.65;+25048,+25047,;2~WP-start~1
 Creation.
9999999.65;+25049,+25047,;.01~JUN 21, 2022@07:31:36
9999999.65;+25050,+25047,;.01~JUL 13, 2022@09:05:12
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25048^1
25049^2
25050^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II CLINICAL PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>25041</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4090318433</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25041,;.01~VA-ONC KID STAGE II CLINICAL PATHWAY
9999999.64;+25041,;.03~VA-ONCOLOGY PATHWAYS [C]
9999999.64;+25041,;.08~YES
9999999.64;+25041,;.1~FACTOR
9999999.64;+25041,;100~NATIONAL
9999999.64;+25041,;101~VHA ONCOLOGY
9999999.64;+25041,;200~Kidney Cancer - Stage II Clinical Pathway
9999999.64;+25041,;201~WP-start~1
Designates that the Kidney Cancer Stage II Clinical Pathway was opened.
9999999.65;+25042,+25041,;.01~JUN 17, 2022@09:14:02
9999999.65;+25042,+25041,;2~WP-start~1
 Creation.
9999999.65;+25043,+25041,;.01~JUN 21, 2022@07:19:22
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25042^1
25043^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I CLINICAL PATHWAY [C]</POINT_01>
<INTERNAL_ENTRY_NUMBER>25021</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1666417896</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25021,;.01~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25021,;.08~YES
9999999.64;+25021,;.1~CATEGORY
9999999.64;+25021,;100~NATIONAL
9999999.64;+25021,;101~VHA ONCOLOGY
9999999.64;+25021,;200~Kidney Cancer-Stage I Clinical Pathway
9999999.64;+25021,;201~WP-start~2
Category for all health factors in Kidney Cancer - Stage I Clinical 
Pathway
9999999.65;+25022,+25021,;.01~JUN 17, 2022@07:12:56
9999999.65;+25022,+25021,;2~WP-start~1
 Creation.
9999999.65;+25023,+25021,;.01~JUN 21, 2022@07:40:08
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25022^1
25023^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1B ACTIVE SURVEILLANCE</POINT_01>
<INTERNAL_ENTRY_NUMBER>25034</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>886757430</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25034,;.01~VA-ONC KID STAGE I T1B ACTIVE SURVEILLANCE
9999999.64;+25034,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25034,;.08~YES
9999999.64;+25034,;.1~FACTOR
9999999.64;+25034,;100~NATIONAL
9999999.64;+25034,;101~VHA ONCOLOGY
9999999.64;+25034,;200~Kidney CA-Stage I T1b Active Surveillance
9999999.64;+25034,;201~WP-start~7
Kidney Cancer - Stage I T1b; on pathway active surveillance (if not 
surgical candidate or medical frail); 
Follow up annually for 5 years:
-history and physical
-comprehensive metabolic panel  
-chest x-ray/CT
-abdominal CT/MRI with contrast (within 1st 6 months, then annually)
9999999.65;+25035,+25034,;.01~JUN 17, 2022@07:23:43
9999999.65;+25035,+25034,;2~WP-start~1
 Creation.
9999999.65;+25036,+25034,;.01~JUN 21, 2022@07:28:31
9999999.65;+25037,+25034,;.01~JUL 13, 2022@08:22:37
9999999.65;+25038,+25034,;.01~AUG 25, 2022@07:01:21
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25035^1
25036^2
25037^3
25038^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1B ABLATIVE PROCEDURES W SURV</POINT_01>
<INTERNAL_ENTRY_NUMBER>25035</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>382376007</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25035,;.01~VA-ONC KID STAGE I T1B ABLATIVE PROCEDURES W SURV
9999999.64;+25035,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25035,;.08~YES
9999999.64;+25035,;.1~FACTOR
9999999.64;+25035,;100~NATIONAL
9999999.64;+25035,;101~VHA ONCOLOGY
9999999.64;+25035,;200~Kidney CA-Stage I T1b Ablative Procedures then Surveillance
9999999.64;+25035,;201~WP-start~6
Kidney Cancer - Stage I T1b; on pathway ablative procedures
Surveillance annually for 5 years:
-history and physical
-comprehensive metabolic panel
-chest x-ray/CT
-abdominal CT/MRI with contrast (within 1st 6 months, then annually)
9999999.65;+25036,+25035,;.01~JUN 17, 2022@07:24:12
9999999.65;+25036,+25035,;2~WP-start~1
 Creation.
9999999.65;+25037,+25035,;.01~JUN 21, 2022@07:28:15
9999999.65;+25038,+25035,;.01~JUL 13, 2022@08:22:25
9999999.65;+25039,+25035,;.01~AUG 25, 2022@06:58:51
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25036^1
25037^2
25038^3
25039^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1B RADICAL NEPHRECTOMY W SURV</POINT_01>
<INTERNAL_ENTRY_NUMBER>25033</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2577629799</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25033,;.01~VA-ONC KID STAGE I T1B RADICAL NEPHRECTOMY W SURV
9999999.64;+25033,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25033,;.08~YES
9999999.64;+25033,;.1~FACTOR
9999999.64;+25033,;100~NATIONAL
9999999.64;+25033,;101~VHA ONCOLOGY
9999999.64;+25033,;200~Kidney CA-Stage I T1b Radical Nephrectomy then Surveillance
9999999.64;+25033,;201~WP-start~6
Kidney Cancer - Stage I T1b; on pathway radical nephrectomy
Surveillance annually for 5 years:
-history and physical
-comprehensive metabolic panel
-chest x-ray/CT
-abdominal CT/MRI with contrast (within 1st 6 months, then annually)
9999999.65;+25034,+25033,;.01~JUN 17, 2022@07:22:09
9999999.65;+25034,+25033,;2~WP-start~1
 Creation.
9999999.65;+25035,+25033,;.01~JUN 21, 2022@07:29:41
9999999.65;+25036,+25033,;.01~JUL 13, 2022@08:23:43
9999999.65;+25037,+25033,;.01~AUG 25, 2022@07:00:37
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25034^1
25035^2
25036^3
25037^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1B OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25037</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2539496426</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25037,;.01~VA-ONC KID STAGE I T1B OFF PATH RSN
9999999.64;+25037,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25037,;.08~YES
9999999.64;+25037,;.1~FACTOR
9999999.64;+25037,;100~NATIONAL
9999999.64;+25037,;101~VHA ONCOLOGY
9999999.64;+25037,;200~Kidney CA-Stage I T1b Off Pathway Reason
9999999.64;+25037,;201~WP-start~1
Kidney Cancer - Stage I T1b; off pathway reason
9999999.65;+25038,+25037,;.01~JUN 17, 2022@07:25:11
9999999.65;+25038,+25037,;2~WP-start~1
 Creation.
9999999.65;+25039,+25037,;.01~JUN 21, 2022@07:29:07
9999999.65;+25040,+25037,;.01~JUL 13, 2022@08:23:06
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25038^1
25039^2
25040^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1B OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25036</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1135521591</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25036,;.01~VA-ONC KID STAGE I T1B OFF PATH TX
9999999.64;+25036,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25036,;.08~YES
9999999.64;+25036,;.1~FACTOR
9999999.64;+25036,;100~NATIONAL
9999999.64;+25036,;101~VHA ONCOLOGY
9999999.64;+25036,;200~Kidney CA-Stage I T1b Off Pathway Treatment
9999999.64;+25036,;201~WP-start~1
Kidney Cancer - Stage I T1b; off pathway treatment
9999999.65;+25037,+25036,;.01~JUN 17, 2022@07:24:42
9999999.65;+25037,+25036,;2~WP-start~1
 Creation.
9999999.65;+25038,+25036,;.01~JUN 21, 2022@07:29:26
9999999.65;+25039,+25036,;.01~JUL 13, 2022@08:23:18
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25037^1
25038^2
25039^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1B PARTIAL NEPHRECTOMY W SURV</POINT_01>
<INTERNAL_ENTRY_NUMBER>25032</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1678853999</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25032,;.01~VA-ONC KID STAGE I T1B PARTIAL NEPHRECTOMY W SURV
9999999.64;+25032,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25032,;.08~YES
9999999.64;+25032,;.1~FACTOR
9999999.64;+25032,;100~NATIONAL
9999999.64;+25032,;101~VHA ONCOLOGY
9999999.64;+25032,;200~Kidney CA-Stage I T1b Partial Nephrectomy then Surveillance
9999999.64;+25032,;201~WP-start~6
Kidney Cancer - Stage I T1b; on pathway partial nephrectomy
Surveillance annually for 5 years:
-history and physical
-comprehensive metabolic panel
-chest x-ray/CT
-abdominal CT/MRI with contrast (within 1st 6 months, then annually)
9999999.65;+25033,+25032,;.01~JUN 17, 2022@07:21:29
9999999.65;+25033,+25032,;2~WP-start~1
 Creation.
9999999.65;+25034,+25032,;.01~JUN 21, 2022@07:29:55
9999999.65;+25035,+25032,;.01~JUL 13, 2022@08:23:31
9999999.65;+25036,+25032,;.01~AUG 25, 2022@06:59:43
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25033^1
25034^2
25035^3
25036^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1B CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25031</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>728793305</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25031,;.01~VA-ONC KID STAGE I T1B CLINICAL TRIAL
9999999.64;+25031,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25031,;.08~YES
9999999.64;+25031,;.1~FACTOR
9999999.64;+25031,;100~NATIONAL
9999999.64;+25031,;101~VHA ONCOLOGY
9999999.64;+25031,;200~Kidney CA-Stage I T1b Clinical Trial
9999999.64;+25031,;201~WP-start~1
Kidney Cancer - Stage I T1b; on pathway clinical trial
9999999.65;+25032,+25031,;.01~JUN 17, 2022@07:20:49
9999999.65;+25032,+25031,;2~WP-start~1
 Creation.
9999999.65;+25033,+25031,;.01~JUN 21, 2022@07:28:51
9999999.65;+25034,+25031,;.01~JUL 13, 2022@08:22:52
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25032^1
25033^2
25034^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1A ACTIVE SURVEILLANCE</POINT_01>
<INTERNAL_ENTRY_NUMBER>25024</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3347643852</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25024,;.01~VA-ONC KID STAGE I T1A ACTIVE SURVEILLANCE
9999999.64;+25024,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25024,;.08~YES
9999999.64;+25024,;.1~FACTOR
9999999.64;+25024,;100~NATIONAL
9999999.64;+25024,;101~VHA ONCOLOGY
9999999.64;+25024,;200~Kidney Ca-Stage I T1a Active Surveillance
9999999.64;+25024,;201~WP-start~7
Kidney Cancer - Stage I T1a; on pathway active surveillance (preferred 
for renal masses less than or equal to 3 cm); 
Surveillance annually for 5 years:
-history and physical
-comprehensive metabolic panel
-chest x-ray/CT
-abdominal CT/MRI with contrast (within 1st 6 months, then annually)
9999999.65;+25025,+25024,;.01~JUN 17, 2022@07:16:04
9999999.65;+25025,+25024,;2~WP-start~1
 Creation.
9999999.65;+25026,+25024,;.01~JUN 21, 2022@07:25:56
9999999.65;+25027,+25024,;.01~JUL 13, 2022@08:20:20
9999999.65;+25028,+25024,;.01~AUG 25, 2022@06:55:09
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25025^1
25026^2
25027^3
25028^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1A RENAL BIOPSY W SURV</POINT_01>
<INTERNAL_ENTRY_NUMBER>25028</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>438969470</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25028,;.01~VA-ONC KID STAGE I T1A RENAL BIOPSY W SURV
9999999.64;+25028,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25028,;.08~YES
9999999.64;+25028,;.1~FACTOR
9999999.64;+25028,;100~NATIONAL
9999999.64;+25028,;101~VHA ONCOLOGY
9999999.64;+25028,;200~Kidney CA-Stage I T1a Renal Biopsy then Surveillance
9999999.64;+25028,;201~WP-start~6
Kidney Cancer - Stage I T1a; on pathway renal biopsy
Surveillance annually for 5 years:
-history and physical
-comprehensive metabolic panel
-chest x-ray/CT
-abdominal CT/MRI with contrast (within 1st 6 months, then annually)
9999999.65;+25029,+25028,;.01~JUN 17, 2022@07:18:48
9999999.65;+25029,+25028,;2~WP-start~1
 Creation.
9999999.65;+25030,+25028,;.01~JUN 21, 2022@07:27:54
9999999.65;+25031,+25028,;.01~JUL 13, 2022@08:22:13
9999999.65;+25032,+25028,;.01~AUG 25, 2022@06:57:47
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25029^1
25030^2
25031^3
25032^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1A ABLATIVE PROCEDURES W SURV</POINT_01>
<INTERNAL_ENTRY_NUMBER>25027</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1799949875</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25027,;.01~VA-ONC KID STAGE I T1A ABLATIVE PROCEDURES W SURV
9999999.64;+25027,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25027,;.08~YES
9999999.64;+25027,;.1~FACTOR
9999999.64;+25027,;100~NATIONAL
9999999.64;+25027,;101~VHA ONCOLOGY
9999999.64;+25027,;200~Kidney CA-Stage I T1a Ablative Procedures then Surveillance
9999999.64;+25027,;201~WP-start~7
Kidney Cancer - Stage I T1a; on pathway ablative procedures then 
surveillance
Surveillance annually for 5 years:
    -history and physical
    -comprehensive metabolic panel
    -chest x-ray/CT
    -abdominal CT/MRI with contrast (within 1st 6 months, then annually)
9999999.65;+25028,+25027,;.01~JUN 17, 2022@07:18:06
9999999.65;+25028,+25027,;2~WP-start~1
 Creation.
9999999.65;+25029,+25027,;.01~JUN 21, 2022@07:25:42
9999999.65;+25030,+25027,;.01~JUL 13, 2022@08:19:58
9999999.65;+25031,+25027,;.01~AUG 25, 2022@06:52:41
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25028^1
25029^2
25030^3
25031^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1A RADICAL NEPHRECTOMY W SURV</POINT_01>
<INTERNAL_ENTRY_NUMBER>25026</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>12892607</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25026,;.01~VA-ONC KID STAGE I T1A RADICAL NEPHRECTOMY W SURV
9999999.64;+25026,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25026,;.08~YES
9999999.64;+25026,;.1~FACTOR
9999999.64;+25026,;100~NATIONAL
9999999.64;+25026,;101~VHA ONCOLOGY
9999999.64;+25026,;200~Kidney CA-Stage I T1a Radical Nephrectomy then Surveillance
9999999.64;+25026,;201~WP-start~6
Kidney Cancer - Stage I T1a; on pathway radical nephrectomy
Surveillance annually for 5 years:
-history and physical
-comprehensive metabolic panel
-chest x-ray/CT
-abdominal CT/MRI with contrast (within 1st 6 months, then annually)
9999999.65;+25027,+25026,;.01~JUN 17, 2022@07:17:28
9999999.65;+25027,+25026,;2~WP-start~1
 Creation.
9999999.65;+25028,+25026,;.01~JUN 21, 2022@07:27:35
9999999.65;+25029,+25026,;.01~JUL 13, 2022@08:21:56
9999999.65;+25030,+25026,;.01~AUG 25, 2022@06:56:48
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25027^1
25028^2
25029^3
25030^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1A OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25030</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3622663351</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25030,;.01~VA-ONC KID STAGE I T1A OFF PATH RSN
9999999.64;+25030,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25030,;.08~YES
9999999.64;+25030,;.1~FACTOR
9999999.64;+25030,;100~NATIONAL
9999999.64;+25030,;101~VHA ONCOLOGY
9999999.64;+25030,;200~Kidney CA-Stage I T1a Off Pathway Reason
9999999.64;+25030,;201~WP-start~1
Kidney Cancer - Stage I T1a; off pathway reason
9999999.65;+25031,+25030,;.01~JUN 17, 2022@07:19:58
9999999.65;+25031,+25030,;2~WP-start~1
 Creation.
9999999.65;+25032,+25030,;.01~JUN 21, 2022@07:26:44
9999999.65;+25033,+25030,;.01~JUL 13, 2022@08:20:57
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25031^1
25032^2
25033^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1A OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25029</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3408552494</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25029,;.01~VA-ONC KID STAGE I T1A OFF PATH TX
9999999.64;+25029,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25029,;.08~YES
9999999.64;+25029,;.1~FACTOR
9999999.64;+25029,;100~NATIONAL
9999999.64;+25029,;101~VHA ONCOLOGY
9999999.64;+25029,;200~Kidney CA-Stage I T1a Off Pathway Treatment
9999999.64;+25029,;201~WP-start~1
Kidney Cancer - Stage I T1a; off pathway treatment
9999999.65;+25030,+25029,;.01~JUN 17, 2022@07:19:23
9999999.65;+25030,+25029,;2~WP-start~1
 Creation.
9999999.65;+25031,+25029,;.01~JUN 21, 2022@07:27:02
9999999.65;+25032,+25029,;.01~JUL 13, 2022@08:21:19
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25030^1
25031^2
25032^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1A PARTIAL NEPHRECTOMY W SURV</POINT_01>
<INTERNAL_ENTRY_NUMBER>25025</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1860456144</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25025,;.01~VA-ONC KID STAGE I T1A PARTIAL NEPHRECTOMY W SURV
9999999.64;+25025,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25025,;.08~YES
9999999.64;+25025,;.1~FACTOR
9999999.64;+25025,;100~NATIONAL
9999999.64;+25025,;101~VHA ONCOLOGY
9999999.64;+25025,;200~Kidney CA-Stage I T1a Partial Nephrectomy then Surveillance
9999999.64;+25025,;201~WP-start~7
Kidney Cancer - Stage I T1a; on pathway partial nephrectomy then 
surveillance
Surveillance annually for 5 years:
    -history and physical
    -comprehensive metabolic panel
    -chest x-ray/CT
    -abdominal CT/MRI with contrast (within 1st 6 months, then annually)
9999999.65;+25026,+25025,;.01~JUN 17, 2022@07:16:42
9999999.65;+25026,+25025,;2~WP-start~1
 Creation.
9999999.65;+25027,+25025,;.01~JUN 21, 2022@07:27:14
9999999.65;+25028,+25025,;.01~JUL 13, 2022@08:21:31
9999999.65;+25029,+25025,;.01~AUG 25, 2022@06:53:51
9999999.65;+25030,+25025,;.01~SEP 15, 2022@07:52:43
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25026^1
25027^2
25028^3
25029^4
25030^5
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1A CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25023</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3479767674</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25023,;.01~VA-ONC KID STAGE I T1A CLINICAL TRIAL
9999999.64;+25023,;.03~VA-ONC KID STAGE I CLINICAL PATHWAY [C]
9999999.64;+25023,;.08~YES
9999999.64;+25023,;.1~FACTOR
9999999.64;+25023,;100~NATIONAL
9999999.64;+25023,;101~VHA ONCOLOGY
9999999.64;+25023,;200~Kidney Ca-Stage I T1a Clinical Trial
9999999.64;+25023,;201~WP-start~1
Kidney Cancer - Stage I T1a; on pathway clinical trial
9999999.65;+25024,+25023,;.01~JUN 17, 2022@07:14:19
9999999.65;+25024,+25023,;2~WP-start~1
 Creation.
9999999.65;+25025,+25023,;.01~JUN 21, 2022@07:26:19
9999999.65;+25026,+25023,;.01~JUL 13, 2022@08:20:41
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25024^1
25025^2
25026^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I CLINICAL PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>25022</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1091932452</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25022,;.01~VA-ONC KID STAGE I CLINICAL PATHWAY
9999999.64;+25022,;.03~VA-ONCOLOGY PATHWAYS [C]
9999999.64;+25022,;.08~YES
9999999.64;+25022,;.1~FACTOR
9999999.64;+25022,;100~NATIONAL
9999999.64;+25022,;101~VHA ONCOLOGY
9999999.64;+25022,;200~Kidney Cancer-Stage I Clinical Pathway
9999999.64;+25022,;201~WP-start~1
Designates that the Kidney Cancer Stage I Clinical Pathway was opened.
9999999.65;+25023,+25022,;.01~JUN 17, 2022@07:13:32
9999999.65;+25023,+25022,;2~WP-start~1
 Creation.
9999999.65;+25024,+25022,;.01~JUN 21, 2022@07:39:55
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25023^1
25024^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER IN/POOR OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25155</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>302076848</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25155,;.01~VA-ONC KID STAGE IV NOT CAND INTER IN/POOR OFF PATH RSN
9999999.64;+25155,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25155,;.08~YES
9999999.64;+25155,;.1~FACTOR
9999999.64;+25155,;.11~INACTIVE
9999999.64;+25155,;100~NATIONAL
9999999.64;+25155,;101~VHA ONCOLOGY
9999999.64;+25155,;200~Kidney CA-Stage IV Not Cand Inter Inter/Poor Risk Off Path Rsn
9999999.64;+25155,;201~WP-start~3
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group; off pathway reason
9999999.65;+25156,+25155,;.01~JUL 13, 2022@07:31:02
9999999.65;+25156,+25155,;2~WP-start~1
 Creation.
9999999.65;+25157,+25155,;.01~FEB 24, 2025@11:11:16
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25156^1
25157^2
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER IN/POOR OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25142</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3021710014</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25142,;.01~VA-ONC KID STAGE IV PROG AFTER INTER IN/POOR OFF PATH TX
9999999.64;+25142,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25142,;.08~YES
9999999.64;+25142,;.1~FACTOR
9999999.64;+25142,;.11~INACTIVE
9999999.64;+25142,;100~NATIONAL
9999999.64;+25142,;101~VHA ONCOLOGY
9999999.64;+25142,;200~Kidney CA-Stage IV Prog After Inter In/Poor Risk Off Path Tx
9999999.64;+25142,;201~WP-start~3
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group; off pathway treatment
9999999.65;+25143,+25142,;.01~JUL 11, 2022@10:37:49
9999999.65;+25143,+25142,;2~WP-start~1
 Creation.
9999999.65;+25144,+25142,;.01~JUL 13, 2022@07:45:24
9999999.65;+25145,+25142,;.01~FEB 24, 2025@11:04:40
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25143^1
25144^2
25145^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER IN/POOR IPI+NIVO</POINT_01>
<INTERNAL_ENTRY_NUMBER>25141</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3704221726</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25141,;.01~VA-ONC KID STAGE IV PROG AFTER INTER IN/POOR IPI+NIVO
9999999.64;+25141,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25141,;.08~YES
9999999.64;+25141,;.1~FACTOR
9999999.64;+25141,;.11~INACTIVE
9999999.64;+25141,;100~NATIONAL
9999999.64;+25141,;101~VHA ONCOLOGY
9999999.64;+25141,;200~Kidney CA-Stage IV Prog After Inter In/Poor Risk Ipi+Nivo
9999999.64;+25141,;201~WP-start~3
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group; on pathway ipilimumab and nivolumab
9999999.65;+25142,+25141,;.01~JUL 11, 2022@10:37:16
9999999.65;+25142,+25141,;2~WP-start~1
 Creation.
9999999.65;+25143,+25141,;.01~JUL 13, 2022@07:44:49
9999999.65;+25144,+25141,;.01~OCT 13, 2022@09:19:06
9999999.65;+25145,+25141,;.01~FEB 24, 2025@11:04:11
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25142^1
25143^2
25144^3
25145^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER IN/POOR CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25140</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3828333279</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25140,;.01~VA-ONC KID STAGE IV PROG AFTER INTER IN/POOR CLINICAL TRIAL
9999999.64;+25140,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25140,;.08~YES
9999999.64;+25140,;.1~FACTOR
9999999.64;+25140,;.11~INACTIVE
9999999.64;+25140,;100~NATIONAL
9999999.64;+25140,;101~VHA ONCOLOGY
9999999.64;+25140,;200~Kidney CA-Stage IV Prog After Inter In/Poor Risk Clin Trial
9999999.64;+25140,;201~WP-start~3
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group; on pathway clinical trial
9999999.65;+25141,+25140,;.01~JUL 11, 2022@10:36:33
9999999.65;+25141,+25140,;2~WP-start~1
 Creation.
9999999.65;+25142,+25140,;.01~JUL 13, 2022@07:44:28
9999999.65;+25143,+25140,;.01~FEB 24, 2025@11:03:29
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25141^1
25142^2
25143^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROG AFTER INTER IN/POOR OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>25135</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2360867563</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25135,;.01~VA-ONC KID STAGE IV PROG AFTER INTER IN/POOR OFF PATH RSN
9999999.64;+25135,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25135,;.08~YES
9999999.64;+25135,;.1~FACTOR
9999999.64;+25135,;.11~INACTIVE
9999999.64;+25135,;100~NATIONAL
9999999.64;+25135,;101~VHA ONCOLOGY
9999999.64;+25135,;200~Kidney CA-Stage IV Prog After Inter In/Poor Risk Off Path Rsn
9999999.64;+25135,;201~WP-start~3
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group; off pathway reason
9999999.65;+25136,+25135,;.01~JUL 11, 2022@10:26:46
9999999.65;+25136,+25135,;2~WP-start~1
 Creation.
9999999.65;+25137,+25135,;.01~JUL 13, 2022@07:45:08
9999999.65;+25138,+25135,;.01~FEB 24, 2025@11:04:23
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25136^1
25137^2
25138^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER IN/POOR OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>25134</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>820462761</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25134,;.01~VA-ONC KID STAGE IV NOT CAND INTER IN/POOR OFF PATH TX
9999999.64;+25134,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25134,;.08~YES
9999999.64;+25134,;.1~FACTOR
9999999.64;+25134,;.11~INACTIVE
9999999.64;+25134,;100~NATIONAL
9999999.64;+25134,;101~VHA ONCOLOGY
9999999.64;+25134,;200~Kidney CA-Stage IV Prog After Inter In/Poor Risk Off Path Tx
9999999.64;+25134,;201~WP-start~3
Kidney Cancer-Stage IV progression after intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group; off pathway treatment
9999999.65;+25135,+25134,;.01~JUL 11, 2022@10:24:30
9999999.65;+25135,+25134,;2~WP-start~1
 Creation.
9999999.65;+25136,+25134,;.01~JUL 13, 2022@07:41:25
9999999.65;+25137,+25134,;.01~FEB 24, 2025@11:11:30
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25135^1
25136^2
25137^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER IN/POOR IPI+NIVO</POINT_01>
<INTERNAL_ENTRY_NUMBER>25133</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3469769652</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25133,;.01~VA-ONC KID STAGE IV NOT CAND INTER IN/POOR IPI+NIVO
9999999.64;+25133,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25133,;.08~YES
9999999.64;+25133,;.1~FACTOR
9999999.64;+25133,;.11~INACTIVE
9999999.64;+25133,;100~NATIONAL
9999999.64;+25133,;101~VHA ONCOLOGY
9999999.64;+25133,;200~Kidney CA-Stage IV Not Cand Inter Inter/Poor Risk Ipi+Nivo
9999999.64;+25133,;201~WP-start~3
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group; on pathway ipilimumab and nivolumab
9999999.65;+25134,+25133,;.01~JUL 11, 2022@10:21:09
9999999.65;+25134,+25133,;2~WP-start~1
 Creation.
9999999.65;+25135,+25133,;.01~JUL 13, 2022@07:40:42
9999999.65;+25136,+25133,;.01~OCT 13, 2022@09:17:39
9999999.65;+25137,+25133,;.01~FEB 24, 2025@11:11:03
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25134^1
25135^2
25136^3
25137^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NOT CAND INTER IN/POOR CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>25132</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2343202539</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25132,;.01~VA-ONC KID STAGE IV NOT CAND INTER IN/POOR CLINICAL TRIAL
9999999.64;+25132,;.03~VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
9999999.64;+25132,;.08~YES
9999999.64;+25132,;.1~FACTOR
9999999.64;+25132,;.11~INACTIVE
9999999.64;+25132,;100~NATIONAL
9999999.64;+25132,;101~VHA ONCOLOGY
9999999.64;+25132,;200~Kidney CA-Stage IV Not Cand Inter Inter/Poor Risk Clin Trial
9999999.64;+25132,;201~WP-start~3
Kidney Cancer-Stage IV not a candidate for an intervention (cytoreductive 
nephrectomy or metastasis directed therapy) considered to be in an 
intermediate or poor risk group; on pathway clinical trial
9999999.65;+25133,+25132,;.01~JUL 11, 2022@10:20:28
9999999.65;+25133,+25132,;2~WP-start~1
 Creation.
9999999.65;+25134,+25132,;.01~JUL 13, 2022@07:40:11
9999999.65;+25135,+25132,;.01~FEB 24, 2025@11:10:46
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25133^1
25134^2
25135^3
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH FACTORS</FILE_NAME>
<FILE_NUMBER>9999999.64</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III S/P SURG ADJ PEMBRO W SURV</POINT_01>
<INTERNAL_ENTRY_NUMBER>25017</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>74721496</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
9999999.64;+25017,;.01~VA-ONC KID STAGE III S/P SURG ADJ PEMBRO W SURV
9999999.64;+25017,;.03~VA-ONC KID STAGE III CLINICAL PATHWAY [C]
9999999.64;+25017,;.08~YES
9999999.64;+25017,;.1~FACTOR
9999999.64;+25017,;.11~INACTIVE
9999999.64;+25017,;100~NATIONAL
9999999.64;+25017,;101~VHA ONCOLOGY
9999999.64;+25017,;200~Kidney CA-Stage III S/P Surgery Adj Pembro then Surveillance
9999999.64;+25017,;201~WP-start~7
Kidney Cancer - Stage III after radical nephrectomy; on pathway adjuvant 
pembrolizumab for one year then surveillance
Follow up every 3-6 months for 3 Years, then annually for 2 years: 
       -history and physical
       -comprehensive metabolic panel 
       -abdominal CT/MRI with contrast
       -chest x-ray/CT
9999999.65;+25018,+25017,;.01~JUN 17, 2022@07:06:48
9999999.65;+25018,+25017,;2~WP-start~1
 Creation.
9999999.65;+25019,+25017,;.01~JUN 21, 2022@07:37:10
9999999.65;+25020,+25017,;.01~JUL 13, 2022@09:12:44
9999999.65;+25021,+25017,;.01~AUG 25, 2022@06:42:25
9999999.65;+25022,+25017,;.01~NOV 20, 2025@11:08:13
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
25018^1
25019^2
25020^3
25021^4
25022^5
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER SPONSOR</FILE_NAME>
<FILE_NUMBER>811.6</FILE_NUMBER>
<POINT_01>VHA ONCOLOGY</POINT_01>
<INTERNAL_ENTRY_NUMBER>39</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2932841009</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
811.6;+39,;.01~VHA ONCOLOGY
811.6;+39,;100~NATIONAL
811.63;+40,+39,;.01~06/09/2026@10:31:10
811.63;+40,+39,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
40^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER TERM</FILE_NAME>
<FILE_NUMBER>811.5</FILE_NUMBER>
<POINT_01>VA-REMINDER UPDATE_2_0_578</POINT_01>
<INTERNAL_ENTRY_NUMBER>3509</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2475063846</CHECKSUM>
<SELECTED>YES</SELECTED>
<FILEMAN_FDA>
<![CDATA[
811.5;+3509,;.01~VA-REMINDER UPDATE_2_0_578
811.5;+3509,;100~NATIONAL
811.52;+3510,+3509,;.01~HF.VA-UPDATE_2_0_578
811.52;+3510,+3509,;11~0
811.52;+3510,+3509,;15~NO
811.53;+3511,+3509,;.01~06/09/2026@10:31:10
811.53;+3511,+3509,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
3510^1
3511^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH SUMMARY COMPONENT</FILE_NAME>
<FILE_NUMBER>142.1</FILE_NUMBER>
<POINT_01>PCE HEALTH FACTORS SELECTED</POINT_01>
<INTERNAL_ENTRY_NUMBER>203</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1531877056</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
142.1;+203,;.01~PCE HEALTH FACTORS SELECTED
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH SUMMARY TYPE</FILE_NAME>
<FILE_NUMBER>142</FILE_NUMBER>
<POINT_01>VA-ONCOLOGY PATHWAYS KIDNEY</POINT_01>
<INTERNAL_ENTRY_NUMBER>2683</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1644689377</CHECKSUM>
<SELECTED>YES</SELECTED>
<FILEMAN_FDA>
<![CDATA[
142;+2683,;.01~VA-ONCOLOGY PATHWAYS KIDNEY
142;+2683,;.08~yes
142;+2683,;99~66935,42587
142.01;+2684,+2683,;.01~5
142.01;+2684,+2683,;1~PCE HEALTH FACTORS SELECTED
142.01;+2684,+2683,;2~1
142.01;+2684,+2683,;5~Health Factor Select
142.14;+2685,+2684,+2683,;.01~F.VA-ONC KID STAGE I CLINICAL PATHWAY [C]
142.14;+2686,+2684,+2683,;.01~F.VA-ONC KID STAGE II CLINICAL PATHWAY [C]
142.14;+2687,+2684,+2683,;.01~F.VA-ONC KID STAGE III CLINICAL PATHWAY [C]
142.14;+2688,+2684,+2683,;.01~F.VA-ONC KID STAGE IV CLINICAL PATHWAY [C]
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
2684^5
2685^1
2686^2
2687^3
2688^4
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>HEALTH SUMMARY OBJECTS</FILE_NAME>
<FILE_NUMBER>142.5</FILE_NUMBER>
<POINT_01>VA-ONCOLOGY PATHWAYS KIDNEY (TIU)</POINT_01>
<INTERNAL_ENTRY_NUMBER>6600713</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3379138404</CHECKSUM>
<SELECTED>YES</SELECTED>
<FILEMAN_FDA>
<![CDATA[
142.5;+6600713,;.01~VA-ONCOLOGY PATHWAYS KIDNEY (TIU)
142.5;+6600713,;.03~VA-ONCOLOGY PATHWAYS KIDNEY
142.5;+6600713,;.05~YES
142.5;+6600713,;.06~YES
142.5;+6600713,;.07~NO
142.5;+6600713,;.08~NO
142.5;+6600713,;.09~NO
142.5;+6600713,;.1~NO
142.5;+6600713,;.11~NO
142.5;+6600713,;.12~NO
142.5;+6600713,;.13~NO
142.5;+6600713,;.14~NO
142.5;+6600713,;.15~NO
142.5;+6600713,;.16~NO
142.5;+6600713,;.18~APR 27, 2023@10:19:25
142.5;+6600713,;.19~APR 02, 2024@09:47:15
142.5;+6600713,;.2~NO
142.5;+6600713,;1~WP-start~1
for National Oncology Kidney pathways template 4-27-23 agh
142.5;+6600713,;2~No Kidney pathways data found
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>TIU DOCUMENT DEFINITION</FILE_NAME>
<FILE_NUMBER>8925.1</FILE_NUMBER>
<POINT_01>VA-ONCOLOGY PATHWAYS KIDNEY</POINT_01>
<INTERNAL_ENTRY_NUMBER>4078</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>179892382</CHECKSUM>
<SELECTED>YES</SELECTED>
<FILEMAN_FDA>
<![CDATA[
8925.1;+4078,;.01~VA-ONCOLOGY PATHWAYS KIDNEY
8925.1;+4078,;.03~VA-ONCOLOGY PATHWAYS KIDNEY
8925.1;+4078,;.04~OBJECT
8925.1;+4078,;.07~ACTIVE
8925.1;+4078,;9~S X=$$TIU^GMTSOBJ(DFN,VA-ONCOLOGY PATHWAYS KIDNEY (TIU))
8925.1;+4078,;99~
]]>
</FILEMAN_FDA>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>PXRM GF VIEW BUTTON</POINT_01>
<INTERNAL_ENTRY_NUMBER>38861</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1501895938</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+38861,;.01~PXRM GF VIEW BUTTON
801.41;+38861,;4~prompt
801.41;+38861,;23~YES
801.41;+38861,;24~View Data
801.41;+38861,;46~GF_VIEW
801.41;+38861,;100~NATIONAL
801.44;+38862,+38861,;.01~06/09/2026@10:31:10
801.44;+38862,+38861,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38862^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA VIEW PRESUMPTIVE CONDITIONS</POINT_01>
<INTERNAL_ENTRY_NUMBER>71028</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1597109066</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+71028,;.01~VA-ONC PRCA VIEW PRESUMPTIVE CONDITIONS
801.41;+71028,;4~dialog element
801.41;+71028,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+71028,;23~YES
801.41;+71028,;25~WP-start~1
{FLD:VA-ONC PRESUMPTIVE CONDITIONS}
801.41;+71028,;35~WP-start~22
Prostate Cancer-Presumptive Conditions:\\
======================================\\
 
VA automatically presumes that certain disabilities were caused by 
military service (presumptive conditions). This is because of the unique
circumstances of a specific Veteran's military service. If a Veteran is
diagnosed with a presumptive condition and meets the service requirements
for the presumption, disability compensation may be awarded.\\
 
Vietnam Veterans-Agent Orange Exposure in Specified Locations\\and Time 
Periods:\\
-------------------------------------------------------------\\
   -Prostate cancer
 
Gulf War and Post 9/11 Veterans-Burn Pits/Fine Particulate Matter 
\\Exposure in Specified Locations and Time Periods:\\
-----------------------------------------------------------------\\
   -Reproductive cancer of any type\\
 
 
For more information, please visit U.S. Department of Veterans Affairs - 
Presumptive Disability Benefits (domain.ext)
801.41;+71028,;51~SUPPRESS
801.41;+71028,;100~NATIONAL
801.412;+71029,+71028,;.01~5
801.412;+71029,+71028,;2~PXRM GF VIEW BUTTON
801.412;+71029,+71028,;6~VIEW Prostate Presumptive Conditions
801.44;+71030,+71028,;.01~06/09/2026@10:31:10
801.44;+71030,+71028,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
71029^1
71030^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>45345</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1161991404</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+45345,;.01~VA-ONC OFF PATHWAY
801.41;+45345,;4~prompt
801.41;+45345,;24~   
801.41;+45345,;46~COM
801.41;+45345,;100~NATIONAL
801.4145;+45346,+45345,;.01~1
801.4145;+45346,+45345,;2~Patient preference/declined
801.4145;+45347,+45345,;.01~2
801.4145;+45347,+45345,;2~Toxicity and/or comorbidity
801.4145;+45348,+45345,;.01~3
801.4145;+45348,+45345,;2~Prior treatment continued
801.4145;+45349,+45345,;.01~4
801.4145;+45349,+45345,;2~Prior treatment precludes
801.4145;+45350,+45345,;.01~5
801.4145;+45350,+45345,;2~Pathway guidance needs update
801.4145;+45351,+45345,;.01~6
801.4145;+45351,+45345,;2~Patient barriers
801.4145;+45352,+45345,;.01~8
801.4145;+45352,+45345,;2~Other:
801.4145;+45353,+45345,;.01~7
801.4145;+45353,+45345,;2~Treatment unavailable
801.44;+45354,+45345,;.01~06/09/2026@10:31:10
801.44;+45354,+45345,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45346^1
45347^2
45348^3
45349^4
45350^5
45351^6
45352^8
45353^9
45354^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 NEUROENDO COMP OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>53364</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2136045745</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53364,;.01~VA-ONC PRCA CRPC M1 NEUROENDO COMP OFF PATH RSN
801.41;+53364,;4~dialog element
801.41;+53364,;15~HF.VA-ONC PRCA CRPC M1 1ST NEUROENDOCRINE OFF PATH RSN
801.41;+53364,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+53364,;51~SUPPRESS
801.41;+53364,;100~NATIONAL
801.412;+53365,+53364,;.01~5
801.412;+53365,+53364,;2~VA-ONC OFF PATHWAY
801.412;+53365,+53364,;7~YES
801.412;+53365,+53364,;9~YES
801.44;+53366,+53364,;.01~06/09/2026@10:31:10
801.44;+53366,+53364,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53365^1
53366^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC BLANK</POINT_01>
<INTERNAL_ENTRY_NUMBER>46240</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>274383172</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+46240,;.01~VA-ONC BLANK
801.41;+46240,;4~prompt
801.41;+46240,;24~   
801.41;+46240,;46~COM
801.41;+46240,;100~NATIONAL
801.44;+46241,+46240,;.01~06/09/2026@10:31:10
801.44;+46241,+46240,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
46241^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 NEUROENDO COMP OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>53363</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3074109478</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53363,;.01~VA-ONC PRCA CRPC M1 NEUROENDO COMP OFF PATH TX
801.41;+53363,;4~dialog element
801.41;+53363,;15~HF.VA-ONC PRCA CRPC M1 1ST NEUROENDOCRINE OFF PATH TX
801.41;+53363,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+53363,;51~SUPPRESS
801.41;+53363,;100~NATIONAL
801.412;+53364,+53363,;.01~5
801.412;+53364,+53363,;2~VA-ONC BLANK
801.412;+53364,+53363,;9~YES
801.44;+53365,+53363,;.01~06/09/2026@10:31:10
801.44;+53365,+53363,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53364^1
53365^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 NEUROENDO COMP OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>53362</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3821071879</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53362,;.01~VA-GP ONC PRCA CRPC M1 NEUROENDO COMP OFF PATHWAY
801.41;+53362,;4~dialog group
801.41;+53362,;6~YES
801.41;+53362,;7~2
801.41;+53362,;23~YES
801.41;+53362,;25~WP-start~1
Off pathway:
801.41;+53362,;100~NATIONAL
801.412;+53363,+53362,;.01~20
801.412;+53363,+53362,;2~VA-ONC PRCA CRPC M1 NEUROENDO COMP OFF PATH TX
801.412;+53364,+53362,;.01~40
801.412;+53364,+53362,;2~VA-ONC PRCA CRPC M1 NEUROENDO COMP OFF PATH RSN
801.44;+53365,+53362,;.01~06/09/2026@10:31:10
801.44;+53365,+53362,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53363^1
53364^2
53365^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 NEUROENDO COMP PLATINUM</POINT_01>
<INTERNAL_ENTRY_NUMBER>44776</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3470171055</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44776,;.01~VA-ONC PRCA CRPC M1 NEUROENDO COMP PLATINUM
801.41;+44776,;4~dialog element
801.41;+44776,;15~HF.VA-ONC PRCA CRPC M1 1ST NEUROENDOCRINE PLATINUM
801.41;+44776,;25~WP-start~1
Platinum-based combination (no regimen proven more effective than another)
801.41;+44776,;35~WP-start~1
Veteran has elected to pursue TREATMENT with PLATINUM-BASED COMBINATION.
801.41;+44776,;100~NATIONAL
801.44;+44777,+44776,;.01~06/09/2026@10:31:10
801.44;+44777,+44776,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44777^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>45369</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>475371082</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+45369,;.01~VA-ONC CLINICAL TRIAL
801.41;+45369,;4~prompt
801.41;+45369,;24~Clinical Trial:
801.41;+45369,;46~COM
801.41;+45369,;100~NATIONAL
801.44;+45370,+45369,;.01~06/09/2026@10:31:10
801.44;+45370,+45369,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45370^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 NEUROENDO COMP CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>44432</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3278512410</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44432,;.01~VA-ONC PRCA CRPC M1 NEUROENDO COMP CLINICAL TRIAL
801.41;+44432,;4~dialog element
801.41;+44432,;15~HF.VA-ONC PRCA CRPC M1 1ST NEUROENDOCRINE CLINICAL TRIAL
801.41;+44432,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+44432,;35~WP-start~1
Veteran has elected to pursue:
801.41;+44432,;100~NATIONAL
801.412;+44433,+44432,;.01~5
801.412;+44433,+44432,;2~VA-ONC CLINICAL TRIAL
801.412;+44433,+44432,;9~YES
801.44;+44434,+44432,;.01~06/09/2026@10:31:10
801.44;+44434,+44432,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44433^1
44434^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 NEUROENDO COMP</POINT_01>
<INTERNAL_ENTRY_NUMBER>44115</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2549320051</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44115,;.01~VA-GP ONC PRCA CRPC M1 NEUROENDO COMP
801.41;+44115,;4~dialog group
801.41;+44115,;6~YES
801.41;+44115,;7~2
801.41;+44115,;9~NONE OR ONE SELECTION
801.41;+44115,;25~WP-start~1
Neuroendocrine Component:
801.41;+44115,;100~NATIONAL
801.412;+44116,+44115,;.01~20
801.412;+44116,+44115,;2~VA-ONC PRCA CRPC M1 NEUROENDO COMP CLINICAL TRIAL
801.412;+44117,+44115,;.01~40
801.412;+44117,+44115,;2~VA-ONC PRCA CRPC M1 NEUROENDO COMP PLATINUM
801.412;+44118,+44115,;.01~60
801.412;+44118,+44115,;2~VA-GP ONC PRCA CRPC M1 NEUROENDO COMP OFF PATHWAY
801.44;+44119,+44115,;.01~06/09/2026@10:31:10
801.44;+44119,+44115,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44116^1
44117^2
44118^3
44119^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &gt;2 CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>53402</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>628368710</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53402,;.01~VA-ONC PRCA CRPC M1 >2 CLINICAL TRIAL
801.41;+53402,;4~dialog element
801.41;+53402,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG >2 CLINICAL TRIAL
801.41;+53402,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+53402,;35~WP-start~1
Veteran has elected to pursue:
801.41;+53402,;100~NATIONAL
801.412;+53403,+53402,;.01~5
801.412;+53403,+53402,;2~VA-ONC CLINICAL TRIAL
801.412;+53403,+53402,;9~YES
801.44;+53404,+53402,;.01~06/09/2026@10:31:10
801.44;+53404,+53402,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53403^1
53404^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PALLIATIVE CARE CONSULT</POINT_01>
<INTERNAL_ENTRY_NUMBER>57674</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>589117325</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57674,;.01~VA-ONC PALLIATIVE CARE CONSULT
801.41;+57674,;4~dialog element
801.41;+57674,;51~SUPPRESS
801.41;+57674,;100~NATIONAL
801.44;+57675,+57674,;.01~06/09/2026@10:31:10
801.44;+57675,+57674,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57675^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &gt;2 REFER PALL CARE</POINT_01>
<INTERNAL_ENTRY_NUMBER>44534</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>690346087</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44534,;.01~VA-GP ONC PRCA CRPC M1 >2 REFER PALL CARE
801.41;+44534,;4~dialog group
801.41;+44534,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG >2 REFER PALLIATIVE CARE
801.41;+44534,;25~WP-start~1
Refer to Palliative Care
801.41;+44534,;35~WP-start~1
Veteran has elected to pursue REFERRAL to PALLIATIVE CARE.
801.41;+44534,;100~NATIONAL
801.412;+44535,+44534,;.01~20
801.412;+44535,+44534,;2~VA-ONC PALLIATIVE CARE CONSULT
801.44;+44536,+44534,;.01~06/09/2026@10:31:10
801.44;+44536,+44534,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44535^1
44536^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &gt;2 OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>53361</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1246220811</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53361,;.01~VA-ONC PRCA CRPC M1 >2 OFF PATH RSN
801.41;+53361,;4~dialog element
801.41;+53361,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG >2 OFF PATH RSN
801.41;+53361,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+53361,;51~SUPPRESS
801.41;+53361,;100~NATIONAL
801.412;+53362,+53361,;.01~5
801.412;+53362,+53361,;2~VA-ONC OFF PATHWAY
801.412;+53362,+53361,;7~YES
801.412;+53362,+53361,;9~YES
801.44;+53363,+53361,;.01~06/09/2026@10:31:10
801.44;+53363,+53361,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53362^1
53363^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &gt;2 OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>53360</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3486061048</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53360,;.01~VA-ONC PRCA CRPC M1 >2 OFF PATH TX
801.41;+53360,;4~dialog element
801.41;+53360,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG >2 OFF PATH TX
801.41;+53360,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+53360,;51~SUPPRESS
801.41;+53360,;100~NATIONAL
801.412;+53361,+53360,;.01~5
801.412;+53361,+53360,;2~VA-ONC BLANK
801.412;+53361,+53360,;9~YES
801.44;+53362,+53360,;.01~06/09/2026@10:31:10
801.44;+53362,+53360,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53361^1
53362^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &gt;2 OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>53359</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1567509486</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53359,;.01~VA-GP ONC PRCA CRPC M1 >2 OFF PATHWAY
801.41;+53359,;4~dialog group
801.41;+53359,;6~YES
801.41;+53359,;7~2
801.41;+53359,;23~YES
801.41;+53359,;25~WP-start~1
Off pathway:
801.41;+53359,;100~NATIONAL
801.412;+53360,+53359,;.01~10
801.412;+53360,+53359,;2~VA-ONC PRCA CRPC M1 >2 OFF PATH TX
801.412;+53361,+53359,;.01~30
801.412;+53361,+53359,;2~VA-ONC PRCA CRPC M1 >2 OFF PATH RSN
801.44;+53362,+53359,;.01~06/09/2026@10:31:10
801.44;+53362,+53359,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53360^1
53361^2
53362^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &gt;2 MAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>44114</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>155009470</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44114,;.01~VA-GP ONC PRCA CRPC M1 >2 MAIN
801.41;+44114,;4~dialog group
801.41;+44114,;6~YES
801.41;+44114,;7~2
801.41;+44114,;9~NONE OR ONE SELECTION
801.41;+44114,;25~WP-start~1
Adenocarcinoma (ECOG greater than 2):
801.41;+44114,;100~NATIONAL
801.412;+44115,+44114,;.01~40
801.412;+44115,+44114,;2~VA-GP ONC PRCA CRPC M1 >2 OFF PATHWAY
801.412;+44116,+44114,;.01~20
801.412;+44116,+44114,;2~VA-GP ONC PRCA CRPC M1 >2 REFER PALL CARE
801.412;+44117,+44114,;.01~10
801.412;+44117,+44114,;2~VA-ONC PRCA CRPC M1 >2 CLINICAL TRIAL
801.44;+44118,+44114,;.01~06/09/2026@10:31:10
801.44;+44118,+44114,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44115^2
44116^4
44117^5
44118^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO CONTRA ABI BRCA - ABIRATERONE</POINT_01>
<INTERNAL_ENTRY_NUMBER>70806</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2085858351</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+70806,;.01~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA - ABIRATERONE
801.41;+70806,;4~dialog element
801.41;+70806,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA - ABIRATERONE
801.41;+70806,;25~WP-start~1
Abiraterone
801.41;+70806,;35~WP-start~1
Veteran has elected to pursue TREATMENT WITH ABIRATERONE.
801.41;+70806,;100~NATIONAL
801.44;+70807,+70806,;.01~06/09/2026@10:31:11
801.44;+70807,+70806,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
70807^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO CONTRA ABI BRCA - OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>70805</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2666365186</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+70805,;.01~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA - OFF PATH RSN
801.41;+70805,;4~dialog element
801.41;+70805,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA - OFF PATH RSN
801.41;+70805,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+70805,;51~SUPPRESS
801.41;+70805,;100~NATIONAL
801.412;+70806,+70805,;.01~5
801.412;+70806,+70805,;2~VA-ONC OFF PATHWAY
801.412;+70806,+70805,;7~YES
801.412;+70806,+70805,;9~YES
801.44;+70807,+70805,;.01~06/09/2026@10:31:11
801.44;+70807,+70805,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
70806^1
70807^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO CONTRA ABI BRCA - OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>70804</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>127044526</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+70804,;.01~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA - OFF PATH TX
801.41;+70804,;4~dialog element
801.41;+70804,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA - OFF PATH TX
801.41;+70804,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+70804,;51~SUPPRESS
801.41;+70804,;100~NATIONAL
801.412;+70805,+70804,;.01~5
801.412;+70805,+70804,;2~VA-ONC BLANK
801.412;+70805,+70804,;9~YES
801.44;+70806,+70804,;.01~06/09/2026@10:31:11
801.44;+70806,+70804,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
70805^1
70806^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 NO CONTRA ABI BRCA - OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>70803</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2696009456</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+70803,;.01~VA-GP ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA - OFF PATH
801.41;+70803,;4~dialog group
801.41;+70803,;6~YES
801.41;+70803,;7~2
801.41;+70803,;23~YES
801.41;+70803,;25~WP-start~1
Off pathway:
801.41;+70803,;100~NATIONAL
801.412;+70804,+70803,;.01~10
801.412;+70804,+70803,;2~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA - OFF PATH TX
801.412;+70805,+70803,;.01~20
801.412;+70805,+70803,;2~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA - OFF PATH RSN
801.44;+70806,+70803,;.01~06/09/2026@10:31:11
801.44;+70806,+70803,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
70804^1
70805^2
70806^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO CONTRA ABI BRCA - CL TR</POINT_01>
<INTERNAL_ENTRY_NUMBER>70802</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1068571187</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+70802,;.01~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA - CL TR
801.41;+70802,;4~dialog element
801.41;+70802,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA - CLIN TRIAL
801.41;+70802,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+70802,;35~WP-start~1
Veteran has elected to pursue:
801.41;+70802,;100~NATIONAL
801.412;+70803,+70802,;.01~5
801.412;+70803,+70802,;2~VA-ONC CLINICAL TRIAL
801.412;+70803,+70802,;9~YES
801.44;+70804,+70802,;.01~06/09/2026@10:31:11
801.44;+70804,+70802,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
70803^1
70804^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 NO CONTRA ABI BRCA -</POINT_01>
<INTERNAL_ENTRY_NUMBER>70796</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3545352816</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+70796,;.01~VA-GP ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA -
801.41;+70796,;4~dialog group
801.41;+70796,;6~YES
801.41;+70796,;7~2
801.41;+70796,;9~NONE OR ONE SELECTION
801.41;+70796,;25~WP-start~1
Negative BRCA mutation:
801.41;+70796,;100~NATIONAL
801.412;+70797,+70796,;.01~20
801.412;+70797,+70796,;2~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA - CL TR
801.412;+70798,+70796,;.01~60
801.412;+70798,+70796,;2~VA-GP ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA - OFF PATH
801.412;+70799,+70796,;.01~40
801.412;+70799,+70796,;2~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA - ABIRATERONE
801.44;+70800,+70796,;.01~06/09/2026@10:31:11
801.44;+70800,+70796,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
70797^1
70798^2
70799^3
70800^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO CONTRA ABI BRCA + ABI/OLA</POINT_01>
<INTERNAL_ENTRY_NUMBER>70801</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>114864946</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+70801,;.01~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA + ABI/OLA
801.41;+70801,;4~dialog element
801.41;+70801,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA + OLAPARIB/ABIRATERONE
801.41;+70801,;25~WP-start~1
Olaparib and abiraterone
801.41;+70801,;35~WP-start~1
Veteran has elected to pursue TREATMENT with OLAPARIB and ABIRATERONE.
801.41;+70801,;100~NATIONAL
801.44;+70802,+70801,;.01~06/09/2026@10:31:11
801.44;+70802,+70801,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
70802^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO CONTRA ABI BRCA + OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>70799</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1615629107</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+70799,;.01~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA + OFF PATH TX
801.41;+70799,;4~dialog element
801.41;+70799,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA + OFF PATH TX
801.41;+70799,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+70799,;51~SUPPRESS
801.41;+70799,;100~NATIONAL
801.412;+70800,+70799,;.01~5
801.412;+70800,+70799,;2~VA-ONC BLANK
801.412;+70800,+70799,;9~YES
801.44;+70801,+70799,;.01~06/09/2026@10:31:11
801.44;+70801,+70799,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
70800^1
70801^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO CONTRA ABI BRCA + OFF PATH REAS</POINT_01>
<INTERNAL_ENTRY_NUMBER>70800</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4009223332</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+70800,;.01~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA + OFF PATH REAS
801.41;+70800,;4~dialog element
801.41;+70800,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+70800,;51~SUPPRESS
801.41;+70800,;100~NATIONAL
801.4118;+70801,+70800,;.01~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA + OFF PATH RSN
801.412;+70802,+70800,;.01~5
801.412;+70802,+70800,;2~VA-ONC OFF PATHWAY
801.412;+70802,+70800,;7~YES
801.412;+70802,+70800,;9~YES
801.44;+70803,+70800,;.01~06/09/2026@10:31:11
801.44;+70803,+70800,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
70801^1
70802^1
70803^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 NO CONTRA ABI BRCA + OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>70798</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2149267022</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+70798,;.01~VA-GP ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA + OFF PATH
801.41;+70798,;4~dialog group
801.41;+70798,;6~YES
801.41;+70798,;7~2
801.41;+70798,;23~YES
801.41;+70798,;25~WP-start~1
Off pathway:
801.41;+70798,;100~NATIONAL
801.412;+70799,+70798,;.01~20
801.412;+70799,+70798,;2~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA + OFF PATH REAS
801.412;+70800,+70798,;.01~10
801.412;+70800,+70798,;2~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA + OFF PATH TX
801.44;+70801,+70798,;.01~06/09/2026@10:31:11
801.44;+70801,+70798,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
70799^1
70800^2
70801^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO CONTRA ABI BRCA + CL TR</POINT_01>
<INTERNAL_ENTRY_NUMBER>70797</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>587252245</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+70797,;.01~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA + CL TR
801.41;+70797,;4~dialog element
801.41;+70797,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 BRCA + CLIN TRIAL
801.41;+70797,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+70797,;35~WP-start~1
Veteran has elected to pursue:
801.41;+70797,;100~NATIONAL
801.412;+70798,+70797,;.01~5
801.412;+70798,+70797,;2~VA-ONC CLINICAL TRIAL
801.412;+70798,+70797,;9~YES
801.44;+70799,+70797,;.01~06/09/2026@10:31:11
801.44;+70799,+70797,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
70798^1
70799^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 NO CONTRA ABI BRCA +</POINT_01>
<INTERNAL_ENTRY_NUMBER>70795</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3742293588</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+70795,;.01~VA-GP ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA +
801.41;+70795,;4~dialog group
801.41;+70795,;6~YES
801.41;+70795,;7~2
801.41;+70795,;9~NONE OR ONE SELECTION
801.41;+70795,;25~WP-start~1
Positive BRCA mutation:
801.41;+70795,;100~NATIONAL
801.412;+70796,+70795,;.01~20
801.412;+70796,+70795,;2~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA + CL TR
801.412;+70797,+70795,;.01~60
801.412;+70797,+70795,;2~VA-GP ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA + OFF PATH
801.412;+70798,+70795,;.01~40
801.412;+70798,+70795,;2~VA-ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA + ABI/OLA
801.44;+70799,+70795,;.01~06/09/2026@10:31:11
801.44;+70799,+70795,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
70796^1
70797^2
70798^3
70799^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 NO PRIOR ARPI</POINT_01>
<INTERNAL_ENTRY_NUMBER>86073</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4054227767</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86073,;.01~VA-GP ONC PRCA CRPC M1 <=2 NO PRIOR ARPI
801.41;+86073,;4~dialog group
801.41;+86073,;6~YES
801.41;+86073,;7~2
801.41;+86073,;9~ONE SELECTION ONLY
801.41;+86073,;25~WP-start~1
No prior ARPI (Androgen Receptor Pathway Inhibitors) Therapy:
801.41;+86073,;52~INDENT
801.41;+86073,;100~NATIONAL
801.412;+86074,+86073,;.01~10
801.412;+86074,+86073,;2~VA-GP ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA +
801.412;+86075,+86073,;.01~20
801.412;+86075,+86073,;2~VA-GP ONC PRCA CRPC M1 <=2 NO CONTRA ABI BRCA -
801.44;+86076,+86073,;.01~06/09/2026@10:31:11
801.44;+86076,+86073,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86074^1
86075^2
86076^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO DOCE RADIUM</POINT_01>
<INTERNAL_ENTRY_NUMBER>86090</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>892247951</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86090,;.01~VA-ONC PRCA CRPC M1 <=2 NO DOCE RADIUM
801.41;+86090,;4~dialog element
801.41;+86090,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE RAD223+ADT
801.41;+86090,;25~WP-start~1
Radium223 and ADT
801.41;+86090,;35~WP-start~2
Veteran has elected to pursue TREATMENT with RADIUM223 and ANDROGEN 
DEPRIVATION THERAPY (ADT).
801.41;+86090,;100~NATIONAL
801.44;+86091,+86090,;.01~06/09/2026@10:31:11
801.44;+86091,+86090,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86091^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO DOCE PEMBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>86088</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1279776402</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86088,;.01~VA-ONC PRCA CRPC M1 <=2 NO DOCE PEMBRO
801.41;+86088,;4~dialog element
801.41;+86088,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE PEMB+ADT
801.41;+86088,;25~WP-start~1
Pembrolizumab and ADT
801.41;+86088,;35~WP-start~2
Veteran has elected to pursue TREATMENT with PEMBROLIZUMAB ANDROGEN 
DEPRIVATION THERAPY (ADT).
801.41;+86088,;100~NATIONAL
801.44;+86089,+86088,;.01~06/09/2026@10:31:11
801.44;+86089,+86088,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86089^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO DOCE OLAP</POINT_01>
<INTERNAL_ENTRY_NUMBER>86091</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2991874218</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86091,;.01~VA-ONC PRCA CRPC M1 <=2 NO DOCE OLAP
801.41;+86091,;4~dialog element
801.41;+86091,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE OLAP+ADT
801.41;+86091,;25~WP-start~1
Olaparib and ADT
801.41;+86091,;35~WP-start~2
Veteran has elected to pursue TREATMENT with OLAPARIB and ANDROGEN 
DEPRIVATION THERAPY (ADT).
801.41;+86091,;100~NATIONAL
801.44;+86092,+86091,;.01~06/09/2026@10:31:11
801.44;+86092,+86091,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86092^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO DOCE LU177</POINT_01>
<INTERNAL_ENTRY_NUMBER>86092</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4222148895</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86092,;.01~VA-ONC PRCA CRPC M1 <=2 NO DOCE LU177
801.41;+86092,;4~dialog element
801.41;+86092,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE LU177+ADT
801.41;+86092,;25~WP-start~1
Lutetium 177-PSMA and ADT
801.41;+86092,;35~WP-start~2
Veteran has elected to pursue TREATMENT with LUTETIUM 177-PSMA (prostate 
specific membrane antigen) and ANDROGEN DEPRIVATION THERAPY (ADT).
801.41;+86092,;100~NATIONAL
801.44;+86093,+86092,;.01~06/09/2026@10:31:11
801.44;+86093,+86092,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86093^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO DOCE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>86095</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3192747938</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86095,;.01~VA-ONC PRCA CRPC M1 <=2 NO DOCE CLIN TRIAL
801.41;+86095,;4~dialog element
801.41;+86095,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE CLIN TRIAL
801.41;+86095,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+86095,;35~WP-start~1
Veteran has elected to pursue:
801.41;+86095,;100~NATIONAL
801.412;+86096,+86095,;.01~5
801.412;+86096,+86095,;2~VA-ONC CLINICAL TRIAL
801.412;+86096,+86095,;9~YES
801.44;+86097,+86095,;.01~06/09/2026@10:31:11
801.44;+86097,+86095,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86096^1
86097^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO DOCE OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>86098</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2286460022</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86098,;.01~VA-ONC PRCA CRPC M1 <=2 NO DOCE OFF PATH RSN
801.41;+86098,;4~dialog element
801.41;+86098,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE OFF PATH RSN
801.41;+86098,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+86098,;51~SUPPRESS
801.41;+86098,;100~NATIONAL
801.412;+86099,+86098,;.01~5
801.412;+86099,+86098,;2~VA-ONC OFF PATHWAY
801.412;+86099,+86098,;7~YES
801.412;+86099,+86098,;9~YES
801.44;+86100,+86098,;.01~06/09/2026@10:31:11
801.44;+86100,+86098,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86099^1
86100^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 NO DOCE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>86097</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1567527814</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86097,;.01~VA-ONC PRCA CRPC M1 <=2 NO DOCE OFF PATH TX
801.41;+86097,;4~dialog element
801.41;+86097,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ NO DOCE OFF PATH TX
801.41;+86097,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+86097,;51~SUPPRESS
801.41;+86097,;100~NATIONAL
801.412;+86098,+86097,;.01~5
801.412;+86098,+86097,;2~VA-ONC BLANK
801.412;+86098,+86097,;9~YES
801.44;+86099,+86097,;.01~06/09/2026@10:31:11
801.44;+86099,+86097,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86098^1
86099^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 NO DOCE OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>86096</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1384550390</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86096,;.01~VA-GP ONC PRCA CRPC M1 <=2 NO DOCE OFF PATHWAY
801.41;+86096,;4~dialog group
801.41;+86096,;6~YES
801.41;+86096,;7~2
801.41;+86096,;23~YES
801.41;+86096,;25~WP-start~1
Off pathway:
801.41;+86096,;100~NATIONAL
801.412;+86097,+86096,;.01~10
801.412;+86097,+86096,;2~VA-ONC PRCA CRPC M1 <=2 NO DOCE OFF PATH TX
801.412;+86098,+86096,;.01~20
801.412;+86098,+86096,;2~VA-ONC PRCA CRPC M1 <=2 NO DOCE OFF PATH RSN
801.44;+86099,+86096,;.01~06/09/2026@10:31:11
801.44;+86099,+86096,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86097^1
86098^2
86099^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 PRIOR NO DOCE CAND</POINT_01>
<INTERNAL_ENTRY_NUMBER>86076</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2605421600</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86076,;.01~VA-GP ONC PRCA CRPC M1 <=2 PRIOR NO DOCE CAND
801.41;+86076,;4~dialog group
801.41;+86076,;6~YES
801.41;+86076,;7~2
801.41;+86076,;9~ONE SELECTION ONLY
801.41;+86076,;25~WP-start~1
Not a candidate for docetaxel:
801.41;+86076,;100~NATIONAL
801.412;+86077,+86076,;.01~20
801.412;+86077,+86076,;2~VA-ONC PRCA CRPC M1 <=2 NO DOCE OLAP
801.412;+86078,+86076,;.01~25
801.412;+86078,+86076,;2~VA-ONC PRCA CRPC M1 <=2 NO DOCE PEMBRO
801.412;+86079,+86076,;.01~30
801.412;+86079,+86076,;2~VA-ONC PRCA CRPC M1 <=2 NO DOCE RADIUM
801.412;+86080,+86076,;.01~35
801.412;+86080,+86076,;2~VA-GP ONC PRCA CRPC M1 <=2 NO DOCE OFF PATHWAY
801.412;+86081,+86076,;.01~5
801.412;+86081,+86076,;2~VA-ONC PRCA CRPC M1 <=2 NO DOCE CLIN TRIAL
801.412;+86082,+86076,;.01~15
801.412;+86082,+86076,;2~VA-ONC PRCA CRPC M1 <=2 NO DOCE LU177
801.44;+86083,+86076,;.01~06/09/2026@10:31:11
801.44;+86083,+86076,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86077^10
86078^11
86079^12
86080^6
86081^7
86082^9
86083^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 DOCE OFF PATH REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>86083</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2453012615</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86083,;.01~VA-ONC PRCA CRPC M1 <=2 DOCE OFF PATH REASON
801.41;+86083,;4~dialog element
801.41;+86083,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ DOCE OFF PATH RSN
801.41;+86083,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+86083,;51~SUPPRESS
801.41;+86083,;100~NATIONAL
801.412;+86084,+86083,;.01~5
801.412;+86084,+86083,;2~VA-ONC OFF PATHWAY
801.412;+86084,+86083,;7~YES
801.412;+86084,+86083,;9~YES
801.44;+86085,+86083,;.01~06/09/2026@10:31:11
801.44;+86085,+86083,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86084^1
86085^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 DOCE OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>86084</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>396909225</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86084,;.01~VA-ONC PRCA CRPC M1 <=2 DOCE OFF PATH TX
801.41;+86084,;4~dialog element
801.41;+86084,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ DOCE OFF PATH TX
801.41;+86084,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+86084,;51~SUPPRESS
801.41;+86084,;100~NATIONAL
801.412;+86085,+86084,;.01~5
801.412;+86085,+86084,;2~VA-ONC BLANK
801.412;+86085,+86084,;9~YES
801.44;+86086,+86084,;.01~06/09/2026@10:31:11
801.44;+86086,+86084,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86085^1
86086^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 DOCE OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>86085</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>645545480</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86085,;.01~VA-GP ONC PRCA CRPC M1 <=2 DOCE OFF PATHWAY
801.41;+86085,;4~dialog group
801.41;+86085,;6~YES
801.41;+86085,;7~2
801.41;+86085,;23~YES
801.41;+86085,;25~WP-start~1
Off pathway:
801.41;+86085,;100~NATIONAL
801.412;+86086,+86085,;.01~10
801.412;+86086,+86085,;2~VA-ONC PRCA CRPC M1 <=2 DOCE OFF PATH TX
801.412;+86087,+86085,;.01~20
801.412;+86087,+86085,;2~VA-ONC PRCA CRPC M1 <=2 DOCE OFF PATH REASON
801.44;+86088,+86085,;.01~06/09/2026@10:31:11
801.44;+86088,+86085,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86086^1
86087^2
86088^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 DOCE CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>86078</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2883320335</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86078,;.01~VA-ONC PRCA CRPC M1 <=2 DOCE CLIN TRIAL
801.41;+86078,;4~dialog element
801.41;+86078,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ DOCE CLIN TRIAL
801.41;+86078,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+86078,;35~WP-start~1
Veteran has elected to pursue:
801.41;+86078,;100~NATIONAL
801.412;+86079,+86078,;.01~5
801.412;+86079,+86078,;2~VA-ONC CLINICAL TRIAL
801.412;+86079,+86078,;9~YES
801.44;+86080,+86078,;.01~06/09/2026@10:31:11
801.44;+86080,+86078,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86079^1
86080^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 DOCE DOCETAXEL</POINT_01>
<INTERNAL_ENTRY_NUMBER>86077</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1049515295</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86077,;.01~VA-ONC PRCA CRPC M1 <=2 DOCE DOCETAXEL
801.41;+86077,;4~dialog element
801.41;+86077,;15~HF.VA-ONC PRCA CRPC M1 1ST ECOG <=2 ARPI+ DOCE DOCETAXEL+ADT
801.41;+86077,;25~WP-start~1
Docetaxel and ADT
801.41;+86077,;35~WP-start~2
Veteran has elected to pursue TREATMENT with DOCETAXEL and ANDROGEN 
DEPRIVATION THERAPY (ADT).
801.41;+86077,;100~NATIONAL
801.44;+86078,+86077,;.01~06/09/2026@10:31:11
801.44;+86078,+86077,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86078^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 PRIOR DOCE CAND</POINT_01>
<INTERNAL_ENTRY_NUMBER>86075</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>778444414</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86075,;.01~VA-GP ONC PRCA CRPC M1 <=2 PRIOR DOCE CAND
801.41;+86075,;4~dialog group
801.41;+86075,;6~YES
801.41;+86075,;7~2
801.41;+86075,;9~ONE SELECTION ONLY
801.41;+86075,;25~WP-start~1
Candidate for docetaxel:
801.41;+86075,;100~NATIONAL
801.412;+86076,+86075,;.01~10
801.412;+86076,+86075,;2~VA-ONC PRCA CRPC M1 <=2 DOCE DOCETAXEL
801.412;+86077,+86075,;.01~5
801.412;+86077,+86075,;2~VA-ONC PRCA CRPC M1 <=2 DOCE CLIN TRIAL
801.412;+86078,+86075,;.01~20
801.412;+86078,+86075,;2~VA-GP ONC PRCA CRPC M1 <=2 DOCE OFF PATHWAY
801.44;+86079,+86075,;.01~06/09/2026@10:31:11
801.44;+86079,+86075,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86076^1
86077^2
86078^3
86079^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 PRIOR ARPI</POINT_01>
<INTERNAL_ENTRY_NUMBER>86074</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3539650757</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86074,;.01~VA-GP ONC PRCA CRPC M1 <=2 PRIOR ARPI
801.41;+86074,;4~dialog group
801.41;+86074,;6~YES
801.41;+86074,;7~2
801.41;+86074,;9~ONE SELECTION ONLY
801.41;+86074,;25~WP-start~1
Prior ARPI (Androgen Receptor Pathway Inhibitors) Therapy:
801.41;+86074,;52~INDENT
801.41;+86074,;100~NATIONAL
801.412;+86075,+86074,;.01~20
801.412;+86075,+86074,;2~VA-GP ONC PRCA CRPC M1 <=2 PRIOR DOCE CAND
801.412;+86076,+86074,;.01~40
801.412;+86076,+86074,;2~VA-GP ONC PRCA CRPC M1 <=2 PRIOR NO DOCE CAND
801.44;+86077,+86074,;.01~06/09/2026@10:31:11
801.44;+86077,+86074,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86075^1
86076^2
86077^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>55840</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3532045703</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+55840,;.01~VA-GP ONC PRCA CRPC M1 <=2 SUBMAIN
801.41;+55840,;4~dialog group
801.41;+55840,;6~YES
801.41;+55840,;9~NONE OR ONE SELECTION
801.41;+55840,;51~SUPPRESS
801.41;+55840,;100~NATIONAL
801.412;+55841,+55840,;.01~20
801.412;+55841,+55840,;2~VA-GP ONC PRCA CRPC M1 <=2 PRIOR ARPI
801.412;+55842,+55840,;.01~40
801.412;+55842,+55840,;2~VA-GP ONC PRCA CRPC M1 <=2 NO PRIOR ARPI
801.44;+55843,+55840,;.01~06/09/2026@10:31:11
801.44;+55843,+55840,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
55841^1
55842^2
55843^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 VIEW BOX</POINT_01>
<INTERNAL_ENTRY_NUMBER>55839</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1531348403</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+55839,;.01~VA-ONC PRCA CRPC M1 <=2 VIEW BOX
801.41;+55839,;4~dialog element
801.41;+55839,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+55839,;23~YES
801.41;+55839,;25~WP-start~1
++ Testosterone goal less than 50 ++
801.41;+55839,;35~WP-start~18
ARPI:\\ -includes abiraterone, apalutamide, darolutamide, enzalutamide
 
Lu177-PSMA contraindications:\\ -cannot be given with radium 223,
cabazitaxel, or investigational product;\\  patient can continue standard
care i.e. AR-directed therapy
 
Olaparib:\\ -prescribe if patient has HRRm (Homologous Recombination
Repair mutation)
 
Pembrolizumab:\\ -prescribe if patient has MSI-H (microsatellite 
instability-high),\\  dMMR (deficient mismatch repair) or TMB high in
tumor agnostic fashion
 
Radium 223:\\ -prescribe if patient has symptomatic bone metastases and no
visceral disease
 
Abiraterone:\\ -if bone only disease; or if not a candidate for 
abiraterone,\\  consider radium plus enzalutamide
801.41;+55839,;51~SUPPRESS
801.41;+55839,;100~NATIONAL
801.412;+55840,+55839,;.01~5
801.412;+55840,+55839,;2~PXRM GF VIEW BUTTON
801.412;+55840,+55839,;6~VIEW pathway footnotes
801.412;+55840,+55839,;8~YES
801.44;+55841,+55839,;.01~06/09/2026@10:31:11
801.44;+55841,+55839,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
55840^1
55841^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 MAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>44113</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1420511797</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44113,;.01~VA-GP ONC PRCA CRPC M1 <=2 MAIN
801.41;+44113,;4~dialog group
801.41;+44113,;6~YES
801.41;+44113,;7~2
801.41;+44113,;25~WP-start~1
Adenocarcinoma (ECOG 0-1-2):
801.41;+44113,;52~INDENT
801.41;+44113,;100~NATIONAL
801.412;+44114,+44113,;.01~20
801.412;+44114,+44113,;2~VA-ONC PRCA CRPC M1 <=2 VIEW BOX
801.412;+44115,+44113,;.01~40
801.412;+44115,+44113,;2~VA-GP ONC PRCA CRPC M1 <=2 SUBMAIN
801.44;+44116,+44113,;.01~06/09/2026@10:31:11
801.44;+44116,+44113,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44114^3
44115^4
44116^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 FIRST LINE</POINT_01>
<INTERNAL_ENTRY_NUMBER>44116</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1813383730</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44116,;.01~VA-GP ONC PRCA CRPC M1 FIRST LINE
801.41;+44116,;4~dialog group
801.41;+44116,;6~YES
801.41;+44116,;7~2
801.41;+44116,;9~NONE OR ONE SELECTION
801.41;+44116,;25~WP-start~1
First Line:
801.41;+44116,;52~INDENT
801.41;+44116,;100~NATIONAL
801.412;+44117,+44116,;.01~20
801.412;+44117,+44116,;2~VA-GP ONC PRCA CRPC M1 <=2 MAIN
801.412;+44118,+44116,;.01~40
801.412;+44118,+44116,;2~VA-GP ONC PRCA CRPC M1 >2 MAIN
801.412;+44119,+44116,;.01~60
801.412;+44119,+44116,;2~VA-GP ONC PRCA CRPC M1 NEUROENDO COMP
801.44;+44120,+44116,;.01~06/09/2026@10:31:11
801.44;+44120,+44116,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44117^1
44118^2
44119^3
44120^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD VIEW BOX</POINT_01>
<INTERNAL_ENTRY_NUMBER>103447</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3146003969</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+103447,;.01~VA-ONC PRCA CRPC M1 <=2 3RD VIEW BOX
801.41;+103447,;4~dialog element
801.41;+103447,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+103447,;23~YES
801.41;+103447,;25~WP-start~1
++ Testosterone goal less than 50 ++
801.41;+103447,;35~WP-start~25
Docetaxel:\\ -if greater than 3 months since docetaxel and no 
disease\\  progression on docetaxel
 
Lu177-PSMA contraindications:\\ -cannot be given with radium 223,
cabazitaxel, or investigational product;\\  patient can continue standard
care i.e. AR-directed therapy
 
Abiraterone:\\ -prescribe if not previously received (response unlikely 
if previously\\  progressed on enzalutamide or other androgen receptor 
antagonist)
 
Enzalutamide:\\ -prescribe if not previously received (response unlikely 
if previously\\  progressed on abiraterone); contraindications include 
severe impairment\\  (CrCl <30ml/min), seizure history, and/or brain 
metastases/active\\  epidural disease
 
Olaparib:\\ -prescribe if patient has HRRm (Homologous Recombination
Repair mutation)
 
Pembrolizumab:\\ -prescribe if patient has MSI-H (microsatellite 
instability-high),\\  dMMR (deficient mismatch repair) or TMB high in
tumor agnostic fashion
 
Radium 223:\\ -prescribe if patient has symptomatic bone metastases and no
visceral disease
801.41;+103447,;51~SUPPRESS
801.41;+103447,;100~NATIONAL
801.412;+103448,+103447,;.01~5
801.412;+103448,+103447,;2~PXRM GF VIEW BUTTON
801.412;+103448,+103447,;6~VIEW pathway footnotes
801.412;+103448,+103447,;8~YES
801.44;+103449,+103447,;.01~06/09/2026@10:31:11
801.44;+103449,+103447,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
103448^1
103449^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD LU177 N OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>109261</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3099217112</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109261,;.01~VA-ONC PRCA CRPC M1 <=2 3RD LU177 N OFF PATH RSN
801.41;+109261,;4~dialog element
801.41;+109261,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- OFF PATH RSN
801.41;+109261,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+109261,;51~SUPPRESS
801.41;+109261,;100~NATIONAL
801.412;+109262,+109261,;.01~5
801.412;+109262,+109261,;2~VA-ONC OFF PATHWAY
801.412;+109262,+109261,;7~YES
801.412;+109262,+109261,;9~YES
801.44;+109263,+109261,;.01~06/09/2026@10:31:11
801.44;+109263,+109261,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109262^1
109263^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD LU177 N OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>109263</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1762328446</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109263,;.01~VA-ONC PRCA CRPC M1 <=2 3RD LU177 N OFF PATH TX
801.41;+109263,;4~dialog element
801.41;+109263,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- OFF PATH TX
801.41;+109263,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+109263,;51~SUPPRESS
801.41;+109263,;100~NATIONAL
801.412;+109264,+109263,;.01~5
801.412;+109264,+109263,;2~VA-ONC BLANK
801.412;+109264,+109263,;9~YES
801.44;+109265,+109263,;.01~06/09/2026@10:31:11
801.44;+109265,+109263,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109264^1
109265^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 3RD LU177 N OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>109259</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3825570521</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109259,;.01~VA-GP ONC PRCA CRPC M1 <=2 3RD LU177 N OFF PATH
801.41;+109259,;4~dialog group
801.41;+109259,;6~YES
801.41;+109259,;7~2
801.41;+109259,;23~YES
801.41;+109259,;25~WP-start~1
Off pathway:
801.41;+109259,;100~NATIONAL
801.412;+109260,+109259,;.01~10
801.412;+109260,+109259,;2~VA-ONC PRCA CRPC M1 <=2 3RD LU177 N OFF PATH TX
801.412;+109261,+109259,;.01~20
801.412;+109261,+109259,;2~VA-ONC PRCA CRPC M1 <=2 3RD LU177 N OFF PATH RSN
801.44;+109262,+109259,;.01~06/09/2026@10:31:11
801.44;+109262,+109259,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109260^1
109261^2
109262^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD LUI77 N RADIUM</POINT_01>
<INTERNAL_ENTRY_NUMBER>109268</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>889183654</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109268,;.01~VA-ONC PRCA CRPC M1 <=2 3RD LUI77 N RADIUM
801.41;+109268,;4~dialog element
801.41;+109268,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- RADIUM+ADT
801.41;+109268,;25~WP-start~1
Radium 223 and ADT
801.41;+109268,;35~WP-start~2
Veteran has elected to pursue TREATMENT with RADIUM 223 and ANDROGEN 
DEPRIVATION THERAPY (ADT).
801.41;+109268,;100~NATIONAL
801.44;+109269,+109268,;.01~06/09/2026@10:31:11
801.44;+109269,+109268,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109269^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD LUI77 N PEMBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>109267</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1052818402</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109267,;.01~VA-ONC PRCA CRPC M1 <=2 3RD LUI77 N PEMBRO
801.41;+109267,;4~dialog element
801.41;+109267,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- PEMBRO+ADT
801.41;+109267,;25~WP-start~1
Pembrolizumab and ADT
801.41;+109267,;35~WP-start~2
Veteran has elected to pursue TREATMENT with PEMBROLIZUMAB and ANDROGEN 
DEPRIVATION THERAPY (ADT).
801.41;+109267,;100~NATIONAL
801.44;+109268,+109267,;.01~06/09/2026@10:31:11
801.44;+109268,+109267,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109268^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD LUI77 N OLAP</POINT_01>
<INTERNAL_ENTRY_NUMBER>109266</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2763830609</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109266,;.01~VA-ONC PRCA CRPC M1 <=2 3RD LUI77 N OLAP
801.41;+109266,;4~dialog element
801.41;+109266,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- OLAP+ADT
801.41;+109266,;25~WP-start~1
Olaparib and ADT
801.41;+109266,;35~WP-start~2
Veteran has elected to pursue TREATMENT with OLAPARIB and ANDROGEN 
DEPRIVATION THERAPY (ADT).
801.41;+109266,;100~NATIONAL
801.44;+109267,+109266,;.01~06/09/2026@10:31:11
801.44;+109267,+109266,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109267^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD LUI77 N ENZA</POINT_01>
<INTERNAL_ENTRY_NUMBER>109265</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2013567714</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109265,;.01~VA-ONC PRCA CRPC M1 <=2 3RD LUI77 N ENZA
801.41;+109265,;4~dialog element
801.41;+109265,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- ENZA+ADT
801.41;+109265,;25~WP-start~1
Enzalutamide and ADT
801.41;+109265,;35~WP-start~2
Veteran has elected to pursue TREATMENT with ENZALUTAMIDE and ANDROGEN 
DEPRIVATION THERAPY (ADT).
801.41;+109265,;100~NATIONAL
801.44;+109266,+109265,;.01~06/09/2026@10:31:11
801.44;+109266,+109265,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109266^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD LUI77 N ABI+PRED</POINT_01>
<INTERNAL_ENTRY_NUMBER>109264</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1584149664</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109264,;.01~VA-ONC PRCA CRPC M1 <=2 3RD LUI77 N ABI+PRED
801.41;+109264,;4~dialog element
801.41;+109264,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- ABI+PRED+ADT
801.41;+109264,;25~WP-start~1
Abiraterone, prednisone, and ADT
801.41;+109264,;35~WP-start~2
Veteran has elected to pursue TREATMENT with ABIRATERONE, PREDNISONE and
ANDROGEN DEPRIVATION THERAPY (ADT).
801.41;+109264,;100~NATIONAL
801.44;+109265,+109264,;.01~06/09/2026@10:31:11
801.44;+109265,+109264,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109265^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD LU177 N CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>109256</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>520838321</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109256,;.01~VA-ONC PRCA CRPC M1 <=2 3RD LU177 N CLIN TRIAL
801.41;+109256,;4~dialog element
801.41;+109256,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177- CLIN TRIAL
801.41;+109256,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+109256,;35~WP-start~1
Veteran has elected to pursue:
801.41;+109256,;100~NATIONAL
801.412;+109257,+109256,;.01~5
801.412;+109257,+109256,;2~VA-ONC CLINICAL TRIAL
801.412;+109257,+109256,;9~YES
801.44;+109258,+109256,;.01~06/09/2026@10:31:11
801.44;+109258,+109256,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109257^1
109258^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 3RD LU177 CAND NO</POINT_01>
<INTERNAL_ENTRY_NUMBER>109269</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1279724339</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109269,;.01~VA-GP ONC PRCA CRPC M1 <=2 3RD LU177 CAND NO
801.41;+109269,;4~dialog group
801.41;+109269,;6~YES
801.41;+109269,;7~2
801.41;+109269,;9~NONE OR ONE SELECTION
801.41;+109269,;25~WP-start~1
Not a candidate for LU177-PSMA:
801.41;+109269,;100~NATIONAL
801.412;+109270,+109269,;.01~10
801.412;+109270,+109269,;2~VA-ONC PRCA CRPC M1 <=2 3RD LU177 N CLIN TRIAL
801.412;+109271,+109269,;.01~20
801.412;+109271,+109269,;2~VA-ONC PRCA CRPC M1 <=2 3RD LUI77 N ABI+PRED
801.412;+109272,+109269,;.01~30
801.412;+109272,+109269,;2~VA-ONC PRCA CRPC M1 <=2 3RD LUI77 N ENZA
801.412;+109273,+109269,;.01~40
801.412;+109273,+109269,;2~VA-ONC PRCA CRPC M1 <=2 3RD LUI77 N OLAP
801.412;+109274,+109269,;.01~50
801.412;+109274,+109269,;2~VA-ONC PRCA CRPC M1 <=2 3RD LUI77 N PEMBRO
801.412;+109275,+109269,;.01~60
801.412;+109275,+109269,;2~VA-ONC PRCA CRPC M1 <=2 3RD LUI77 N RADIUM
801.412;+109276,+109269,;.01~70
801.412;+109276,+109269,;2~VA-GP ONC PRCA CRPC M1 <=2 3RD LU177 N OFF PATH
801.44;+109277,+109269,;.01~06/09/2026@10:31:11
801.44;+109277,+109269,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109270^1
109271^2
109272^3
109273^4
109274^5
109275^6
109276^7
109277^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD LU177 Y OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>109260</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1127077130</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109260,;.01~VA-ONC PRCA CRPC M1 <=2 3RD LU177 Y OFF PATH RSN
801.41;+109260,;4~dialog element
801.41;+109260,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177+ OFF PATH RSN
801.41;+109260,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+109260,;51~SUPPRESS
801.41;+109260,;100~NATIONAL
801.412;+109261,+109260,;.01~5
801.412;+109261,+109260,;2~VA-ONC OFF PATHWAY
801.412;+109261,+109260,;7~YES
801.412;+109261,+109260,;9~YES
801.44;+109262,+109260,;.01~06/09/2026@10:31:11
801.44;+109262,+109260,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109261^1
109262^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD LU177 Y OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>109262</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3455909294</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109262,;.01~VA-ONC PRCA CRPC M1 <=2 3RD LU177 Y OFF PATH TX
801.41;+109262,;4~dialog element
801.41;+109262,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177+ OFF PATH TX
801.41;+109262,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+109262,;51~SUPPRESS
801.41;+109262,;100~NATIONAL
801.412;+109263,+109262,;.01~5
801.412;+109263,+109262,;2~VA-ONC BLANK
801.412;+109263,+109262,;9~YES
801.44;+109264,+109262,;.01~06/09/2026@10:31:11
801.44;+109264,+109262,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109263^1
109264^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 3RD LU177 Y OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>109258</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2776730203</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109258,;.01~VA-GP ONC PRCA CRPC M1 <=2 3RD LU177 Y OFF PATH
801.41;+109258,;4~dialog group
801.41;+109258,;6~YES
801.41;+109258,;7~2
801.41;+109258,;23~YES
801.41;+109258,;25~WP-start~1
Off pathway:
801.41;+109258,;100~LOCAL
801.412;+109259,+109258,;.01~10
801.412;+109259,+109258,;2~VA-ONC PRCA CRPC M1 <=2 3RD LU177 Y OFF PATH TX
801.412;+109260,+109258,;.01~20
801.412;+109260,+109258,;2~VA-ONC PRCA CRPC M1 <=2 3RD LU177 Y OFF PATH RSN
801.44;+109261,+109258,;.01~06/09/2026@10:31:11
801.44;+109261,+109258,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109259^1
109260^2
109261^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD LU177 Y LU177 PSMA</POINT_01>
<INTERNAL_ENTRY_NUMBER>109257</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2487434081</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109257,;.01~VA-ONC PRCA CRPC M1 <=2 3RD LU177 Y LU177 PSMA
801.41;+109257,;4~dialog element
801.41;+109257,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177+ LU177-PSMA+ADT
801.41;+109257,;25~WP-start~1
Lutetium-177 PSMA and ADT
801.41;+109257,;35~WP-start~2
Veteran has elected to pursue TREATMENT with LUTETIUM-177 PROSTATE 
SPECIFIC MEMBRANE ANTIGEN (PSMA) and ANDROGEN DEPRIVATION THERAPY (ADT).
801.41;+109257,;100~NATIONAL
801.44;+109258,+109257,;.01~06/09/2026@10:31:11
801.44;+109258,+109257,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109258^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD LU177 Y CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>109255</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3233465520</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109255,;.01~VA-ONC PRCA CRPC M1 <=2 3RD LU177 Y CLIN TRIAL
801.41;+109255,;4~dialog element
801.41;+109255,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX-/LU177+ CLIN TRIAL
801.41;+109255,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+109255,;35~WP-start~1
Veteran has elected to pursue:
801.41;+109255,;100~NATIONAL
801.412;+109256,+109255,;.01~5
801.412;+109256,+109255,;2~VA-ONC CLINICAL TRIAL
801.412;+109256,+109255,;9~YES
801.44;+109257,+109255,;.01~06/09/2026@10:31:11
801.44;+109257,+109255,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109256^1
109257^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 3RD LU177 CAND YES</POINT_01>
<INTERNAL_ENTRY_NUMBER>109270</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2079000470</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109270,;.01~VA-GP ONC PRCA CRPC M1 <=2 3RD LU177 CAND YES
801.41;+109270,;4~dialog group
801.41;+109270,;6~YES
801.41;+109270,;7~2
801.41;+109270,;9~NONE OR ONE SELECTION
801.41;+109270,;25~WP-start~1
Candidate for LU177-PSMA:
801.41;+109270,;100~NATIONAL
801.412;+109271,+109270,;.01~10
801.412;+109271,+109270,;2~VA-ONC PRCA CRPC M1 <=2 3RD LU177 Y CLIN TRIAL
801.412;+109272,+109270,;.01~20
801.412;+109272,+109270,;2~VA-ONC PRCA CRPC M1 <=2 3RD LU177 Y LU177 PSMA
801.412;+109273,+109270,;.01~30
801.412;+109273,+109270,;2~VA-GP ONC PRCA CRPC M1 <=2 3RD LU177 Y OFF PATH
801.44;+109274,+109270,;.01~06/09/2026@10:31:11
801.44;+109274,+109270,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109271^1
109272^2
109273^3
109274^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 3RD CONTRA TAX SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>109271</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1248880684</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109271,;.01~VA-GP ONC PRCA CRPC M1 <=2 3RD CONTRA TAX SUBMAIN
801.41;+109271,;4~dialog group
801.41;+109271,;6~YES
801.41;+109271,;7~2
801.41;+109271,;9~NONE OR ONE SELECTION
801.41;+109271,;25~WP-start~1
Not a candidate for taxane:
801.41;+109271,;52~INDENT
801.41;+109271,;100~NATIONAL
801.412;+109272,+109271,;.01~15
801.412;+109272,+109271,;2~VA-GP ONC PRCA CRPC M1 <=2 3RD LU177 CAND YES
801.412;+109273,+109271,;.01~30
801.412;+109273,+109271,;2~VA-GP ONC PRCA CRPC M1 <=2 3RD LU177 CAND NO
801.44;+109274,+109271,;.01~06/09/2026@10:31:11
801.44;+109274,+109271,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109272^1
109273^2
109274^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD NO CONTRA TAX CAB</POINT_01>
<INTERNAL_ENTRY_NUMBER>109250</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2777837945</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109250,;.01~VA-ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX CAB
801.41;+109250,;4~dialog element
801.41;+109250,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX CABAZITAXEL+ADT
801.41;+109250,;25~WP-start~1
Cabazitaxel and ADT
801.41;+109250,;35~WP-start~2
Veteran has elected to pursue TREATMENT with CABAZITAXEL and ANDROGEN
DEPRIVATION THERAPY (ADT).
801.41;+109250,;100~NATIONAL
801.44;+109251,+109250,;.01~06/09/2026@10:31:11
801.44;+109251,+109250,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109251^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD NO CONTRA TAX OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>109251</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2329567857</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109251,;.01~VA-ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX OFF PATH RSN
801.41;+109251,;4~dialog element
801.41;+109251,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX OFF PATH RSN
801.41;+109251,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+109251,;51~SUPPRESS
801.41;+109251,;100~NATIONAL
801.412;+109252,+109251,;.01~5
801.412;+109252,+109251,;2~VA-ONC OFF PATHWAY
801.412;+109252,+109251,;7~YES
801.412;+109252,+109251,;9~YES
801.44;+109253,+109251,;.01~06/09/2026@10:31:11
801.44;+109253,+109251,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109252^1
109253^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD NO CONTRA TAX OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>109252</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3147565559</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109252,;.01~VA-ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX OFF PATH TX
801.41;+109252,;4~dialog element
801.41;+109252,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX OFF PATH TX
801.41;+109252,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+109252,;51~SUPPRESS
801.41;+109252,;100~NATIONAL
801.412;+109253,+109252,;.01~5
801.412;+109253,+109252,;2~VA-ONC BLANK
801.412;+109253,+109252,;9~YES
801.44;+109254,+109252,;.01~06/09/2026@10:31:11
801.44;+109254,+109252,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109253^1
109254^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 3RD NO CONTRA TAX OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>109253</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3316431682</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109253,;.01~VA-GP ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX OFF PATH
801.41;+109253,;4~dialog group
801.41;+109253,;6~YES
801.41;+109253,;7~2
801.41;+109253,;23~YES
801.41;+109253,;25~WP-start~1
Off pathway:
801.41;+109253,;100~NATIONAL
801.412;+109254,+109253,;.01~10
801.412;+109254,+109253,;2~VA-ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX OFF PATH TX
801.412;+109255,+109253,;.01~20
801.412;+109255,+109253,;2~VA-ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX OFF PATH RSN
801.44;+109256,+109253,;.01~06/09/2026@10:31:11
801.44;+109256,+109253,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109254^1
109255^2
109256^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD NO CONTRA TAX DOCE</POINT_01>
<INTERNAL_ENTRY_NUMBER>109249</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3761534809</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109249,;.01~VA-ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX DOCE
801.41;+109249,;4~dialog element
801.41;+109249,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX DOCETAXEL+ADT
801.41;+109249,;25~WP-start~1
Docetaxel and ADT
801.41;+109249,;35~WP-start~2
Veteran has elected to pursue TREATMENT with DOCETAXEL and ANDROGEN
DEPRIVATION THERAPY (ADT).
801.41;+109249,;100~NATIONAL
801.44;+109250,+109249,;.01~06/09/2026@10:31:11
801.44;+109250,+109249,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109250^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 3RD NO CONTRA TAX CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>109248</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3805969055</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109248,;.01~VA-ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX CLIN TRIAL
801.41;+109248,;4~dialog element
801.41;+109248,;15~HF.VA-ONC PRCA CRPC M1 3RD ECOG <=2 TAX CLIN TRIAL
801.41;+109248,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+109248,;35~WP-start~1
Veteran has elected to pursue:
801.41;+109248,;100~NATIONAL
801.412;+109249,+109248,;.01~5
801.412;+109249,+109248,;2~VA-ONC CLINICAL TRIAL
801.412;+109249,+109248,;9~YES
801.44;+109250,+109248,;.01~06/09/2026@10:31:11
801.44;+109250,+109248,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109249^1
109250^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 3RD NO CONTRA TAX SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>109254</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1316047153</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+109254,;.01~VA-GP ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX SUBMAIN
801.41;+109254,;4~dialog group
801.41;+109254,;6~YES
801.41;+109254,;7~2
801.41;+109254,;9~NONE OR ONE SELECTION
801.41;+109254,;25~WP-start~1
Candidate for taxane:
801.41;+109254,;52~INDENT
801.41;+109254,;100~NATIONAL
801.412;+109255,+109254,;.01~10
801.412;+109255,+109254,;2~VA-ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX CLIN TRIAL
801.412;+109256,+109254,;.01~20
801.412;+109256,+109254,;2~VA-ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX DOCE
801.412;+109257,+109254,;.01~40
801.412;+109257,+109254,;2~VA-GP ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX OFF PATH
801.412;+109258,+109254,;.01~30
801.412;+109258,+109254,;2~VA-ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX CAB
801.44;+109259,+109254,;.01~06/09/2026@10:31:11
801.44;+109259,+109254,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
109255^1
109256^2
109257^4
109258^5
109259^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 3RD SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>56498</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4116204853</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+56498,;.01~VA-GP ONC PRCA CRPC M1 <=2 3RD SUBMAIN
801.41;+56498,;4~dialog group
801.41;+56498,;6~YES
801.41;+56498,;9~NONE OR ONE SELECTION
801.41;+56498,;51~SUPPRESS
801.41;+56498,;100~NATIONAL
801.412;+56499,+56498,;.01~20
801.412;+56499,+56498,;2~VA-GP ONC PRCA CRPC M1 <=2 3RD NO CONTRA TAX SUBMAIN
801.412;+56500,+56498,;.01~40
801.412;+56500,+56498,;2~VA-GP ONC PRCA CRPC M1 <=2 3RD CONTRA TAX SUBMAIN
801.44;+56501,+56498,;.01~06/09/2026@10:31:11
801.44;+56501,+56498,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
56499^3
56500^4
56501^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 3RD MAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>53188</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2994054038</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53188,;.01~VA-GP ONC PRCA CRPC M1 <=2 3RD MAIN
801.41;+53188,;4~dialog group
801.41;+53188,;6~YES
801.41;+53188,;7~2
801.41;+53188,;25~WP-start~1
Third line (ECOG 0-1-2, after ARPI and Docetaxel):
801.41;+53188,;52~INDENT
801.41;+53188,;100~NATIONAL
801.412;+53189,+53188,;.01~20
801.412;+53189,+53188,;2~VA-GP ONC PRCA CRPC M1 <=2 3RD SUBMAIN
801.412;+53190,+53188,;.01~10
801.412;+53190,+53188,;2~VA-ONC PRCA CRPC M1 <=2 3RD VIEW BOX
801.44;+53191,+53188,;.01~06/09/2026@10:31:11
801.44;+53191,+53188,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53189^6
53190^7
53191^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 2ND VIEW BOX</POINT_01>
<INTERNAL_ENTRY_NUMBER>103475</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2077718027</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+103475,;.01~VA-ONC PRCA CRPC M1 <=2 2ND VIEW BOX
801.41;+103475,;4~dialog element
801.41;+103475,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+103475,;23~YES
801.41;+103475,;25~WP-start~1
++ Testosterone goal less than 50 ++
801.41;+103475,;35~WP-start~14
 
Lu177-PSMA contraindications:\\ -cannot be given with radium 223,
cabazitaxel, or investigational product;\\  patient can continue standard
care i.e. AR-directed therapy
 
Olaparib:\\ -prescribe if patient has HRRm (Homologous Recombination
Repair mutation)
 
Pembrolizumab:\\ -prescribe if patient has MSI-H (microsatellite 
instability-high),\\  dMMR (deficient mismatch repair) or TMB high in
tumor agnostic fashion
 
Radium 223:\\ -prescribe if patient has symptomatic bone metastases and no
visceral disease
801.41;+103475,;51~SUPPRESS
801.41;+103475,;100~NATIONAL
801.412;+103476,+103475,;.01~5
801.412;+103476,+103475,;2~PXRM GF VIEW BUTTON
801.412;+103476,+103475,;6~VIEW pathway footnotes
801.412;+103476,+103475,;8~YES
801.44;+103477,+103475,;.01~06/09/2026@10:31:11
801.44;+103477,+103475,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
103476^1
103477^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE YES ENZALUTAMIDE</POINT_01>
<INTERNAL_ENTRY_NUMBER>44498</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>368160798</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44498,;.01~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES ENZALUTAMIDE
801.41;+44498,;4~dialog element
801.41;+44498,;15~HF.VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE ENZALUT+ADT
801.41;+44498,;25~WP-start~1
Enzalutamide and ADT
801.41;+44498,;35~WP-start~2
Veteran has elected to pursue TREATMENT with ENZALUTAMIDE and ANDROGEN 
DEPRIVATION THERAPY (ADT).
801.41;+44498,;100~NATIONAL
801.44;+44499,+44498,;.01~06/09/2026@10:31:11
801.44;+44499,+44498,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44499^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE YES RADIUM 223</POINT_01>
<INTERNAL_ENTRY_NUMBER>44768</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2905177795</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44768,;.01~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES RADIUM 223
801.41;+44768,;4~dialog element
801.41;+44768,;15~HF.VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE RADIUM 223+ADT
801.41;+44768,;25~WP-start~1
Radium 223 and ADT
801.41;+44768,;35~WP-start~2
Veteran has elected to pursue TREATMENT with RADIUM 223 and ANDROGEN 
DEPRIVATION THERAPY (ADT).
801.41;+44768,;100~NATIONAL
801.44;+44769,+44768,;.01~06/09/2026@10:31:11
801.44;+44769,+44768,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44769^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE YES PEMBROLIZUMAB</POINT_01>
<INTERNAL_ENTRY_NUMBER>44098</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1669290336</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44098,;.01~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES PEMBROLIZUMAB
801.41;+44098,;4~dialog element
801.41;+44098,;15~HF.VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE PEMBRO+ADT
801.41;+44098,;25~WP-start~1
Pembrolizumab and ADT
801.41;+44098,;35~WP-start~2
Veteran has elected to pursue TREATMENT with PEMBROLIZUMAB ANDROGEN 
DEPRIVATION THERAPY (ADT).
801.41;+44098,;100~NATIONAL
801.44;+44099,+44098,;.01~06/09/2026@10:31:11
801.44;+44099,+44098,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44099^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE YES OLAPARIB</POINT_01>
<INTERNAL_ENTRY_NUMBER>44769</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3316778873</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44769,;.01~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES OLAPARIB
801.41;+44769,;4~dialog element
801.41;+44769,;15~HF.VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE OLAPARIB+ADT
801.41;+44769,;25~WP-start~1
Olaparib and ADT
801.41;+44769,;35~WP-start~2
Veteran has elected to pursue TREATMENT with OLAPARIB and ANDROGEN 
DEPRIVATION THERAPY (ADT).
801.41;+44769,;100~NATIONAL
801.44;+44770,+44769,;.01~06/09/2026@10:31:11
801.44;+44770,+44769,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44770^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE YES LU177</POINT_01>
<INTERNAL_ENTRY_NUMBER>74179</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>634476098</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+74179,;.01~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES LU177
801.41;+74179,;4~dialog element
801.41;+74179,;15~HF.VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE LU177+ADT
801.41;+74179,;25~WP-start~1
Lutetium 177-PSMA and ADT
801.41;+74179,;35~WP-start~2
Veteran has elected to pursue TREATMENT with LUTETIUM 177-PSMA (prostate 
specific membrane antigen) and ANDROGEN DEPRIVATION THERAPY (ADT).
801.41;+74179,;100~NATIONAL
801.44;+74180,+74179,;.01~06/09/2026@10:31:11
801.44;+74180,+74179,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
74180^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE YES OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>53376</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4266977319</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53376,;.01~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES OFF PATH RSN
801.41;+53376,;4~dialog element
801.41;+53376,;15~HF.VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE OFF PATH RSN
801.41;+53376,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+53376,;51~SUPPRESS
801.41;+53376,;100~NATIONAL
801.412;+53377,+53376,;.01~5
801.412;+53377,+53376,;2~VA-ONC OFF PATHWAY
801.412;+53377,+53376,;7~YES
801.412;+53377,+53376,;9~YES
801.44;+53378,+53376,;.01~06/09/2026@10:31:11
801.44;+53378,+53376,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53377^1
53378^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE YES OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>53375</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>571405614</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53375,;.01~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES OFF PATH TX
801.41;+53375,;4~dialog element
801.41;+53375,;15~HF.VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE OFF PATH TX
801.41;+53375,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+53375,;51~SUPPRESS
801.41;+53375,;100~NATIONAL
801.412;+53376,+53375,;.01~5
801.412;+53376,+53375,;2~VA-ONC BLANK
801.412;+53376,+53375,;9~YES
801.44;+53377,+53375,;.01~06/09/2026@10:31:11
801.44;+53377,+53375,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53376^1
53377^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE YES OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>53374</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2472250514</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53374,;.01~VA-GP ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES OFF PATHWAY
801.41;+53374,;4~dialog group
801.41;+53374,;6~YES
801.41;+53374,;7~2
801.41;+53374,;23~YES
801.41;+53374,;25~WP-start~1
Off pathway:
801.41;+53374,;100~NATIONAL
801.412;+53375,+53374,;.01~20
801.412;+53375,+53374,;2~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES OFF PATH TX
801.412;+53376,+53374,;.01~40
801.412;+53376,+53374,;2~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES OFF PATH RSN
801.44;+53377,+53374,;.01~06/09/2026@10:31:11
801.44;+53377,+53374,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53375^1
53376^2
53377^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE YES CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>53373</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>647228991</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53373,;.01~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES CLIN TRIAL
801.41;+53373,;4~dialog element
801.41;+53373,;15~HF.VA-ONC PRCA CRPC M1 2ND ECOG <=2 CONTRA DOCE CLINICAL TRIAL
801.41;+53373,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+53373,;35~WP-start~1
Veteran has elected to pursue:
801.41;+53373,;100~NATIONAL
801.412;+53374,+53373,;.01~5
801.412;+53374,+53373,;2~VA-ONC CLINICAL TRIAL
801.412;+53374,+53373,;9~YES
801.44;+53375,+53373,;.01~06/09/2026@10:31:11
801.44;+53375,+53373,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53374^1
53375^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE YES</POINT_01>
<INTERNAL_ENTRY_NUMBER>53185</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1488184183</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53185,;.01~VA-GP ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES
801.41;+53185,;4~dialog group
801.41;+53185,;6~YES
801.41;+53185,;7~2
801.41;+53185,;9~NONE OR ONE SELECTION
801.41;+53185,;25~WP-start~1
Not a candidate for docetaxel:
801.41;+53185,;100~NATIONAL
801.412;+53186,+53185,;.01~10
801.412;+53186,+53185,;2~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES CLIN TRIAL
801.412;+53187,+53185,;.01~90
801.412;+53187,+53185,;2~VA-GP ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES OFF PATHWAY
801.412;+53188,+53185,;.01~50
801.412;+53188,+53185,;2~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES LU177
801.412;+53189,+53185,;.01~60
801.412;+53189,+53185,;2~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES OLAPARIB
801.412;+53190,+53185,;.01~70
801.412;+53190,+53185,;2~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES PEMBROLIZUMAB
801.412;+53191,+53185,;.01~80
801.412;+53191,+53185,;2~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES RADIUM 223
801.412;+53192,+53185,;.01~20
801.412;+53192,+53185,;2~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES ENZALUTAMIDE
801.44;+53193,+53185,;.01~06/09/2026@10:31:11
801.44;+53193,+53185,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53186^13
53187^14
53188^18
53189^19
53190^20
53191^21
53192^22
53193^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE NO OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>53372</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1600513874</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53372,;.01~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE NO OFF PATH RSN
801.41;+53372,;4~dialog element
801.41;+53372,;15~HF.VA-ONC PRCA CRPC M1 2ND ECOG <=2 OFF PATH RSN
801.41;+53372,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+53372,;51~SUPPRESS
801.41;+53372,;100~NATIONAL
801.412;+53373,+53372,;.01~5
801.412;+53373,+53372,;2~VA-ONC OFF PATHWAY
801.412;+53373,+53372,;7~YES
801.412;+53373,+53372,;9~YES
801.44;+53374,+53372,;.01~06/09/2026@10:31:11
801.44;+53374,+53372,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53373^1
53374^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE NO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>53371</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2576521281</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53371,;.01~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE NO OFF PATH TX
801.41;+53371,;4~dialog element
801.41;+53371,;15~HF.VA-ONC PRCA CRPC M1 2ND ECOG <=2 OFF PATH TX
801.41;+53371,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+53371,;51~SUPPRESS
801.41;+53371,;100~NATIONAL
801.412;+53372,+53371,;.01~5
801.412;+53372,+53371,;2~VA-ONC BLANK
801.412;+53372,+53371,;9~YES
801.44;+53373,+53371,;.01~06/09/2026@10:31:11
801.44;+53373,+53371,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53372^1
53373^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE NO OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>53370</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3864481034</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+53370,;.01~VA-GP ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE NO OFF PATHWAY
801.41;+53370,;4~dialog group
801.41;+53370,;6~YES
801.41;+53370,;7~2
801.41;+53370,;23~YES
801.41;+53370,;25~WP-start~1
Off pathway:
801.41;+53370,;100~NATIONAL
801.412;+53371,+53370,;.01~20
801.412;+53371,+53370,;2~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE NO OFF PATH TX
801.412;+53372,+53370,;.01~40
801.412;+53372,+53370,;2~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE NO OFF PATH RSN
801.44;+53373,+53370,;.01~06/09/2026@10:31:11
801.44;+53373,+53370,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
53371^1
53372^2
53373^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE NO CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>45556</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2901063185</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+45556,;.01~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE NO CLINICAL TRIAL
801.41;+45556,;4~dialog element
801.41;+45556,;15~HF.VA-ONC PRCA CRPC M1 2ND ECOG <=2 CLIN TRIAL
801.41;+45556,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+45556,;35~WP-start~1
Veteran has elected to pursue:
801.41;+45556,;100~NATIONAL
801.412;+45557,+45556,;.01~5
801.412;+45557,+45556,;2~VA-ONC CLINICAL TRIAL
801.412;+45557,+45556,;9~YES
801.44;+45558,+45556,;.01~06/09/2026@10:31:11
801.44;+45558,+45556,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
45557^1
45558^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA CRPC M1 2ND CONTRA DOCE NO DOXETAXEL</POINT_01>
<INTERNAL_ENTRY_NUMBER>44519</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1554611600</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44519,;.01~VA-ONC PRCA CRPC M1 2ND CONTRA DOCE NO DOXETAXEL
801.41;+44519,;4~dialog element
801.41;+44519,;15~HF.VA-ONC PRCA CRPC M1 2ND ECOG <=2 DOCETAXEL+ADT
801.41;+44519,;25~WP-start~1
Docetaxel and ADT (until progression or intolerable toxicity)
801.41;+44519,;35~WP-start~2
Veteran has elected to pursue TREATMENT with DOCETAXEL and ANDROGEN 
DEPRIVATION THERAPY (ADT) until progression or intolerable toxicity.
801.41;+44519,;100~NATIONAL
801.44;+44520,+44519,;.01~06/09/2026@10:31:11
801.44;+44520,+44519,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44520^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 2ND CONTRA DOCE NO</POINT_01>
<INTERNAL_ENTRY_NUMBER>44122</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>255300334</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44122,;.01~VA-GP ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE NO
801.41;+44122,;4~dialog group
801.41;+44122,;6~YES
801.41;+44122,;7~2
801.41;+44122,;9~NONE OR ONE SELECTION
801.41;+44122,;25~WP-start~1
Candidate for docetaxel:
801.41;+44122,;100~NATIONAL
801.412;+44123,+44122,;.01~40
801.412;+44123,+44122,;2~VA-ONC PRCA CRPC M1 2ND CONTRA DOCE NO DOXETAXEL
801.412;+44124,+44122,;.01~20
801.412;+44124,+44122,;2~VA-ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE NO CLINICAL TRIAL
801.412;+44125,+44122,;.01~60
801.412;+44125,+44122,;2~VA-GP ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE NO OFF PATHWAY
801.44;+44126,+44122,;.01~06/09/2026@10:31:11
801.44;+44126,+44122,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44123^14
44124^15
44125^16
44126^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 2ND LINE SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>56028</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3365324359</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+56028,;.01~VA-GP ONC PRCA CRPC M1 <=2 2ND LINE SUBMAIN
801.41;+56028,;4~dialog group
801.41;+56028,;6~YES
801.41;+56028,;9~NONE OR ONE SELECTION
801.41;+56028,;51~SUPPRESS
801.41;+56028,;100~NATIONAL
801.412;+56029,+56028,;.01~20
801.412;+56029,+56028,;2~VA-GP ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE NO
801.412;+56030,+56028,;.01~40
801.412;+56030,+56028,;2~VA-GP ONC PRCA CRPC M1 <=2 2ND CONTRA DOCE YES
801.44;+56031,+56028,;.01~06/09/2026@10:31:11
801.44;+56031,+56028,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
56029^1
56030^2
56031^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 &lt;=2 2ND LINE</POINT_01>
<INTERNAL_ENTRY_NUMBER>44120</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4194372434</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44120,;.01~VA-GP ONC PRCA CRPC M1 <=2 2ND LINE
801.41;+44120,;4~dialog group
801.41;+44120,;6~YES
801.41;+44120,;7~2
801.41;+44120,;25~WP-start~1
Second Line (ECOG 0-1-2, after ARPI):
801.41;+44120,;52~INDENT
801.41;+44120,;100~NATIONAL
801.412;+44121,+44120,;.01~60
801.412;+44121,+44120,;2~VA-GP ONC PRCA CRPC M1 <=2 2ND LINE SUBMAIN
801.412;+44122,+44120,;.01~10
801.412;+44122,+44120,;2~VA-ONC PRCA CRPC M1 <=2 2ND VIEW BOX
801.44;+44123,+44120,;.01~06/09/2026@10:31:11
801.44;+44123,+44120,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44121^5
44122^6
44123^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>44112</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3064021917</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44112,;.01~VA-GP ONC PRCA CRPC M1 SUBMAIN
801.41;+44112,;4~dialog group
801.41;+44112,;6~YES
801.41;+44112,;9~NONE OR ONE SELECTION
801.41;+44112,;15~HF.VA-ONC PRCA CRPC M1 PATHWAY
801.41;+44112,;23~YES
801.41;+44112,;25~WP-start~2
++ Consider biopsy in setting of visceral disease or atypical 
progression\\   (scan worsening without overt PSA progression). ++
801.41;+44112,;51~SUPPRESS
801.41;+44112,;100~NATIONAL
801.412;+44113,+44112,;.01~60
801.412;+44113,+44112,;2~VA-GP ONC PRCA CRPC M1 <=2 2ND LINE
801.412;+44114,+44112,;.01~90
801.412;+44114,+44112,;2~VA-GP ONC PRCA CRPC M1 <=2 3RD MAIN
801.412;+44115,+44112,;.01~20
801.412;+44115,+44112,;2~VA-GP ONC PRCA CRPC M1 FIRST LINE
801.44;+44116,+44112,;.01~06/09/2026@10:31:11
801.44;+44116,+44112,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44113^4
44114^6
44115^9
44116^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC PRCA CRPC M1 MAIN GROUP CHECK BOX</POINT_01>
<INTERNAL_ENTRY_NUMBER>44568</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3468561119</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+44568,;.01~VA-GP ONC PRCA CRPC M1 MAIN GROUP CHECK BOX
801.41;+44568,;4~dialog group
801.41;+44568,;6~YES
801.41;+44568,;7~2
801.41;+44568,;25~WP-start~1
Castrate Resistant Prostate Cancer (CRPC) M1 Clinical Pathway:
801.41;+44568,;35~WP-start~2
Castrate Resistant Prostate Cancer (CRPC) M1 Clinical Pathway
=============================================================
801.41;+44568,;100~NATIONAL
801.412;+44569,+44568,;.01~10
801.412;+44569,+44568,;2~VA-GP ONC PRCA CRPC M1 SUBMAIN
801.44;+44570,+44568,;.01~06/09/2026@10:31:11
801.44;+44570,+44568,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
44569^1
44570^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PRCA UPDATE 2026</POINT_01>
<INTERNAL_ENTRY_NUMBER>110952</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4202794891</CHECKSUM>
<SELECTED>YES</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+110952,;.01~VA-ONC PRCA UPDATE 2026
801.41;+110952,;4~dialog group
801.41;+110952,;100~NATIONAL
801.412;+110953,+110952,;.01~5
801.412;+110953,+110952,;2~VA-GP ONC PRCA CRPC M1 MAIN GROUP CHECK BOX
801.412;+110954,+110952,;.01~10
801.412;+110954,+110952,;2~VA-ONC PRCA VIEW PRESUMPTIVE CONDITIONS
801.44;+110955,+110952,;.01~06/09/2026@10:31:11
801.44;+110955,+110952,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
110953^1
110954^2
110955^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV NON-CC FN</POINT_01>
<INTERNAL_ENTRY_NUMBER>108971</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>580854109</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108971,;.01~VA-ONC KID STAGE IV NON-CC FN
801.41;+108971,;4~dialog element
801.41;+108971,;23~YES
801.41;+108971,;25~WP-start~3
++ For collecting duct or medullary subtypes, consider cytoxic 
chemotherapy;\\   for urothelial subtypes, follow the Bladder Cancer 
Upper GU Tract\\   Carcinoma pathway ++
801.41;+108971,;51~SUPPRESS
801.41;+108971,;100~NATIONAL
801.44;+108972,+108971,;.01~06/09/2026@10:31:11
801.44;+108972,+108971,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108972^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER NO OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>108247</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1296288905</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108247,;.01~VA-ONC KID STG IV NCC INTER NO OFF PATH RSN
801.41;+108247,;4~dialog element
801.41;+108247,;15~HF.VA-ONC KID STG IV NCC INTER NO OFF PATH RSN
801.41;+108247,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+108247,;51~SUPPRESS
801.41;+108247,;100~NATIONAL
801.412;+108248,+108247,;.01~5
801.412;+108248,+108247,;2~VA-ONC OFF PATHWAY
801.412;+108248,+108247,;7~YES
801.412;+108248,+108247,;9~YES
801.44;+108249,+108247,;.01~06/09/2026@10:31:11
801.44;+108249,+108247,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108248^1
108249^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER NO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>108248</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1628541523</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108248,;.01~VA-ONC KID STG IV NCC INTER NO OFF PATH TX
801.41;+108248,;4~dialog element
801.41;+108248,;15~HF.VA-ONC KID STG IV NCC INTER NO OFF PATH TX
801.41;+108248,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+108248,;51~SUPPRESS
801.41;+108248,;100~NATIONAL
801.412;+108249,+108248,;.01~5
801.412;+108249,+108248,;2~VA-ONC BLANK
801.412;+108249,+108248,;9~YES
801.44;+108250,+108248,;.01~06/09/2026@10:31:11
801.44;+108250,+108248,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108249^1
108250^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STG IV NCC INTER NO OFF PTHWY</POINT_01>
<INTERNAL_ENTRY_NUMBER>108249</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>243392104</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108249,;.01~VA-GP ONC KID STG IV NCC INTER NO OFF PTHWY
801.41;+108249,;4~dialog group
801.41;+108249,;6~YES
801.41;+108249,;7~2
801.41;+108249,;23~YES
801.41;+108249,;25~WP-start~1
Off pathway:
801.41;+108249,;100~NATIONAL
801.412;+108250,+108249,;.01~10
801.412;+108250,+108249,;2~VA-ONC KID STG IV NCC INTER NO OFF PATH TX
801.412;+108251,+108249,;.01~20
801.412;+108251,+108249,;2~VA-ONC KID STG IV NCC INTER NO OFF PATH RSN
801.44;+108252,+108249,;.01~06/09/2026@10:31:11
801.44;+108252,+108249,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108250^1
108251^2
108252^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PEMBRO+LEN FN</POINT_01>
<INTERNAL_ENTRY_NUMBER>108253</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1905987363</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108253,;.01~VA-ONC KID STAGE IV PEMBRO+LEN FN
801.41;+108253,;4~dialog element
801.41;+108253,;23~YES
801.41;+108253,;25~WP-start~4
++ Candidate for immunotherapy = patient without autoimmune disease,
   primary immune deficiency, concurrent immunosuppression (including
   prednisone equivalent >10mg/day), or prior allogeneic HSCT/solid
   organ transplant. ++
801.41;+108253,;51~SUPPRESS
801.41;+108253,;100~NATIONAL
801.44;+108254,+108253,;.01~06/09/2026@10:31:11
801.44;+108254,+108253,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108254^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STG IV NCC INTER NO PEMB+LEN</POINT_01>
<INTERNAL_ENTRY_NUMBER>108244</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1792092723</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108244,;.01~VA-GP ONC KID STG IV NCC INTER NO PEMB+LEN
801.41;+108244,;4~dialog group
801.41;+108244,;7~2
801.41;+108244,;15~HF.VA-ONC KID STG IV NCC INTER NO PEMB+LEN
801.41;+108244,;25~WP-start~1
Pembrolizumab and lenvatinib
801.41;+108244,;35~WP-start~1
Veteran has elected to pursue TREATMENT with PEMBROLIZUMAB and LENVATINIB.
801.41;+108244,;100~NATIONAL
801.412;+108245,+108244,;.01~10
801.412;+108245,+108244,;2~VA-ONC KID STAGE IV PEMBRO+LEN FN
801.44;+108246,+108244,;.01~06/09/2026@10:31:11
801.44;+108246,+108244,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108245^3
108246^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER NO CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>108243</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4025960313</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108243,;.01~VA-ONC KID STG IV NCC INTER NO CLIN TRIAL
801.41;+108243,;4~dialog element
801.41;+108243,;15~HF.VA-ONC KID STG IV NCC INTER NO CLIN TRIAL
801.41;+108243,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+108243,;35~WP-start~1
Veteran has elected to pursue:
801.41;+108243,;100~NATIONAL
801.412;+108244,+108243,;.01~5
801.412;+108244,+108243,;2~VA-ONC CLINICAL TRIAL
801.412;+108244,+108243,;9~YES
801.44;+108245,+108243,;.01~06/09/2026@10:31:11
801.44;+108245,+108243,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108244^1
108245^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV NCC INTER NO</POINT_01>
<INTERNAL_ENTRY_NUMBER>108242</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>512373885</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108242,;.01~VA-GP ONC KID STAGE IV NCC INTER NO
801.41;+108242,;4~dialog group
801.41;+108242,;6~YES
801.41;+108242,;7~2
801.41;+108242,;9~NONE OR ONE SELECTION
801.41;+108242,;25~WP-start~1
Not a candidate for cytoreductive nephrectomy or metastatic therapy:
801.41;+108242,;52~INDENT
801.41;+108242,;100~NATIONAL
801.412;+108243,+108242,;.01~10
801.412;+108243,+108242,;2~VA-ONC KID STG IV NCC INTER NO CLIN TRIAL
801.412;+108244,+108242,;.01~20
801.412;+108244,+108242,;2~VA-GP ONC KID STG IV NCC INTER NO PEMB+LEN
801.412;+108245,+108242,;.01~30
801.412;+108245,+108242,;2~VA-GP ONC KID STG IV NCC INTER NO OFF PTHWY
801.44;+108246,+108242,;.01~06/09/2026@10:31:12
801.44;+108246,+108242,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108243^1
108244^2
108245^3
108246^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV SURVEILLANCE TXT</POINT_01>
<INTERNAL_ENTRY_NUMBER>57967</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1199382530</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57967,;.01~VA-ONC KID STAGE IV SURVEILLANCE TXT
801.41;+57967,;4~dialog element
801.41;+57967,;25~WP-start~5
Follow up every 6-16 weeks for 5 years if receiving systemic therapy:   
   -history and physical   
   -comprehensive metabolic panel (based on therapy used)
Follow up at baseline, then every 12 weeks for 5 years:\\   -abdominal
CT/MRI with contrast\\   -chest x-ray/CT
801.41;+57967,;51~SUPPRESS
801.41;+57967,;100~NATIONAL
801.44;+57968,+57967,;.01~06/09/2026@10:31:12
801.44;+57968,+57967,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57968^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STG IV NCC INTER PST DZ- SURVEILLANCE</POINT_01>
<INTERNAL_ENTRY_NUMBER>108235</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3946270536</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108235,;.01~VA-GP ONC KID STG IV NCC INTER PST DZ- SURVEILLANCE
801.41;+108235,;4~dialog group
801.41;+108235,;7~2
801.41;+108235,;15~HF.VA-ONC KID STG IV NCC NO PERSIST S/P INTER SURVEILLANCE
801.41;+108235,;25~WP-start~1
Active surveillance:
801.41;+108235,;35~WP-start~1
Veteran has elected to pursue ACTIVE SURVEILLANCE.
801.41;+108235,;52~INDENT
801.41;+108235,;100~NATIONAL
801.412;+108236,+108235,;.01~20
801.412;+108236,+108235,;2~VA-ONC KID STAGE IV SURVEILLANCE TXT
801.44;+108237,+108235,;.01~06/09/2026@10:31:12
801.44;+108237,+108235,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108236^1
108237^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER PST DZ- OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>108229</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4218107907</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108229,;.01~VA-ONC KID STG IV NCC INTER PST DZ- OFF PATH RSN
801.41;+108229,;4~dialog element
801.41;+108229,;15~HF.VA-ONC KID STG IV NCC NO PERSIST S/P INTER OFF PATH RSN
801.41;+108229,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+108229,;51~SUPPRESS
801.41;+108229,;100~NATIONAL
801.412;+108230,+108229,;.01~5
801.412;+108230,+108229,;2~VA-ONC OFF PATHWAY
801.412;+108230,+108229,;7~YES
801.412;+108230,+108229,;9~YES
801.44;+108231,+108229,;.01~06/09/2026@10:31:12
801.44;+108231,+108229,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108230^1
108231^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER PST DZ- OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>108230</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>12562599</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108230,;.01~VA-ONC KID STG IV NCC INTER PST DZ- OFF PATH TX
801.41;+108230,;4~dialog element
801.41;+108230,;15~HF.VA-ONC KID STG IV NCC NO PERSIST S/P INTER OFF PATH TX
801.41;+108230,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+108230,;51~SUPPRESS
801.41;+108230,;100~NATIONAL
801.412;+108231,+108230,;.01~5
801.412;+108231,+108230,;2~VA-ONC BLANK
801.412;+108231,+108230,;9~YES
801.44;+108232,+108230,;.01~06/09/2026@10:31:12
801.44;+108232,+108230,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108231^1
108232^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STG IV NCC INTER PST DZ- OFF PTHWY</POINT_01>
<INTERNAL_ENTRY_NUMBER>108231</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4258073580</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108231,;.01~VA-GP ONC KID STG IV NCC INTER PST DZ- OFF PTHWY
801.41;+108231,;4~dialog group
801.41;+108231,;6~YES
801.41;+108231,;7~2
801.41;+108231,;23~YES
801.41;+108231,;25~WP-start~1
Off pathway:
801.41;+108231,;100~NATIONAL
801.412;+108232,+108231,;.01~10
801.412;+108232,+108231,;2~VA-ONC KID STG IV NCC INTER PST DZ- OFF PATH TX
801.412;+108233,+108231,;.01~20
801.412;+108233,+108231,;2~VA-ONC KID STG IV NCC INTER PST DZ- OFF PATH RSN
801.44;+108234,+108231,;.01~06/09/2026@10:31:12
801.44;+108234,+108231,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108232^1
108233^2
108234^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER PST DZ- CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>108228</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1651929835</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108228,;.01~VA-ONC KID STG IV NCC INTER PST DZ- CLIN TRIAL
801.41;+108228,;4~dialog element
801.41;+108228,;15~HF.VA-ONC KID STG IV NCC NO PERSIST S/P INTER CLIN TRIAL
801.41;+108228,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+108228,;35~WP-start~1
Veteran has elected to pursue:
801.41;+108228,;100~NATIONAL
801.412;+108229,+108228,;.01~5
801.412;+108229,+108228,;2~VA-ONC CLINICAL TRIAL
801.412;+108229,+108228,;9~YES
801.44;+108230,+108228,;.01~06/09/2026@10:31:12
801.44;+108230,+108228,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108229^1
108230^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STG IV NCC INTER AFTER PERSIST N</POINT_01>
<INTERNAL_ENTRY_NUMBER>108215</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1452026126</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108215,;.01~VA-GP ONC KID STG IV NCC INTER AFTER PERSIST N
801.41;+108215,;4~dialog group
801.41;+108215,;6~YES
801.41;+108215,;7~2
801.41;+108215,;9~NONE OR ONE SELECTION
801.41;+108215,;25~WP-start~1
No persistent disease:
801.41;+108215,;100~NATIONAL
801.412;+108216,+108215,;.01~10
801.412;+108216,+108215,;2~VA-ONC KID STG IV NCC INTER PST DZ- CLIN TRIAL
801.412;+108217,+108215,;.01~30
801.412;+108217,+108215,;2~VA-GP ONC KID STG IV NCC INTER PST DZ- OFF PTHWY
801.412;+108218,+108215,;.01~20
801.412;+108218,+108215,;2~VA-GP ONC KID STG IV NCC INTER PST DZ- SURVEILLANCE
801.44;+108219,+108215,;.01~06/09/2026@10:31:12
801.44;+108219,+108215,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108216^1
108217^2
108218^3
108219^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER PST DZ+ OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>108221</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3107838456</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108221,;.01~VA-ONC KID STG IV NCC INTER PST DZ+ OFF PATH RSN
801.41;+108221,;4~dialog element
801.41;+108221,;15~HF.VA-ONC KID STG IV NCC PERSIST S/P INTER OFF PATH RSN
801.41;+108221,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+108221,;51~SUPPRESS
801.41;+108221,;100~NATIONAL
801.412;+108222,+108221,;.01~5
801.412;+108222,+108221,;2~VA-ONC OFF PATHWAY
801.412;+108222,+108221,;7~YES
801.412;+108222,+108221,;9~YES
801.44;+108223,+108221,;.01~06/09/2026@10:31:12
801.44;+108223,+108221,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108222^1
108223^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER PST DZ+ OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>108220</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3126448250</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108220,;.01~VA-ONC KID STG IV NCC INTER PST DZ+ OFF PATH TX
801.41;+108220,;4~dialog element
801.41;+108220,;15~HF.VA-ONC KID STG IV NCC PERSIST S/P INTER OFF PATH TX
801.41;+108220,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+108220,;51~SUPPRESS
801.41;+108220,;100~NATIONAL
801.412;+108221,+108220,;.01~5
801.412;+108221,+108220,;2~VA-ONC BLANK
801.412;+108221,+108220,;9~YES
801.44;+108222,+108220,;.01~06/09/2026@10:31:12
801.44;+108222,+108220,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108221^1
108222^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STG IV NCC INTER PST DZ+ OFF PTHWY</POINT_01>
<INTERNAL_ENTRY_NUMBER>108219</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1763958035</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108219,;.01~VA-GP ONC KID STG IV NCC INTER PST DZ+ OFF PTHWY
801.41;+108219,;4~dialog group
801.41;+108219,;6~YES
801.41;+108219,;7~2
801.41;+108219,;23~YES
801.41;+108219,;25~WP-start~1
Off pathway:
801.41;+108219,;100~NATIONAL
801.412;+108220,+108219,;.01~10
801.412;+108220,+108219,;2~VA-ONC KID STG IV NCC INTER PST DZ+ OFF PATH TX
801.412;+108221,+108219,;.01~20
801.412;+108221,+108219,;2~VA-ONC KID STG IV NCC INTER PST DZ+ OFF PATH RSN
801.44;+108222,+108219,;.01~06/09/2026@10:31:12
801.44;+108222,+108219,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108220^1
108221^2
108222^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STG IV NCC INTER AFTER PST DZ+ PEMB+LEN</POINT_01>
<INTERNAL_ENTRY_NUMBER>108217</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2940513821</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108217,;.01~VA-GP ONC KID STG IV NCC INTER AFTER PST DZ+ PEMB+LEN
801.41;+108217,;4~dialog group
801.41;+108217,;7~2
801.41;+108217,;15~HF.VA-ONC KID STG IV NCC PERSIST S/P INTER PEMB+LEN
801.41;+108217,;25~WP-start~1
Pembrolizumab and lenvatinib
801.41;+108217,;35~WP-start~1
Veteran has elected to pursue TREATMENT with PEMBROLIZUMAB and LENVATINIB.
801.41;+108217,;100~NATIONAL
801.412;+108218,+108217,;.01~10
801.412;+108218,+108217,;2~VA-ONC KID STAGE IV PEMBRO+LEN FN
801.44;+108219,+108217,;.01~06/09/2026@10:31:12
801.44;+108219,+108217,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108218^1
108219^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER PST DZ+ CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>108218</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3233646423</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108218,;.01~VA-ONC KID STG IV NCC INTER PST DZ+ CLIN TRIAL
801.41;+108218,;4~dialog element
801.41;+108218,;15~HF.VA-ONC KID STG IV NCC PERSIST S/P INTER CLIN TRIAL
801.41;+108218,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+108218,;35~WP-start~1
Veteran has elected to pursue:
801.41;+108218,;100~NATIONAL
801.412;+108219,+108218,;.01~5
801.412;+108219,+108218,;2~VA-ONC CLINICAL TRIAL
801.412;+108219,+108218,;9~YES
801.44;+108220,+108218,;.01~06/09/2026@10:31:12
801.44;+108220,+108218,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108219^1
108220^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STG IV NCC INTER AFTER PERSIST Y</POINT_01>
<INTERNAL_ENTRY_NUMBER>108214</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1158959444</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108214,;.01~VA-GP ONC KID STG IV NCC INTER AFTER PERSIST Y
801.41;+108214,;4~dialog group
801.41;+108214,;6~YES
801.41;+108214,;7~2
801.41;+108214,;9~NONE OR ONE SELECTION
801.41;+108214,;25~WP-start~1
Persistent disease:
801.41;+108214,;100~NATIONAL
801.412;+108215,+108214,;.01~10
801.412;+108215,+108214,;2~VA-ONC KID STG IV NCC INTER PST DZ+ CLIN TRIAL
801.412;+108216,+108214,;.01~20
801.412;+108216,+108214,;2~VA-GP ONC KID STG IV NCC INTER AFTER PST DZ+ PEMB+LEN
801.412;+108217,+108214,;.01~30
801.412;+108217,+108214,;2~VA-GP ONC KID STG IV NCC INTER PST DZ+ OFF PTHWY
801.44;+108218,+108214,;.01~06/09/2026@10:31:12
801.44;+108218,+108214,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108215^1
108216^2
108217^3
108218^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STG IV NCC INTER AFTER MAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>108213</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>937117431</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108213,;.01~VA-GP ONC KID STG IV NCC INTER AFTER MAIN
801.41;+108213,;4~dialog group
801.41;+108213,;6~YES
801.41;+108213,;7~2
801.41;+108213,;9~NONE OR ONE SELECTION
801.41;+108213,;25~WP-start~2
After intervention (cytoreductive nephrectomy or metastasis directed
therapy):
801.41;+108213,;52~INDENT
801.41;+108213,;100~NATIONAL
801.412;+108214,+108213,;.01~20
801.412;+108214,+108213,;2~VA-GP ONC KID STG IV NCC INTER AFTER PERSIST Y
801.412;+108215,+108213,;.01~40
801.412;+108215,+108213,;2~VA-GP ONC KID STG IV NCC INTER AFTER PERSIST N
801.44;+108216,+108213,;.01~06/09/2026@10:31:12
801.44;+108216,+108213,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108214^1
108215^2
108216^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER YES OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>108212</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2130639781</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108212,;.01~VA-ONC KID STG IV NCC INTER YES OFF PATH RSN
801.41;+108212,;4~dialog element
801.41;+108212,;15~HF.VA-ONC KID STG IV NCC INTER OFF PATH RSN
801.41;+108212,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+108212,;51~SUPPRESS
801.41;+108212,;100~NATIONAL
801.412;+108213,+108212,;.01~5
801.412;+108213,+108212,;2~VA-ONC OFF PATHWAY
801.412;+108213,+108212,;7~YES
801.412;+108213,+108212,;9~YES
801.44;+108214,+108212,;.01~06/09/2026@10:31:12
801.44;+108214,+108212,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108213^1
108214^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER YES OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>108211</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3023080047</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108211,;.01~VA-ONC KID STG IV NCC INTER YES OFF PATH TX
801.41;+108211,;4~dialog element
801.41;+108211,;15~HF.VA-ONC KID STG IV NCC INTER OFF PATH TX
801.41;+108211,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+108211,;51~SUPPRESS
801.41;+108211,;100~NATIONAL
801.412;+108212,+108211,;.01~5
801.412;+108212,+108211,;2~VA-ONC BLANK
801.412;+108212,+108211,;9~YES
801.44;+108213,+108211,;.01~06/09/2026@10:31:12
801.44;+108213,+108211,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108212^1
108213^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STG IV NCC INTER YES OFF PTHWY</POINT_01>
<INTERNAL_ENTRY_NUMBER>108210</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>862784821</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108210,;.01~VA-GP ONC KID STG IV NCC INTER YES OFF PTHWY
801.41;+108210,;4~dialog group
801.41;+108210,;6~YES
801.41;+108210,;7~2
801.41;+108210,;23~YES
801.41;+108210,;25~WP-start~1
Off pathway:
801.41;+108210,;100~NATIONAL
801.412;+108211,+108210,;.01~10
801.412;+108211,+108210,;2~VA-ONC KID STG IV NCC INTER YES OFF PATH TX
801.412;+108212,+108210,;.01~20
801.412;+108212,+108210,;2~VA-ONC KID STG IV NCC INTER YES OFF PATH RSN
801.44;+108213,+108210,;.01~06/09/2026@10:31:12
801.44;+108213,+108210,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108211^1
108212^2
108213^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STG IV NCC INTER YES METS DIRECT TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>108209</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1033251110</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108209,;.01~VA-GP ONC KID STG IV NCC INTER YES METS DIRECT TX
801.41;+108209,;4~dialog group
801.41;+108209,;15~HF.VA-ONC KID STG IV NCC INTER METS DIRECTED TX
801.41;+108209,;25~WP-start~1
Metastasis directed therapy
801.41;+108209,;35~WP-start~1
Veteran has elected to pursue METASTASIS DIRECTED THERAPY.
801.41;+108209,;100~NATIONAL
801.44;+108210,+108209,;.01~06/09/2026@10:31:12
801.44;+108210,+108209,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108210^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC UROLOGY CONSULT</POINT_01>
<INTERNAL_ENTRY_NUMBER>57673</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2290752606</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57673,;.01~VA-ONC UROLOGY CONSULT
801.41;+57673,;4~dialog element
801.41;+57673,;51~SUPPRESS
801.41;+57673,;100~NATIONAL
801.44;+57674,+57673,;.01~06/09/2026@10:31:12
801.44;+57674,+57673,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57674^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STG IV NCC INTER YES CYTO NEPH</POINT_01>
<INTERNAL_ENTRY_NUMBER>108208</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3734619120</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108208,;.01~VA-GP ONC KID STG IV NCC INTER YES CYTO NEPH
801.41;+108208,;4~dialog group
801.41;+108208,;15~HF.VA-ONC KID STG IV NCC INTER CYTO NEPHRECTOMY
801.41;+108208,;25~WP-start~1
Cytoreductive nephrectomy
801.41;+108208,;35~WP-start~1
Veteran has elected to pursue CYTOREDUCTIVE NEPHRECTOMY.
801.41;+108208,;100~NATIONAL
801.412;+108209,+108208,;.01~20
801.412;+108209,+108208,;2~VA-ONC UROLOGY CONSULT
801.44;+108210,+108208,;.01~06/09/2026@10:31:12
801.44;+108210,+108208,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108209^1
108210^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STG IV NCC INTER YES CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>108207</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1608071772</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108207,;.01~VA-ONC KID STG IV NCC INTER YES CLIN TRIAL
801.41;+108207,;4~dialog element
801.41;+108207,;15~HF.VA-ONC KID STG IV NCC INTER CLIN TRIAL
801.41;+108207,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+108207,;35~WP-start~1
Veteran has elected to pursue:
801.41;+108207,;100~NATIONAL
801.412;+108208,+108207,;.01~5
801.412;+108208,+108207,;2~VA-ONC CLINICAL TRIAL
801.412;+108208,+108207,;9~YES
801.44;+108209,+108207,;.01~06/09/2026@10:31:12
801.44;+108209,+108207,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108208^1
108209^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV NCC INTER YES</POINT_01>
<INTERNAL_ENTRY_NUMBER>108206</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>427748786</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108206,;.01~VA-GP ONC KID STAGE IV NCC INTER YES
801.41;+108206,;4~dialog group
801.41;+108206,;6~YES
801.41;+108206,;7~2
801.41;+108206,;9~NONE OR ONE SELECTION
801.41;+108206,;25~WP-start~2
Candidate for intervention (cytoreductive nephrectomy or metastasis
directed therapy):
801.41;+108206,;35~WP-start~1
Candidate for intervention:
801.41;+108206,;100~NATIONAL
801.412;+108207,+108206,;.01~10
801.412;+108207,+108206,;2~VA-ONC KID STG IV NCC INTER YES CLIN TRIAL
801.412;+108208,+108206,;.01~20
801.412;+108208,+108206,;2~VA-GP ONC KID STG IV NCC INTER YES CYTO NEPH
801.412;+108209,+108206,;.01~30
801.412;+108209,+108206,;2~VA-GP ONC KID STG IV NCC INTER YES METS DIRECT TX
801.412;+108210,+108206,;.01~40
801.412;+108210,+108206,;2~VA-GP ONC KID STG IV NCC INTER YES OFF PTHWY
801.44;+108211,+108206,;.01~06/09/2026@10:31:12
801.44;+108211,+108206,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108207^1
108208^2
108209^3
108210^4
108211^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV NCC SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>108205</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2525353508</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108205,;.01~VA-GP ONC KID STAGE IV NCC SUBMAIN
801.41;+108205,;4~dialog group
801.41;+108205,;6~YES
801.41;+108205,;9~NONE OR ONE SELECTION
801.41;+108205,;25~WP-start~1
After multidisciplinary discussion:
801.41;+108205,;51~SUPPRESS
801.41;+108205,;52~INDENT
801.41;+108205,;100~NATIONAL
801.412;+108206,+108205,;.01~20
801.412;+108206,+108205,;2~VA-GP ONC KID STAGE IV NCC INTER YES
801.412;+108207,+108205,;.01~60
801.412;+108207,+108205,;2~VA-GP ONC KID STG IV NCC INTER AFTER MAIN
801.412;+108208,+108205,;.01~80
801.412;+108208,+108205,;2~VA-GP ONC KID STAGE IV NCC INTER NO
801.44;+108209,+108205,;.01~06/09/2026@10:31:12
801.44;+108209,+108205,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108206^20
108207^21
108208^22
108209^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV NON-CC MAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>108181</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3825226702</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108181,;.01~VA-GP ONC KID STAGE IV NON-CC MAIN
801.41;+108181,;4~dialog group
801.41;+108181,;6~YES
801.41;+108181,;7~2
801.41;+108181,;25~WP-start~1
Stage IV or Relapsed Non-Clear Cell - Kidney Cancer Clinical Pathway
801.41;+108181,;35~WP-start~3
VA National Stage IV or Relapsed Non-Clear Cell -
          Kidney Cancer Clinical Pathway
=================================================
801.41;+108181,;100~NATIONAL
801.41;+108181,;101~VHA ONCOLOGY
801.412;+108182,+108181,;.01~40
801.412;+108182,+108181,;2~VA-GP ONC KID STAGE IV NCC SUBMAIN
801.412;+108183,+108181,;.01~10
801.412;+108183,+108181,;2~VA-ONC KID STAGE IV NON-CC FN
801.44;+108184,+108181,;.01~06/09/2026@10:31:12
801.44;+108184,+108181,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108182^1
108183^2
108184^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV BRAIN IMAGING</POINT_01>
<INTERNAL_ENTRY_NUMBER>95621</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>908566406</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95621,;.01~VA-ONC KID STAGE IV BRAIN IMAGING
801.41;+95621,;4~dialog element
801.41;+95621,;23~YES
801.41;+95621,;25~WP-start~1
++ Order brain imaging if mets suspected. ++
801.41;+95621,;51~SUPPRESS
801.41;+95621,;100~NATIONAL
801.44;+95622,+95621,;.01~06/09/2026@10:31:12
801.44;+95622,+95621,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95622^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV RISK GROUPS</POINT_01>
<INTERNAL_ENTRY_NUMBER>58719</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1206226974</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+58719,;.01~VA-ONC KID STAGE IV RISK GROUPS
801.41;+58719,;4~dialog element
801.41;+58719,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+58719,;23~YES
801.41;+58719,;25~WP-start~2
International Metastatic Renal Cell Carcinoma Database Consortium 
(IMDC) Criteria:
801.41;+58719,;35~WP-start~7
Prognostic Factors:\\ -less than one year from time of diagnosis to 
systemic therapy\\ -performance status <80% (Karnofsky)\\ -hemoglobin < 
lower limit of normal\\ -calcium > upper limit of normal\\ -neutrophil >
upper limit of normal\\ -platelets > upper limit of normal
 
Prognostic Risk Groups:\\ -favorable (no prognostic factors)\\ 
-intermediate (1-2 prognostic factors)\\ -poor (3-6 prognostic factors)
801.41;+58719,;51~SUPPRESS
801.41;+58719,;100~NATIONAL
801.412;+58720,+58719,;.01~5
801.412;+58720,+58719,;2~PXRM GF VIEW BUTTON
801.412;+58720,+58719,;6~VIEW IMDC Criteria
801.44;+58721,+58719,;.01~06/09/2026@10:31:12
801.44;+58721,+58719,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
58720^1
58721^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROGRESS OFF PATH REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>57948</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3497848767</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57948,;.01~VA-ONC KID STAGE IV PROGRESS OFF PATH REASON
801.41;+57948,;4~dialog element
801.41;+57948,;15~HF.VA-ONC KID STAGE IV PROGRESS AFTER 1ST LINE OFF PATH RSN
801.41;+57948,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+57948,;51~SUPPRESS
801.41;+57948,;100~NATIONAL
801.412;+57949,+57948,;.01~5
801.412;+57949,+57948,;2~VA-ONC OFF PATHWAY
801.412;+57949,+57948,;7~YES
801.412;+57949,+57948,;9~YES
801.44;+57950,+57948,;.01~06/09/2026@10:31:12
801.44;+57950,+57948,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57949^1
57950^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROGRESS OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57947</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3173936053</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57947,;.01~VA-ONC KID STAGE IV PROGRESS OFF PATH TX
801.41;+57947,;4~dialog element
801.41;+57947,;15~HF.VA-ONC KID STAGE IV PROGRESS AFTER 1ST LINE OFF PATH TX
801.41;+57947,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+57947,;51~SUPPRESS
801.41;+57947,;100~NATIONAL
801.412;+57948,+57947,;.01~5
801.412;+57948,+57947,;2~VA-ONC BLANK
801.412;+57948,+57947,;9~YES
801.44;+57949,+57947,;.01~06/09/2026@10:31:12
801.44;+57949,+57947,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57948^1
57949^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV PROGRESS OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57946</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1011082511</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57946,;.01~VA-GP ONC KID STAGE IV PROGRESS OFF PATHWAY
801.41;+57946,;4~dialog group
801.41;+57946,;6~YES
801.41;+57946,;7~2
801.41;+57946,;23~YES
801.41;+57946,;25~WP-start~1
Off pathway:
801.41;+57946,;100~NATIONAL
801.412;+57947,+57946,;.01~10
801.412;+57947,+57946,;2~VA-ONC KID STAGE IV PROGRESS OFF PATH TX
801.412;+57948,+57946,;.01~20
801.412;+57948,+57946,;2~VA-ONC KID STAGE IV PROGRESS OFF PATH REASON
801.44;+57949,+57946,;.01~06/09/2026@10:31:12
801.44;+57949,+57946,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57947^1
57948^2
57949^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROGRESS CABO</POINT_01>
<INTERNAL_ENTRY_NUMBER>57945</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2093035660</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57945,;.01~VA-ONC KID STAGE IV PROGRESS CABO
801.41;+57945,;4~dialog element
801.41;+57945,;15~HF.VA-ONC KID STAGE IV PROGRESS AFTER 1ST LINE CABOZANTINIB
801.41;+57945,;25~WP-start~1
Cabozantinib
801.41;+57945,;35~WP-start~1
Veteran has elected to pursue TREATMENT with CABOZANTINIB.
801.41;+57945,;100~NATIONAL
801.44;+57946,+57945,;.01~06/09/2026@10:31:12
801.44;+57946,+57945,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57946^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PROGRESS CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57944</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1871128777</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57944,;.01~VA-ONC KID STAGE IV PROGRESS CLINICAL TRIAL
801.41;+57944,;4~dialog element
801.41;+57944,;15~HF.VA-ONC KID STAGE IV PROGRESS AFTER 1ST LINE CLINICAL TRIAL
801.41;+57944,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+57944,;35~WP-start~1
Veteran has elected to pursue:
801.41;+57944,;100~NATIONAL
801.412;+57945,+57944,;.01~5
801.412;+57945,+57944,;2~VA-ONC CLINICAL TRIAL
801.412;+57945,+57944,;9~YES
801.44;+57946,+57944,;.01~06/09/2026@10:31:12
801.44;+57946,+57944,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57945^1
57946^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV PROGRESS</POINT_01>
<INTERNAL_ENTRY_NUMBER>57943</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3194435187</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57943,;.01~VA-GP ONC KID STAGE IV PROGRESS
801.41;+57943,;4~dialog group
801.41;+57943,;6~YES
801.41;+57943,;7~2
801.41;+57943,;9~NONE OR ONE SELECTION
801.41;+57943,;25~WP-start~1
Progression after first line systemic therapy:
801.41;+57943,;100~NATIONAL
801.412;+57944,+57943,;.01~20
801.412;+57944,+57943,;2~VA-ONC KID STAGE IV PROGRESS CLINICAL TRIAL
801.412;+57945,+57943,;.01~40
801.412;+57945,+57943,;2~VA-ONC KID STAGE IV PROGRESS CABO
801.412;+57946,+57943,;.01~60
801.412;+57946,+57943,;2~VA-GP ONC KID STAGE IV PROGRESS OFF PATHWAY
801.44;+57947,+57943,;.01~06/09/2026@10:31:12
801.44;+57947,+57943,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57944^1
57945^2
57946^3
57947^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER NO FAVOR OFF PATH REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>57922</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3001242760</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57922,;.01~VA-ONC KID STAGE IV INTER NO FAVOR OFF PATH REASON
801.41;+57922,;4~dialog element
801.41;+57922,;15~HF.VA-ONC KID STAGE IV NOT CAND INTER FAVOR OFF PATH RSN
801.41;+57922,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+57922,;51~SUPPRESS
801.41;+57922,;100~NATIONAL
801.412;+57923,+57922,;.01~5
801.412;+57923,+57922,;2~VA-ONC OFF PATHWAY
801.412;+57923,+57922,;7~YES
801.412;+57923,+57922,;9~YES
801.44;+57924,+57922,;.01~06/09/2026@10:31:12
801.44;+57924,+57922,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57923^1
57924^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER NO FAVOR OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57921</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1043352583</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57921,;.01~VA-ONC KID STAGE IV INTER NO FAVOR OFF PATH TX
801.41;+57921,;4~dialog element
801.41;+57921,;15~HF.VA-ONC KID STAGE IV NOT CAND INTER FAVOR OFF PATH TX
801.41;+57921,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+57921,;51~SUPPRESS
801.41;+57921,;100~NATIONAL
801.412;+57922,+57921,;.01~5
801.412;+57922,+57921,;2~VA-ONC BLANK
801.412;+57922,+57921,;9~YES
801.44;+57923,+57921,;.01~06/09/2026@10:31:12
801.44;+57923,+57921,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57922^1
57923^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER NO FAVOR OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57920</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1364552903</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57920,;.01~VA-GP ONC KID STAGE IV INTER NO FAVOR OFF PATHWAY
801.41;+57920,;4~dialog group
801.41;+57920,;6~YES
801.41;+57920,;7~2
801.41;+57920,;23~YES
801.41;+57920,;25~WP-start~1
Off pathway:
801.41;+57920,;100~NATIONAL
801.412;+57921,+57920,;.01~10
801.412;+57921,+57920,;2~VA-ONC KID STAGE IV INTER NO FAVOR OFF PATH TX
801.412;+57922,+57920,;.01~20
801.412;+57922,+57920,;2~VA-ONC KID STAGE IV INTER NO FAVOR OFF PATH REASON
801.44;+57923,+57920,;.01~06/09/2026@10:31:12
801.44;+57923,+57920,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57921^1
57922^2
57923^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV PEMBRO+AXIT FN</POINT_01>
<INTERNAL_ENTRY_NUMBER>86421</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2223508898</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+86421,;.01~VA-ONC KID STAGE IV PEMBRO+AXIT FN
801.41;+86421,;4~dialog element
801.41;+86421,;23~YES
801.41;+86421,;25~WP-start~4
++ If Veteran is a candidate for immunotherapy and Tyrosine Kinase
Inhibitor\\   (TKI); no Immune Checkpoint Inhibitor or TKI combination
has shown overall\\   survival in favorable risk; active surveillance
may be used in certain\\   situations. ++
801.41;+86421,;51~SUPPRESS
801.41;+86421,;100~NATIONAL
801.44;+86422,+86421,;.01~06/09/2026@10:31:12
801.44;+86422,+86421,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
86422^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER NO FAVOR PEMBRO+AXIT</POINT_01>
<INTERNAL_ENTRY_NUMBER>57919</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1816356048</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57919,;.01~VA-GP ONC KID STAGE IV INTER NO FAVOR PEMBRO+AXIT
801.41;+57919,;4~dialog group
801.41;+57919,;7~2
801.41;+57919,;15~HF.VA-ONC KID STAGE IV NOT CAND INTER FAVOR PEMBRO+AXIT
801.41;+57919,;25~WP-start~1
Pembrolizumab and axitinib\\
801.41;+57919,;35~WP-start~1
Veteran has elected to pursue TREATMENT with PEMBROLIZUMAB and AXITINIB.
801.41;+57919,;100~NATIONAL
801.412;+57920,+57919,;.01~5
801.412;+57920,+57919,;2~VA-ONC KID STAGE IV PEMBRO+AXIT FN
801.44;+57921,+57919,;.01~06/09/2026@10:31:12
801.44;+57921,+57919,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57920^1
57921^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER NO FAVOR CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57918</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2836605203</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57918,;.01~VA-ONC KID STAGE IV INTER NO FAVOR CLINICAL TRIAL
801.41;+57918,;4~dialog element
801.41;+57918,;15~HF.VA-ONC KID STAGE IV NOT CAND INTER FAVOR CLINICAL TRIAL
801.41;+57918,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+57918,;35~WP-start~1
Veteran has elected to pursue:
801.41;+57918,;100~NATIONAL
801.412;+57919,+57918,;.01~5
801.412;+57919,+57918,;2~VA-ONC CLINICAL TRIAL
801.412;+57919,+57918,;9~YES
801.44;+57920,+57918,;.01~06/09/2026@10:31:12
801.44;+57920,+57918,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57919^1
57920^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER NO FAVOR</POINT_01>
<INTERNAL_ENTRY_NUMBER>57916</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>48102497</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57916,;.01~VA-GP ONC KID STAGE IV INTER NO FAVOR
801.41;+57916,;4~dialog group
801.41;+57916,;6~YES
801.41;+57916,;7~2
801.41;+57916,;9~NONE OR ONE SELECTION
801.41;+57916,;25~WP-start~1
Favorable risk group (first line therapy):
801.41;+57916,;100~NATIONAL
801.412;+57917,+57916,;.01~20
801.412;+57917,+57916,;2~VA-ONC KID STAGE IV INTER NO FAVOR CLINICAL TRIAL
801.412;+57918,+57916,;.01~40
801.412;+57918,+57916,;2~VA-GP ONC KID STAGE IV INTER NO FAVOR PEMBRO+AXIT
801.412;+57919,+57916,;.01~60
801.412;+57919,+57916,;2~VA-GP ONC KID STAGE IV INTER NO FAVOR OFF PATHWAY
801.44;+57920,+57916,;.01~06/09/2026@10:31:12
801.44;+57920,+57916,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57917^1
57918^2
57919^3
57920^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER NO POOR NO THREAT/SX OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>95991</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3660255008</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95991,;.01~VA-ONC KID STAGE IV INTER NO POOR NO THREAT/SX OFF PATH RSN
801.41;+95991,;4~dialog element
801.41;+95991,;15~HF.VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX OFF PATH RSN
801.41;+95991,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+95991,;51~SUPPRESS
801.41;+95991,;100~NATIONAL
801.412;+95992,+95991,;.01~5
801.412;+95992,+95991,;2~VA-ONC OFF PATHWAY
801.412;+95992,+95991,;7~YES
801.412;+95992,+95991,;9~YES
801.44;+95993,+95991,;.01~06/09/2026@10:31:12
801.44;+95993,+95991,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95992^1
95993^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER NO POOR NO THREAT/SX OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>95990</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1956158243</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95990,;.01~VA-ONC KID STAGE IV INTER NO POOR NO THREAT/SX OFF PATH TX
801.41;+95990,;4~dialog element
801.41;+95990,;15~HF.VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX OFF PATH TX
801.41;+95990,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+95990,;51~SUPPRESS
801.41;+95990,;100~NATIONAL
801.412;+95991,+95990,;.01~5
801.412;+95991,+95990,;2~VA-ONC BLANK
801.412;+95991,+95990,;9~YES
801.44;+95992,+95990,;.01~06/09/2026@10:31:12
801.44;+95992,+95990,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95991^1
95992^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER NO POOR NO THREAT/SX OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>95988</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3439300065</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95988,;.01~VA-GP ONC KID STAGE IV INTER NO POOR NO THREAT/SX OFF PATH
801.41;+95988,;4~dialog group
801.41;+95988,;6~YES
801.41;+95988,;7~2
801.41;+95988,;23~YES
801.41;+95988,;25~WP-start~1
Off pathway:
801.41;+95988,;100~NATIONAL
801.412;+95989,+95988,;.01~10
801.412;+95989,+95988,;2~VA-ONC KID STAGE IV INTER NO POOR NO THREAT/SX OFF PATH TX
801.412;+95990,+95988,;.01~20
801.412;+95990,+95988,;2~VA-ONC KID STAGE IV INTER NO POOR NO THREAT/SX OFF PATH RSN
801.44;+95991,+95988,;.01~06/09/2026@10:31:12
801.44;+95991,+95988,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95989^1
95990^2
95991^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER NO POOR NO THREAT/SX IPI+NIVO</POINT_01>
<INTERNAL_ENTRY_NUMBER>95987</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>43414322</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95987,;.01~VA-ONC KID STAGE IV INTER NO POOR NO THREAT/SX IPI+NIVO
801.41;+95987,;4~dialog element
801.41;+95987,;15~HF.VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX IPI+NIVO
801.41;+95987,;25~WP-start~1
Ipilimumab and nivolumab
801.41;+95987,;35~WP-start~1
Veteran has elected to pursue TREATMENT with IPILIMUMAB and NIVOLUMAB.
801.41;+95987,;100~NATIONAL
801.44;+95988,+95987,;.01~06/09/2026@10:31:12
801.44;+95988,+95987,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95988^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER NO POOR NO THREAT/SX CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>95985</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4061661918</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95985,;.01~VA-ONC KID STAGE IV INTER NO POOR NO THREAT/SX CLIN TRIAL
801.41;+95985,;4~dialog element
801.41;+95985,;15~HF.VA-ONC KID STAGE IV NOT CAND INTER NO THREAT/SX CLIN TRIAL
801.41;+95985,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+95985,;35~WP-start~1
Veteran has elected to pursue:
801.41;+95985,;100~NATIONAL
801.412;+95986,+95985,;.01~5
801.412;+95986,+95985,;2~VA-ONC CLINICAL TRIAL
801.412;+95986,+95985,;9~YES
801.44;+95987,+95985,;.01~06/09/2026@10:31:12
801.44;+95987,+95985,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95986^1
95987^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER NO POOR NO THREAT/SX</POINT_01>
<INTERNAL_ENTRY_NUMBER>95650</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3199116298</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95650,;.01~VA-GP ONC KID STAGE IV INTER NO POOR NO THREAT/SX
801.41;+95650,;4~dialog group
801.41;+95650,;6~YES
801.41;+95650,;7~2
801.41;+95650,;9~NONE OR ONE SELECTION
801.41;+95650,;25~WP-start~1
No life threatening or symptomatic tumor:
801.41;+95650,;100~NATIONAL
801.412;+95651,+95650,;.01~10
801.412;+95651,+95650,;2~VA-ONC KID STAGE IV INTER NO POOR NO THREAT/SX CLIN TRIAL
801.412;+95652,+95650,;.01~20
801.412;+95652,+95650,;2~VA-ONC KID STAGE IV INTER NO POOR NO THREAT/SX IPI+NIVO
801.412;+95653,+95650,;.01~30
801.412;+95653,+95650,;2~VA-GP ONC KID STAGE IV INTER NO POOR NO THREAT/SX OFF PATH
801.44;+95654,+95650,;.01~06/09/2026@10:31:12
801.44;+95654,+95650,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95651^4
95652^5
95653^6
95654^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER NO POOR THREAT/SX OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>95657</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3357802526</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95657,;.01~VA-ONC KID STAGE IV INTER NO POOR THREAT/SX OFF PATH RSN
801.41;+95657,;4~dialog element
801.41;+95657,;15~HF.VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX OFF PATH RSN
801.41;+95657,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+95657,;51~SUPPRESS
801.41;+95657,;100~NATIONAL
801.412;+95658,+95657,;.01~5
801.412;+95658,+95657,;2~VA-ONC OFF PATHWAY
801.412;+95658,+95657,;7~YES
801.412;+95658,+95657,;9~YES
801.44;+95659,+95657,;.01~06/09/2026@10:31:12
801.44;+95659,+95657,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95658^1
95659^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER NO POOR THREAT/SX OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>95656</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1378955916</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95656,;.01~VA-ONC KID STAGE IV INTER NO POOR THREAT/SX OFF PATH TX
801.41;+95656,;4~dialog element
801.41;+95656,;15~HF.VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX OFF PATH TX
801.41;+95656,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+95656,;51~SUPPRESS
801.41;+95656,;100~NATIONAL
801.412;+95657,+95656,;.01~5
801.412;+95657,+95656,;2~VA-ONC BLANK
801.412;+95657,+95656,;9~YES
801.44;+95658,+95656,;.01~06/09/2026@10:31:12
801.44;+95658,+95656,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95657^1
95658^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER NO POOR THREAT/SX OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>95655</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1544786521</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95655,;.01~VA-GP ONC KID STAGE IV INTER NO POOR THREAT/SX OFF PATH
801.41;+95655,;4~dialog group
801.41;+95655,;6~YES
801.41;+95655,;7~2
801.41;+95655,;23~YES
801.41;+95655,;25~WP-start~1
Off pathway:
801.41;+95655,;100~NATIONAL
801.412;+95656,+95655,;.01~10
801.412;+95656,+95655,;2~VA-ONC KID STAGE IV INTER NO POOR THREAT/SX OFF PATH TX
801.412;+95657,+95655,;.01~20
801.412;+95657,+95655,;2~VA-ONC KID STAGE IV INTER NO POOR THREAT/SX OFF PATH RSN
801.44;+95658,+95655,;.01~06/09/2026@10:31:12
801.44;+95658,+95655,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95656^1
95657^2
95658^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER NO POOR THREAT/SX PEMB+AX</POINT_01>
<INTERNAL_ENTRY_NUMBER>95652</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3857692680</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95652,;.01~VA-ONC KID STAGE IV INTER NO POOR THREAT/SX PEMB+AX
801.41;+95652,;4~dialog group
801.41;+95652,;7~2
801.41;+95652,;15~HF.VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX PEMB+AXIT
801.41;+95652,;25~WP-start~1
Pembrolizumab and axitinib
801.41;+95652,;35~WP-start~1
Veteran has elected to pursue TREATMENT with PEMBROLIZUMAB and AXITINIB.
801.41;+95652,;100~NATIONAL
801.412;+95653,+95652,;.01~10
801.412;+95653,+95652,;2~VA-ONC KID STAGE IV PEMBRO+AXIT FN
801.44;+95654,+95652,;.01~06/09/2026@10:31:12
801.44;+95654,+95652,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95653^1
95654^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER NO POOR THREAT/SX CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>95654</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2083949174</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95654,;.01~VA-ONC KID STAGE IV INTER NO POOR THREAT/SX CLIN TRIAL
801.41;+95654,;4~dialog element
801.41;+95654,;15~HF.VA-ONC KID STAGE IV NOT CAND INTER THREAT/SX CLIN TRIAL
801.41;+95654,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+95654,;35~WP-start~1
Veteran has elected to pursue:
801.41;+95654,;100~NATIONAL
801.412;+95655,+95654,;.01~5
801.412;+95655,+95654,;2~VA-ONC CLINICAL TRIAL
801.412;+95655,+95654,;9~YES
801.44;+95656,+95654,;.01~06/09/2026@10:31:12
801.44;+95656,+95654,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95655^1
95656^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER NO POOR THREAT/SX</POINT_01>
<INTERNAL_ENTRY_NUMBER>95649</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1825022944</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95649,;.01~VA-GP ONC KID STAGE IV INTER NO POOR THREAT/SX
801.41;+95649,;4~dialog group
801.41;+95649,;6~YES
801.41;+95649,;7~2
801.41;+95649,;9~NONE OR ONE SELECTION
801.41;+95649,;25~WP-start~1
Life threatening or symptomatic tumor:
801.41;+95649,;100~NATIONAL
801.412;+95650,+95649,;.01~10
801.412;+95650,+95649,;2~VA-ONC KID STAGE IV INTER NO POOR THREAT/SX CLIN TRIAL
801.412;+95651,+95649,;.01~20
801.412;+95651,+95649,;2~VA-ONC KID STAGE IV INTER NO POOR THREAT/SX PEMB+AX
801.412;+95652,+95649,;.01~30
801.412;+95652,+95649,;2~VA-GP ONC KID STAGE IV INTER NO POOR THREAT/SX OFF PATH
801.44;+95653,+95649,;.01~06/09/2026@10:31:12
801.44;+95653,+95649,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95650^1
95651^2
95652^3
95653^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER NO POOR</POINT_01>
<INTERNAL_ENTRY_NUMBER>57917</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2849995363</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57917,;.01~VA-GP ONC KID STAGE IV INTER NO POOR
801.41;+57917,;4~dialog group
801.41;+57917,;6~YES
801.41;+57917,;7~2
801.41;+57917,;9~NONE OR ONE SELECTION
801.41;+57917,;25~WP-start~1
Intermediate or poor risk group (first line therapy):
801.41;+57917,;100~NATIONAL
801.412;+57918,+57917,;.01~15
801.412;+57918,+57917,;2~VA-GP ONC KID STAGE IV INTER NO POOR THREAT/SX
801.412;+57919,+57917,;.01~30
801.412;+57919,+57917,;2~VA-GP ONC KID STAGE IV INTER NO POOR NO THREAT/SX
801.44;+57920,+57917,;.01~06/09/2026@10:31:12
801.44;+57920,+57917,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57918^4
57919^5
57920^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER NO MAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>60337</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4166921690</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+60337,;.01~VA-GP ONC KID STAGE IV INTER NO MAIN
801.41;+60337,;4~dialog group
801.41;+60337,;6~YES
801.41;+60337,;7~2
801.41;+60337,;9~NONE OR ONE SELECTION
801.41;+60337,;25~WP-start~2
Not a candidate for intervention (cytoreductive nephrectomy or metastasis
directed therapy):
801.41;+60337,;52~INDENT
801.41;+60337,;100~NATIONAL
801.412;+60338,+60337,;.01~20
801.412;+60338,+60337,;2~VA-GP ONC KID STAGE IV INTER NO POOR
801.412;+60339,+60337,;.01~50
801.412;+60339,+60337,;2~VA-GP ONC KID STAGE IV INTER NO FAVOR
801.44;+60340,+60337,;.01~06/09/2026@10:31:12
801.44;+60340,+60337,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
60338^1
60339^2
60340^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID PEMBRO FN</POINT_01>
<INTERNAL_ENTRY_NUMBER>108131</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1400172235</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108131,;.01~VA-ONC KID PEMBRO FN
801.41;+108131,;4~dialog element
801.41;+108131,;23~YES
801.41;+108131,;25~WP-start~4
++ Consider pembrolizumab therapy if clear cell stage M1 with NED, 
one\\   year duration; must take into account life expectancy; for
non-clear\\   cell histology, surveillance or clinical trial
recommended. ++
801.41;+108131,;51~SUPPRESS
801.41;+108131,;100~NATIONAL
801.44;+108132,+108131,;.01~06/09/2026@10:31:12
801.44;+108132,+108131,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108132^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER AFTER PERSIST NO PEMBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>108130</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2561761551</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+108130,;.01~VA-GP ONC KID STAGE IV INTER AFTER PERSIST NO PEMBRO
801.41;+108130,;4~dialog group
801.41;+108130,;7~2
801.41;+108130,;15~HF.VA-ONC KID STAGE IV NO PROG AFTER INTER PEMBRO
801.41;+108130,;25~WP-start~1
Pembrolizumab
801.41;+108130,;35~WP-start~1
Veteran has elected to pursue TREATMENT with PEMBROLIZUMAB.
801.41;+108130,;100~NATIONAL
801.412;+108131,+108130,;.01~5
801.412;+108131,+108130,;2~VA-ONC KID PEMBRO FN
801.44;+108132,+108130,;.01~06/09/2026@10:31:12
801.44;+108132,+108130,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
108131^1
108132^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER AFTER PERSIST NO SURV</POINT_01>
<INTERNAL_ENTRY_NUMBER>57937</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4044636226</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57937,;.01~VA-GP ONC KID STAGE IV INTER AFTER PERSIST NO SURV
801.41;+57937,;4~dialog group
801.41;+57937,;7~2
801.41;+57937,;15~HF.VA-ONC KID STAGE IV NO PROG AFTER INTER SURVEILLANCE
801.41;+57937,;25~WP-start~1
Active surveillance:
801.41;+57937,;35~WP-start~1
Veteran has elected to pursue ACTIVE SURVEILLANCE.
801.41;+57937,;52~INDENT
801.41;+57937,;100~NATIONAL
801.412;+57938,+57937,;.01~20
801.412;+57938,+57937,;2~VA-ONC KID STAGE IV SURVEILLANCE TXT
801.44;+57939,+57937,;.01~06/09/2026@10:31:12
801.44;+57939,+57937,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57938^1
57939^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER PERSIST NO OFF PATH REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>57940</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1589721639</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57940,;.01~VA-ONC KID STAGE IV INTER AFTER PERSIST NO OFF PATH REASON
801.41;+57940,;4~dialog element
801.41;+57940,;15~HF.VA-ONC KID STAGE IV NO PROG AFTER INTER OFF PATH RSN
801.41;+57940,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+57940,;51~SUPPRESS
801.41;+57940,;100~NATIONAL
801.412;+57941,+57940,;.01~5
801.412;+57941,+57940,;2~VA-ONC OFF PATHWAY
801.412;+57941,+57940,;7~YES
801.412;+57941,+57940,;9~YES
801.44;+57942,+57940,;.01~06/09/2026@10:31:12
801.44;+57942,+57940,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57941^1
57942^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER PERSIST NO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57939</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2262076363</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57939,;.01~VA-ONC KID STAGE IV INTER AFTER PERSIST NO OFF PATH TX
801.41;+57939,;4~dialog element
801.41;+57939,;15~HF.VA-ONC KID STAGE IV NO PROG AFTER INTER OFF PATH TX
801.41;+57939,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+57939,;51~SUPPRESS
801.41;+57939,;100~NATIONAL
801.412;+57940,+57939,;.01~5
801.412;+57940,+57939,;2~VA-ONC BLANK
801.412;+57940,+57939,;9~YES
801.44;+57941,+57939,;.01~06/09/2026@10:31:12
801.44;+57941,+57939,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57940^1
57941^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER AFTER PERSIST NO OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57938</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>661658834</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57938,;.01~VA-GP ONC KID STAGE IV INTER AFTER PERSIST NO OFF PATHWAY
801.41;+57938,;4~dialog group
801.41;+57938,;6~YES
801.41;+57938,;7~2
801.41;+57938,;23~YES
801.41;+57938,;25~WP-start~1
Off pathway:
801.41;+57938,;100~NATIONAL
801.412;+57939,+57938,;.01~10
801.412;+57939,+57938,;2~VA-ONC KID STAGE IV INTER AFTER PERSIST NO OFF PATH TX
801.412;+57940,+57938,;.01~20
801.412;+57940,+57938,;2~VA-ONC KID STAGE IV INTER AFTER PERSIST NO OFF PATH REASON
801.44;+57941,+57938,;.01~06/09/2026@10:31:12
801.44;+57941,+57938,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57939^1
57940^2
57941^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER PERSIST NO CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57936</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2818908270</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57936,;.01~VA-ONC KID STAGE IV INTER AFTER PERSIST NO CLINICAL TRIAL
801.41;+57936,;4~dialog element
801.41;+57936,;15~HF.VA-ONC KID STAGE IV NO PROG AFTER INTER CLINICAL TRIAL
801.41;+57936,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+57936,;35~WP-start~1
Veteran has elected to pursue:
801.41;+57936,;100~NATIONAL
801.412;+57937,+57936,;.01~5
801.412;+57937,+57936,;2~VA-ONC CLINICAL TRIAL
801.412;+57937,+57936,;9~YES
801.44;+57938,+57936,;.01~06/09/2026@10:31:12
801.44;+57938,+57936,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57937^1
57938^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER AFTER PERSIST NO</POINT_01>
<INTERNAL_ENTRY_NUMBER>57935</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2542049714</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57935,;.01~VA-GP ONC KID STAGE IV INTER AFTER PERSIST NO
801.41;+57935,;4~dialog group
801.41;+57935,;6~YES
801.41;+57935,;7~2
801.41;+57935,;9~NONE OR ONE SELECTION
801.41;+57935,;25~WP-start~1
No persistent disease:
801.41;+57935,;100~NATIONAL
801.412;+57936,+57935,;.01~10
801.412;+57936,+57935,;2~VA-ONC KID STAGE IV INTER AFTER PERSIST NO CLINICAL TRIAL
801.412;+57937,+57935,;.01~40
801.412;+57937,+57935,;2~VA-GP ONC KID STAGE IV INTER AFTER PERSIST NO OFF PATHWAY
801.412;+57938,+57935,;.01~30
801.412;+57938,+57935,;2~VA-GP ONC KID STAGE IV INTER AFTER PERSIST NO SURV
801.412;+57939,+57935,;.01~20
801.412;+57939,+57935,;2~VA-GP ONC KID STAGE IV INTER AFTER PERSIST NO PEMBRO
801.44;+57940,+57935,;.01~06/09/2026@10:31:12
801.44;+57940,+57935,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57936^4
57937^5
57938^6
57939^7
57940^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER FAVOR OFF PATH REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>57934</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3574236619</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57934,;.01~VA-ONC KID STAGE IV INTER AFTER FAVOR OFF PATH REASON
801.41;+57934,;4~dialog element
801.41;+57934,;15~HF.VA-ONC KID STAGE IV PROG AFTER INTER FAVOR OFF PATH RSN
801.41;+57934,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+57934,;51~SUPPRESS
801.41;+57934,;100~NATIONAL
801.412;+57935,+57934,;.01~5
801.412;+57935,+57934,;2~VA-ONC OFF PATHWAY
801.412;+57935,+57934,;7~YES
801.412;+57935,+57934,;9~YES
801.44;+57936,+57934,;.01~06/09/2026@10:31:12
801.44;+57936,+57934,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57935^1
57936^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER FAVOR OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57933</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3427894572</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57933,;.01~VA-ONC KID STAGE IV INTER AFTER FAVOR OFF PATH TX
801.41;+57933,;4~dialog element
801.41;+57933,;15~HF.VA-ONC KID STAGE IV PROG AFTER INTER FAVOR OFF PATH TX
801.41;+57933,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+57933,;51~SUPPRESS
801.41;+57933,;100~NATIONAL
801.412;+57934,+57933,;.01~5
801.412;+57934,+57933,;2~VA-ONC BLANK
801.412;+57934,+57933,;9~YES
801.44;+57935,+57933,;.01~06/09/2026@10:31:12
801.44;+57935,+57933,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57934^1
57935^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER AFTER FAVOR OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57932</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3557141741</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57932,;.01~VA-GP ONC KID STAGE IV INTER AFTER FAVOR OFF PATHWAY
801.41;+57932,;4~dialog group
801.41;+57932,;6~YES
801.41;+57932,;7~2
801.41;+57932,;23~YES
801.41;+57932,;25~WP-start~1
Off pathway:
801.41;+57932,;100~NATIONAL
801.412;+57933,+57932,;.01~10
801.412;+57933,+57932,;2~VA-ONC KID STAGE IV INTER AFTER FAVOR OFF PATH TX
801.412;+57934,+57932,;.01~20
801.412;+57934,+57932,;2~VA-ONC KID STAGE IV INTER AFTER FAVOR OFF PATH REASON
801.44;+57935,+57932,;.01~06/09/2026@10:31:12
801.44;+57935,+57932,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57933^1
57934^2
57935^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER AFTER FAVOR PEMBRO+AXIT</POINT_01>
<INTERNAL_ENTRY_NUMBER>57931</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3806460740</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57931,;.01~VA-GP ONC KID STAGE IV INTER AFTER FAVOR PEMBRO+AXIT
801.41;+57931,;4~dialog group
801.41;+57931,;7~2
801.41;+57931,;15~HF.VA-ONC KID STAGE IV PROG AFTER INTER FAVOR PEMBRO+AXIT
801.41;+57931,;25~WP-start~1
Pembrolizumab and axitinib
801.41;+57931,;35~WP-start~1
Veteran has elected to pursue TREATMENT with PEMBROLIZUMAB and AXITINIB.
801.41;+57931,;100~NATIONAL
801.412;+57932,+57931,;.01~5
801.412;+57932,+57931,;2~VA-ONC KID STAGE IV PEMBRO+AXIT FN
801.44;+57933,+57931,;.01~06/09/2026@10:31:12
801.44;+57933,+57931,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57932^1
57933^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER FAVOR CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57930</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>248110352</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57930,;.01~VA-ONC KID STAGE IV INTER AFTER FAVOR CLINICAL TRIAL
801.41;+57930,;4~dialog element
801.41;+57930,;15~HF.VA-ONC KID STAGE IV PROG AFTER INTER FAVOR CLINICAL TRIAL
801.41;+57930,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+57930,;35~WP-start~1
Veteran has elected to pursue:
801.41;+57930,;100~NATIONAL
801.412;+57931,+57930,;.01~5
801.412;+57931,+57930,;2~VA-ONC CLINICAL TRIAL
801.412;+57931,+57930,;9~YES
801.44;+57932,+57930,;.01~06/09/2026@10:31:12
801.44;+57932,+57930,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57931^1
57932^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER AFTER FAVOR</POINT_01>
<INTERNAL_ENTRY_NUMBER>57928</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1775090801</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57928,;.01~VA-GP ONC KID STAGE IV INTER AFTER FAVOR
801.41;+57928,;4~dialog group
801.41;+57928,;6~YES
801.41;+57928,;7~2
801.41;+57928,;9~NONE OR ONE SELECTION
801.41;+57928,;25~WP-start~1
Persistant disease, favorable risk group (first line therapy):
801.41;+57928,;100~NATIONAL
801.412;+57929,+57928,;.01~20
801.412;+57929,+57928,;2~VA-ONC KID STAGE IV INTER AFTER FAVOR CLINICAL TRIAL
801.412;+57930,+57928,;.01~40
801.412;+57930,+57928,;2~VA-GP ONC KID STAGE IV INTER AFTER FAVOR PEMBRO+AXIT
801.412;+57931,+57928,;.01~60
801.412;+57931,+57928,;2~VA-GP ONC KID STAGE IV INTER AFTER FAVOR OFF PATHWAY
801.44;+57932,+57928,;.01~06/09/2026@10:31:12
801.44;+57932,+57928,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57929^1
57930^2
57931^3
57932^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER NO THREAT/SX OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>95982</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2002660341</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95982,;.01~VA-ONC KID STAGE IV INTER AFTER NO THREAT/SX OFF PATH RSN
801.41;+95982,;4~dialog element
801.41;+95982,;15~HF.VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX OFF PATH RSN
801.41;+95982,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+95982,;51~SUPPRESS
801.41;+95982,;100~NATIONAL
801.412;+95983,+95982,;.01~5
801.412;+95983,+95982,;2~VA-ONC OFF PATHWAY
801.412;+95983,+95982,;7~YES
801.412;+95983,+95982,;9~YES
801.44;+95984,+95982,;.01~06/09/2026@10:31:12
801.44;+95984,+95982,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95983^1
95984^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER NO THREAT/SX OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>95981</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1443177949</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95981,;.01~VA-ONC KID STAGE IV INTER AFTER NO THREAT/SX OFF PATH TX
801.41;+95981,;4~dialog element
801.41;+95981,;15~HF.VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX OFF PATH TX
801.41;+95981,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+95981,;51~SUPPRESS
801.41;+95981,;100~NATIONAL
801.412;+95982,+95981,;.01~5
801.412;+95982,+95981,;2~VA-ONC BLANK
801.412;+95982,+95981,;9~YES
801.44;+95983,+95981,;.01~06/09/2026@10:31:12
801.44;+95983,+95981,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95982^1
95983^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER AFTER NO THREAT/SX OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>95980</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3966904005</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95980,;.01~VA-GP ONC KID STAGE IV INTER AFTER NO THREAT/SX OFF PATH
801.41;+95980,;4~dialog group
801.41;+95980,;6~YES
801.41;+95980,;7~2
801.41;+95980,;23~YES
801.41;+95980,;25~WP-start~1
Off pathway:
801.41;+95980,;100~NATIONAL
801.412;+95981,+95980,;.01~10
801.412;+95981,+95980,;2~VA-ONC KID STAGE IV INTER AFTER NO THREAT/SX OFF PATH TX
801.412;+95982,+95980,;.01~20
801.412;+95982,+95980,;2~VA-ONC KID STAGE IV INTER AFTER NO THREAT/SX OFF PATH RSN
801.44;+95983,+95980,;.01~06/09/2026@10:31:12
801.44;+95983,+95980,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95981^1
95982^2
95983^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER NO THREAT/SX IPI+NIVO</POINT_01>
<INTERNAL_ENTRY_NUMBER>95979</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2177238312</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95979,;.01~VA-ONC KID STAGE IV INTER AFTER NO THREAT/SX IPI+NIVO
801.41;+95979,;4~dialog element
801.41;+95979,;15~HF.VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX IPI+NIVO
801.41;+95979,;25~WP-start~1
Ipilimumab and nivolumab
801.41;+95979,;35~WP-start~1
Veteran has elected to pursue TREATMENT with IPILIMUMAB and NIVOLUMAB.
801.41;+95979,;100~NATIONAL
801.44;+95980,+95979,;.01~06/09/2026@10:31:12
801.44;+95980,+95979,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95980^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER NO THREAT/SX CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>95978</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>5423491</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95978,;.01~VA-ONC KID STAGE IV INTER AFTER NO THREAT/SX CLIN TRIAL
801.41;+95978,;4~dialog element
801.41;+95978,;15~HF.VA-ONC KID STAGE IV PROG AFTER INTER NO THREAT/SX CLIN TRIAL
801.41;+95978,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+95978,;35~WP-start~1
Veteran has elected to pursue:
801.41;+95978,;100~NATIONAL
801.412;+95979,+95978,;.01~5
801.412;+95979,+95978,;2~VA-ONC CLINICAL TRIAL
801.412;+95979,+95978,;9~YES
801.44;+95980,+95978,;.01~06/09/2026@10:31:12
801.44;+95980,+95978,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95979^1
95980^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER AFTER NO THREAT/SX</POINT_01>
<INTERNAL_ENTRY_NUMBER>95625</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3901804884</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95625,;.01~VA-GP ONC KID STAGE IV INTER AFTER NO THREAT/SX
801.41;+95625,;4~dialog group
801.41;+95625,;6~YES
801.41;+95625,;7~2
801.41;+95625,;9~NONE OR ONE SELECTION
801.41;+95625,;25~WP-start~1
No life threatening or symptomatic tumor:
801.41;+95625,;100~NATIONAL
801.412;+95626,+95625,;.01~10
801.412;+95626,+95625,;2~VA-ONC KID STAGE IV INTER AFTER NO THREAT/SX CLIN TRIAL
801.412;+95627,+95625,;.01~20
801.412;+95627,+95625,;2~VA-ONC KID STAGE IV INTER AFTER NO THREAT/SX IPI+NIVO
801.412;+95628,+95625,;.01~30
801.412;+95628,+95625,;2~VA-GP ONC KID STAGE IV INTER AFTER NO THREAT/SX OFF PATH
801.44;+95629,+95625,;.01~06/09/2026@10:31:12
801.44;+95629,+95625,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95626^1
95627^2
95628^3
95629^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER THREAT/SX OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>95636</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>609872811</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95636,;.01~VA-ONC KID STAGE IV INTER AFTER THREAT/SX OFF PATH RSN
801.41;+95636,;4~dialog element
801.41;+95636,;15~HF.VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX OFF PATH RSN
801.41;+95636,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+95636,;51~SUPPRESS
801.41;+95636,;100~NATIONAL
801.412;+95637,+95636,;.01~5
801.412;+95637,+95636,;2~VA-ONC OFF PATHWAY
801.412;+95637,+95636,;7~YES
801.412;+95637,+95636,;9~YES
801.44;+95638,+95636,;.01~06/09/2026@10:31:12
801.44;+95638,+95636,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95637^1
95638^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER THREAT/SX OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>95634</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2032575276</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95634,;.01~VA-ONC KID STAGE IV INTER AFTER THREAT/SX OFF PATH TX
801.41;+95634,;4~dialog element
801.41;+95634,;15~HF.VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX OFF PATH TX
801.41;+95634,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+95634,;51~SUPPRESS
801.41;+95634,;100~NATIONAL
801.412;+95635,+95634,;.01~5
801.412;+95635,+95634,;2~VA-ONC BLANK
801.412;+95635,+95634,;9~YES
801.44;+95636,+95634,;.01~06/09/2026@10:31:12
801.44;+95636,+95634,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95635^1
95636^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER AFTER THREAT/SX OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>95633</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1197907295</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95633,;.01~VA-GP ONC KID STAGE IV INTER AFTER THREAT/SX OFF PATH
801.41;+95633,;4~dialog group
801.41;+95633,;6~YES
801.41;+95633,;7~2
801.41;+95633,;23~YES
801.41;+95633,;25~WP-start~1
Off pathway:
801.41;+95633,;100~NATIONAL
801.412;+95634,+95633,;.01~10
801.412;+95634,+95633,;2~VA-ONC KID STAGE IV INTER AFTER THREAT/SX OFF PATH TX
801.412;+95635,+95633,;.01~20
801.412;+95635,+95633,;2~VA-ONC KID STAGE IV INTER AFTER THREAT/SX OFF PATH RSN
801.44;+95636,+95633,;.01~06/09/2026@10:31:12
801.44;+95636,+95633,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95634^1
95635^2
95636^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER THREAT/SX PEMB+AX</POINT_01>
<INTERNAL_ENTRY_NUMBER>95632</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1856552068</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95632,;.01~VA-ONC KID STAGE IV INTER AFTER THREAT/SX PEMB+AX
801.41;+95632,;4~dialog group
801.41;+95632,;7~2
801.41;+95632,;15~HF.VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX PEMB+AXIT
801.41;+95632,;25~WP-start~1
Pembrolizumab and axitinib
801.41;+95632,;35~WP-start~1
Veteran has elected to pursue TREATMENT with PEMBROLIZUMAB and AXITINIB.
801.41;+95632,;100~NATIONAL
801.412;+95633,+95632,;.01~10
801.412;+95633,+95632,;2~VA-ONC KID STAGE IV PEMBRO+AXIT FN
801.44;+95634,+95632,;.01~06/09/2026@10:31:12
801.44;+95634,+95632,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95633^1
95634^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER AFTER THREAT/SX CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>95630</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2631262043</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95630,;.01~VA-ONC KID STAGE IV INTER AFTER THREAT/SX CLIN TRIAL
801.41;+95630,;4~dialog element
801.41;+95630,;15~HF.VA-ONC KID STAGE IV PROG AFTER INTER THREAT/SX CLIN TRIAL
801.41;+95630,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+95630,;35~WP-start~1
Veteran has elected to pursue:
801.41;+95630,;100~NATIONAL
801.412;+95631,+95630,;.01~5
801.412;+95631,+95630,;2~VA-ONC CLINICAL TRIAL
801.412;+95631,+95630,;9~YES
801.44;+95632,+95630,;.01~06/09/2026@10:31:12
801.44;+95632,+95630,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95631^1
95632^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER AFTER THREAT/SX</POINT_01>
<INTERNAL_ENTRY_NUMBER>95623</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>517637518</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+95623,;.01~VA-GP ONC KID STAGE IV INTER AFTER THREAT/SX
801.41;+95623,;4~dialog group
801.41;+95623,;6~YES
801.41;+95623,;7~2
801.41;+95623,;9~NONE OR ONE SELECTION
801.41;+95623,;25~WP-start~1
Life threatening or symptomatic tumor:
801.41;+95623,;100~NATIONAL
801.412;+95624,+95623,;.01~10
801.412;+95624,+95623,;2~VA-ONC KID STAGE IV INTER AFTER THREAT/SX CLIN TRIAL
801.412;+95625,+95623,;.01~20
801.412;+95625,+95623,;2~VA-ONC KID STAGE IV INTER AFTER THREAT/SX PEMB+AX
801.412;+95626,+95623,;.01~30
801.412;+95626,+95623,;2~VA-GP ONC KID STAGE IV INTER AFTER THREAT/SX OFF PATH
801.44;+95627,+95623,;.01~06/09/2026@10:31:12
801.44;+95627,+95623,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
95624^1
95625^2
95626^3
95627^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER AFTER POOR</POINT_01>
<INTERNAL_ENTRY_NUMBER>57929</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>699651387</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57929,;.01~VA-GP ONC KID STAGE IV INTER AFTER POOR
801.41;+57929,;4~dialog group
801.41;+57929,;6~YES
801.41;+57929,;7~2
801.41;+57929,;9~NONE OR ONE SELECTION
801.41;+57929,;25~WP-start~1
Persistent disease, intermediate or poor risk group (first line therapy):
801.41;+57929,;100~NATIONAL
801.412;+57930,+57929,;.01~15
801.412;+57930,+57929,;2~VA-GP ONC KID STAGE IV INTER AFTER THREAT/SX
801.412;+57931,+57929,;.01~30
801.412;+57931,+57929,;2~VA-GP ONC KID STAGE IV INTER AFTER NO THREAT/SX
801.44;+57932,+57929,;.01~06/09/2026@10:31:12
801.44;+57932,+57929,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57930^1
57931^2
57932^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER AFTER MAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>60331</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>936079180</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+60331,;.01~VA-GP ONC KID STAGE IV INTER AFTER MAIN
801.41;+60331,;4~dialog group
801.41;+60331,;6~YES
801.41;+60331,;7~2
801.41;+60331,;9~NONE OR ONE SELECTION
801.41;+60331,;25~WP-start~2
After intervention (cytoreductive nephrectomy or metastasis directed
therapy):
801.41;+60331,;52~INDENT
801.41;+60331,;100~NATIONAL
801.412;+60332,+60331,;.01~80
801.412;+60332,+60331,;2~VA-GP ONC KID STAGE IV INTER AFTER POOR
801.412;+60333,+60331,;.01~120
801.412;+60333,+60331,;2~VA-GP ONC KID STAGE IV INTER AFTER FAVOR
801.412;+60334,+60331,;.01~150
801.412;+60334,+60331,;2~VA-GP ONC KID STAGE IV INTER AFTER PERSIST NO
801.44;+60335,+60331,;.01~06/09/2026@10:31:12
801.44;+60335,+60331,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
60332^2
60333^3
60334^4
60335^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER YES METS DIRECT TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57911</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2121131821</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57911,;.01~VA-GP ONC KID STAGE IV INTER YES METS DIRECT TX
801.41;+57911,;4~dialog group
801.41;+57911,;15~HF.VA-ONC KID STAGE IV CAND INTER METASTASIS DIRECTED TX
801.41;+57911,;25~WP-start~1
Metastasis directed therapy
801.41;+57911,;35~WP-start~1
Veteran has elected to pursue METASTASIS DIRECTED THERAPY.
801.41;+57911,;100~NATIONAL
801.44;+57912,+57911,;.01~06/09/2026@10:31:12
801.44;+57912,+57911,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57912^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER YES CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57909</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2896765275</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57909,;.01~VA-ONC KID STAGE IV INTER YES CLINICAL TRIAL
801.41;+57909,;4~dialog element
801.41;+57909,;15~HF.VA-ONC KID STAGE IV CAND INTER CLINICAL TRIAL
801.41;+57909,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+57909,;35~WP-start~1
Veteran has elected to pursue:
801.41;+57909,;100~NATIONAL
801.412;+57910,+57909,;.01~5
801.412;+57910,+57909,;2~VA-ONC CLINICAL TRIAL
801.412;+57910,+57909,;9~YES
801.44;+57911,+57909,;.01~06/09/2026@10:31:12
801.44;+57911,+57909,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57910^1
57911^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER YES OFF PATH REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>57914</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2621582022</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57914,;.01~VA-ONC KID STAGE IV INTER YES OFF PATH REASON
801.41;+57914,;4~dialog element
801.41;+57914,;15~HF.VA-ONC KID STAGE IV CAND INTER OFF PATH RSN
801.41;+57914,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+57914,;51~SUPPRESS
801.41;+57914,;100~NATIONAL
801.412;+57915,+57914,;.01~5
801.412;+57915,+57914,;2~VA-ONC OFF PATHWAY
801.412;+57915,+57914,;7~YES
801.412;+57915,+57914,;9~YES
801.44;+57916,+57914,;.01~06/09/2026@10:31:12
801.44;+57916,+57914,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57915^1
57916^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE IV INTER YES OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57913</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2014938539</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57913,;.01~VA-ONC KID STAGE IV INTER YES OFF PATH TX
801.41;+57913,;4~dialog element
801.41;+57913,;15~HF.VA-ONC KID STAGE IV CAND INTER OFF PATH TX
801.41;+57913,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+57913,;51~SUPPRESS
801.41;+57913,;100~NATIONAL
801.412;+57914,+57913,;.01~5
801.412;+57914,+57913,;2~VA-ONC BLANK
801.412;+57914,+57913,;9~YES
801.44;+57915,+57913,;.01~06/09/2026@10:31:12
801.44;+57915,+57913,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57914^1
57915^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER YES OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57912</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3062436902</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57912,;.01~VA-GP ONC KID STAGE IV INTER YES OFF PATHWAY
801.41;+57912,;4~dialog group
801.41;+57912,;6~YES
801.41;+57912,;7~2
801.41;+57912,;23~YES
801.41;+57912,;25~WP-start~1
Off pathway:
801.41;+57912,;100~NATIONAL
801.412;+57913,+57912,;.01~10
801.412;+57913,+57912,;2~VA-ONC KID STAGE IV INTER YES OFF PATH TX
801.412;+57914,+57912,;.01~20
801.412;+57914,+57912,;2~VA-ONC KID STAGE IV INTER YES OFF PATH REASON
801.44;+57915,+57912,;.01~06/09/2026@10:31:12
801.44;+57915,+57912,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57913^1
57914^2
57915^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER YES CYTO NEPH</POINT_01>
<INTERNAL_ENTRY_NUMBER>57910</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2511151630</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57910,;.01~VA-GP ONC KID STAGE IV INTER YES CYTO NEPH
801.41;+57910,;4~dialog group
801.41;+57910,;15~HF.VA-ONC KID STAGE IV CAND INTER CYTO NEPHRECTOMY
801.41;+57910,;25~WP-start~1
Cytoreductive nephrectomy
801.41;+57910,;35~WP-start~1
Veteran has elected to pursue CYTOREDUCTIVE NEPHRECTOMY.
801.41;+57910,;100~NATIONAL
801.412;+57911,+57910,;.01~20
801.412;+57911,+57910,;2~VA-ONC UROLOGY CONSULT
801.44;+57912,+57910,;.01~06/09/2026@10:31:12
801.44;+57912,+57910,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57911^1
57912^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV INTER YES</POINT_01>
<INTERNAL_ENTRY_NUMBER>57908</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2266807080</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57908,;.01~VA-GP ONC KID STAGE IV INTER YES
801.41;+57908,;4~dialog group
801.41;+57908,;6~YES
801.41;+57908,;7~2
801.41;+57908,;9~NONE OR ONE SELECTION
801.41;+57908,;25~WP-start~2
Candidate for intervention (cytoreductive nephrectomy or metastasis
directed therapy):
801.41;+57908,;35~WP-start~1
Candidate for intervention:
801.41;+57908,;100~NATIONAL
801.412;+57909,+57908,;.01~20
801.412;+57909,+57908,;2~VA-GP ONC KID STAGE IV INTER YES CYTO NEPH
801.412;+57910,+57908,;.01~30
801.412;+57910,+57908,;2~VA-GP ONC KID STAGE IV INTER YES OFF PATHWAY
801.412;+57911,+57908,;.01~10
801.412;+57911,+57908,;2~VA-ONC KID STAGE IV INTER YES CLINICAL TRIAL
801.412;+57912,+57908,;.01~25
801.412;+57912,+57908,;2~VA-GP ONC KID STAGE IV INTER YES METS DIRECT TX
801.44;+57913,+57908,;.01~06/09/2026@10:31:12
801.44;+57913,+57908,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57909^2
57910^3
57911^4
57912^5
57913^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>57907</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2971156431</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57907,;.01~VA-GP ONC KID STAGE IV SUBMAIN
801.41;+57907,;4~dialog group
801.41;+57907,;6~YES
801.41;+57907,;9~NONE OR ONE SELECTION
801.41;+57907,;25~WP-start~1
After multidisciplinary discussion:
801.41;+57907,;51~SUPPRESS
801.41;+57907,;52~INDENT
801.41;+57907,;100~NATIONAL
801.412;+57908,+57907,;.01~50
801.412;+57908,+57907,;2~VA-GP ONC KID STAGE IV INTER AFTER MAIN
801.412;+57909,+57907,;.01~100
801.412;+57909,+57907,;2~VA-GP ONC KID STAGE IV INTER NO MAIN
801.412;+57910,+57907,;.01~120
801.412;+57910,+57907,;2~VA-GP ONC KID STAGE IV PROGRESS
801.412;+57911,+57907,;.01~20
801.412;+57911,+57907,;2~VA-GP ONC KID STAGE IV INTER YES
801.44;+57912,+57907,;.01~06/09/2026@10:31:12
801.44;+57912,+57907,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57908^17
57909^18
57910^19
57911^6
57912^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE IV MAIN CHECK BOX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57906</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1410601038</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57906,;.01~VA-GP ONC KID STAGE IV MAIN CHECK BOX
801.41;+57906,;4~dialog group
801.41;+57906,;6~YES
801.41;+57906,;7~2
801.41;+57906,;15~HF.VA-ONC KID STAGE IV CLINICAL PATHWAY
801.41;+57906,;25~WP-start~1
Stage IV or Relapsed Clear Cell - Kidney Cancer Clinical Pathway
801.41;+57906,;35~WP-start~3
VA National Stage IV or Relapsed Clear Cell - Kidney
              Cancer Clinical Pathway
====================================================
801.41;+57906,;100~NATIONAL
801.412;+57907,+57906,;.01~60
801.412;+57907,+57906,;2~VA-GP ONC KID STAGE IV SUBMAIN
801.412;+57908,+57906,;.01~40
801.412;+57908,+57906,;2~VA-ONC KID STAGE IV RISK GROUPS
801.412;+57909,+57906,;.01~20
801.412;+57909,+57906,;2~VA-ONC KID STAGE IV BRAIN IMAGING
801.44;+57910,+57906,;.01~06/09/2026@10:31:12
801.44;+57910,+57906,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57907^1
57908^2
57909^3
57910^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III NOT CAND ADJ PEMBRO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>106092</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>121062411</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+106092,;.01~VA-ONC KID STAGE III NOT CAND ADJ PEMBRO OFF PATH TX
801.41;+106092,;4~dialog element
801.41;+106092,;15~HF.VA-ONC KID STAGE III S/P SURG PEM NO OFF PTH TX
801.41;+106092,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+106092,;51~SUPPRESS
801.41;+106092,;100~NATIONAL
801.412;+106093,+106092,;.01~5
801.412;+106093,+106092,;2~VA-ONC BLANK
801.412;+106093,+106092,;9~YES
801.44;+106094,+106092,;.01~06/09/2026@10:31:12
801.44;+106094,+106092,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
106093^1
106094^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III NOT CAND ADJ PEMBRO OFF PATH RSN</POINT_01>
<INTERNAL_ENTRY_NUMBER>106091</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1190103431</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+106091,;.01~VA-ONC KID STAGE III NOT CAND ADJ PEMBRO OFF PATH RSN
801.41;+106091,;4~dialog element
801.41;+106091,;15~HF.VA-ONC KID STAGE III S/P SURG PEM NO OFF PTH RSN
801.41;+106091,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+106091,;51~SUPPRESS
801.41;+106091,;100~NATIONAL
801.412;+106092,+106091,;.01~5
801.412;+106092,+106091,;2~VA-ONC OFF PATHWAY
801.412;+106092,+106091,;7~YES
801.412;+106092,+106091,;9~YES
801.44;+106093,+106091,;.01~06/09/2026@10:31:13
801.44;+106093,+106091,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
106092^1
106093^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III NOT CAND ADJ PEMBRO OFF PATH</POINT_01>
<INTERNAL_ENTRY_NUMBER>106090</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>653087431</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+106090,;.01~VA-GP ONC KID STAGE III NOT CAND ADJ PEMBRO OFF PATH
801.41;+106090,;4~dialog group
801.41;+106090,;6~YES
801.41;+106090,;7~2
801.41;+106090,;23~YES
801.41;+106090,;25~WP-start~1
Off pathway:
801.41;+106090,;100~LOCAL
801.412;+106091,+106090,;.01~20
801.412;+106091,+106090,;2~VA-ONC KID STAGE III NOT CAND ADJ PEMBRO OFF PATH RSN
801.412;+106092,+106090,;.01~10
801.412;+106092,+106090,;2~VA-ONC KID STAGE III NOT CAND ADJ PEMBRO OFF PATH TX
801.44;+106093,+106090,;.01~06/09/2026@10:31:13
801.44;+106093,+106090,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
106091^2
106092^3
106093^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II/III SURVEILLANCE TXT</POINT_01>
<INTERNAL_ENTRY_NUMBER>57966</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>746283252</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57966,;.01~VA-ONC KID STAGE II/III SURVEILLANCE TXT
801.41;+57966,;4~dialog element
801.41;+57966,;25~WP-start~3
Follow up every 3-6 months for 3 years, then annually for 2 years:     
   -history and physical\\   -comprehensive metabolic panel
   -abdominal CT/MRI with contrast\\   -chest x-ray/CT
801.41;+57966,;51~SUPPRESS
801.41;+57966,;100~NATIONAL
801.44;+57967,+57966,;.01~06/09/2026@10:31:13
801.44;+57967,+57966,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57967^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III NOT CAND ADJ PEMBRO SURV</POINT_01>
<INTERNAL_ENTRY_NUMBER>106089</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1558357972</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+106089,;.01~VA-GP ONC KID STAGE III NOT CAND ADJ PEMBRO SURV
801.41;+106089,;4~dialog group
801.41;+106089,;6~YES
801.41;+106089,;7~2
801.41;+106089,;15~HF.VA-ONC KID STAGE III S/P SURG PEM NO SURVEILLANCE
801.41;+106089,;25~WP-start~1
Active surveillance:
801.41;+106089,;35~WP-start~1
Veteran has elected to pursue ACTIVE SURVEILLANCE.
801.41;+106089,;100~NATIONAL
801.412;+106090,+106089,;.01~10
801.412;+106090,+106089,;2~VA-ONC KID STAGE II/III SURVEILLANCE TXT
801.44;+106091,+106089,;.01~06/09/2026@10:31:13
801.44;+106091,+106089,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
106090^1
106091^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III NOT CAND ADJ PEMBRO CLIN TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>106088</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3377283332</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+106088,;.01~VA-ONC KID STAGE III NOT CAND ADJ PEMBRO CLIN TRIAL
801.41;+106088,;4~dialog element
801.41;+106088,;15~HF.VA-ONC KID STAGE III S/P SURG PEM NO CLIN TRIAL
801.41;+106088,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+106088,;35~WP-start~1
Veteran has elected to pursue:
801.41;+106088,;100~NATIONAL
801.412;+106089,+106088,;.01~5
801.412;+106089,+106088,;2~VA-ONC CLINICAL TRIAL
801.412;+106089,+106088,;9~YES
801.44;+106090,+106088,;.01~06/09/2026@10:31:13
801.44;+106090,+106088,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
106089^1
106090^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III NOT CAND ADJ PEMBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>106086</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1430234172</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+106086,;.01~VA-GP ONC KID STAGE III NOT CAND ADJ PEMBRO
801.41;+106086,;4~dialog group
801.41;+106086,;6~YES
801.41;+106086,;7~2
801.41;+106086,;9~NONE OR ONE SELECTION
801.41;+106086,;25~WP-start~1
Not a candidate for adjuvant pembrolizumab:
801.41;+106086,;35~WP-start~1
Veteran is not a candidate for adjuvant pembrolizumab. 
801.41;+106086,;52~INDENT
801.41;+106086,;100~NATIONAL
801.412;+106087,+106086,;.01~10
801.412;+106087,+106086,;2~VA-ONC KID STAGE III NOT CAND ADJ PEMBRO CLIN TRIAL
801.412;+106088,+106086,;.01~20
801.412;+106088,+106086,;2~VA-GP ONC KID STAGE III NOT CAND ADJ PEMBRO SURV
801.412;+106089,+106086,;.01~30
801.412;+106089,+106086,;2~VA-GP ONC KID STAGE III NOT CAND ADJ PEMBRO OFF PATH
801.44;+106090,+106086,;.01~06/09/2026@10:31:13
801.44;+106090,+106086,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
106087^1
106088^2
106089^3
106090^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III ADJ PEMBRO OFF PATH REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>57899</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>512937108</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57899,;.01~VA-ONC KID STAGE III ADJ PEMBRO OFF PATH REASON
801.41;+57899,;4~dialog element
801.41;+57899,;15~HF.VA-ONC KID STAGE III S/P SURG OFF PATH RSN
801.41;+57899,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+57899,;51~SUPPRESS
801.41;+57899,;100~NATIONAL
801.412;+57900,+57899,;.01~5
801.412;+57900,+57899,;2~VA-ONC OFF PATHWAY
801.412;+57900,+57899,;7~YES
801.412;+57900,+57899,;9~YES
801.44;+57901,+57899,;.01~06/09/2026@10:31:13
801.44;+57901,+57899,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57900^1
57901^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III ADJ PEMBRO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57898</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2383231198</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57898,;.01~VA-ONC KID STAGE III ADJ PEMBRO OFF PATH TX
801.41;+57898,;4~dialog element
801.41;+57898,;15~HF.VA-ONC KID STAGE III S/P SURG OFF PATH TX
801.41;+57898,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+57898,;51~SUPPRESS
801.41;+57898,;100~NATIONAL
801.412;+57899,+57898,;.01~5
801.412;+57899,+57898,;2~VA-ONC BLANK
801.412;+57899,+57898,;9~YES
801.44;+57900,+57898,;.01~06/09/2026@10:31:13
801.44;+57900,+57898,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57899^1
57900^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III ADJ PEMBRO OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57897</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1296365241</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57897,;.01~VA-GP ONC KID STAGE III ADJ PEMBRO OFF PATHWAY
801.41;+57897,;4~dialog group
801.41;+57897,;6~YES
801.41;+57897,;7~2
801.41;+57897,;23~YES
801.41;+57897,;25~WP-start~1
Off pathway:
801.41;+57897,;100~NATIONAL
801.412;+57898,+57897,;.01~10
801.412;+57898,+57897,;2~VA-ONC KID STAGE III ADJ PEMBRO OFF PATH TX
801.412;+57899,+57897,;.01~20
801.412;+57899,+57897,;2~VA-ONC KID STAGE III ADJ PEMBRO OFF PATH REASON
801.44;+57900,+57897,;.01~06/09/2026@10:31:13
801.44;+57900,+57897,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57898^1
57899^2
57900^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III ADJ PEMBRO SURV</POINT_01>
<INTERNAL_ENTRY_NUMBER>106087</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1187251545</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+106087,;.01~VA-GP ONC KID STAGE III ADJ PEMBRO SURV
801.41;+106087,;4~dialog group
801.41;+106087,;6~YES
801.41;+106087,;7~2
801.41;+106087,;15~HF.VA-ONC KID STAGE III S/P SURG ADJ PEMB SURVEILLANCE
801.41;+106087,;25~WP-start~1
Active surveillance:
801.41;+106087,;35~WP-start~1
Veteran has elected to pursue ACTIVE SURVEILLANCE.
801.41;+106087,;100~NATIONAL
801.412;+106088,+106087,;.01~10
801.412;+106088,+106087,;2~VA-ONC KID STAGE II/III SURVEILLANCE TXT
801.44;+106089,+106087,;.01~06/09/2026@10:31:13
801.44;+106089,+106087,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
106088^1
106089^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III ADJ PEMBRO 1YR</POINT_01>
<INTERNAL_ENTRY_NUMBER>57896</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2006882283</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57896,;.01~VA-GP ONC KID STAGE III ADJ PEMBRO 1YR
801.41;+57896,;4~dialog group
801.41;+57896,;6~YES
801.41;+57896,;7~2
801.41;+57896,;15~HF.VA-ONC KID STAGE III S/P SURG ADJ PEMBRO
801.41;+57896,;25~WP-start~1
Adjuvant pembrolizumab for one year
801.41;+57896,;35~WP-start~2
Veteran has elected to pursue TREATMENT with ADJUVANT PEMBROLIZUMAB for 
ONE YEAR.
801.41;+57896,;52~INDENT
801.41;+57896,;100~NATIONAL
801.44;+57897,+57896,;.01~06/09/2026@10:31:13
801.44;+57897,+57896,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57897^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III ADJ PEMBRO CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57870</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2274189611</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57870,;.01~VA-ONC KID STAGE III ADJ PEMBRO CLINICAL TRIAL
801.41;+57870,;4~dialog element
801.41;+57870,;15~HF.VA-ONC KID STAGE III S/P SURG CLINICAL TRIAL
801.41;+57870,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+57870,;35~WP-start~1
Veteran has elected to pursue:
801.41;+57870,;100~NATIONAL
801.412;+57871,+57870,;.01~5
801.412;+57871,+57870,;2~VA-ONC CLINICAL TRIAL
801.412;+57871,+57870,;9~YES
801.44;+57872,+57870,;.01~06/09/2026@10:31:13
801.44;+57872,+57870,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57871^1
57872^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III ADJ PEMBRO PREFER SDM</POINT_01>
<INTERNAL_ENTRY_NUMBER>106085</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2901407002</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+106085,;.01~VA-GP ONC KID STAGE III ADJ PEMBRO PREFER SDM
801.41;+106085,;4~dialog group
801.41;+106085,;6~YES
801.41;+106085,;9~NONE OR ONE SELECTION
801.41;+106085,;25~WP-start~1
Veteran preference after shared decision making:
801.41;+106085,;51~SUPPRESS
801.41;+106085,;52~INDENT
801.41;+106085,;100~NATIONAL
801.412;+106086,+106085,;.01~10
801.412;+106086,+106085,;2~VA-ONC KID STAGE III ADJ PEMBRO CLINICAL TRIAL
801.412;+106087,+106085,;.01~20
801.412;+106087,+106085,;2~VA-GP ONC KID STAGE III ADJ PEMBRO 1YR
801.412;+106088,+106085,;.01~30
801.412;+106088,+106085,;2~VA-GP ONC KID STAGE III ADJ PEMBRO SURV
801.412;+106089,+106085,;.01~40
801.412;+106089,+106085,;2~VA-GP ONC KID STAGE III ADJ PEMBRO OFF PATHWAY
801.44;+106090,+106085,;.01~06/09/2026@10:31:13
801.44;+106090,+106085,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
106086^1
106087^2
106088^3
106089^4
106090^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III CAND ADJ PEMBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>106084</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2202378205</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+106084,;.01~VA-GP ONC KID STAGE III CAND ADJ PEMBRO
801.41;+106084,;4~dialog group
801.41;+106084,;7~2
801.41;+106084,;25~WP-start~1
Candidate for adjuvant pembrolizumab:
801.41;+106084,;35~WP-start~1
Veteran is a candidate for adjuvant pembrolizumab.
801.41;+106084,;100~NATIONAL
801.412;+106085,+106084,;.01~20
801.412;+106085,+106084,;2~VA-GP ONC KID STAGE III ADJ PEMBRO PREFER SDM
801.44;+106086,+106084,;.01~06/09/2026@10:31:13
801.44;+106086,+106084,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
106085^1
106086^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III CAND ADJ PEMBRO MAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>106124</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1328765221</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+106124,;.01~VA-GP ONC KID STAGE III CAND ADJ PEMBRO MAIN
801.41;+106124,;4~dialog group
801.41;+106124,;6~YES
801.41;+106124,;7~2
801.41;+106124,;9~NONE OR ONE SELECTION
801.41;+106124,;51~SUPPRESS
801.41;+106124,;100~NATIONAL
801.412;+106125,+106124,;.01~20
801.412;+106125,+106124,;2~VA-GP ONC KID STAGE III CAND ADJ PEMBRO
801.412;+106126,+106124,;.01~40
801.412;+106126,+106124,;2~VA-GP ONC KID STAGE III NOT CAND ADJ PEMBRO
801.44;+106127,+106124,;.01~06/09/2026@10:31:13
801.44;+106127,+106124,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
106125^1
106126^2
106127^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID PEMBRO INSTRUCTIONS</POINT_01>
<INTERNAL_ENTRY_NUMBER>57848</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1409096128</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57848,;.01~VA-ONC KID PEMBRO INSTRUCTIONS
801.41;+57848,;4~dialog element
801.41;+57848,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+57848,;23~YES
801.41;+57848,;25~WP-start~1
Pembrolizumab therapy consideration and risk of recurrence:
801.41;+57848,;35~WP-start~10
  Consider pembrolizumab therapy for one year if clear cell stage II
with\\  nuclear grade 4 or sarcomatoid differentiation, tumor stage III
or\\  higher, regional lymph node metastasis, or stage M1 with NED; must
take\\  into consideration life expectancy; surveillance or clinical
trial\\  recommended for non-clear cell histology.
 
  Risk of Recurrence - evaluate the likely outcome of the Veteran's
surgical\\  treatment; consider the use of postoperative prognostic
nomogram such as\\  Memorial Sloan Kettering Center's Kidney Cancer
Nomograms.
801.41;+57848,;51~SUPPRESS
801.41;+57848,;100~NATIONAL
801.412;+57849,+57848,;.01~5
801.412;+57849,+57848,;2~PXRM GF VIEW BUTTON
801.412;+57849,+57848,;6~VIEW Adj Pembrolizumab
801.44;+57850,+57848,;.01~06/09/2026@10:31:13
801.44;+57850,+57848,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57849^1
57850^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III ADJ PEMBRO SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>57895</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2640537944</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57895,;.01~VA-GP ONC KID STAGE III ADJ PEMBRO SUBMAIN
801.41;+57895,;4~dialog group
801.41;+57895,;6~YES
801.41;+57895,;7~2
801.41;+57895,;25~WP-start~1
After radical nephrectomy:
801.41;+57895,;52~INDENT
801.41;+57895,;100~NATIONAL
801.412;+57896,+57895,;.01~5
801.412;+57896,+57895,;2~VA-ONC KID PEMBRO INSTRUCTIONS
801.412;+57897,+57895,;.01~20
801.412;+57897,+57895,;2~VA-GP ONC KID STAGE III CAND ADJ PEMBRO MAIN
801.44;+57898,+57895,;.01~06/09/2026@10:31:13
801.44;+57898,+57895,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57896^4
57897^5
57898^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III SURG CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57869</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>382977827</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57869,;.01~VA-ONC KID STAGE III SURG CLINICAL TRIAL
801.41;+57869,;4~dialog element
801.41;+57869,;15~HF.VA-ONC KID STAGE III SURG CLINICAL TRIAL
801.41;+57869,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+57869,;35~WP-start~1
Veteran has elected to pursue:
801.41;+57869,;100~NATIONAL
801.412;+57870,+57869,;.01~5
801.412;+57870,+57869,;2~VA-ONC CLINICAL TRIAL
801.412;+57870,+57869,;9~YES
801.44;+57871,+57869,;.01~06/09/2026@10:31:13
801.44;+57871,+57869,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57870^1
57871^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III SURG OFF PATH REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>57894</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1468163917</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57894,;.01~VA-ONC KID STAGE III SURG OFF PATH REASON
801.41;+57894,;4~dialog element
801.41;+57894,;15~HF.VA-ONC KID STAGE III SURG OFF PATH RSN
801.41;+57894,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+57894,;51~SUPPRESS
801.41;+57894,;100~NATIONAL
801.412;+57895,+57894,;.01~5
801.412;+57895,+57894,;2~VA-ONC OFF PATHWAY
801.412;+57895,+57894,;7~YES
801.412;+57895,+57894,;9~YES
801.44;+57896,+57894,;.01~06/09/2026@10:31:13
801.44;+57896,+57894,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57895^1
57896^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE III SURG OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57893</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1128083359</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57893,;.01~VA-ONC KID STAGE III SURG OFF PATH TX
801.41;+57893,;4~dialog element
801.41;+57893,;15~HF.VA-ONC KID STAGE III SURG OFF PATH TX
801.41;+57893,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+57893,;51~SUPPRESS
801.41;+57893,;100~NATIONAL
801.412;+57894,+57893,;.01~5
801.412;+57894,+57893,;2~VA-ONC BLANK
801.412;+57894,+57893,;9~YES
801.44;+57895,+57893,;.01~06/09/2026@10:31:13
801.44;+57895,+57893,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57894^1
57895^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III SURG OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57892</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2659696712</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57892,;.01~VA-GP ONC KID STAGE III SURG OFF PATHWAY
801.41;+57892,;4~dialog group
801.41;+57892,;6~YES
801.41;+57892,;7~2
801.41;+57892,;23~YES
801.41;+57892,;25~WP-start~1
Off pathway:
801.41;+57892,;100~NATIONAL
801.412;+57893,+57892,;.01~10
801.412;+57893,+57892,;2~VA-ONC KID STAGE III SURG OFF PATH TX
801.412;+57894,+57892,;.01~20
801.412;+57894,+57892,;2~VA-ONC KID STAGE III SURG OFF PATH REASON
801.44;+57895,+57892,;.01~06/09/2026@10:31:13
801.44;+57895,+57892,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57893^1
57894^2
57895^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III SURG RAD NEPHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57891</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1204968386</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57891,;.01~VA-GP ONC KID STAGE III SURG RAD NEPHRECTOMY
801.41;+57891,;4~dialog group
801.41;+57891,;15~HF.VA-ONC KID STAGE III SURG RADICAL NEPHRECTOMY
801.41;+57891,;25~WP-start~1
Radical nephrectomy
801.41;+57891,;35~WP-start~1
Veteran has elected to pursue RADICAL NEPHRECTOMY.
801.41;+57891,;100~NATIONAL
801.412;+57892,+57891,;.01~20
801.412;+57892,+57891,;2~VA-ONC UROLOGY CONSULT
801.44;+57893,+57891,;.01~06/09/2026@10:31:13
801.44;+57893,+57891,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57892^1
57893^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III SURG SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>57883</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1223940642</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57883,;.01~VA-GP ONC KID STAGE III SURG SUBMAIN
801.41;+57883,;4~dialog group
801.41;+57883,;6~YES
801.41;+57883,;7~2
801.41;+57883,;9~NONE OR ONE SELECTION
801.41;+57883,;25~WP-start~1
Surgical intervention:
801.41;+57883,;100~NATIONAL
801.412;+57884,+57883,;.01~20
801.412;+57884,+57883,;2~VA-GP ONC KID STAGE III SURG RAD NEPHRECTOMY
801.412;+57885,+57883,;.01~30
801.412;+57885,+57883,;2~VA-GP ONC KID STAGE III SURG OFF PATHWAY
801.412;+57886,+57883,;.01~10
801.412;+57886,+57883,;2~VA-ONC KID STAGE III SURG CLINICAL TRIAL
801.44;+57887,+57883,;.01~06/09/2026@10:31:13
801.44;+57887,+57883,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57884^2
57885^3
57886^4
57887^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>57868</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2043585197</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57868,;.01~VA-GP ONC KID STAGE III SUBMAIN
801.41;+57868,;4~dialog group
801.41;+57868,;6~YES
801.41;+57868,;9~NONE OR ONE SELECTION
801.41;+57868,;51~SUPPRESS
801.41;+57868,;100~NATIONAL
801.412;+57869,+57868,;.01~20
801.412;+57869,+57868,;2~VA-GP ONC KID STAGE III SURG SUBMAIN
801.412;+57870,+57868,;.01~40
801.412;+57870,+57868,;2~VA-GP ONC KID STAGE III ADJ PEMBRO SUBMAIN
801.44;+57871,+57868,;.01~06/09/2026@10:31:13
801.44;+57871,+57868,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57869^6
57870^7
57871^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE III MAIN CHECK BOX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57867</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1003957119</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57867,;.01~VA-GP ONC KID STAGE III MAIN CHECK BOX
801.41;+57867,;4~dialog group
801.41;+57867,;7~2
801.41;+57867,;9~NONE OR ONE SELECTION
801.41;+57867,;15~HF.VA-ONC KID STAGE III CLINICAL PATHWAY
801.41;+57867,;25~WP-start~1
Stage III - Kidney Cancer Clinical Pathway
801.41;+57867,;35~WP-start~2
VA National Stage III - Kidney Cancer Clinical Pathway
======================================================
801.41;+57867,;100~NATIONAL
801.412;+57868,+57867,;.01~60
801.412;+57868,+57867,;2~VA-GP ONC KID STAGE III SUBMAIN
801.44;+57869,+57867,;.01~06/09/2026@10:31:13
801.44;+57869,+57867,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57868^1
57869^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II SURGERY OFF PATH REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>57865</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1852225811</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57865,;.01~VA-ONC KID STAGE II SURGERY OFF PATH REASON
801.41;+57865,;4~dialog element
801.41;+57865,;15~HF.VA-ONC KID STAGE II SURGERY OFF PATH RSN
801.41;+57865,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+57865,;51~SUPPRESS
801.41;+57865,;100~NATIONAL
801.412;+57866,+57865,;.01~5
801.412;+57866,+57865,;2~VA-ONC OFF PATHWAY
801.412;+57866,+57865,;7~YES
801.412;+57866,+57865,;9~YES
801.44;+57867,+57865,;.01~06/09/2026@10:31:13
801.44;+57867,+57865,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57866^1
57867^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II SURGERY OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57864</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3185368022</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57864,;.01~VA-ONC KID STAGE II SURGERY OFF PATH TX
801.41;+57864,;4~dialog element
801.41;+57864,;15~HF.VA-ONC KID STAGE II SURGERY OFF PATH TX
801.41;+57864,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+57864,;51~SUPPRESS
801.41;+57864,;100~NATIONAL
801.412;+57865,+57864,;.01~5
801.412;+57865,+57864,;2~VA-ONC BLANK
801.412;+57865,+57864,;7~YES
801.412;+57865,+57864,;9~YES
801.44;+57866,+57864,;.01~06/09/2026@10:31:13
801.44;+57866,+57864,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57865^1
57866^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II SURGERY OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57863</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2581587588</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57863,;.01~VA-GP ONC KID STAGE II SURGERY OFF PATHWAY
801.41;+57863,;4~dialog group
801.41;+57863,;6~YES
801.41;+57863,;7~2
801.41;+57863,;23~YES
801.41;+57863,;25~WP-start~1
Off pathway:
801.41;+57863,;100~NATIONAL
801.412;+57864,+57863,;.01~10
801.412;+57864,+57863,;2~VA-ONC KID STAGE II SURGERY OFF PATH TX
801.412;+57865,+57863,;.01~20
801.412;+57865,+57863,;2~VA-ONC KID STAGE II SURGERY OFF PATH REASON
801.44;+57866,+57863,;.01~06/09/2026@10:31:13
801.44;+57866,+57863,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57864^1
57865^2
57866^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II SURGERY RAD NEPHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57862</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2153242228</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57862,;.01~VA-GP ONC KID STAGE II SURGERY RAD NEPHRECTOMY
801.41;+57862,;4~dialog group
801.41;+57862,;15~HF.VA-ONC KID STAGE II SURGERY RADICAL NEPHRECTOMY
801.41;+57862,;25~WP-start~1
Radical nephrectomy
801.41;+57862,;35~WP-start~1
Veteran has elected to pursue RADICAL NEPHRECTOMY.
801.41;+57862,;100~NATIONAL
801.412;+57863,+57862,;.01~20
801.412;+57863,+57862,;2~VA-ONC UROLOGY CONSULT
801.44;+57864,+57862,;.01~06/09/2026@10:31:13
801.44;+57864,+57862,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57863^1
57864^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II SURGERY PARTIAL NEPHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57861</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2970648256</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57861,;.01~VA-GP ONC KID STAGE II SURGERY PARTIAL NEPHRECTOMY
801.41;+57861,;4~dialog group
801.41;+57861,;15~HF.VA-ONC KID STAGE II SURGERY PARTIAL NEPHRECTOMY
801.41;+57861,;25~WP-start~1
Partial nephrectomy
801.41;+57861,;35~WP-start~1
Veteran has elected to pursue PARTIAL NEPHRECTOMY.
801.41;+57861,;100~NATIONAL
801.412;+57862,+57861,;.01~20
801.412;+57862,+57861,;2~VA-ONC UROLOGY CONSULT
801.44;+57863,+57861,;.01~06/09/2026@10:31:13
801.44;+57863,+57861,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57862^1
57863^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II SURGERY CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57860</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2610505413</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57860,;.01~VA-ONC KID STAGE II SURGERY CLINICAL TRIAL
801.41;+57860,;4~dialog element
801.41;+57860,;15~HF.VA-ONC KID STAGE II SURGERY CLINICAL TRIAL
801.41;+57860,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+57860,;35~WP-start~1
Veteran has elected to pursue:
801.41;+57860,;100~NATIONAL
801.412;+57861,+57860,;.01~5
801.412;+57861,+57860,;2~VA-ONC CLINICAL TRIAL
801.412;+57861,+57860,;9~YES
801.44;+57862,+57860,;.01~06/09/2026@10:31:13
801.44;+57862,+57860,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57861^1
57862^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II SURGERY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57859</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>538831024</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57859,;.01~VA-GP ONC KID STAGE II SURGERY
801.41;+57859,;4~dialog group
801.41;+57859,;6~YES
801.41;+57859,;7~2
801.41;+57859,;9~NONE OR ONE SELECTION
801.41;+57859,;25~WP-start~1
Surgical intervention:
801.41;+57859,;52~INDENT
801.41;+57859,;100~NATIONAL
801.412;+57860,+57859,;.01~20
801.412;+57860,+57859,;2~VA-ONC KID STAGE II SURGERY CLINICAL TRIAL
801.412;+57861,+57859,;.01~60
801.412;+57861,+57859,;2~VA-GP ONC KID STAGE II SURGERY PARTIAL NEPHRECTOMY
801.412;+57862,+57859,;.01~80
801.412;+57862,+57859,;2~VA-GP ONC KID STAGE II SURGERY RAD NEPHRECTOMY
801.412;+57863,+57859,;.01~100
801.412;+57863,+57859,;2~VA-GP ONC KID STAGE II SURGERY OFF PATHWAY
801.44;+57864,+57859,;.01~06/09/2026@10:31:13
801.44;+57864,+57859,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57860^2
57861^3
57862^4
57863^5
57864^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO SURVEILLANCE</POINT_01>
<INTERNAL_ENTRY_NUMBER>57965</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2660745872</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57965,;.01~VA-GP ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO SURVEILLANCE
801.41;+57965,;4~dialog group
801.41;+57965,;6~YES
801.41;+57965,;7~2
801.41;+57965,;15~HF.VA-ONC KID STAGE II NO ADJ PEMBRO SURVEILLANCE
801.41;+57965,;25~WP-start~1
Active surveillance:
801.41;+57965,;35~WP-start~1
Veteran has elected to pursue ACTIVE SURVEILLANCE.
801.41;+57965,;52~INDENT
801.41;+57965,;100~NATIONAL
801.412;+57966,+57965,;.01~20
801.412;+57966,+57965,;2~VA-ONC KID STAGE II/III SURVEILLANCE TXT
801.44;+57967,+57965,;.01~06/09/2026@10:31:13
801.44;+57967,+57965,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57966^1
57967^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO OFF PATH REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>57857</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2873172740</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57857,;.01~VA-ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO OFF PATH REASON
801.41;+57857,;4~dialog element
801.41;+57857,;15~HF.VA-ONC KID STAGE II NO ADJ PEMBRO OFF PATH RSN
801.41;+57857,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+57857,;51~SUPPRESS
801.41;+57857,;100~NATIONAL
801.412;+57858,+57857,;.01~5
801.412;+57858,+57857,;2~VA-ONC OFF PATHWAY
801.412;+57858,+57857,;7~YES
801.412;+57858,+57857,;9~YES
801.44;+57859,+57857,;.01~06/09/2026@10:31:13
801.44;+57859,+57857,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57858^1
57859^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57856</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>245677520</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57856,;.01~VA-ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO OFF PATH TX
801.41;+57856,;4~dialog element
801.41;+57856,;15~HF.VA-ONC KID STAGE II NO ADJ PEMBRO OFF PATH TX
801.41;+57856,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+57856,;51~SUPPRESS
801.41;+57856,;100~NATIONAL
801.412;+57857,+57856,;.01~5
801.412;+57857,+57856,;2~VA-ONC BLANK
801.412;+57857,+57856,;7~YES
801.412;+57857,+57856,;9~YES
801.44;+57858,+57856,;.01~06/09/2026@10:31:13
801.44;+57858,+57856,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57857^1
57858^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57855</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1374467401</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57855,;.01~VA-GP ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO OFF PATHWAY
801.41;+57855,;4~dialog group
801.41;+57855,;6~YES
801.41;+57855,;7~2
801.41;+57855,;23~YES
801.41;+57855,;25~WP-start~1
Off pathway:
801.41;+57855,;100~NATIONAL
801.412;+57856,+57855,;.01~10
801.412;+57856,+57855,;2~VA-ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO OFF PATH TX
801.412;+57857,+57855,;.01~20
801.412;+57857,+57855,;2~VA-ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO OFF PATH REASON
801.44;+57858,+57855,;.01~06/09/2026@10:31:13
801.44;+57858,+57855,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57856^1
57857^2
57858^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57853</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4068686922</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57853,;.01~VA-ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO CLINICAL TRIAL
801.41;+57853,;4~dialog element
801.41;+57853,;15~HF.VA-ONC KID STAGE II NO ADJ PEMBRO CLINICAL TRIAL
801.41;+57853,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+57853,;35~WP-start~1
Veteran has elected to pursue:
801.41;+57853,;100~NATIONAL
801.412;+57854,+57853,;.01~5
801.412;+57854,+57853,;2~VA-ONC CLINICAL TRIAL
801.412;+57854,+57853,;9~YES
801.44;+57855,+57853,;.01~06/09/2026@10:31:13
801.44;+57855,+57853,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57854^1
57855^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>57852</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2936345110</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57852,;.01~VA-GP ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO
801.41;+57852,;4~dialog group
801.41;+57852,;6~YES
801.41;+57852,;7~2
801.41;+57852,;9~NONE OR ONE SELECTION
801.41;+57852,;25~WP-start~1
Not a candidate for adjuvant pembrolizumab:
801.41;+57852,;35~WP-start~1
Veteran is not a candidate for adjuvant pembrolizumab.
801.41;+57852,;100~NATIONAL
801.412;+57853,+57852,;.01~10
801.412;+57853,+57852,;2~VA-ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO CLINICAL TRIAL
801.412;+57854,+57852,;.01~30
801.412;+57854,+57852,;2~VA-GP ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO OFF PATHWAY
801.412;+57855,+57852,;.01~15
801.412;+57855,+57852,;2~VA-GP ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO SURVEILLANCE
801.44;+57856,+57852,;.01~06/09/2026@10:31:13
801.44;+57856,+57852,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57853^1
57854^3
57855^4
57856^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II CANDIDATE ADJ PEMBRO SURVE</POINT_01>
<INTERNAL_ENTRY_NUMBER>106076</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4099627809</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+106076,;.01~VA-GP ONC KID STAGE II CANDIDATE ADJ PEMBRO SURVE
801.41;+106076,;4~dialog group
801.41;+106076,;6~YES
801.41;+106076,;7~2
801.41;+106076,;15~HF.VA-ONC KID STAGE II ADJ PEMBRO SURVEILLANCE
801.41;+106076,;25~WP-start~1
Active surveillance:
801.41;+106076,;35~WP-start~1
Veteran has elected to pursue ACTIVE SURVEILLANCE.
801.41;+106076,;100~NATIONAL
801.412;+106077,+106076,;.01~10
801.412;+106077,+106076,;2~VA-ONC KID STAGE II/III SURVEILLANCE TXT
801.44;+106078,+106076,;.01~06/09/2026@10:31:13
801.44;+106078,+106076,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
106077^1
106078^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II CANDIDATE ADJ PEMBRO OFF PATH REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>57851</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1969180104</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57851,;.01~VA-ONC KID STAGE II CANDIDATE ADJ PEMBRO OFF PATH REASON
801.41;+57851,;4~dialog element
801.41;+57851,;15~HF.VA-ONC KID STAGE II CAND ADJ PEMBRO OFF PATH RSN
801.41;+57851,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+57851,;51~SUPPRESS
801.41;+57851,;100~NATIONAL
801.412;+57852,+57851,;.01~5
801.412;+57852,+57851,;2~VA-ONC OFF PATHWAY
801.412;+57852,+57851,;7~YES
801.412;+57852,+57851,;9~YES
801.44;+57853,+57851,;.01~06/09/2026@10:31:13
801.44;+57853,+57851,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57852^1
57853^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II CANDIDATE ADJ PEMBRO OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57850</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1549640693</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57850,;.01~VA-ONC KID STAGE II CANDIDATE ADJ PEMBRO OFF PATH TX
801.41;+57850,;4~dialog element
801.41;+57850,;15~HF.VA-ONC KID STAGE II CAND ADJ PEMBRO OFF PATH TX
801.41;+57850,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+57850,;51~SUPPRESS
801.41;+57850,;100~NATIONAL
801.412;+57851,+57850,;.01~5
801.412;+57851,+57850,;2~VA-ONC BLANK
801.412;+57851,+57850,;7~YES
801.412;+57851,+57850,;9~YES
801.44;+57852,+57850,;.01~06/09/2026@10:31:13
801.44;+57852,+57850,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57851^1
57852^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II CANDIDATE ADJ PEMBRO OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57849</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1709680708</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57849,;.01~VA-GP ONC KID STAGE II CANDIDATE ADJ PEMBRO OFF PATHWAY
801.41;+57849,;4~dialog group
801.41;+57849,;6~YES
801.41;+57849,;7~2
801.41;+57849,;23~YES
801.41;+57849,;25~WP-start~1
Off pathway:
801.41;+57849,;100~NATIONAL
801.412;+57850,+57849,;.01~10
801.412;+57850,+57849,;2~VA-ONC KID STAGE II CANDIDATE ADJ PEMBRO OFF PATH TX
801.412;+57851,+57849,;.01~20
801.412;+57851,+57849,;2~VA-ONC KID STAGE II CANDIDATE ADJ PEMBRO OFF PATH REASON
801.44;+57852,+57849,;.01~06/09/2026@10:31:13
801.44;+57852,+57849,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57850^1
57851^2
57852^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II CANDIDATE ADJ PEMBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>57847</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3827023163</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57847,;.01~VA-ONC KID STAGE II CANDIDATE ADJ PEMBRO
801.41;+57847,;4~dialog element
801.41;+57847,;15~HF.VA-ONC KID STAGE II CAND ADJ PEMBRO
801.41;+57847,;25~WP-start~1
Adjuvant pembrolizumab for one year
801.41;+57847,;35~WP-start~2
Veteran has elected to pursue TREATMENT with ADJUVANT PEMBROLIZUMAB for 
ONE YEAR.
801.41;+57847,;100~NATIONAL
801.44;+57848,+57847,;.01~06/09/2026@10:31:13
801.44;+57848,+57847,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57848^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE II CANDIDATE ADJ PEMBRO CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57846</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1704076621</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57846,;.01~VA-ONC KID STAGE II CANDIDATE ADJ PEMBRO CLINICAL TRIAL
801.41;+57846,;4~dialog element
801.41;+57846,;15~HF.VA-ONC KID STAGE II CAND ADJ PEMBRO CLINICAL TRIAL
801.41;+57846,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+57846,;35~WP-start~1
Veteran has elected to pursue:
801.41;+57846,;100~NATIONAL
801.412;+57847,+57846,;.01~5
801.412;+57847,+57846,;2~VA-ONC CLINICAL TRIAL
801.412;+57847,+57846,;9~YES
801.44;+57848,+57846,;.01~06/09/2026@10:31:13
801.44;+57848,+57846,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57847^1
57848^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II ADJ PEMBRO PREFER SDM</POINT_01>
<INTERNAL_ENTRY_NUMBER>106075</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2473095072</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+106075,;.01~VA-GP ONC KID STAGE II ADJ PEMBRO PREFER SDM
801.41;+106075,;4~dialog group
801.41;+106075,;6~YES
801.41;+106075,;9~NONE OR ONE SELECTION
801.41;+106075,;25~WP-start~1
Veteran preference after shared decision making:
801.41;+106075,;51~SUPPRESS
801.41;+106075,;52~INDENT
801.41;+106075,;100~NATIONAL
801.412;+106076,+106075,;.01~10
801.412;+106076,+106075,;2~VA-ONC KID STAGE II CANDIDATE ADJ PEMBRO CLINICAL TRIAL
801.412;+106077,+106075,;.01~20
801.412;+106077,+106075,;2~VA-ONC KID STAGE II CANDIDATE ADJ PEMBRO
801.412;+106078,+106075,;.01~40
801.412;+106078,+106075,;2~VA-GP ONC KID STAGE II CANDIDATE ADJ PEMBRO OFF PATHWAY
801.412;+106079,+106075,;.01~30
801.412;+106079,+106075,;2~VA-GP ONC KID STAGE II CANDIDATE ADJ PEMBRO SURVE
801.44;+106080,+106075,;.01~06/09/2026@10:31:13
801.44;+106080,+106075,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
106076^1
106077^2
106078^3
106079^4
106080^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II CANDIDATE ADJ PEMBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>57845</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>795069782</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57845,;.01~VA-GP ONC KID STAGE II CANDIDATE ADJ PEMBRO
801.41;+57845,;4~dialog group
801.41;+57845,;7~2
801.41;+57845,;25~WP-start~1
Candidate for adjuvant pembrolizumab:
801.41;+57845,;35~WP-start~1
Veteran is a candidate for adjuvant pembrolizumab.
801.41;+57845,;100~NATIONAL
801.412;+57846,+57845,;.01~20
801.412;+57846,+57845,;2~VA-GP ONC KID STAGE II ADJ PEMBRO PREFER SDM
801.44;+57847,+57845,;.01~06/09/2026@10:31:13
801.44;+57847,+57845,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57846^1
57847^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II CAND ADJ PEMBRO MAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>106125</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>561034078</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+106125,;.01~VA-GP ONC KID STAGE II CAND ADJ PEMBRO MAIN
801.41;+106125,;4~dialog group
801.41;+106125,;6~YES
801.41;+106125,;7~2
801.41;+106125,;9~NONE OR ONE SELECTION
801.41;+106125,;51~SUPPRESS
801.41;+106125,;100~NATIONAL
801.412;+106126,+106125,;.01~20
801.412;+106126,+106125,;2~VA-GP ONC KID STAGE II CANDIDATE ADJ PEMBRO
801.412;+106127,+106125,;.01~40
801.412;+106127,+106125,;2~VA-GP ONC KID STAGE II NOT CANDIDATE ADJ PEMBRO
801.44;+106128,+106125,;.01~06/09/2026@10:31:13
801.44;+106128,+106125,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
106126^1
106127^2
106128^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II ADJ PEMBRO</POINT_01>
<INTERNAL_ENTRY_NUMBER>57858</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>247264206</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57858,;.01~VA-GP ONC KID STAGE II ADJ PEMBRO
801.41;+57858,;4~dialog group
801.41;+57858,;6~YES
801.41;+57858,;7~2
801.41;+57858,;25~WP-start~1
After partial or radical nephrectomy:
801.41;+57858,;52~INDENT
801.41;+57858,;100~NATIONAL
801.412;+57859,+57858,;.01~20
801.412;+57859,+57858,;2~VA-ONC KID PEMBRO INSTRUCTIONS
801.412;+57860,+57858,;.01~40
801.412;+57860,+57858,;2~VA-GP ONC KID STAGE II CAND ADJ PEMBRO MAIN
801.44;+57861,+57858,;.01~06/09/2026@10:31:13
801.44;+57861,+57858,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57859^3
57860^4
57861^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE II MAIN CHECK BOX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57844</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2909018855</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57844,;.01~VA-GP ONC KID STAGE II MAIN CHECK BOX
801.41;+57844,;4~dialog group
801.41;+57844,;6~YES
801.41;+57844,;7~2
801.41;+57844,;9~NONE OR ONE SELECTION
801.41;+57844,;15~HF.VA-ONC KID STAGE II CLINICAL PATHWAY
801.41;+57844,;25~WP-start~1
Stage II - Kidney Cancer Clinical Pathway
801.41;+57844,;35~WP-start~2
VA National Stage II - Kidney Cancer Clinical Pathway
=====================================================
801.41;+57844,;100~NATIONAL
801.412;+57845,+57844,;.01~50
801.412;+57845,+57844,;2~VA-GP ONC KID STAGE II ADJ PEMBRO
801.412;+57846,+57844,;.01~20
801.412;+57846,+57844,;2~VA-GP ONC KID STAGE II SURGERY
801.44;+57847,+57844,;.01~06/09/2026@10:31:13
801.44;+57847,+57844,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57845^4
57846^5
57847^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I SURVEILLANCE TXT NO RIGOROUS</POINT_01>
<INTERNAL_ENTRY_NUMBER>61849</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>304517870</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+61849,;.01~VA-ONC KID STAGE I SURVEILLANCE TXT NO RIGOROUS
801.41;+61849,;4~dialog element
801.41;+61849,;25~WP-start~4
Surveillance annually for 5 years:\\   -history and physical   
   -comprehensive metabolic panel
   -abdominal CT/MRI with contrast (within first 6 months, then annually)
   -chest x-ray/CT (as clinically indicated)
801.41;+61849,;51~SUPPRESS
801.41;+61849,;100~NATIONAL
801.44;+61850,+61849,;.01~06/09/2026@10:31:13
801.44;+61850,+61849,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
61850^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I T1B ACTIVE SURVEILLANCE</POINT_01>
<INTERNAL_ENTRY_NUMBER>57964</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1977950910</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57964,;.01~VA-GP ONC KID STAGE I T1B ACTIVE SURVEILLANCE
801.41;+57964,;4~dialog group
801.41;+57964,;6~YES
801.41;+57964,;7~2
801.41;+57964,;15~HF.VA-ONC KID STAGE I T1B ACTIVE SURVEILLANCE
801.41;+57964,;25~WP-start~1
Active surveillance (not a surgical candidate or medically frail):
801.41;+57964,;35~WP-start~1
Veteran has elected to pursue ACTIVE SURVEILLANCE.
801.41;+57964,;52~INDENT
801.41;+57964,;100~NATIONAL
801.412;+57965,+57964,;.01~20
801.412;+57965,+57964,;2~VA-ONC KID STAGE I SURVEILLANCE TXT NO RIGOROUS
801.44;+57966,+57964,;.01~06/09/2026@10:31:13
801.44;+57966,+57964,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57965^1
57966^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC RADIATION ONCOLOGY CONSULT</POINT_01>
<INTERNAL_ENTRY_NUMBER>57669</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1031719635</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57669,;.01~VA-ONC RADIATION ONCOLOGY CONSULT
801.41;+57669,;4~dialog element
801.41;+57669,;51~SUPPRESS
801.41;+57669,;100~NATIONAL
801.44;+57670,+57669,;.01~06/09/2026@10:31:13
801.44;+57670,+57669,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57670^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I T1B ABLATIVE PROCEDURES</POINT_01>
<INTERNAL_ENTRY_NUMBER>57786</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2066700281</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57786,;.01~VA-GP ONC KID STAGE I T1B ABLATIVE PROCEDURES
801.41;+57786,;4~dialog group
801.41;+57786,;6~YES
801.41;+57786,;7~2
801.41;+57786,;15~HF.VA-ONC KID STAGE I T1B ABLATIVE PROCEDURES W SURV
801.41;+57786,;25~WP-start~1
Ablative procedures, including SBRT, then active surveillance:
801.41;+57786,;35~WP-start~2
Veteran has elected to pursue ABLATIVE PROCEDURES, including STEREOTACTIC 
BODY RADIOTHERAPY, then ACTIVE SURVEILLANCE.
801.41;+57786,;52~INDENT
801.41;+57786,;100~NATIONAL
801.412;+57787,+57786,;.01~40
801.412;+57787,+57786,;2~VA-ONC RADIATION ONCOLOGY CONSULT
801.412;+57788,+57786,;.01~20
801.412;+57788,+57786,;2~VA-ONC KID STAGE I SURVEILLANCE TXT NO RIGOROUS
801.44;+57789,+57786,;.01~06/09/2026@10:31:13
801.44;+57789,+57786,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57787^2
57788^3
57789^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I SURVEILLANCE TXT</POINT_01>
<INTERNAL_ENTRY_NUMBER>57950</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>937077404</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57950,;.01~VA-ONC KID STAGE I SURVEILLANCE TXT
801.41;+57950,;4~dialog element
801.41;+57950,;25~WP-start~6
Surveillance annually for 5 years:\\   -history and physical   
   -comprehensive metabolic panel
   -abdominal CT/MRI with contrast (within first 6 months, then annually)
   -chest x-ray/CT (as clinically indicated)
++ More rigorous schedule if positive margins, sarcomatoid features, or
high grade. ++
801.41;+57950,;35~WP-start~4
Surveillance annually for 5 years:\\   -history and physical   
   -comprehensive metabolic panel
   -abdominal CT/MRI with contrast (within first 6 months, then annually)
   -chest x-ray/CT (as clinically indicated)
801.41;+57950,;51~SUPPRESS
801.41;+57950,;100~NATIONAL
801.44;+57951,+57950,;.01~06/09/2026@10:31:13
801.44;+57951,+57950,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57951^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I T1B RADICAL NEPHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57761</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1108691059</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57761,;.01~VA-GP ONC KID STAGE I T1B RADICAL NEPHRECTOMY
801.41;+57761,;4~dialog group
801.41;+57761,;6~YES
801.41;+57761,;7~2
801.41;+57761,;15~HF.VA-ONC KID STAGE I T1B RADICAL NEPHRECTOMY W SURV
801.41;+57761,;25~WP-start~1
Radical nephrectomy, then active surveillance:
801.41;+57761,;35~WP-start~2
Veteran has elected to pursue RADICAL NEPHRECTOMY, then ACTIVE 
SURVEILLANCE.
801.41;+57761,;52~INDENT
801.41;+57761,;100~NATIONAL
801.412;+57762,+57761,;.01~40
801.412;+57762,+57761,;2~VA-ONC KID STAGE I SURVEILLANCE TXT
801.412;+57763,+57761,;.01~60
801.412;+57763,+57761,;2~VA-ONC UROLOGY CONSULT
801.44;+57764,+57761,;.01~06/09/2026@10:31:13
801.44;+57764,+57761,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57762^1
57763^2
57764^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1B OFF PATH REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>57843</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2579649998</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57843,;.01~VA-ONC KID STAGE I T1B OFF PATH REASON
801.41;+57843,;4~dialog element
801.41;+57843,;15~HF.VA-ONC KID STAGE I T1B OFF PATH RSN
801.41;+57843,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+57843,;51~SUPPRESS
801.41;+57843,;100~NATIONAL
801.412;+57844,+57843,;.01~5
801.412;+57844,+57843,;2~VA-ONC OFF PATHWAY
801.412;+57844,+57843,;7~YES
801.412;+57844,+57843,;9~YES
801.44;+57845,+57843,;.01~06/09/2026@10:31:13
801.44;+57845,+57843,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57844^1
57845^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1B OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57842</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4279996589</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57842,;.01~VA-ONC KID STAGE I T1B OFF PATH TX
801.41;+57842,;4~dialog element
801.41;+57842,;15~HF.VA-ONC KID STAGE I T1B OFF PATH TX
801.41;+57842,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+57842,;51~SUPPRESS
801.41;+57842,;100~NATIONAL
801.412;+57843,+57842,;.01~5
801.412;+57843,+57842,;2~VA-ONC BLANK
801.412;+57843,+57842,;7~YES
801.412;+57843,+57842,;9~YES
801.44;+57844,+57842,;.01~06/09/2026@10:31:13
801.44;+57844,+57842,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57843^1
57844^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I T1B OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57841</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1097289950</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57841,;.01~VA-GP ONC KID STAGE I T1B OFF PATHWAY
801.41;+57841,;4~dialog group
801.41;+57841,;6~YES
801.41;+57841,;7~2
801.41;+57841,;23~YES
801.41;+57841,;25~WP-start~1
Off pathway:
801.41;+57841,;100~NATIONAL
801.412;+57842,+57841,;.01~10
801.412;+57842,+57841,;2~VA-ONC KID STAGE I T1B OFF PATH TX
801.412;+57843,+57841,;.01~20
801.412;+57843,+57841,;2~VA-ONC KID STAGE I T1B OFF PATH REASON
801.44;+57844,+57841,;.01~06/09/2026@10:31:13
801.44;+57844,+57841,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57842^1
57843^2
57844^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I T1B PARTIAL NEPHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57732</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3900311027</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57732,;.01~VA-GP ONC KID STAGE I T1B PARTIAL NEPHRECTOMY
801.41;+57732,;4~dialog group
801.41;+57732,;6~YES
801.41;+57732,;7~2
801.41;+57732,;15~HF.VA-ONC KID STAGE I T1B PARTIAL NEPHRECTOMY W SURV
801.41;+57732,;25~WP-start~1
Partial nephrectomy, then active surveillance:
801.41;+57732,;35~WP-start~2
Veteran has elected to pursue PARTIAL NEPHRECTOMY, then ACTIVE 
SURVEILLANCE.
801.41;+57732,;52~INDENT
801.41;+57732,;100~NATIONAL
801.412;+57733,+57732,;.01~20
801.412;+57733,+57732,;2~VA-ONC KID STAGE I SURVEILLANCE TXT
801.412;+57734,+57732,;.01~40
801.412;+57734,+57732,;2~VA-ONC UROLOGY CONSULT
801.44;+57735,+57732,;.01~06/09/2026@10:31:13
801.44;+57735,+57732,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57733^1
57734^2
57735^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1B CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57731</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>837145970</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57731,;.01~VA-ONC KID STAGE I T1B CLINICAL TRIAL
801.41;+57731,;4~dialog element
801.41;+57731,;15~HF.VA-ONC KID STAGE I T1B CLINICAL TRIAL
801.41;+57731,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+57731,;35~WP-start~1
Veteran has elected to pursue:
801.41;+57731,;100~NATIONAL
801.412;+57732,+57731,;.01~5
801.412;+57732,+57731,;2~VA-ONC CLINICAL TRIAL
801.412;+57732,+57731,;9~YES
801.44;+57733,+57731,;.01~06/09/2026@10:31:13
801.44;+57733,+57731,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57732^1
57733^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I T1B</POINT_01>
<INTERNAL_ENTRY_NUMBER>57730</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3687685781</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57730,;.01~VA-GP ONC KID STAGE I T1B
801.41;+57730,;4~dialog group
801.41;+57730,;6~YES
801.41;+57730,;7~2
801.41;+57730,;9~NONE OR ONE SELECTION
801.41;+57730,;25~WP-start~1
T1b (cancer is bigger than 4cm):
801.41;+57730,;52~INDENT
801.41;+57730,;100~NATIONAL
801.412;+57731,+57730,;.01~10
801.412;+57731,+57730,;2~VA-ONC KID STAGE I T1B CLINICAL TRIAL
801.412;+57732,+57730,;.01~40
801.412;+57732,+57730,;2~VA-GP ONC KID STAGE I T1B PARTIAL NEPHRECTOMY
801.412;+57733,+57730,;.01~120
801.412;+57733,+57730,;2~VA-GP ONC KID STAGE I T1B OFF PATHWAY
801.412;+57734,+57730,;.01~60
801.412;+57734,+57730,;2~VA-GP ONC KID STAGE I T1B RADICAL NEPHRECTOMY
801.412;+57735,+57730,;.01~100
801.412;+57735,+57730,;2~VA-GP ONC KID STAGE I T1B ABLATIVE PROCEDURES
801.412;+57736,+57730,;.01~80
801.412;+57736,+57730,;2~VA-GP ONC KID STAGE I T1B ACTIVE SURVEILLANCE
801.44;+57737,+57730,;.01~06/09/2026@10:31:13
801.44;+57737,+57730,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57731^1
57732^3
57733^4
57734^5
57735^7
57736^8
57737^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I T1A ACTIVE SURVEILLANCE</POINT_01>
<INTERNAL_ENTRY_NUMBER>57952</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3870308932</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57952,;.01~VA-GP ONC KID STAGE I T1A ACTIVE SURVEILLANCE
801.41;+57952,;4~dialog group
801.41;+57952,;6~YES
801.41;+57952,;7~2
801.41;+57952,;13~DONE ELSEWHERE (HISTORICAL)
801.41;+57952,;15~HF.VA-ONC KID STAGE I T1A ACTIVE SURVEILLANCE
801.41;+57952,;25~WP-start~2
Active surveillance (preferred for renal masses less than or equal to 3 
cm):
801.41;+57952,;35~WP-start~1
Veteran has elected to pursue ACTIVE SURVEILLANCE.
801.41;+57952,;52~INDENT
801.41;+57952,;100~NATIONAL
801.412;+57953,+57952,;.01~30
801.412;+57953,+57952,;2~VA-ONC KID STAGE I SURVEILLANCE TXT NO RIGOROUS
801.44;+57954,+57952,;.01~06/09/2026@10:31:13
801.44;+57954,+57952,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57953^2
57954^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I T1A RENAL BIOPSY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57729</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4276940296</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57729,;.01~VA-GP ONC KID STAGE I T1A RENAL BIOPSY
801.41;+57729,;4~dialog group
801.41;+57729,;6~YES
801.41;+57729,;7~2
801.41;+57729,;15~HF.VA-ONC KID STAGE I T1A RENAL BIOPSY W SURV
801.41;+57729,;25~WP-start~1
Renal biopsy, then active surveillance:
801.41;+57729,;35~WP-start~1
Veteran has elected to pursue RENAL BIOPSY, then ACTIVE SURVEILLANCE.
801.41;+57729,;52~INDENT
801.41;+57729,;100~NATIONAL
801.412;+57730,+57729,;.01~40
801.412;+57730,+57729,;2~VA-ONC RADIATION ONCOLOGY CONSULT
801.412;+57731,+57729,;.01~20
801.412;+57731,+57729,;2~VA-ONC KID STAGE I SURVEILLANCE TXT
801.44;+57732,+57729,;.01~06/09/2026@10:31:13
801.44;+57732,+57729,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57730^2
57731^4
57732^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I T1A ABLATIVE PROCEDURES</POINT_01>
<INTERNAL_ENTRY_NUMBER>57728</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3443713673</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57728,;.01~VA-GP ONC KID STAGE I T1A ABLATIVE PROCEDURES
801.41;+57728,;4~dialog group
801.41;+57728,;6~YES
801.41;+57728,;7~2
801.41;+57728,;15~HF.VA-ONC KID STAGE I T1A ABLATIVE PROCEDURES W SURV
801.41;+57728,;25~WP-start~1
Ablative procedures, including SBRT, then active surveillance:
801.41;+57728,;35~WP-start~2
Veteran has elected to pursue ABLATIVE PROCEDURES, including STEREOTACTIC 
BODY RADIOTHERAPY, then ACTIVE SURVEILLANCE.
801.41;+57728,;52~INDENT
801.41;+57728,;100~NATIONAL
801.412;+57729,+57728,;.01~40
801.412;+57729,+57728,;2~VA-ONC RADIATION ONCOLOGY CONSULT
801.412;+57730,+57728,;.01~20
801.412;+57730,+57728,;2~VA-ONC KID STAGE I SURVEILLANCE TXT NO RIGOROUS
801.44;+57731,+57728,;.01~06/09/2026@10:31:13
801.44;+57731,+57728,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57729^2
57730^4
57731^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I T1A RADICAL NEPHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57727</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>447146192</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57727,;.01~VA-GP ONC KID STAGE I T1A RADICAL NEPHRECTOMY
801.41;+57727,;4~dialog group
801.41;+57727,;6~YES
801.41;+57727,;7~2
801.41;+57727,;15~HF.VA-ONC KID STAGE I T1A RADICAL NEPHRECTOMY W SURV
801.41;+57727,;25~WP-start~1
Radical nephrectomy, then active surveillance:
801.41;+57727,;35~WP-start~2
Veteran has elected to pursue RADICAL NEPHRECTOMY, then ACTIVE 
SURVEILLANCE.
801.41;+57727,;52~INDENT
801.41;+57727,;100~NATIONAL
801.412;+57728,+57727,;.01~40
801.412;+57728,+57727,;2~VA-ONC UROLOGY CONSULT
801.412;+57729,+57727,;.01~20
801.412;+57729,+57727,;2~VA-ONC KID STAGE I SURVEILLANCE TXT
801.44;+57730,+57727,;.01~06/09/2026@10:31:13
801.44;+57730,+57727,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57728^2
57729^3
57730^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1A OFF PATH REASON</POINT_01>
<INTERNAL_ENTRY_NUMBER>57726</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4040726098</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57726,;.01~VA-ONC KID STAGE I T1A OFF PATH REASON
801.41;+57726,;4~dialog element
801.41;+57726,;15~HF.VA-ONC KID STAGE I T1A OFF PATH RSN
801.41;+57726,;25~WP-start~1
{FLD:VA-ONC OFF REASON TXT}
801.41;+57726,;51~SUPPRESS
801.41;+57726,;100~NATIONAL
801.412;+57727,+57726,;.01~5
801.412;+57727,+57726,;2~VA-ONC OFF PATHWAY
801.412;+57727,+57726,;7~YES
801.412;+57727,+57726,;9~YES
801.44;+57728,+57726,;.01~06/09/2026@10:31:13
801.44;+57728,+57726,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57727^1
57728^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1A OFF PATH TX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57725</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1045236678</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57725,;.01~VA-ONC KID STAGE I T1A OFF PATH TX
801.41;+57725,;4~dialog element
801.41;+57725,;15~HF.VA-ONC KID STAGE I T1A OFF PATH TX
801.41;+57725,;25~WP-start~1
Veteran has elected to pursue: {FLD:VA-ONC TREATMENT REASON}
801.41;+57725,;51~SUPPRESS
801.41;+57725,;100~NATIONAL
801.412;+57726,+57725,;.01~5
801.412;+57726,+57725,;2~VA-ONC BLANK
801.412;+57726,+57725,;7~YES
801.412;+57726,+57725,;9~YES
801.44;+57727,+57725,;.01~06/09/2026@10:31:13
801.44;+57727,+57725,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57726^1
57727^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I T1A OFF PATHWAY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57724</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1525196265</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57724,;.01~VA-GP ONC KID STAGE I T1A OFF PATHWAY
801.41;+57724,;4~dialog group
801.41;+57724,;6~YES
801.41;+57724,;7~2
801.41;+57724,;23~YES
801.41;+57724,;25~WP-start~1
Off pathway:
801.41;+57724,;100~NATIONAL
801.412;+57725,+57724,;.01~10
801.412;+57725,+57724,;2~VA-ONC KID STAGE I T1A OFF PATH TX
801.412;+57726,+57724,;.01~20
801.412;+57726,+57724,;2~VA-ONC KID STAGE I T1A OFF PATH REASON
801.44;+57727,+57724,;.01~06/09/2026@10:31:13
801.44;+57727,+57724,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57725^1
57726^2
57727^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I T1A PARTIAL NEPHRECTOMY</POINT_01>
<INTERNAL_ENTRY_NUMBER>57723</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1551945164</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57723,;.01~VA-GP ONC KID STAGE I T1A PARTIAL NEPHRECTOMY
801.41;+57723,;4~dialog group
801.41;+57723,;6~YES
801.41;+57723,;7~2
801.41;+57723,;15~HF.VA-ONC KID STAGE I T1A PARTIAL NEPHRECTOMY W SURV
801.41;+57723,;25~WP-start~1
Partial nephrectomy, then active surveillance:
801.41;+57723,;35~WP-start~2
Veteran has elected to pursue PARTIAL NEPHRECTOMY, then ACTIVE 
SURVEILLANCE.
801.41;+57723,;52~INDENT
801.41;+57723,;100~NATIONAL
801.412;+57724,+57723,;.01~20
801.412;+57724,+57723,;2~VA-ONC KID STAGE I SURVEILLANCE TXT
801.412;+57725,+57723,;.01~40
801.412;+57725,+57723,;2~VA-ONC UROLOGY CONSULT
801.44;+57726,+57723,;.01~06/09/2026@10:31:13
801.44;+57726,+57723,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57724^1
57725^2
57726^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID STAGE I T1A CLINICAL TRIAL</POINT_01>
<INTERNAL_ENTRY_NUMBER>57721</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>182870366</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57721,;.01~VA-ONC KID STAGE I T1A CLINICAL TRIAL
801.41;+57721,;4~dialog element
801.41;+57721,;15~HF.VA-ONC KID STAGE I T1A CLINICAL TRIAL
801.41;+57721,;25~WP-start~1
{FLD:VA-ONC CLINICAL TRIAL}
801.41;+57721,;35~WP-start~1
Veteran has elected to pursue:
801.41;+57721,;100~NATIONAL
801.412;+57722,+57721,;.01~5
801.412;+57722,+57721,;2~VA-ONC CLINICAL TRIAL
801.412;+57722,+57721,;9~YES
801.44;+57723,+57721,;.01~06/09/2026@10:31:13
801.44;+57723,+57721,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57722^1
57723^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I T1A</POINT_01>
<INTERNAL_ENTRY_NUMBER>57720</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3024412421</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57720,;.01~VA-GP ONC KID STAGE I T1A
801.41;+57720,;4~dialog group
801.41;+57720,;6~YES
801.41;+57720,;7~2
801.41;+57720,;9~NONE OR ONE SELECTION
801.41;+57720,;25~WP-start~1
T1a (cancer is 4cm or smaller):
801.41;+57720,;52~INDENT
801.41;+57720,;100~NATIONAL
801.412;+57721,+57720,;.01~10
801.412;+57721,+57720,;2~VA-ONC KID STAGE I T1A CLINICAL TRIAL
801.412;+57722,+57720,;.01~40
801.412;+57722,+57720,;2~VA-GP ONC KID STAGE I T1A PARTIAL NEPHRECTOMY
801.412;+57723,+57720,;.01~120
801.412;+57723,+57720,;2~VA-GP ONC KID STAGE I T1A OFF PATHWAY
801.412;+57724,+57720,;.01~60
801.412;+57724,+57720,;2~VA-GP ONC KID STAGE I T1A RADICAL NEPHRECTOMY
801.412;+57725,+57720,;.01~80
801.412;+57725,+57720,;2~VA-GP ONC KID STAGE I T1A ABLATIVE PROCEDURES
801.412;+57726,+57720,;.01~100
801.412;+57726,+57720,;2~VA-GP ONC KID STAGE I T1A RENAL BIOPSY
801.412;+57727,+57720,;.01~20
801.412;+57727,+57720,;2~VA-GP ONC KID STAGE I T1A ACTIVE SURVEILLANCE
801.44;+57728,+57720,;.01~06/09/2026@10:31:13
801.44;+57728,+57720,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57721^1
57722^3
57723^4
57724^5
57725^6
57726^7
57727^8
57728^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID STAGE I MAIN CHECK BOX</POINT_01>
<INTERNAL_ENTRY_NUMBER>57719</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4170392837</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57719,;.01~VA-GP ONC KID STAGE I MAIN CHECK BOX
801.41;+57719,;4~dialog group
801.41;+57719,;6~YES
801.41;+57719,;7~2
801.41;+57719,;9~NONE OR ONE SELECTION
801.41;+57719,;15~HF.VA-ONC KID STAGE I CLINICAL PATHWAY
801.41;+57719,;25~WP-start~1
Stage I - Kidney Cancer Clinical Pathway
801.41;+57719,;35~WP-start~2
VA National Stage I - Kidney Cancer Clinical Pathway
====================================================
801.41;+57719,;100~NATIONAL
801.412;+57720,+57719,;.01~20
801.412;+57720,+57719,;2~VA-GP ONC KID STAGE I T1A
801.412;+57721,+57719,;.01~40
801.412;+57721,+57719,;2~VA-GP ONC KID STAGE I T1B
801.44;+57722,+57719,;.01~06/09/2026@10:31:13
801.44;+57722,+57719,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57720^1
57721^2
57722^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID PATHWAYS SUBMAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>57904</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1508203914</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57904,;.01~VA-GP ONC KID PATHWAYS SUBMAIN
801.41;+57904,;4~dialog group
801.41;+57904,;6~YES
801.41;+57904,;9~NONE OR ONE SELECTION
801.41;+57904,;51~SUPPRESS
801.41;+57904,;100~NATIONAL
801.412;+57905,+57904,;.01~60
801.412;+57905,+57904,;2~VA-GP ONC KID STAGE I MAIN CHECK BOX
801.412;+57906,+57904,;.01~100
801.412;+57906,+57904,;2~VA-GP ONC KID STAGE II MAIN CHECK BOX
801.412;+57907,+57904,;.01~140
801.412;+57907,+57904,;2~VA-GP ONC KID STAGE III MAIN CHECK BOX
801.412;+57908,+57904,;.01~200
801.412;+57908,+57904,;2~VA-GP ONC KID STAGE IV MAIN CHECK BOX
801.412;+57909,+57904,;.01~220
801.412;+57909,+57904,;2~VA-GP ONC KID STAGE IV NON-CC MAIN
801.44;+57910,+57904,;.01~06/09/2026@10:31:13
801.44;+57910,+57904,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57905^1
57906^2
57907^3
57908^4
57909^5
57910^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID INITIAL WORK UP VIEW PATHWAY INSTRUCTIONS</POINT_01>
<INTERNAL_ENTRY_NUMBER>57968</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>129365188</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57968,;.01~VA-ONC KID INITIAL WORK UP VIEW PATHWAY INSTRUCTIONS
801.41;+57968,;4~dialog element
801.41;+57968,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+57968,;23~YES
801.41;+57968,;25~WP-start~1
{FLD:VA-ONC INSTRUCTIONS ON/OFF PATHWAY}
801.41;+57968,;35~WP-start~19
Initial Workup for Kidney Cancer:\\
================================\\
1. Consider genetic counseling evaluation for multiple or bilateral 
renal\\   masses, family history, or young age.\\
2. Consider renal biopsy if this would effect management.\\
3. If Urothelial carcinoma is suspected, consider urine cytology, 
ureteroscopy,\\   or percutaneous biopsy.\\
4. Treatment decisions dependent on patient comorbidities, surgical\\ 
  complexity, and shared decision making.
 
Recommended diagnostics:\\
=======================\\
-CT abdomen/pelvis\\
-chest x-ray\\
-if clinically indicated, consider bone scan, brain MRI, or chest CT\\
-CMP\\
-CBC with differential\\
-lactate dehydrogenase\\
-urinalysis
801.41;+57968,;51~SUPPRESS
801.41;+57968,;100~NATIONAL
801.412;+57969,+57968,;.01~5
801.412;+57969,+57968,;2~PXRM GF VIEW BUTTON
801.412;+57969,+57968,;6~VIEW Initial Workup
801.412;+57969,+57968,;8~YES
801.44;+57970,+57968,;.01~06/09/2026@10:31:13
801.44;+57970,+57968,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57969^1
57970^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-EL ONC DASHED LINE NO SHOW</POINT_01>
<INTERNAL_ENTRY_NUMBER>38513</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>923036641</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+38513,;.01~VA-EL ONC DASHED LINE NO SHOW
801.41;+38513,;4~dialog element
801.41;+38513,;23~YES
801.41;+38513,;25~WP-start~1
========================================================
801.41;+38513,;51~SUPPRESS
801.41;+38513,;100~NATIONAL
801.44;+38514,+38513,;.01~06/09/2026@10:31:13
801.44;+38514,+38513,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
38514^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KIDNEY PATHWAYS PREVIOUS DATA CLICK TO INCLUDE</POINT_01>
<INTERNAL_ENTRY_NUMBER>88284</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2572832271</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+88284,;.01~VA-ONC KIDNEY PATHWAYS PREVIOUS DATA CLICK TO INCLUDE
801.41;+88284,;4~dialog element
801.41;+88284,;25~WP-start~1
Include previous Oncology documentation in progress note\\
801.41;+88284,;35~WP-start~3
\\Previous Oncology Pathways documented:
  |VA-ONCOLOGY PATHWAYS KIDNEY|\\
========================================================
801.41;+88284,;100~NATIONAL
801.44;+88285,+88284,;.01~06/09/2026@10:31:13
801.44;+88285,+88284,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
88285^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KIDNEY PATHWAYS PRIOR DATA OBJECT</POINT_01>
<INTERNAL_ENTRY_NUMBER>88283</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>2312877228</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+88283,;.01~VA-ONC KIDNEY PATHWAYS PRIOR DATA OBJECT
801.41;+88283,;4~dialog element
801.41;+88283,;23~YES
801.41;+88283,;25~WP-start~3
=======================================================\\
Oncology Pathways Documented:\\
|VA-ONCOLOGY PATHWAYS KIDNEY|\\
801.41;+88283,;51~SUPPRESS
801.41;+88283,;100~NATIONAL
801.44;+88284,+88283,;.01~06/09/2026@10:31:13
801.44;+88284,+88283,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
88284^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID VIEW PRESUMPTIVE CONDITIONS</POINT_01>
<INTERNAL_ENTRY_NUMBER>73343</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3971487296</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+73343,;.01~VA-ONC KID VIEW PRESUMPTIVE CONDITIONS
801.41;+73343,;4~dialog element
801.41;+73343,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+73343,;23~YES
801.41;+73343,;25~WP-start~1
{FLD:VA-ONC PRESUMPTIVE CONDITIONS}
801.41;+73343,;35~WP-start~27
Kidney Cancer-Presumptive Conditions:\\
====================================\\
 
VA automatically presumes that certain disabilities were caused by 
military service (presumptive conditions). This is because of the unique
circumstances of a specific Veteran's military service. If a Veteran is
diagnosed with a presumptive condition and meets the service requirements
for the presumption, disability compensation may be awarded.\\
 
Radiation Exposed Veterans-Ionizing Radiation Exposure in\\Specified 
Locations and Time Periods:\\
---------------------------------------------------------\\
   -Kidney cancer
 
Veteran Stationed at Camp Lejeune-Served at 30 days (consecutive\\or 
nonconsecutive) from August 1, 1953 to December 31, 1987:\\
----------------------------------------------------------------\\
   -Kidney cancer
 
Gulf War and Post 9/11 Veterans-Burn Pits/Fine Particulate Matter 
\\Exposure in Specified Locations and Time Periods:\\
-----------------------------------------------------------------\\
   -Kidney cancer
 
 
For more information, please visit U.S. Department of Veterans Affairs - 
Presumptive Disability Benefits (domain.ext) 
801.41;+73343,;51~SUPPRESS
801.41;+73343,;100~NATIONAL
801.412;+73344,+73343,;.01~5
801.412;+73344,+73343,;2~PXRM GF VIEW BUTTON
801.412;+73344,+73343,;6~VIEW Kidney Presumptive Conditions
801.44;+73345,+73343,;.01~06/09/2026@10:31:13
801.44;+73345,+73343,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
73344^1
73345^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID SHAREPOINT VIEW ABBREVIATION</POINT_01>
<INTERNAL_ENTRY_NUMBER>73342</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>4237134456</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+73342,;.01~VA-ONC KID SHAREPOINT VIEW ABBREVIATION
801.41;+73342,;4~dialog element
801.41;+73342,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+73342,;23~YES
801.41;+73342,;25~WP-start~1
{FLD:VA-ONC PATHWAYS SHAREPOINT}
801.41;+73342,;35~WP-start~9
Abbreviations:\\   CBC = Complete Blood Count\\   CMP = Comprehensive
Metabolic Panel\\   CT = Computerized Tomography\\   ICI = Immune 
Checkpoint Inhibitor\\   M1 = Metastasis in distant organ or tissue\\   
MRI = Magnetic Resonance Imaging\\   NCT = National Clinical Trial\\   NED
= No Evidence of Disease\\   SBRT = Stereotactic Body Radiotherapy\\   T1
= Cancer is only inside the kidney and is no bigger than 7cm \\   T1a =
Cancer is only inside the kidney and is 4cm or smaller\\   T1b = Cancer is
only inside the kidney and is greater than 4cm\\   TKI = Tyrosine Kinase 
Inhibitor
801.41;+73342,;51~SUPPRESS
801.41;+73342,;100~NATIONAL
801.412;+73343,+73342,;.01~5
801.412;+73343,+73342,;2~PXRM GF VIEW BUTTON
801.412;+73343,+73342,;6~VIEW Abbreviations
801.44;+73344,+73342,;.01~06/09/2026@10:31:13
801.44;+73344,+73342,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
73343^1
73344^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC PATHWAY GEN INSTRUCT/INTENDED USER</POINT_01>
<INTERNAL_ENTRY_NUMBER>49891</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1563233907</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+49891,;.01~VA-ONC PATHWAY GEN INSTRUCT/INTENDED USER
801.41;+49891,;4~dialog element
801.41;+49891,;15~GF.VIEW PROGRESS NOTE TEXT
801.41;+49891,;23~YES
801.41;+49891,;25~WP-start~6
Intended User: Oncology Practitioners: Physician (Attending, Resident,
Fellow), Nurse Practitioner,\\               Physician Assistant, 
Clinical Pharmacist Practitioner, Pathologist, Clinical Nurse
               Specialist, Surgical Oncologist, and Radiation Oncologist
 
++ For help finding a Clinical Trial, email: {FLD:VA-ONC CT RN NAV} ++
801.41;+49891,;35~WP-start~61
Oncology Clinical Pathways are a decision support tool designed by 
interdisciplinary subject matter experts for all members of a Veteran's
care team to use for the treatment of specific cancers.
 
Clinical Pathways templates facilitate the documentation of medical 
decision-making. 
 
Document using the pathway templates when a treatment decision is made. 
Documentation of historical treatments is not necessary (except for 
molecular testing).
 
Pathway recommended care is stated for each pathway. Indicate use 
of the pathway by checking the check box. Recommended treatment listed 
is considered 'On Pathway', unless otherwise stated.
 
Clinical trial and shared decision making always considered on pathway.
Document the name and number of the clinical trial.\\
    Please contact CancerClinicalTrialsNavigation@domain.ext for\\
     assistance with cancer trial navigation.
 
If off pathway, document the treatment that is being pursued and a reason
why treating off pathway.\\
    Off Pathway Options:\\
      Patient preference/declined: Patient prefers not to receive the 
treatment\\        specified on pathway or declines that treatment after
the provider has\\        discussed the evidence and best clinical
practice.\\
      Toxicity and/or comorbidity: Provider does not recommend on 
pathway\\        treatment due to concerns about anticipated toxicities or
due to medical\\        problems the patient has that impact their
eligibility for the on\\        pathway treatment.\\
      Prior treatment continued: Patient was started on another treatment 
prior\\        to pathways and a change in therapy is not indicated.\\
      Prior treatment precludes: Patient's prior cancer history or 
treatment\\        precludes abiding by the pathway.\\
      Pathway guidance needs update: Pathway or CPRS template has not 
been\\        updated to reflect most recent data.\\
      Patient barriers: Patient related factors other than medical issues 
that\\        potentially make them not eligible for on pathway choice,
such as\\        transportation issues, support barriers, etc.\\
      Treatment unavailable: Specified on pathway treatments are not 
available\\        at specific center due to national shortages, or other
factors.
 
Some templates have detailed instructions that provide specific data 
definitions of each selection.
 
Document that molecular testing has been ordered for complete data 
capture (i.e., molecular testing completed 3 years ago, choose 
'Previously ordered'). 
 
When a choice is followed by a colon (:), there will be more selections 
revealed when clicked.
 
Uncheck a checkbox if you change your mind and do not wish to indicate 
use for a section of the pathway.
 
If you click Finish on the template, any selections you made will
add health factors to the encounter. If you make an incorrect selection
and click Finish, you should remove the incorrect health factor from the 
encounter.
801.41;+49891,;51~SUPPRESS
801.41;+49891,;100~NATIONAL
801.412;+49892,+49891,;.01~5
801.412;+49892,+49891,;2~PXRM GF VIEW BUTTON
801.412;+49892,+49891,;6~VIEW General Instructions
801.412;+49892,+49891,;8~YES
801.44;+49893,+49891,;.01~06/09/2026@10:31:13
801.44;+49893,+49891,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
49892^1
49893^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONC KID PATHWAYS VERSION</POINT_01>
<INTERNAL_ENTRY_NUMBER>57900</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>3508468227</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57900,;.01~VA-ONC KID PATHWAYS VERSION
801.41;+57900,;4~dialog element
801.41;+57900,;23~YES
801.41;+57900,;25~WP-start~1
Kidney Cancer Clinical Pathways v4.1
801.41;+57900,;51~SUPPRESS
801.41;+57900,;100~NATIONAL
801.44;+57901,+57900,;.01~06/09/2026@10:31:13
801.44;+57901,+57900,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57901^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID INTRO MAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>88340</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>1840447788</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+88340,;.01~VA-GP ONC KID INTRO MAIN
801.41;+88340,;4~dialog group
801.41;+88340,;51~SUPPRESS
801.41;+88340,;100~NATIONAL
801.412;+88341,+88340,;.01~10
801.412;+88341,+88340,;2~VA-ONC KID PATHWAYS VERSION
801.412;+88342,+88340,;.01~20
801.412;+88342,+88340,;2~VA-ONC PATHWAY GEN INSTRUCT/INTENDED USER
801.412;+88343,+88340,;.01~30
801.412;+88343,+88340,;2~VA-ONC KID SHAREPOINT VIEW ABBREVIATION
801.412;+88344,+88340,;.01~40
801.412;+88344,+88340,;2~VA-ONC KID VIEW PRESUMPTIVE CONDITIONS
801.412;+88345,+88340,;.01~50
801.412;+88345,+88340,;2~VA-ONC KIDNEY PATHWAYS PRIOR DATA OBJECT
801.412;+88346,+88340,;.01~60
801.412;+88346,+88340,;2~VA-ONC KIDNEY PATHWAYS PREVIOUS DATA CLICK TO INCLUDE
801.412;+88347,+88340,;.01~70
801.412;+88347,+88340,;2~VA-EL ONC DASHED LINE NO SHOW
801.412;+88348,+88340,;.01~80
801.412;+88348,+88340,;2~VA-ONC KID INITIAL WORK UP VIEW PATHWAY INSTRUCTIONS
801.44;+88349,+88340,;.01~06/09/2026@10:31:14
801.44;+88349,+88340,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
88341^1
88342^2
88343^3
88344^4
88345^5
88346^6
88347^7
88348^8
88349^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-GP ONC KID PATHWAYS MAIN</POINT_01>
<INTERNAL_ENTRY_NUMBER>57866</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>633946835</CHECKSUM>
<SELECTED>NO</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57866,;.01~VA-GP ONC KID PATHWAYS MAIN
801.41;+57866,;4~dialog group
801.41;+57866,;7~2
801.41;+57866,;51~SUPPRESS
801.41;+57866,;52~INDENT
801.41;+57866,;100~NATIONAL
801.412;+57867,+57866,;.01~20
801.412;+57867,+57866,;2~VA-GP ONC KID INTRO MAIN
801.412;+57868,+57866,;.01~40
801.412;+57868,+57866,;2~VA-GP ONC KID PATHWAYS SUBMAIN
801.44;+57869,+57866,;.01~06/09/2026@10:31:14
801.44;+57869,+57866,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57867^1
57868^2
57869^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<FILEMAN_FILE>
<FILE_NAME>REMINDER DIALOG</FILE_NAME>
<FILE_NUMBER>801.41</FILE_NUMBER>
<POINT_01>VA-ONCOLOGY KIDNEY CANCER PATHWAYS</POINT_01>
<INTERNAL_ENTRY_NUMBER>57718</INTERNAL_ENTRY_NUMBER>
<CHECKSUM>930919775</CHECKSUM>
<SELECTED>YES</SELECTED>
<FILEMAN_FDA>
<![CDATA[
801.41;+57718,;.01~VA-ONCOLOGY KIDNEY CANCER PATHWAYS
801.41;+57718,;4~reminder dialog
801.41;+57718,;100~NATIONAL
801.412;+57719,+57718,;.01~20
801.412;+57719,+57718,;2~VA-GP ONC KID PATHWAYS MAIN
801.44;+57720,+57718,;.01~06/09/2026@10:31:14
801.44;+57720,+57718,;2~WP-start~1
Exchange Stub
]]>
</FILEMAN_FDA>
<IEN_ROOT>
<![CDATA[
57719^3
57720^1
]]>
</IEN_ROOT>
</FILEMAN_FILE>
<INDEX>
<NUMBER_OF_COMPONENTS>472</NUMBER_OF_COMPONENTS>
<COMPONENT>
<FDA_END>40</FDA_END>
<FDA_START>35</FDA_START>
<FILE_START>26</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>67</FDA_END>
<FDA_START>53</FDA_START>
<FILE_START>44</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>94</FDA_END>
<FDA_START>80</FDA_START>
<FILE_START>71</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>121</FDA_END>
<FDA_START>107</FDA_START>
<FILE_START>98</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>148</FDA_END>
<FDA_START>134</FDA_START>
<FILE_START>125</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>176</FDA_END>
<FDA_START>161</FDA_START>
<FILE_START>152</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>203</FDA_END>
<FDA_START>189</FDA_START>
<FILE_START>180</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>230</FDA_END>
<FDA_START>216</FDA_START>
<FILE_START>207</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>246</FDA_END>
<FDA_START>243</FDA_START>
<FILE_START>234</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>271</FDA_END>
<FDA_START>259</FDA_START>
<FILE_START>250</FILE_START>
<IEN_ROOT_END>277</IEN_ROOT_END>
<IEN_ROOT_START>276</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>299</FDA_END>
<FDA_START>290</FDA_START>
<FILE_START>281</FILE_START>
<IEN_ROOT_END>305</IEN_ROOT_END>
<IEN_ROOT_START>304</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>333</FDA_END>
<FDA_START>318</FDA_START>
<FILE_START>309</FILE_START>
<IEN_ROOT_END>341</IEN_ROOT_END>
<IEN_ROOT_START>338</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>367</FDA_END>
<FDA_START>354</FDA_START>
<FILE_START>345</FILE_START>
<IEN_ROOT_END>375</IEN_ROOT_END>
<IEN_ROOT_START>372</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>401</FDA_END>
<FDA_START>388</FDA_START>
<FILE_START>379</FILE_START>
<IEN_ROOT_END>409</IEN_ROOT_END>
<IEN_ROOT_START>406</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>435</FDA_END>
<FDA_START>422</FDA_START>
<FILE_START>413</FILE_START>
<IEN_ROOT_END>443</IEN_ROOT_END>
<IEN_ROOT_START>440</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>470</FDA_END>
<FDA_START>456</FDA_START>
<FILE_START>447</FILE_START>
<IEN_ROOT_END>477</IEN_ROOT_END>
<IEN_ROOT_START>475</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>502</FDA_END>
<FDA_START>490</FDA_START>
<FILE_START>481</FILE_START>
<IEN_ROOT_END>509</IEN_ROOT_END>
<IEN_ROOT_START>507</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>537</FDA_END>
<FDA_START>522</FDA_START>
<FILE_START>513</FILE_START>
<IEN_ROOT_END>545</IEN_ROOT_END>
<IEN_ROOT_START>542</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>571</FDA_END>
<FDA_START>558</FDA_START>
<FILE_START>549</FILE_START>
<IEN_ROOT_END>579</IEN_ROOT_END>
<IEN_ROOT_START>576</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>604</FDA_END>
<FDA_START>592</FDA_START>
<FILE_START>583</FILE_START>
<IEN_ROOT_END>609</IEN_ROOT_END>
<IEN_ROOT_START>609</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>634</FDA_END>
<FDA_START>622</FDA_START>
<FILE_START>613</FILE_START>
<IEN_ROOT_END>639</IEN_ROOT_END>
<IEN_ROOT_START>639</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>664</FDA_END>
<FDA_START>652</FDA_START>
<FILE_START>643</FILE_START>
<IEN_ROOT_END>669</IEN_ROOT_END>
<IEN_ROOT_START>669</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>696</FDA_END>
<FDA_START>682</FDA_START>
<FILE_START>673</FILE_START>
<IEN_ROOT_END>702</IEN_ROOT_END>
<IEN_ROOT_START>701</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>729</FDA_END>
<FDA_START>715</FDA_START>
<FILE_START>706</FILE_START>
<IEN_ROOT_END>735</IEN_ROOT_END>
<IEN_ROOT_START>734</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>760</FDA_END>
<FDA_START>748</FDA_START>
<FILE_START>739</FILE_START>
<IEN_ROOT_END>765</IEN_ROOT_END>
<IEN_ROOT_START>765</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>790</FDA_END>
<FDA_START>778</FDA_START>
<FILE_START>769</FILE_START>
<IEN_ROOT_END>795</IEN_ROOT_END>
<IEN_ROOT_START>795</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>823</FDA_END>
<FDA_START>808</FDA_START>
<FILE_START>799</FILE_START>
<IEN_ROOT_END>830</IEN_ROOT_END>
<IEN_ROOT_START>828</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>857</FDA_END>
<FDA_START>843</FDA_START>
<FILE_START>834</FILE_START>
<IEN_ROOT_END>863</IEN_ROOT_END>
<IEN_ROOT_START>862</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>890</FDA_END>
<FDA_START>876</FDA_START>
<FILE_START>867</FILE_START>
<IEN_ROOT_END>896</IEN_ROOT_END>
<IEN_ROOT_START>895</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>923</FDA_END>
<FDA_START>909</FDA_START>
<FILE_START>900</FILE_START>
<IEN_ROOT_END>929</IEN_ROOT_END>
<IEN_ROOT_START>928</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>956</FDA_END>
<FDA_START>942</FDA_START>
<FILE_START>933</FILE_START>
<IEN_ROOT_END>962</IEN_ROOT_END>
<IEN_ROOT_START>961</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>991</FDA_END>
<FDA_START>975</FDA_START>
<FILE_START>966</FILE_START>
<IEN_ROOT_END>999</IEN_ROOT_END>
<IEN_ROOT_START>996</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1025</FDA_END>
<FDA_START>1012</FDA_START>
<FILE_START>1003</FILE_START>
<IEN_ROOT_END>1031</IEN_ROOT_END>
<IEN_ROOT_START>1030</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1057</FDA_END>
<FDA_START>1044</FDA_START>
<FILE_START>1035</FILE_START>
<IEN_ROOT_END>1063</IEN_ROOT_END>
<IEN_ROOT_START>1062</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1089</FDA_END>
<FDA_START>1076</FDA_START>
<FILE_START>1067</FILE_START>
<IEN_ROOT_END>1095</IEN_ROOT_END>
<IEN_ROOT_START>1094</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1121</FDA_END>
<FDA_START>1108</FDA_START>
<FILE_START>1099</FILE_START>
<IEN_ROOT_END>1127</IEN_ROOT_END>
<IEN_ROOT_START>1126</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1153</FDA_END>
<FDA_START>1140</FDA_START>
<FILE_START>1131</FILE_START>
<IEN_ROOT_END>1159</IEN_ROOT_END>
<IEN_ROOT_START>1158</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1186</FDA_END>
<FDA_START>1172</FDA_START>
<FILE_START>1163</FILE_START>
<IEN_ROOT_END>1193</IEN_ROOT_END>
<IEN_ROOT_START>1191</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1219</FDA_END>
<FDA_START>1206</FDA_START>
<FILE_START>1197</FILE_START>
<IEN_ROOT_END>1225</IEN_ROOT_END>
<IEN_ROOT_START>1224</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1251</FDA_END>
<FDA_START>1238</FDA_START>
<FILE_START>1229</FILE_START>
<IEN_ROOT_END>1257</IEN_ROOT_END>
<IEN_ROOT_START>1256</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1284</FDA_END>
<FDA_START>1270</FDA_START>
<FILE_START>1261</FILE_START>
<IEN_ROOT_END>1290</IEN_ROOT_END>
<IEN_ROOT_START>1289</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1317</FDA_END>
<FDA_START>1303</FDA_START>
<FILE_START>1294</FILE_START>
<IEN_ROOT_END>1323</IEN_ROOT_END>
<IEN_ROOT_START>1322</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1349</FDA_END>
<FDA_START>1336</FDA_START>
<FILE_START>1327</FILE_START>
<IEN_ROOT_END>1355</IEN_ROOT_END>
<IEN_ROOT_START>1354</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1382</FDA_END>
<FDA_START>1368</FDA_START>
<FILE_START>1359</FILE_START>
<IEN_ROOT_END>1388</IEN_ROOT_END>
<IEN_ROOT_START>1387</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1415</FDA_END>
<FDA_START>1401</FDA_START>
<FILE_START>1392</FILE_START>
<IEN_ROOT_END>1421</IEN_ROOT_END>
<IEN_ROOT_START>1420</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1447</FDA_END>
<FDA_START>1434</FDA_START>
<FILE_START>1425</FILE_START>
<IEN_ROOT_END>1453</IEN_ROOT_END>
<IEN_ROOT_START>1452</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1480</FDA_END>
<FDA_START>1466</FDA_START>
<FILE_START>1457</FILE_START>
<IEN_ROOT_END>1486</IEN_ROOT_END>
<IEN_ROOT_START>1485</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1513</FDA_END>
<FDA_START>1499</FDA_START>
<FILE_START>1490</FILE_START>
<IEN_ROOT_END>1519</IEN_ROOT_END>
<IEN_ROOT_START>1518</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1547</FDA_END>
<FDA_START>1532</FDA_START>
<FILE_START>1523</FILE_START>
<IEN_ROOT_END>1554</IEN_ROOT_END>
<IEN_ROOT_START>1552</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1581</FDA_END>
<FDA_START>1567</FDA_START>
<FILE_START>1558</FILE_START>
<IEN_ROOT_END>1587</IEN_ROOT_END>
<IEN_ROOT_START>1586</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1614</FDA_END>
<FDA_START>1600</FDA_START>
<FILE_START>1591</FILE_START>
<IEN_ROOT_END>1621</IEN_ROOT_END>
<IEN_ROOT_START>1619</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1647</FDA_END>
<FDA_START>1634</FDA_START>
<FILE_START>1625</FILE_START>
<IEN_ROOT_END>1653</IEN_ROOT_END>
<IEN_ROOT_START>1652</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1679</FDA_END>
<FDA_START>1666</FDA_START>
<FILE_START>1657</FILE_START>
<IEN_ROOT_END>1685</IEN_ROOT_END>
<IEN_ROOT_START>1684</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1712</FDA_END>
<FDA_START>1698</FDA_START>
<FILE_START>1689</FILE_START>
<IEN_ROOT_END>1719</IEN_ROOT_END>
<IEN_ROOT_START>1717</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1745</FDA_END>
<FDA_START>1732</FDA_START>
<FILE_START>1723</FILE_START>
<IEN_ROOT_END>1751</IEN_ROOT_END>
<IEN_ROOT_START>1750</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1778</FDA_END>
<FDA_START>1764</FDA_START>
<FILE_START>1755</FILE_START>
<IEN_ROOT_END>1787</IEN_ROOT_END>
<IEN_ROOT_START>1783</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1811</FDA_END>
<FDA_START>1800</FDA_START>
<FILE_START>1791</FILE_START>
<IEN_ROOT_END>1817</IEN_ROOT_END>
<IEN_ROOT_START>1816</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1841</FDA_END>
<FDA_START>1830</FDA_START>
<FILE_START>1821</FILE_START>
<IEN_ROOT_END>1847</IEN_ROOT_END>
<IEN_ROOT_START>1846</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1871</FDA_END>
<FDA_START>1860</FDA_START>
<FILE_START>1851</FILE_START>
<IEN_ROOT_END>1877</IEN_ROOT_END>
<IEN_ROOT_START>1876</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1903</FDA_END>
<FDA_START>1890</FDA_START>
<FILE_START>1881</FILE_START>
<IEN_ROOT_END>1909</IEN_ROOT_END>
<IEN_ROOT_START>1908</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1934</FDA_END>
<FDA_START>1922</FDA_START>
<FILE_START>1913</FILE_START>
<IEN_ROOT_END>1939</IEN_ROOT_END>
<IEN_ROOT_START>1939</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1964</FDA_END>
<FDA_START>1952</FDA_START>
<FILE_START>1943</FILE_START>
<IEN_ROOT_END>1969</IEN_ROOT_END>
<IEN_ROOT_START>1969</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>1994</FDA_END>
<FDA_START>1982</FDA_START>
<FILE_START>1973</FILE_START>
<IEN_ROOT_END>1999</IEN_ROOT_END>
<IEN_ROOT_START>1999</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2025</FDA_END>
<FDA_START>2012</FDA_START>
<FILE_START>2003</FILE_START>
<IEN_ROOT_END>2031</IEN_ROOT_END>
<IEN_ROOT_START>2030</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2055</FDA_END>
<FDA_START>2044</FDA_START>
<FILE_START>2035</FILE_START>
<IEN_ROOT_END>2061</IEN_ROOT_END>
<IEN_ROOT_START>2060</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2086</FDA_END>
<FDA_START>2074</FDA_START>
<FILE_START>2065</FILE_START>
<IEN_ROOT_END>2093</IEN_ROOT_END>
<IEN_ROOT_START>2091</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2118</FDA_END>
<FDA_START>2106</FDA_START>
<FILE_START>2097</FILE_START>
<IEN_ROOT_END>2125</IEN_ROOT_END>
<IEN_ROOT_START>2123</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2150</FDA_END>
<FDA_START>2138</FDA_START>
<FILE_START>2129</FILE_START>
<IEN_ROOT_END>2156</IEN_ROOT_END>
<IEN_ROOT_START>2155</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2180</FDA_END>
<FDA_START>2169</FDA_START>
<FILE_START>2160</FILE_START>
<IEN_ROOT_END>2186</IEN_ROOT_END>
<IEN_ROOT_START>2185</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2211</FDA_END>
<FDA_START>2199</FDA_START>
<FILE_START>2190</FILE_START>
<IEN_ROOT_END>2217</IEN_ROOT_END>
<IEN_ROOT_START>2216</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2244</FDA_END>
<FDA_START>2230</FDA_START>
<FILE_START>2221</FILE_START>
<IEN_ROOT_END>2250</IEN_ROOT_END>
<IEN_ROOT_START>2249</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2278</FDA_END>
<FDA_START>2263</FDA_START>
<FILE_START>2254</FILE_START>
<IEN_ROOT_END>2285</IEN_ROOT_END>
<IEN_ROOT_START>2283</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2313</FDA_END>
<FDA_START>2298</FDA_START>
<FILE_START>2289</FILE_START>
<IEN_ROOT_END>2320</IEN_ROOT_END>
<IEN_ROOT_START>2318</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2347</FDA_END>
<FDA_START>2333</FDA_START>
<FILE_START>2324</FILE_START>
<IEN_ROOT_END>2353</IEN_ROOT_END>
<IEN_ROOT_START>2352</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2386</FDA_END>
<FDA_START>2366</FDA_START>
<FILE_START>2357</FILE_START>
<IEN_ROOT_END>2392</IEN_ROOT_END>
<IEN_ROOT_START>2391</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2419</FDA_END>
<FDA_START>2405</FDA_START>
<FILE_START>2396</FILE_START>
<IEN_ROOT_END>2425</IEN_ROOT_END>
<IEN_ROOT_START>2424</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2452</FDA_END>
<FDA_START>2438</FDA_START>
<FILE_START>2429</FILE_START>
<IEN_ROOT_END>2458</IEN_ROOT_END>
<IEN_ROOT_START>2457</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2485</FDA_END>
<FDA_START>2471</FDA_START>
<FILE_START>2462</FILE_START>
<IEN_ROOT_END>2491</IEN_ROOT_END>
<IEN_ROOT_START>2490</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2518</FDA_END>
<FDA_START>2504</FDA_START>
<FILE_START>2495</FILE_START>
<IEN_ROOT_END>2524</IEN_ROOT_END>
<IEN_ROOT_START>2523</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2551</FDA_END>
<FDA_START>2537</FDA_START>
<FILE_START>2528</FILE_START>
<IEN_ROOT_END>2557</IEN_ROOT_END>
<IEN_ROOT_START>2556</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2584</FDA_END>
<FDA_START>2570</FDA_START>
<FILE_START>2561</FILE_START>
<IEN_ROOT_END>2590</IEN_ROOT_END>
<IEN_ROOT_START>2589</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2617</FDA_END>
<FDA_START>2603</FDA_START>
<FILE_START>2594</FILE_START>
<IEN_ROOT_END>2623</IEN_ROOT_END>
<IEN_ROOT_START>2622</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2650</FDA_END>
<FDA_START>2636</FDA_START>
<FILE_START>2627</FILE_START>
<IEN_ROOT_END>2656</IEN_ROOT_END>
<IEN_ROOT_START>2655</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2683</FDA_END>
<FDA_START>2669</FDA_START>
<FILE_START>2660</FILE_START>
<IEN_ROOT_END>2689</IEN_ROOT_END>
<IEN_ROOT_START>2688</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2716</FDA_END>
<FDA_START>2702</FDA_START>
<FILE_START>2693</FILE_START>
<IEN_ROOT_END>2722</IEN_ROOT_END>
<IEN_ROOT_START>2721</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2749</FDA_END>
<FDA_START>2735</FDA_START>
<FILE_START>2726</FILE_START>
<IEN_ROOT_END>2755</IEN_ROOT_END>
<IEN_ROOT_START>2754</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2782</FDA_END>
<FDA_START>2768</FDA_START>
<FILE_START>2759</FILE_START>
<IEN_ROOT_END>2788</IEN_ROOT_END>
<IEN_ROOT_START>2787</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2815</FDA_END>
<FDA_START>2801</FDA_START>
<FILE_START>2792</FILE_START>
<IEN_ROOT_END>2822</IEN_ROOT_END>
<IEN_ROOT_START>2820</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2849</FDA_END>
<FDA_START>2835</FDA_START>
<FILE_START>2826</FILE_START>
<IEN_ROOT_END>2856</IEN_ROOT_END>
<IEN_ROOT_START>2854</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2885</FDA_END>
<FDA_START>2869</FDA_START>
<FILE_START>2860</FILE_START>
<IEN_ROOT_END>2894</IEN_ROOT_END>
<IEN_ROOT_START>2890</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2921</FDA_END>
<FDA_START>2907</FDA_START>
<FILE_START>2898</FILE_START>
<IEN_ROOT_END>2928</IEN_ROOT_END>
<IEN_ROOT_START>2926</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2955</FDA_END>
<FDA_START>2941</FDA_START>
<FILE_START>2932</FILE_START>
<IEN_ROOT_END>2961</IEN_ROOT_END>
<IEN_ROOT_START>2960</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>2988</FDA_END>
<FDA_START>2974</FDA_START>
<FILE_START>2965</FILE_START>
<IEN_ROOT_END>2994</IEN_ROOT_END>
<IEN_ROOT_START>2993</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3021</FDA_END>
<FDA_START>3007</FDA_START>
<FILE_START>2998</FILE_START>
<IEN_ROOT_END>3027</IEN_ROOT_END>
<IEN_ROOT_START>3026</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3054</FDA_END>
<FDA_START>3040</FDA_START>
<FILE_START>3031</FILE_START>
<IEN_ROOT_END>3060</IEN_ROOT_END>
<IEN_ROOT_START>3059</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3088</FDA_END>
<FDA_START>3073</FDA_START>
<FILE_START>3064</FILE_START>
<IEN_ROOT_END>3094</IEN_ROOT_END>
<IEN_ROOT_START>3093</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3122</FDA_END>
<FDA_START>3107</FDA_START>
<FILE_START>3098</FILE_START>
<IEN_ROOT_END>3128</IEN_ROOT_END>
<IEN_ROOT_START>3127</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3156</FDA_END>
<FDA_START>3141</FDA_START>
<FILE_START>3132</FILE_START>
<IEN_ROOT_END>3162</IEN_ROOT_END>
<IEN_ROOT_START>3161</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3191</FDA_END>
<FDA_START>3175</FDA_START>
<FILE_START>3166</FILE_START>
<IEN_ROOT_END>3198</IEN_ROOT_END>
<IEN_ROOT_START>3196</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3227</FDA_END>
<FDA_START>3211</FDA_START>
<FILE_START>3202</FILE_START>
<IEN_ROOT_END>3234</IEN_ROOT_END>
<IEN_ROOT_START>3232</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3263</FDA_END>
<FDA_START>3247</FDA_START>
<FILE_START>3238</FILE_START>
<IEN_ROOT_END>3270</IEN_ROOT_END>
<IEN_ROOT_START>3268</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3300</FDA_END>
<FDA_START>3283</FDA_START>
<FILE_START>3274</FILE_START>
<IEN_ROOT_END>3308</IEN_ROOT_END>
<IEN_ROOT_START>3305</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3338</FDA_END>
<FDA_START>3321</FDA_START>
<FILE_START>3312</FILE_START>
<IEN_ROOT_END>3346</IEN_ROOT_END>
<IEN_ROOT_START>3343</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3373</FDA_END>
<FDA_START>3359</FDA_START>
<FILE_START>3350</FILE_START>
<IEN_ROOT_END>3379</IEN_ROOT_END>
<IEN_ROOT_START>3378</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3410</FDA_END>
<FDA_START>3392</FDA_START>
<FILE_START>3383</FILE_START>
<IEN_ROOT_END>3416</IEN_ROOT_END>
<IEN_ROOT_START>3415</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3443</FDA_END>
<FDA_START>3429</FDA_START>
<FILE_START>3420</FILE_START>
<IEN_ROOT_END>3449</IEN_ROOT_END>
<IEN_ROOT_START>3448</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3476</FDA_END>
<FDA_START>3462</FDA_START>
<FILE_START>3453</FILE_START>
<IEN_ROOT_END>3482</IEN_ROOT_END>
<IEN_ROOT_START>3481</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3509</FDA_END>
<FDA_START>3495</FDA_START>
<FILE_START>3486</FILE_START>
<IEN_ROOT_END>3515</IEN_ROOT_END>
<IEN_ROOT_START>3514</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3542</FDA_END>
<FDA_START>3528</FDA_START>
<FILE_START>3519</FILE_START>
<IEN_ROOT_END>3548</IEN_ROOT_END>
<IEN_ROOT_START>3547</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3575</FDA_END>
<FDA_START>3561</FDA_START>
<FILE_START>3552</FILE_START>
<IEN_ROOT_END>3581</IEN_ROOT_END>
<IEN_ROOT_START>3580</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3607</FDA_END>
<FDA_START>3594</FDA_START>
<FILE_START>3585</FILE_START>
<IEN_ROOT_END>3612</IEN_ROOT_END>
<IEN_ROOT_START>3612</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3639</FDA_END>
<FDA_START>3625</FDA_START>
<FILE_START>3616</FILE_START>
<IEN_ROOT_END>3645</IEN_ROOT_END>
<IEN_ROOT_START>3644</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3673</FDA_END>
<FDA_START>3658</FDA_START>
<FILE_START>3649</FILE_START>
<IEN_ROOT_END>3679</IEN_ROOT_END>
<IEN_ROOT_START>3678</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3707</FDA_END>
<FDA_START>3692</FDA_START>
<FILE_START>3683</FILE_START>
<IEN_ROOT_END>3713</IEN_ROOT_END>
<IEN_ROOT_START>3712</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3742</FDA_END>
<FDA_START>3726</FDA_START>
<FILE_START>3717</FILE_START>
<IEN_ROOT_END>3749</IEN_ROOT_END>
<IEN_ROOT_START>3747</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3779</FDA_END>
<FDA_START>3762</FDA_START>
<FILE_START>3753</FILE_START>
<IEN_ROOT_END>3787</IEN_ROOT_END>
<IEN_ROOT_START>3784</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3817</FDA_END>
<FDA_START>3800</FDA_START>
<FILE_START>3791</FILE_START>
<IEN_ROOT_END>3825</IEN_ROOT_END>
<IEN_ROOT_START>3822</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3855</FDA_END>
<FDA_START>3838</FDA_START>
<FILE_START>3829</FILE_START>
<IEN_ROOT_END>3863</IEN_ROOT_END>
<IEN_ROOT_START>3860</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3893</FDA_END>
<FDA_START>3876</FDA_START>
<FILE_START>3867</FILE_START>
<IEN_ROOT_END>3901</IEN_ROOT_END>
<IEN_ROOT_START>3898</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3932</FDA_END>
<FDA_START>3914</FDA_START>
<FILE_START>3905</FILE_START>
<IEN_ROOT_END>3941</IEN_ROOT_END>
<IEN_ROOT_START>3937</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>3969</FDA_END>
<FDA_START>3954</FDA_START>
<FILE_START>3945</FILE_START>
<IEN_ROOT_END>3976</IEN_ROOT_END>
<IEN_ROOT_START>3974</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4003</FDA_END>
<FDA_START>3989</FDA_START>
<FILE_START>3980</FILE_START>
<IEN_ROOT_END>4010</IEN_ROOT_END>
<IEN_ROOT_START>4008</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4036</FDA_END>
<FDA_START>4023</FDA_START>
<FILE_START>4014</FILE_START>
<IEN_ROOT_END>4042</IEN_ROOT_END>
<IEN_ROOT_START>4041</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4068</FDA_END>
<FDA_START>4055</FDA_START>
<FILE_START>4046</FILE_START>
<IEN_ROOT_END>4074</IEN_ROOT_END>
<IEN_ROOT_START>4073</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4101</FDA_END>
<FDA_START>4087</FDA_START>
<FILE_START>4078</FILE_START>
<IEN_ROOT_END>4107</IEN_ROOT_END>
<IEN_ROOT_START>4106</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4132</FDA_END>
<FDA_START>4120</FDA_START>
<FILE_START>4111</FILE_START>
<IEN_ROOT_END>4138</IEN_ROOT_END>
<IEN_ROOT_START>4137</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4163</FDA_END>
<FDA_START>4151</FDA_START>
<FILE_START>4142</FILE_START>
<IEN_ROOT_END>4169</IEN_ROOT_END>
<IEN_ROOT_START>4168</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4195</FDA_END>
<FDA_START>4182</FDA_START>
<FILE_START>4173</FILE_START>
<IEN_ROOT_END>4201</IEN_ROOT_END>
<IEN_ROOT_START>4200</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4227</FDA_END>
<FDA_START>4214</FDA_START>
<FILE_START>4205</FILE_START>
<IEN_ROOT_END>4233</IEN_ROOT_END>
<IEN_ROOT_START>4232</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4264</FDA_END>
<FDA_START>4246</FDA_START>
<FILE_START>4237</FILE_START>
<IEN_ROOT_END>4270</IEN_ROOT_END>
<IEN_ROOT_START>4269</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4296</FDA_END>
<FDA_START>4283</FDA_START>
<FILE_START>4274</FILE_START>
<IEN_ROOT_END>4302</IEN_ROOT_END>
<IEN_ROOT_START>4301</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4329</FDA_END>
<FDA_START>4315</FDA_START>
<FILE_START>4306</FILE_START>
<IEN_ROOT_END>4337</IEN_ROOT_END>
<IEN_ROOT_START>4334</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4364</FDA_END>
<FDA_START>4350</FDA_START>
<FILE_START>4341</FILE_START>
<IEN_ROOT_END>4372</IEN_ROOT_END>
<IEN_ROOT_START>4369</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4403</FDA_END>
<FDA_START>4385</FDA_START>
<FILE_START>4376</FILE_START>
<IEN_ROOT_END>4409</IEN_ROOT_END>
<IEN_ROOT_START>4408</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4437</FDA_END>
<FDA_START>4422</FDA_START>
<FILE_START>4413</FILE_START>
<IEN_ROOT_END>4444</IEN_ROOT_END>
<IEN_ROOT_START>4442</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4472</FDA_END>
<FDA_START>4457</FDA_START>
<FILE_START>4448</FILE_START>
<IEN_ROOT_END>4480</IEN_ROOT_END>
<IEN_ROOT_START>4477</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4506</FDA_END>
<FDA_START>4493</FDA_START>
<FILE_START>4484</FILE_START>
<IEN_ROOT_END>4513</IEN_ROOT_END>
<IEN_ROOT_START>4511</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4539</FDA_END>
<FDA_START>4526</FDA_START>
<FILE_START>4517</FILE_START>
<IEN_ROOT_END>4546</IEN_ROOT_END>
<IEN_ROOT_START>4544</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4572</FDA_END>
<FDA_START>4559</FDA_START>
<FILE_START>4550</FILE_START>
<IEN_ROOT_END>4579</IEN_ROOT_END>
<IEN_ROOT_START>4577</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4605</FDA_END>
<FDA_START>4592</FDA_START>
<FILE_START>4583</FILE_START>
<IEN_ROOT_END>4612</IEN_ROOT_END>
<IEN_ROOT_START>4610</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4637</FDA_END>
<FDA_START>4625</FDA_START>
<FILE_START>4616</FILE_START>
<IEN_ROOT_END>4643</IEN_ROOT_END>
<IEN_ROOT_START>4642</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4668</FDA_END>
<FDA_START>4656</FDA_START>
<FILE_START>4647</FILE_START>
<IEN_ROOT_END>4674</IEN_ROOT_END>
<IEN_ROOT_START>4673</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4700</FDA_END>
<FDA_START>4687</FDA_START>
<FILE_START>4678</FILE_START>
<IEN_ROOT_END>4707</IEN_ROOT_END>
<IEN_ROOT_START>4705</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4733</FDA_END>
<FDA_START>4720</FDA_START>
<FILE_START>4711</FILE_START>
<IEN_ROOT_END>4740</IEN_ROOT_END>
<IEN_ROOT_START>4738</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4766</FDA_END>
<FDA_START>4753</FDA_START>
<FILE_START>4744</FILE_START>
<IEN_ROOT_END>4773</IEN_ROOT_END>
<IEN_ROOT_START>4771</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4799</FDA_END>
<FDA_START>4786</FDA_START>
<FILE_START>4777</FILE_START>
<IEN_ROOT_END>4806</IEN_ROOT_END>
<IEN_ROOT_START>4804</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4832</FDA_END>
<FDA_START>4819</FDA_START>
<FILE_START>4810</FILE_START>
<IEN_ROOT_END>4839</IEN_ROOT_END>
<IEN_ROOT_START>4837</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4871</FDA_END>
<FDA_START>4852</FDA_START>
<FILE_START>4843</FILE_START>
<IEN_ROOT_END>4878</IEN_ROOT_END>
<IEN_ROOT_START>4876</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4905</FDA_END>
<FDA_START>4891</FDA_START>
<FILE_START>4882</FILE_START>
<IEN_ROOT_END>4912</IEN_ROOT_END>
<IEN_ROOT_START>4910</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4939</FDA_END>
<FDA_START>4925</FDA_START>
<FILE_START>4916</FILE_START>
<IEN_ROOT_END>4946</IEN_ROOT_END>
<IEN_ROOT_START>4944</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>4973</FDA_END>
<FDA_START>4959</FDA_START>
<FILE_START>4950</FILE_START>
<IEN_ROOT_END>4980</IEN_ROOT_END>
<IEN_ROOT_START>4978</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5011</FDA_END>
<FDA_START>4993</FDA_START>
<FILE_START>4984</FILE_START>
<IEN_ROOT_END>5017</IEN_ROOT_END>
<IEN_ROOT_START>5016</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5044</FDA_END>
<FDA_START>5030</FDA_START>
<FILE_START>5021</FILE_START>
<IEN_ROOT_END>5051</IEN_ROOT_END>
<IEN_ROOT_START>5049</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5078</FDA_END>
<FDA_START>5064</FDA_START>
<FILE_START>5055</FILE_START>
<IEN_ROOT_END>5085</IEN_ROOT_END>
<IEN_ROOT_START>5083</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5115</FDA_END>
<FDA_START>5098</FDA_START>
<FILE_START>5089</FILE_START>
<IEN_ROOT_END>5125</IEN_ROOT_END>
<IEN_ROOT_START>5120</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5152</FDA_END>
<FDA_START>5138</FDA_START>
<FILE_START>5129</FILE_START>
<IEN_ROOT_END>5159</IEN_ROOT_END>
<IEN_ROOT_START>5157</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5184</FDA_END>
<FDA_START>5172</FDA_START>
<FILE_START>5163</FILE_START>
<IEN_ROOT_END>5190</IEN_ROOT_END>
<IEN_ROOT_START>5189</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5215</FDA_END>
<FDA_START>5203</FDA_START>
<FILE_START>5194</FILE_START>
<IEN_ROOT_END>5221</IEN_ROOT_END>
<IEN_ROOT_START>5220</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5254</FDA_END>
<FDA_START>5234</FDA_START>
<FILE_START>5225</FILE_START>
<IEN_ROOT_END>5262</IEN_ROOT_END>
<IEN_ROOT_START>5259</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5294</FDA_END>
<FDA_START>5275</FDA_START>
<FILE_START>5266</FILE_START>
<IEN_ROOT_END>5302</IEN_ROOT_END>
<IEN_ROOT_START>5299</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5334</FDA_END>
<FDA_START>5315</FDA_START>
<FILE_START>5306</FILE_START>
<IEN_ROOT_END>5342</IEN_ROOT_END>
<IEN_ROOT_START>5339</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5368</FDA_END>
<FDA_START>5355</FDA_START>
<FILE_START>5346</FILE_START>
<IEN_ROOT_END>5375</IEN_ROOT_END>
<IEN_ROOT_START>5373</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5401</FDA_END>
<FDA_START>5388</FDA_START>
<FILE_START>5379</FILE_START>
<IEN_ROOT_END>5408</IEN_ROOT_END>
<IEN_ROOT_START>5406</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5440</FDA_END>
<FDA_START>5421</FDA_START>
<FILE_START>5412</FILE_START>
<IEN_ROOT_END>5448</IEN_ROOT_END>
<IEN_ROOT_START>5445</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5474</FDA_END>
<FDA_START>5461</FDA_START>
<FILE_START>5452</FILE_START>
<IEN_ROOT_END>5481</IEN_ROOT_END>
<IEN_ROOT_START>5479</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5514</FDA_END>
<FDA_START>5494</FDA_START>
<FILE_START>5485</FILE_START>
<IEN_ROOT_END>5522</IEN_ROOT_END>
<IEN_ROOT_START>5519</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5554</FDA_END>
<FDA_START>5535</FDA_START>
<FILE_START>5526</FILE_START>
<IEN_ROOT_END>5562</IEN_ROOT_END>
<IEN_ROOT_START>5559</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5595</FDA_END>
<FDA_START>5575</FDA_START>
<FILE_START>5566</FILE_START>
<IEN_ROOT_END>5603</IEN_ROOT_END>
<IEN_ROOT_START>5600</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5635</FDA_END>
<FDA_START>5616</FDA_START>
<FILE_START>5607</FILE_START>
<IEN_ROOT_END>5643</IEN_ROOT_END>
<IEN_ROOT_START>5640</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5669</FDA_END>
<FDA_START>5656</FDA_START>
<FILE_START>5647</FILE_START>
<IEN_ROOT_END>5676</IEN_ROOT_END>
<IEN_ROOT_START>5674</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5702</FDA_END>
<FDA_START>5689</FDA_START>
<FILE_START>5680</FILE_START>
<IEN_ROOT_END>5709</IEN_ROOT_END>
<IEN_ROOT_START>5707</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5743</FDA_END>
<FDA_START>5722</FDA_START>
<FILE_START>5713</FILE_START>
<IEN_ROOT_END>5752</IEN_ROOT_END>
<IEN_ROOT_START>5748</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5778</FDA_END>
<FDA_START>5765</FDA_START>
<FILE_START>5756</FILE_START>
<IEN_ROOT_END>5785</IEN_ROOT_END>
<IEN_ROOT_START>5783</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5810</FDA_END>
<FDA_START>5798</FDA_START>
<FILE_START>5789</FILE_START>
<IEN_ROOT_END>5816</IEN_ROOT_END>
<IEN_ROOT_START>5815</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5844</FDA_END>
<FDA_START>5829</FDA_START>
<FILE_START>5820</FILE_START>
<IEN_ROOT_END>5850</IEN_ROOT_END>
<IEN_ROOT_START>5849</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5879</FDA_END>
<FDA_START>5863</FDA_START>
<FILE_START>5854</FILE_START>
<IEN_ROOT_END>5886</IEN_ROOT_END>
<IEN_ROOT_START>5884</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5916</FDA_END>
<FDA_START>5899</FDA_START>
<FILE_START>5890</FILE_START>
<IEN_ROOT_END>5924</IEN_ROOT_END>
<IEN_ROOT_START>5921</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5953</FDA_END>
<FDA_START>5937</FDA_START>
<FILE_START>5928</FILE_START>
<IEN_ROOT_END>5960</IEN_ROOT_END>
<IEN_ROOT_START>5958</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>5989</FDA_END>
<FDA_START>5973</FDA_START>
<FILE_START>5964</FILE_START>
<IEN_ROOT_END>5996</IEN_ROOT_END>
<IEN_ROOT_START>5994</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6025</FDA_END>
<FDA_START>6009</FDA_START>
<FILE_START>6000</FILE_START>
<IEN_ROOT_END>6032</IEN_ROOT_END>
<IEN_ROOT_START>6030</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6062</FDA_END>
<FDA_START>6045</FDA_START>
<FILE_START>6036</FILE_START>
<IEN_ROOT_END>6070</IEN_ROOT_END>
<IEN_ROOT_START>6067</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6099</FDA_END>
<FDA_START>6083</FDA_START>
<FILE_START>6074</FILE_START>
<IEN_ROOT_END>6106</IEN_ROOT_END>
<IEN_ROOT_START>6104</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6141</FDA_END>
<FDA_START>6119</FDA_START>
<FILE_START>6110</FILE_START>
<IEN_ROOT_END>6150</IEN_ROOT_END>
<IEN_ROOT_START>6146</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6167</FDA_END>
<FDA_START>6163</FDA_START>
<FILE_START>6154</FILE_START>
<IEN_ROOT_END>6172</IEN_ROOT_END>
<IEN_ROOT_START>6172</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6192</FDA_END>
<FDA_START>6185</FDA_START>
<FILE_START>6176</FILE_START>
<IEN_ROOT_END>6198</IEN_ROOT_END>
<IEN_ROOT_START>6197</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6211</FDA_END>
<FDA_START>6211</FDA_START>
<FILE_START>6202</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6234</FDA_END>
<FDA_START>6224</FDA_START>
<FILE_START>6215</FILE_START>
<IEN_ROOT_END>6243</IEN_ROOT_END>
<IEN_ROOT_START>6239</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6275</FDA_END>
<FDA_START>6256</FDA_START>
<FILE_START>6247</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6293</FDA_END>
<FDA_START>6288</FDA_START>
<FILE_START>6279</FILE_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6314</FDA_END>
<FDA_START>6306</FDA_START>
<FILE_START>6297</FILE_START>
<IEN_ROOT_END>6319</IEN_ROOT_END>
<IEN_ROOT_START>6319</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6368</FDA_END>
<FDA_START>6332</FDA_START>
<FILE_START>6323</FILE_START>
<IEN_ROOT_END>6374</IEN_ROOT_END>
<IEN_ROOT_START>6373</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6410</FDA_END>
<FDA_START>6387</FDA_START>
<FILE_START>6378</FILE_START>
<IEN_ROOT_END>6423</IEN_ROOT_END>
<IEN_ROOT_START>6415</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6449</FDA_END>
<FDA_START>6436</FDA_START>
<FILE_START>6427</FILE_START>
<IEN_ROOT_END>6455</IEN_ROOT_END>
<IEN_ROOT_START>6454</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6475</FDA_END>
<FDA_START>6468</FDA_START>
<FILE_START>6459</FILE_START>
<IEN_ROOT_END>6480</IEN_ROOT_END>
<IEN_ROOT_START>6480</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6505</FDA_END>
<FDA_START>6493</FDA_START>
<FILE_START>6484</FILE_START>
<IEN_ROOT_END>6511</IEN_ROOT_END>
<IEN_ROOT_START>6510</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6538</FDA_END>
<FDA_START>6524</FDA_START>
<FILE_START>6515</FILE_START>
<IEN_ROOT_END>6545</IEN_ROOT_END>
<IEN_ROOT_START>6543</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6568</FDA_END>
<FDA_START>6558</FDA_START>
<FILE_START>6549</FILE_START>
<IEN_ROOT_END>6573</IEN_ROOT_END>
<IEN_ROOT_START>6573</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6593</FDA_END>
<FDA_START>6586</FDA_START>
<FILE_START>6577</FILE_START>
<IEN_ROOT_END>6598</IEN_ROOT_END>
<IEN_ROOT_START>6598</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6624</FDA_END>
<FDA_START>6611</FDA_START>
<FILE_START>6602</FILE_START>
<IEN_ROOT_END>6630</IEN_ROOT_END>
<IEN_ROOT_START>6629</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6659</FDA_END>
<FDA_START>6643</FDA_START>
<FILE_START>6634</FILE_START>
<IEN_ROOT_END>6667</IEN_ROOT_END>
<IEN_ROOT_START>6664</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6693</FDA_END>
<FDA_START>6680</FDA_START>
<FILE_START>6671</FILE_START>
<IEN_ROOT_END>6699</IEN_ROOT_END>
<IEN_ROOT_START>6698</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6718</FDA_END>
<FDA_START>6712</FDA_START>
<FILE_START>6703</FILE_START>
<IEN_ROOT_END>6723</IEN_ROOT_END>
<IEN_ROOT_START>6723</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6748</FDA_END>
<FDA_START>6736</FDA_START>
<FILE_START>6727</FILE_START>
<IEN_ROOT_END>6754</IEN_ROOT_END>
<IEN_ROOT_START>6753</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6780</FDA_END>
<FDA_START>6767</FDA_START>
<FILE_START>6758</FILE_START>
<IEN_ROOT_END>6786</IEN_ROOT_END>
<IEN_ROOT_START>6785</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6811</FDA_END>
<FDA_START>6799</FDA_START>
<FILE_START>6790</FILE_START>
<IEN_ROOT_END>6817</IEN_ROOT_END>
<IEN_ROOT_START>6816</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6844</FDA_END>
<FDA_START>6830</FDA_START>
<FILE_START>6821</FILE_START>
<IEN_ROOT_END>6851</IEN_ROOT_END>
<IEN_ROOT_START>6849</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6880</FDA_END>
<FDA_START>6864</FDA_START>
<FILE_START>6855</FILE_START>
<IEN_ROOT_END>6888</IEN_ROOT_END>
<IEN_ROOT_START>6885</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6911</FDA_END>
<FDA_START>6901</FDA_START>
<FILE_START>6892</FILE_START>
<IEN_ROOT_END>6916</IEN_ROOT_END>
<IEN_ROOT_START>6916</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6942</FDA_END>
<FDA_START>6929</FDA_START>
<FILE_START>6920</FILE_START>
<IEN_ROOT_END>6948</IEN_ROOT_END>
<IEN_ROOT_START>6947</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>6973</FDA_END>
<FDA_START>6961</FDA_START>
<FILE_START>6952</FILE_START>
<IEN_ROOT_END>6979</IEN_ROOT_END>
<IEN_ROOT_START>6978</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7006</FDA_END>
<FDA_START>6992</FDA_START>
<FILE_START>6983</FILE_START>
<IEN_ROOT_END>7013</IEN_ROOT_END>
<IEN_ROOT_START>7011</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7039</FDA_END>
<FDA_START>7026</FDA_START>
<FILE_START>7017</FILE_START>
<IEN_ROOT_END>7045</IEN_ROOT_END>
<IEN_ROOT_START>7044</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7074</FDA_END>
<FDA_START>7058</FDA_START>
<FILE_START>7049</FILE_START>
<IEN_ROOT_END>7082</IEN_ROOT_END>
<IEN_ROOT_START>7079</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7105</FDA_END>
<FDA_START>7095</FDA_START>
<FILE_START>7086</FILE_START>
<IEN_ROOT_END>7110</IEN_ROOT_END>
<IEN_ROOT_START>7110</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7135</FDA_END>
<FDA_START>7123</FDA_START>
<FILE_START>7114</FILE_START>
<IEN_ROOT_END>7141</IEN_ROOT_END>
<IEN_ROOT_START>7140</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7167</FDA_END>
<FDA_START>7154</FDA_START>
<FILE_START>7145</FILE_START>
<IEN_ROOT_END>7174</IEN_ROOT_END>
<IEN_ROOT_START>7172</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7201</FDA_END>
<FDA_START>7187</FDA_START>
<FILE_START>7178</FILE_START>
<IEN_ROOT_END>7208</IEN_ROOT_END>
<IEN_ROOT_START>7206</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7234</FDA_END>
<FDA_START>7221</FDA_START>
<FILE_START>7212</FILE_START>
<IEN_ROOT_END>7240</IEN_ROOT_END>
<IEN_ROOT_START>7239</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7269</FDA_END>
<FDA_START>7253</FDA_START>
<FILE_START>7244</FILE_START>
<IEN_ROOT_END>7277</IEN_ROOT_END>
<IEN_ROOT_START>7274</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7305</FDA_END>
<FDA_START>7290</FDA_START>
<FILE_START>7281</FILE_START>
<IEN_ROOT_END>7312</IEN_ROOT_END>
<IEN_ROOT_START>7310</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7336</FDA_END>
<FDA_START>7325</FDA_START>
<FILE_START>7316</FILE_START>
<IEN_ROOT_END>7341</IEN_ROOT_END>
<IEN_ROOT_START>7341</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7365</FDA_END>
<FDA_START>7354</FDA_START>
<FILE_START>7345</FILE_START>
<IEN_ROOT_END>7370</IEN_ROOT_END>
<IEN_ROOT_START>7370</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7394</FDA_END>
<FDA_START>7383</FDA_START>
<FILE_START>7374</FILE_START>
<IEN_ROOT_END>7399</IEN_ROOT_END>
<IEN_ROOT_START>7399</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7423</FDA_END>
<FDA_START>7412</FDA_START>
<FILE_START>7403</FILE_START>
<IEN_ROOT_END>7428</IEN_ROOT_END>
<IEN_ROOT_START>7428</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7454</FDA_END>
<FDA_START>7441</FDA_START>
<FILE_START>7432</FILE_START>
<IEN_ROOT_END>7460</IEN_ROOT_END>
<IEN_ROOT_START>7459</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7486</FDA_END>
<FDA_START>7473</FDA_START>
<FILE_START>7464</FILE_START>
<IEN_ROOT_END>7492</IEN_ROOT_END>
<IEN_ROOT_START>7491</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7517</FDA_END>
<FDA_START>7505</FDA_START>
<FILE_START>7496</FILE_START>
<IEN_ROOT_END>7523</IEN_ROOT_END>
<IEN_ROOT_START>7522</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7550</FDA_END>
<FDA_START>7536</FDA_START>
<FILE_START>7527</FILE_START>
<IEN_ROOT_END>7557</IEN_ROOT_END>
<IEN_ROOT_START>7555</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7592</FDA_END>
<FDA_START>7570</FDA_START>
<FILE_START>7561</FILE_START>
<IEN_ROOT_END>7603</IEN_ROOT_END>
<IEN_ROOT_START>7597</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7629</FDA_END>
<FDA_START>7616</FDA_START>
<FILE_START>7607</FILE_START>
<IEN_ROOT_END>7635</IEN_ROOT_END>
<IEN_ROOT_START>7634</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7660</FDA_END>
<FDA_START>7648</FDA_START>
<FILE_START>7639</FILE_START>
<IEN_ROOT_END>7666</IEN_ROOT_END>
<IEN_ROOT_START>7665</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7693</FDA_END>
<FDA_START>7679</FDA_START>
<FILE_START>7670</FILE_START>
<IEN_ROOT_END>7700</IEN_ROOT_END>
<IEN_ROOT_START>7698</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7726</FDA_END>
<FDA_START>7713</FDA_START>
<FILE_START>7704</FILE_START>
<IEN_ROOT_END>7732</IEN_ROOT_END>
<IEN_ROOT_START>7731</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7756</FDA_END>
<FDA_START>7745</FDA_START>
<FILE_START>7736</FILE_START>
<IEN_ROOT_END>7761</IEN_ROOT_END>
<IEN_ROOT_START>7761</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7790</FDA_END>
<FDA_START>7774</FDA_START>
<FILE_START>7765</FILE_START>
<IEN_ROOT_END>7798</IEN_ROOT_END>
<IEN_ROOT_START>7795</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7826</FDA_END>
<FDA_START>7811</FDA_START>
<FILE_START>7802</FILE_START>
<IEN_ROOT_END>7833</IEN_ROOT_END>
<IEN_ROOT_START>7831</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7858</FDA_END>
<FDA_START>7846</FDA_START>
<FILE_START>7837</FILE_START>
<IEN_ROOT_END>7865</IEN_ROOT_END>
<IEN_ROOT_START>7863</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7911</FDA_END>
<FDA_START>7878</FDA_START>
<FILE_START>7869</FILE_START>
<IEN_ROOT_END>7917</IEN_ROOT_END>
<IEN_ROOT_START>7916</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7944</FDA_END>
<FDA_START>7930</FDA_START>
<FILE_START>7921</FILE_START>
<IEN_ROOT_END>7951</IEN_ROOT_END>
<IEN_ROOT_START>7949</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>7981</FDA_END>
<FDA_START>7964</FDA_START>
<FILE_START>7955</FILE_START>
<IEN_ROOT_END>7989</IEN_ROOT_END>
<IEN_ROOT_START>7986</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8042</FDA_END>
<FDA_START>8002</FDA_START>
<FILE_START>7993</FILE_START>
<IEN_ROOT_END>8048</IEN_ROOT_END>
<IEN_ROOT_START>8047</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8074</FDA_END>
<FDA_START>8061</FDA_START>
<FILE_START>8052</FILE_START>
<IEN_ROOT_END>8080</IEN_ROOT_END>
<IEN_ROOT_START>8079</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8105</FDA_END>
<FDA_START>8093</FDA_START>
<FILE_START>8084</FILE_START>
<IEN_ROOT_END>8111</IEN_ROOT_END>
<IEN_ROOT_START>8110</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8138</FDA_END>
<FDA_START>8124</FDA_START>
<FILE_START>8115</FILE_START>
<IEN_ROOT_END>8145</IEN_ROOT_END>
<IEN_ROOT_START>8143</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8169</FDA_END>
<FDA_START>8158</FDA_START>
<FILE_START>8149</FILE_START>
<IEN_ROOT_END>8174</IEN_ROOT_END>
<IEN_ROOT_START>8174</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8198</FDA_END>
<FDA_START>8187</FDA_START>
<FILE_START>8178</FILE_START>
<IEN_ROOT_END>8203</IEN_ROOT_END>
<IEN_ROOT_START>8203</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8227</FDA_END>
<FDA_START>8216</FDA_START>
<FILE_START>8207</FILE_START>
<IEN_ROOT_END>8232</IEN_ROOT_END>
<IEN_ROOT_START>8232</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8256</FDA_END>
<FDA_START>8245</FDA_START>
<FILE_START>8236</FILE_START>
<IEN_ROOT_END>8261</IEN_ROOT_END>
<IEN_ROOT_START>8261</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8285</FDA_END>
<FDA_START>8274</FDA_START>
<FILE_START>8265</FILE_START>
<IEN_ROOT_END>8290</IEN_ROOT_END>
<IEN_ROOT_START>8290</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8316</FDA_END>
<FDA_START>8303</FDA_START>
<FILE_START>8294</FILE_START>
<IEN_ROOT_END>8322</IEN_ROOT_END>
<IEN_ROOT_START>8321</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8359</FDA_END>
<FDA_START>8335</FDA_START>
<FILE_START>8326</FILE_START>
<IEN_ROOT_END>8371</IEN_ROOT_END>
<IEN_ROOT_START>8364</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8397</FDA_END>
<FDA_START>8384</FDA_START>
<FILE_START>8375</FILE_START>
<IEN_ROOT_END>8403</IEN_ROOT_END>
<IEN_ROOT_START>8402</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8428</FDA_END>
<FDA_START>8416</FDA_START>
<FILE_START>8407</FILE_START>
<IEN_ROOT_END>8434</IEN_ROOT_END>
<IEN_ROOT_START>8433</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8461</FDA_END>
<FDA_START>8447</FDA_START>
<FILE_START>8438</FILE_START>
<IEN_ROOT_END>8468</IEN_ROOT_END>
<IEN_ROOT_START>8466</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8492</FDA_END>
<FDA_START>8481</FDA_START>
<FILE_START>8472</FILE_START>
<IEN_ROOT_END>8497</IEN_ROOT_END>
<IEN_ROOT_START>8497</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8523</FDA_END>
<FDA_START>8510</FDA_START>
<FILE_START>8501</FILE_START>
<IEN_ROOT_END>8529</IEN_ROOT_END>
<IEN_ROOT_START>8528</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8558</FDA_END>
<FDA_START>8542</FDA_START>
<FILE_START>8533</FILE_START>
<IEN_ROOT_END>8566</IEN_ROOT_END>
<IEN_ROOT_START>8563</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8594</FDA_END>
<FDA_START>8579</FDA_START>
<FILE_START>8570</FILE_START>
<IEN_ROOT_END>8601</IEN_ROOT_END>
<IEN_ROOT_START>8599</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8625</FDA_END>
<FDA_START>8614</FDA_START>
<FILE_START>8605</FILE_START>
<IEN_ROOT_END>8630</IEN_ROOT_END>
<IEN_ROOT_START>8630</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8656</FDA_END>
<FDA_START>8643</FDA_START>
<FILE_START>8634</FILE_START>
<IEN_ROOT_END>8662</IEN_ROOT_END>
<IEN_ROOT_START>8661</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8687</FDA_END>
<FDA_START>8675</FDA_START>
<FILE_START>8666</FILE_START>
<IEN_ROOT_END>8693</IEN_ROOT_END>
<IEN_ROOT_START>8692</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8720</FDA_END>
<FDA_START>8706</FDA_START>
<FILE_START>8697</FILE_START>
<IEN_ROOT_END>8727</IEN_ROOT_END>
<IEN_ROOT_START>8725</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8751</FDA_END>
<FDA_START>8740</FDA_START>
<FILE_START>8731</FILE_START>
<IEN_ROOT_END>8756</IEN_ROOT_END>
<IEN_ROOT_START>8756</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8782</FDA_END>
<FDA_START>8769</FDA_START>
<FILE_START>8760</FILE_START>
<IEN_ROOT_END>8788</IEN_ROOT_END>
<IEN_ROOT_START>8787</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8820</FDA_END>
<FDA_START>8801</FDA_START>
<FILE_START>8792</FILE_START>
<IEN_ROOT_END>8829</IEN_ROOT_END>
<IEN_ROOT_START>8825</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8854</FDA_END>
<FDA_START>8842</FDA_START>
<FILE_START>8833</FILE_START>
<IEN_ROOT_END>8861</IEN_ROOT_END>
<IEN_ROOT_START>8859</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8888</FDA_END>
<FDA_START>8874</FDA_START>
<FILE_START>8865</FILE_START>
<IEN_ROOT_END>8895</IEN_ROOT_END>
<IEN_ROOT_START>8893</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8937</FDA_END>
<FDA_START>8908</FDA_START>
<FILE_START>8899</FILE_START>
<IEN_ROOT_END>8943</IEN_ROOT_END>
<IEN_ROOT_START>8942</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8967</FDA_END>
<FDA_START>8956</FDA_START>
<FILE_START>8947</FILE_START>
<IEN_ROOT_END>8972</IEN_ROOT_END>
<IEN_ROOT_START>8972</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>8996</FDA_END>
<FDA_START>8985</FDA_START>
<FILE_START>8976</FILE_START>
<IEN_ROOT_END>9001</IEN_ROOT_END>
<IEN_ROOT_START>9001</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9025</FDA_END>
<FDA_START>9014</FDA_START>
<FILE_START>9005</FILE_START>
<IEN_ROOT_END>9030</IEN_ROOT_END>
<IEN_ROOT_START>9030</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9054</FDA_END>
<FDA_START>9043</FDA_START>
<FILE_START>9034</FILE_START>
<IEN_ROOT_END>9059</IEN_ROOT_END>
<IEN_ROOT_START>9059</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9083</FDA_END>
<FDA_START>9072</FDA_START>
<FILE_START>9063</FILE_START>
<IEN_ROOT_END>9088</IEN_ROOT_END>
<IEN_ROOT_START>9088</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9114</FDA_END>
<FDA_START>9101</FDA_START>
<FILE_START>9092</FILE_START>
<IEN_ROOT_END>9120</IEN_ROOT_END>
<IEN_ROOT_START>9119</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9145</FDA_END>
<FDA_START>9133</FDA_START>
<FILE_START>9124</FILE_START>
<IEN_ROOT_END>9151</IEN_ROOT_END>
<IEN_ROOT_START>9150</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9178</FDA_END>
<FDA_START>9164</FDA_START>
<FILE_START>9155</FILE_START>
<IEN_ROOT_END>9185</IEN_ROOT_END>
<IEN_ROOT_START>9183</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9211</FDA_END>
<FDA_START>9198</FDA_START>
<FILE_START>9189</FILE_START>
<IEN_ROOT_END>9217</IEN_ROOT_END>
<IEN_ROOT_START>9216</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9254</FDA_END>
<FDA_START>9230</FDA_START>
<FILE_START>9221</FILE_START>
<IEN_ROOT_END>9266</IEN_ROOT_END>
<IEN_ROOT_START>9259</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9292</FDA_END>
<FDA_START>9279</FDA_START>
<FILE_START>9270</FILE_START>
<IEN_ROOT_END>9298</IEN_ROOT_END>
<IEN_ROOT_START>9297</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9323</FDA_END>
<FDA_START>9311</FDA_START>
<FILE_START>9302</FILE_START>
<IEN_ROOT_END>9329</IEN_ROOT_END>
<IEN_ROOT_START>9328</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9356</FDA_END>
<FDA_START>9342</FDA_START>
<FILE_START>9333</FILE_START>
<IEN_ROOT_END>9363</IEN_ROOT_END>
<IEN_ROOT_START>9361</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9389</FDA_END>
<FDA_START>9376</FDA_START>
<FILE_START>9367</FILE_START>
<IEN_ROOT_END>9395</IEN_ROOT_END>
<IEN_ROOT_START>9394</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9419</FDA_END>
<FDA_START>9408</FDA_START>
<FILE_START>9399</FILE_START>
<IEN_ROOT_END>9424</IEN_ROOT_END>
<IEN_ROOT_START>9424</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9453</FDA_END>
<FDA_START>9437</FDA_START>
<FILE_START>9428</FILE_START>
<IEN_ROOT_END>9461</IEN_ROOT_END>
<IEN_ROOT_START>9458</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9486</FDA_END>
<FDA_START>9474</FDA_START>
<FILE_START>9465</FILE_START>
<IEN_ROOT_END>9493</IEN_ROOT_END>
<IEN_ROOT_START>9491</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9520</FDA_END>
<FDA_START>9506</FDA_START>
<FILE_START>9497</FILE_START>
<IEN_ROOT_END>9527</IEN_ROOT_END>
<IEN_ROOT_START>9525</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9559</FDA_END>
<FDA_START>9540</FDA_START>
<FILE_START>9531</FILE_START>
<IEN_ROOT_END>9567</IEN_ROOT_END>
<IEN_ROOT_START>9564</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9594</FDA_END>
<FDA_START>9580</FDA_START>
<FILE_START>9571</FILE_START>
<IEN_ROOT_END>9600</IEN_ROOT_END>
<IEN_ROOT_START>9599</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9622</FDA_END>
<FDA_START>9613</FDA_START>
<FILE_START>9604</FILE_START>
<IEN_ROOT_END>9629</IEN_ROOT_END>
<IEN_ROOT_START>9627</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9653</FDA_END>
<FDA_START>9642</FDA_START>
<FILE_START>9633</FILE_START>
<IEN_ROOT_END>9658</IEN_ROOT_END>
<IEN_ROOT_START>9658</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9684</FDA_END>
<FDA_START>9671</FDA_START>
<FILE_START>9662</FILE_START>
<IEN_ROOT_END>9690</IEN_ROOT_END>
<IEN_ROOT_START>9689</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9715</FDA_END>
<FDA_START>9703</FDA_START>
<FILE_START>9694</FILE_START>
<IEN_ROOT_END>9721</IEN_ROOT_END>
<IEN_ROOT_START>9720</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9748</FDA_END>
<FDA_START>9734</FDA_START>
<FILE_START>9725</FILE_START>
<IEN_ROOT_END>9755</IEN_ROOT_END>
<IEN_ROOT_START>9753</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9780</FDA_END>
<FDA_START>9768</FDA_START>
<FILE_START>9759</FILE_START>
<IEN_ROOT_END>9785</IEN_ROOT_END>
<IEN_ROOT_START>9785</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9811</FDA_END>
<FDA_START>9798</FDA_START>
<FILE_START>9789</FILE_START>
<IEN_ROOT_END>9817</IEN_ROOT_END>
<IEN_ROOT_START>9816</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9843</FDA_END>
<FDA_START>9830</FDA_START>
<FILE_START>9821</FILE_START>
<IEN_ROOT_END>9849</IEN_ROOT_END>
<IEN_ROOT_START>9848</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9879</FDA_END>
<FDA_START>9862</FDA_START>
<FILE_START>9853</FILE_START>
<IEN_ROOT_END>9887</IEN_ROOT_END>
<IEN_ROOT_START>9884</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9912</FDA_END>
<FDA_START>9900</FDA_START>
<FILE_START>9891</FILE_START>
<IEN_ROOT_END>9917</IEN_ROOT_END>
<IEN_ROOT_START>9917</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9944</FDA_END>
<FDA_START>9930</FDA_START>
<FILE_START>9921</FILE_START>
<IEN_ROOT_END>9950</IEN_ROOT_END>
<IEN_ROOT_START>9949</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>9976</FDA_END>
<FDA_START>9963</FDA_START>
<FILE_START>9954</FILE_START>
<IEN_ROOT_END>9982</IEN_ROOT_END>
<IEN_ROOT_START>9981</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10007</FDA_END>
<FDA_START>9995</FDA_START>
<FILE_START>9986</FILE_START>
<IEN_ROOT_END>10013</IEN_ROOT_END>
<IEN_ROOT_START>10012</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10040</FDA_END>
<FDA_START>10026</FDA_START>
<FILE_START>10017</FILE_START>
<IEN_ROOT_END>10047</IEN_ROOT_END>
<IEN_ROOT_START>10045</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10073</FDA_END>
<FDA_START>10060</FDA_START>
<FILE_START>10051</FILE_START>
<IEN_ROOT_END>10079</IEN_ROOT_END>
<IEN_ROOT_START>10078</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10108</FDA_END>
<FDA_START>10092</FDA_START>
<FILE_START>10083</FILE_START>
<IEN_ROOT_END>10116</IEN_ROOT_END>
<IEN_ROOT_START>10113</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10142</FDA_END>
<FDA_START>10129</FDA_START>
<FILE_START>10120</FILE_START>
<IEN_ROOT_END>10148</IEN_ROOT_END>
<IEN_ROOT_START>10147</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10173</FDA_END>
<FDA_START>10161</FDA_START>
<FILE_START>10152</FILE_START>
<IEN_ROOT_END>10179</IEN_ROOT_END>
<IEN_ROOT_START>10178</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10206</FDA_END>
<FDA_START>10192</FDA_START>
<FILE_START>10183</FILE_START>
<IEN_ROOT_END>10213</IEN_ROOT_END>
<IEN_ROOT_START>10211</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10239</FDA_END>
<FDA_START>10226</FDA_START>
<FILE_START>10217</FILE_START>
<IEN_ROOT_END>10245</IEN_ROOT_END>
<IEN_ROOT_START>10244</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10271</FDA_END>
<FDA_START>10258</FDA_START>
<FILE_START>10249</FILE_START>
<IEN_ROOT_END>10277</IEN_ROOT_END>
<IEN_ROOT_START>10276</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10306</FDA_END>
<FDA_START>10290</FDA_START>
<FILE_START>10281</FILE_START>
<IEN_ROOT_END>10314</IEN_ROOT_END>
<IEN_ROOT_START>10311</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10343</FDA_END>
<FDA_START>10327</FDA_START>
<FILE_START>10318</FILE_START>
<IEN_ROOT_END>10350</IEN_ROOT_END>
<IEN_ROOT_START>10348</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10376</FDA_END>
<FDA_START>10363</FDA_START>
<FILE_START>10354</FILE_START>
<IEN_ROOT_END>10382</IEN_ROOT_END>
<IEN_ROOT_START>10381</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10407</FDA_END>
<FDA_START>10395</FDA_START>
<FILE_START>10386</FILE_START>
<IEN_ROOT_END>10413</IEN_ROOT_END>
<IEN_ROOT_START>10412</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10440</FDA_END>
<FDA_START>10426</FDA_START>
<FILE_START>10417</FILE_START>
<IEN_ROOT_END>10447</IEN_ROOT_END>
<IEN_ROOT_START>10445</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10470</FDA_END>
<FDA_START>10460</FDA_START>
<FILE_START>10451</FILE_START>
<IEN_ROOT_END>10475</IEN_ROOT_END>
<IEN_ROOT_START>10475</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10494</FDA_END>
<FDA_START>10488</FDA_START>
<FILE_START>10479</FILE_START>
<IEN_ROOT_END>10499</IEN_ROOT_END>
<IEN_ROOT_START>10499</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10524</FDA_END>
<FDA_START>10512</FDA_START>
<FILE_START>10503</FILE_START>
<IEN_ROOT_END>10530</IEN_ROOT_END>
<IEN_ROOT_START>10529</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10556</FDA_END>
<FDA_START>10543</FDA_START>
<FILE_START>10534</FILE_START>
<IEN_ROOT_END>10562</IEN_ROOT_END>
<IEN_ROOT_START>10561</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10596</FDA_END>
<FDA_START>10575</FDA_START>
<FILE_START>10566</FILE_START>
<IEN_ROOT_END>10605</IEN_ROOT_END>
<IEN_ROOT_START>10601</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10635</FDA_END>
<FDA_START>10618</FDA_START>
<FILE_START>10609</FILE_START>
<IEN_ROOT_END>10643</IEN_ROOT_END>
<IEN_ROOT_START>10640</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10674</FDA_END>
<FDA_START>10656</FDA_START>
<FILE_START>10647</FILE_START>
<IEN_ROOT_END>10681</IEN_ROOT_END>
<IEN_ROOT_START>10679</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10703</FDA_END>
<FDA_START>10694</FDA_START>
<FILE_START>10685</FILE_START>
<IEN_ROOT_END>10708</IEN_ROOT_END>
<IEN_ROOT_START>10708</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10743</FDA_END>
<FDA_START>10721</FDA_START>
<FILE_START>10712</FILE_START>
<IEN_ROOT_END>10749</IEN_ROOT_END>
<IEN_ROOT_START>10748</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10775</FDA_END>
<FDA_START>10762</FDA_START>
<FILE_START>10753</FILE_START>
<IEN_ROOT_END>10781</IEN_ROOT_END>
<IEN_ROOT_START>10780</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10806</FDA_END>
<FDA_START>10794</FDA_START>
<FILE_START>10785</FILE_START>
<IEN_ROOT_END>10812</IEN_ROOT_END>
<IEN_ROOT_START>10811</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10839</FDA_END>
<FDA_START>10825</FDA_START>
<FILE_START>10816</FILE_START>
<IEN_ROOT_END>10846</IEN_ROOT_END>
<IEN_ROOT_START>10844</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10869</FDA_END>
<FDA_START>10859</FDA_START>
<FILE_START>10850</FILE_START>
<IEN_ROOT_END>10874</IEN_ROOT_END>
<IEN_ROOT_START>10874</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10900</FDA_END>
<FDA_START>10887</FDA_START>
<FILE_START>10878</FILE_START>
<IEN_ROOT_END>10906</IEN_ROOT_END>
<IEN_ROOT_START>10905</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10935</FDA_END>
<FDA_START>10919</FDA_START>
<FILE_START>10910</FILE_START>
<IEN_ROOT_END>10943</IEN_ROOT_END>
<IEN_ROOT_START>10940</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>10969</FDA_END>
<FDA_START>10956</FDA_START>
<FILE_START>10947</FILE_START>
<IEN_ROOT_END>10975</IEN_ROOT_END>
<IEN_ROOT_START>10974</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11000</FDA_END>
<FDA_START>10988</FDA_START>
<FILE_START>10979</FILE_START>
<IEN_ROOT_END>11006</IEN_ROOT_END>
<IEN_ROOT_START>11005</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11033</FDA_END>
<FDA_START>11019</FDA_START>
<FILE_START>11010</FILE_START>
<IEN_ROOT_END>11040</IEN_ROOT_END>
<IEN_ROOT_START>11038</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11065</FDA_END>
<FDA_START>11053</FDA_START>
<FILE_START>11044</FILE_START>
<IEN_ROOT_END>11070</IEN_ROOT_END>
<IEN_ROOT_START>11070</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11096</FDA_END>
<FDA_START>11083</FDA_START>
<FILE_START>11074</FILE_START>
<IEN_ROOT_END>11102</IEN_ROOT_END>
<IEN_ROOT_START>11101</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11128</FDA_END>
<FDA_START>11115</FDA_START>
<FILE_START>11106</FILE_START>
<IEN_ROOT_END>11134</IEN_ROOT_END>
<IEN_ROOT_START>11133</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11163</FDA_END>
<FDA_START>11147</FDA_START>
<FILE_START>11138</FILE_START>
<IEN_ROOT_END>11171</IEN_ROOT_END>
<IEN_ROOT_START>11168</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11197</FDA_END>
<FDA_START>11184</FDA_START>
<FILE_START>11175</FILE_START>
<IEN_ROOT_END>11203</IEN_ROOT_END>
<IEN_ROOT_START>11202</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11228</FDA_END>
<FDA_START>11216</FDA_START>
<FILE_START>11207</FILE_START>
<IEN_ROOT_END>11234</IEN_ROOT_END>
<IEN_ROOT_START>11233</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11261</FDA_END>
<FDA_START>11247</FDA_START>
<FILE_START>11238</FILE_START>
<IEN_ROOT_END>11268</IEN_ROOT_END>
<IEN_ROOT_START>11266</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11291</FDA_END>
<FDA_START>11281</FDA_START>
<FILE_START>11272</FILE_START>
<IEN_ROOT_END>11296</IEN_ROOT_END>
<IEN_ROOT_START>11296</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11322</FDA_END>
<FDA_START>11309</FDA_START>
<FILE_START>11300</FILE_START>
<IEN_ROOT_END>11328</IEN_ROOT_END>
<IEN_ROOT_START>11327</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11357</FDA_END>
<FDA_START>11341</FDA_START>
<FILE_START>11332</FILE_START>
<IEN_ROOT_END>11365</IEN_ROOT_END>
<IEN_ROOT_START>11362</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11391</FDA_END>
<FDA_START>11378</FDA_START>
<FILE_START>11369</FILE_START>
<IEN_ROOT_END>11397</IEN_ROOT_END>
<IEN_ROOT_START>11396</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11422</FDA_END>
<FDA_START>11410</FDA_START>
<FILE_START>11401</FILE_START>
<IEN_ROOT_END>11428</IEN_ROOT_END>
<IEN_ROOT_START>11427</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11455</FDA_END>
<FDA_START>11441</FDA_START>
<FILE_START>11432</FILE_START>
<IEN_ROOT_END>11462</IEN_ROOT_END>
<IEN_ROOT_START>11460</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11488</FDA_END>
<FDA_START>11475</FDA_START>
<FILE_START>11466</FILE_START>
<IEN_ROOT_END>11494</IEN_ROOT_END>
<IEN_ROOT_START>11493</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11520</FDA_END>
<FDA_START>11507</FDA_START>
<FILE_START>11498</FILE_START>
<IEN_ROOT_END>11526</IEN_ROOT_END>
<IEN_ROOT_START>11525</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11555</FDA_END>
<FDA_START>11539</FDA_START>
<FILE_START>11530</FILE_START>
<IEN_ROOT_END>11563</IEN_ROOT_END>
<IEN_ROOT_START>11560</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11590</FDA_END>
<FDA_START>11576</FDA_START>
<FILE_START>11567</FILE_START>
<IEN_ROOT_END>11597</IEN_ROOT_END>
<IEN_ROOT_START>11595</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11626</FDA_END>
<FDA_START>11610</FDA_START>
<FILE_START>11601</FILE_START>
<IEN_ROOT_END>11633</IEN_ROOT_END>
<IEN_ROOT_START>11631</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11658</FDA_END>
<FDA_START>11646</FDA_START>
<FILE_START>11637</FILE_START>
<IEN_ROOT_END>11663</IEN_ROOT_END>
<IEN_ROOT_START>11663</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11689</FDA_END>
<FDA_START>11676</FDA_START>
<FILE_START>11667</FILE_START>
<IEN_ROOT_END>11695</IEN_ROOT_END>
<IEN_ROOT_START>11694</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11722</FDA_END>
<FDA_START>11708</FDA_START>
<FILE_START>11699</FILE_START>
<IEN_ROOT_END>11728</IEN_ROOT_END>
<IEN_ROOT_START>11727</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11754</FDA_END>
<FDA_START>11741</FDA_START>
<FILE_START>11732</FILE_START>
<IEN_ROOT_END>11760</IEN_ROOT_END>
<IEN_ROOT_START>11759</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11785</FDA_END>
<FDA_START>11773</FDA_START>
<FILE_START>11764</FILE_START>
<IEN_ROOT_END>11791</IEN_ROOT_END>
<IEN_ROOT_START>11790</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11818</FDA_END>
<FDA_START>11804</FDA_START>
<FILE_START>11795</FILE_START>
<IEN_ROOT_END>11825</IEN_ROOT_END>
<IEN_ROOT_START>11823</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11851</FDA_END>
<FDA_START>11838</FDA_START>
<FILE_START>11829</FILE_START>
<IEN_ROOT_END>11857</IEN_ROOT_END>
<IEN_ROOT_START>11856</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11888</FDA_END>
<FDA_START>11870</FDA_START>
<FILE_START>11861</FILE_START>
<IEN_ROOT_END>11897</IEN_ROOT_END>
<IEN_ROOT_START>11893</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11923</FDA_END>
<FDA_START>11910</FDA_START>
<FILE_START>11901</FILE_START>
<IEN_ROOT_END>11929</IEN_ROOT_END>
<IEN_ROOT_START>11928</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11954</FDA_END>
<FDA_START>11942</FDA_START>
<FILE_START>11933</FILE_START>
<IEN_ROOT_END>11960</IEN_ROOT_END>
<IEN_ROOT_START>11959</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>11987</FDA_END>
<FDA_START>11973</FDA_START>
<FILE_START>11964</FILE_START>
<IEN_ROOT_END>11994</IEN_ROOT_END>
<IEN_ROOT_START>11992</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12020</FDA_END>
<FDA_START>12007</FDA_START>
<FILE_START>11998</FILE_START>
<IEN_ROOT_END>12026</IEN_ROOT_END>
<IEN_ROOT_START>12025</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12052</FDA_END>
<FDA_START>12039</FDA_START>
<FILE_START>12030</FILE_START>
<IEN_ROOT_END>12058</IEN_ROOT_END>
<IEN_ROOT_START>12057</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12087</FDA_END>
<FDA_START>12071</FDA_START>
<FILE_START>12062</FILE_START>
<IEN_ROOT_END>12095</IEN_ROOT_END>
<IEN_ROOT_START>12092</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12121</FDA_END>
<FDA_START>12108</FDA_START>
<FILE_START>12099</FILE_START>
<IEN_ROOT_END>12127</IEN_ROOT_END>
<IEN_ROOT_START>12126</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12152</FDA_END>
<FDA_START>12140</FDA_START>
<FILE_START>12131</FILE_START>
<IEN_ROOT_END>12158</IEN_ROOT_END>
<IEN_ROOT_START>12157</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12185</FDA_END>
<FDA_START>12171</FDA_START>
<FILE_START>12162</FILE_START>
<IEN_ROOT_END>12192</IEN_ROOT_END>
<IEN_ROOT_START>12190</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12215</FDA_END>
<FDA_START>12205</FDA_START>
<FILE_START>12196</FILE_START>
<IEN_ROOT_END>12220</IEN_ROOT_END>
<IEN_ROOT_START>12220</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12246</FDA_END>
<FDA_START>12233</FDA_START>
<FILE_START>12224</FILE_START>
<IEN_ROOT_END>12252</IEN_ROOT_END>
<IEN_ROOT_START>12251</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12281</FDA_END>
<FDA_START>12265</FDA_START>
<FILE_START>12256</FILE_START>
<IEN_ROOT_END>12289</IEN_ROOT_END>
<IEN_ROOT_START>12286</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12315</FDA_END>
<FDA_START>12302</FDA_START>
<FILE_START>12293</FILE_START>
<IEN_ROOT_END>12321</IEN_ROOT_END>
<IEN_ROOT_START>12320</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12346</FDA_END>
<FDA_START>12334</FDA_START>
<FILE_START>12325</FILE_START>
<IEN_ROOT_END>12352</IEN_ROOT_END>
<IEN_ROOT_START>12351</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12379</FDA_END>
<FDA_START>12365</FDA_START>
<FILE_START>12356</FILE_START>
<IEN_ROOT_END>12386</IEN_ROOT_END>
<IEN_ROOT_START>12384</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12412</FDA_END>
<FDA_START>12399</FDA_START>
<FILE_START>12390</FILE_START>
<IEN_ROOT_END>12418</IEN_ROOT_END>
<IEN_ROOT_START>12417</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12444</FDA_END>
<FDA_START>12431</FDA_START>
<FILE_START>12422</FILE_START>
<IEN_ROOT_END>12450</IEN_ROOT_END>
<IEN_ROOT_START>12449</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12479</FDA_END>
<FDA_START>12463</FDA_START>
<FILE_START>12454</FILE_START>
<IEN_ROOT_END>12487</IEN_ROOT_END>
<IEN_ROOT_START>12484</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12514</FDA_END>
<FDA_START>12500</FDA_START>
<FILE_START>12491</FILE_START>
<IEN_ROOT_END>12521</IEN_ROOT_END>
<IEN_ROOT_START>12519</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12552</FDA_END>
<FDA_START>12534</FDA_START>
<FILE_START>12525</FILE_START>
<IEN_ROOT_END>12560</IEN_ROOT_END>
<IEN_ROOT_START>12557</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12583</FDA_END>
<FDA_START>12573</FDA_START>
<FILE_START>12564</FILE_START>
<IEN_ROOT_END>12588</IEN_ROOT_END>
<IEN_ROOT_START>12588</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12614</FDA_END>
<FDA_START>12601</FDA_START>
<FILE_START>12592</FILE_START>
<IEN_ROOT_END>12620</IEN_ROOT_END>
<IEN_ROOT_START>12619</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12646</FDA_END>
<FDA_START>12633</FDA_START>
<FILE_START>12624</FILE_START>
<IEN_ROOT_END>12652</IEN_ROOT_END>
<IEN_ROOT_START>12651</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12677</FDA_END>
<FDA_START>12665</FDA_START>
<FILE_START>12656</FILE_START>
<IEN_ROOT_END>12683</IEN_ROOT_END>
<IEN_ROOT_START>12682</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12710</FDA_END>
<FDA_START>12696</FDA_START>
<FILE_START>12687</FILE_START>
<IEN_ROOT_END>12717</IEN_ROOT_END>
<IEN_ROOT_START>12715</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12742</FDA_END>
<FDA_START>12730</FDA_START>
<FILE_START>12721</FILE_START>
<IEN_ROOT_END>12748</IEN_ROOT_END>
<IEN_ROOT_START>12747</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12782</FDA_END>
<FDA_START>12761</FDA_START>
<FILE_START>12752</FILE_START>
<IEN_ROOT_END>12791</IEN_ROOT_END>
<IEN_ROOT_START>12787</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12823</FDA_END>
<FDA_START>12804</FDA_START>
<FILE_START>12795</FILE_START>
<IEN_ROOT_END>12832</IEN_ROOT_END>
<IEN_ROOT_START>12828</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12865</FDA_END>
<FDA_START>12845</FDA_START>
<FILE_START>12836</FILE_START>
<IEN_ROOT_END>12873</IEN_ROOT_END>
<IEN_ROOT_START>12870</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12898</FDA_END>
<FDA_START>12886</FDA_START>
<FILE_START>12877</FILE_START>
<IEN_ROOT_END>12904</IEN_ROOT_END>
<IEN_ROOT_START>12903</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12930</FDA_END>
<FDA_START>12917</FDA_START>
<FILE_START>12908</FILE_START>
<IEN_ROOT_END>12936</IEN_ROOT_END>
<IEN_ROOT_START>12935</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12963</FDA_END>
<FDA_START>12949</FDA_START>
<FILE_START>12940</FILE_START>
<IEN_ROOT_END>12970</IEN_ROOT_END>
<IEN_ROOT_START>12968</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>12993</FDA_END>
<FDA_START>12983</FDA_START>
<FILE_START>12974</FILE_START>
<IEN_ROOT_END>12998</IEN_ROOT_END>
<IEN_ROOT_START>12998</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13025</FDA_END>
<FDA_START>13011</FDA_START>
<FILE_START>13002</FILE_START>
<IEN_ROOT_END>13031</IEN_ROOT_END>
<IEN_ROOT_START>13030</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13057</FDA_END>
<FDA_START>13044</FDA_START>
<FILE_START>13035</FILE_START>
<IEN_ROOT_END>13063</IEN_ROOT_END>
<IEN_ROOT_START>13062</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13095</FDA_END>
<FDA_START>13076</FDA_START>
<FILE_START>13067</FILE_START>
<IEN_ROOT_END>13103</IEN_ROOT_END>
<IEN_ROOT_START>13100</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13129</FDA_END>
<FDA_START>13116</FDA_START>
<FILE_START>13107</FILE_START>
<IEN_ROOT_END>13135</IEN_ROOT_END>
<IEN_ROOT_START>13134</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13160</FDA_END>
<FDA_START>13148</FDA_START>
<FILE_START>13139</FILE_START>
<IEN_ROOT_END>13166</IEN_ROOT_END>
<IEN_ROOT_START>13165</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13193</FDA_END>
<FDA_START>13179</FDA_START>
<FILE_START>13170</FILE_START>
<IEN_ROOT_END>13200</IEN_ROOT_END>
<IEN_ROOT_START>13198</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13227</FDA_END>
<FDA_START>13213</FDA_START>
<FILE_START>13204</FILE_START>
<IEN_ROOT_END>13233</IEN_ROOT_END>
<IEN_ROOT_START>13232</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13260</FDA_END>
<FDA_START>13246</FDA_START>
<FILE_START>13237</FILE_START>
<IEN_ROOT_END>13265</IEN_ROOT_END>
<IEN_ROOT_START>13265</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13291</FDA_END>
<FDA_START>13278</FDA_START>
<FILE_START>13269</FILE_START>
<IEN_ROOT_END>13297</IEN_ROOT_END>
<IEN_ROOT_START>13296</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13329</FDA_END>
<FDA_START>13310</FDA_START>
<FILE_START>13301</FILE_START>
<IEN_ROOT_END>13338</IEN_ROOT_END>
<IEN_ROOT_START>13334</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13363</FDA_END>
<FDA_START>13351</FDA_START>
<FILE_START>13342</FILE_START>
<IEN_ROOT_END>13369</IEN_ROOT_END>
<IEN_ROOT_START>13368</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13395</FDA_END>
<FDA_START>13382</FDA_START>
<FILE_START>13373</FILE_START>
<IEN_ROOT_END>13402</IEN_ROOT_END>
<IEN_ROOT_START>13400</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13439</FDA_END>
<FDA_START>13415</FDA_START>
<FILE_START>13406</FILE_START>
<IEN_ROOT_END>13445</IEN_ROOT_END>
<IEN_ROOT_START>13444</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13472</FDA_END>
<FDA_START>13458</FDA_START>
<FILE_START>13449</FILE_START>
<IEN_ROOT_END>13479</IEN_ROOT_END>
<IEN_ROOT_START>13477</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13505</FDA_END>
<FDA_START>13492</FDA_START>
<FILE_START>13483</FILE_START>
<IEN_ROOT_END>13511</IEN_ROOT_END>
<IEN_ROOT_START>13510</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13537</FDA_END>
<FDA_START>13524</FDA_START>
<FILE_START>13515</FILE_START>
<IEN_ROOT_END>13543</IEN_ROOT_END>
<IEN_ROOT_START>13542</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13568</FDA_END>
<FDA_START>13556</FDA_START>
<FILE_START>13547</FILE_START>
<IEN_ROOT_END>13574</IEN_ROOT_END>
<IEN_ROOT_START>13573</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13601</FDA_END>
<FDA_START>13587</FDA_START>
<FILE_START>13578</FILE_START>
<IEN_ROOT_END>13608</IEN_ROOT_END>
<IEN_ROOT_START>13606</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13633</FDA_END>
<FDA_START>13621</FDA_START>
<FILE_START>13612</FILE_START>
<IEN_ROOT_END>13639</IEN_ROOT_END>
<IEN_ROOT_START>13638</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13668</FDA_END>
<FDA_START>13652</FDA_START>
<FILE_START>13643</FILE_START>
<IEN_ROOT_END>13676</IEN_ROOT_END>
<IEN_ROOT_START>13673</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13701</FDA_END>
<FDA_START>13689</FDA_START>
<FILE_START>13680</FILE_START>
<IEN_ROOT_END>13708</IEN_ROOT_END>
<IEN_ROOT_START>13706</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13736</FDA_END>
<FDA_START>13721</FDA_START>
<FILE_START>13712</FILE_START>
<IEN_ROOT_END>13742</IEN_ROOT_END>
<IEN_ROOT_START>13741</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13768</FDA_END>
<FDA_START>13755</FDA_START>
<FILE_START>13746</FILE_START>
<IEN_ROOT_END>13774</IEN_ROOT_END>
<IEN_ROOT_START>13773</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13800</FDA_END>
<FDA_START>13787</FDA_START>
<FILE_START>13778</FILE_START>
<IEN_ROOT_END>13806</IEN_ROOT_END>
<IEN_ROOT_START>13805</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13833</FDA_END>
<FDA_START>13819</FDA_START>
<FILE_START>13810</FILE_START>
<IEN_ROOT_END>13840</IEN_ROOT_END>
<IEN_ROOT_START>13838</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13865</FDA_END>
<FDA_START>13853</FDA_START>
<FILE_START>13844</FILE_START>
<IEN_ROOT_END>13871</IEN_ROOT_END>
<IEN_ROOT_START>13870</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13896</FDA_END>
<FDA_START>13884</FDA_START>
<FILE_START>13875</FILE_START>
<IEN_ROOT_END>13902</IEN_ROOT_END>
<IEN_ROOT_START>13901</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13928</FDA_END>
<FDA_START>13915</FDA_START>
<FILE_START>13906</FILE_START>
<IEN_ROOT_END>13934</IEN_ROOT_END>
<IEN_ROOT_START>13933</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>13966</FDA_END>
<FDA_START>13947</FDA_START>
<FILE_START>13938</FILE_START>
<IEN_ROOT_END>13975</IEN_ROOT_END>
<IEN_ROOT_START>13971</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14003</FDA_END>
<FDA_START>13988</FDA_START>
<FILE_START>13979</FILE_START>
<IEN_ROOT_END>14009</IEN_ROOT_END>
<IEN_ROOT_START>14008</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14035</FDA_END>
<FDA_START>14022</FDA_START>
<FILE_START>14013</FILE_START>
<IEN_ROOT_END>14041</IEN_ROOT_END>
<IEN_ROOT_START>14040</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14067</FDA_END>
<FDA_START>14054</FDA_START>
<FILE_START>14045</FILE_START>
<IEN_ROOT_END>14073</IEN_ROOT_END>
<IEN_ROOT_START>14072</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14100</FDA_END>
<FDA_START>14086</FDA_START>
<FILE_START>14077</FILE_START>
<IEN_ROOT_END>14107</IEN_ROOT_END>
<IEN_ROOT_START>14105</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14133</FDA_END>
<FDA_START>14120</FDA_START>
<FILE_START>14111</FILE_START>
<IEN_ROOT_END>14139</IEN_ROOT_END>
<IEN_ROOT_START>14138</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14170</FDA_END>
<FDA_START>14152</FDA_START>
<FILE_START>14143</FILE_START>
<IEN_ROOT_END>14178</IEN_ROOT_END>
<IEN_ROOT_START>14175</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14205</FDA_END>
<FDA_START>14191</FDA_START>
<FILE_START>14182</FILE_START>
<IEN_ROOT_END>14211</IEN_ROOT_END>
<IEN_ROOT_START>14210</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14237</FDA_END>
<FDA_START>14224</FDA_START>
<FILE_START>14215</FILE_START>
<IEN_ROOT_END>14243</IEN_ROOT_END>
<IEN_ROOT_START>14242</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14269</FDA_END>
<FDA_START>14256</FDA_START>
<FILE_START>14247</FILE_START>
<IEN_ROOT_END>14275</IEN_ROOT_END>
<IEN_ROOT_START>14274</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14302</FDA_END>
<FDA_START>14288</FDA_START>
<FILE_START>14279</FILE_START>
<IEN_ROOT_END>14309</IEN_ROOT_END>
<IEN_ROOT_START>14307</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14333</FDA_END>
<FDA_START>14322</FDA_START>
<FILE_START>14313</FILE_START>
<IEN_ROOT_END>14338</IEN_ROOT_END>
<IEN_ROOT_START>14338</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14364</FDA_END>
<FDA_START>14351</FDA_START>
<FILE_START>14342</FILE_START>
<IEN_ROOT_END>14370</IEN_ROOT_END>
<IEN_ROOT_START>14369</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14402</FDA_END>
<FDA_START>14383</FDA_START>
<FILE_START>14374</FILE_START>
<IEN_ROOT_END>14411</IEN_ROOT_END>
<IEN_ROOT_START>14407</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14436</FDA_END>
<FDA_START>14424</FDA_START>
<FILE_START>14415</FILE_START>
<IEN_ROOT_END>14442</IEN_ROOT_END>
<IEN_ROOT_START>14441</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14468</FDA_END>
<FDA_START>14455</FDA_START>
<FILE_START>14446</FILE_START>
<IEN_ROOT_END>14475</IEN_ROOT_END>
<IEN_ROOT_START>14473</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14502</FDA_END>
<FDA_START>14488</FDA_START>
<FILE_START>14479</FILE_START>
<IEN_ROOT_END>14509</IEN_ROOT_END>
<IEN_ROOT_START>14507</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14540</FDA_END>
<FDA_START>14522</FDA_START>
<FILE_START>14513</FILE_START>
<IEN_ROOT_END>14547</IEN_ROOT_END>
<IEN_ROOT_START>14545</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14571</FDA_END>
<FDA_START>14560</FDA_START>
<FILE_START>14551</FILE_START>
<IEN_ROOT_END>14576</IEN_ROOT_END>
<IEN_ROOT_START>14576</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14604</FDA_END>
<FDA_START>14589</FDA_START>
<FILE_START>14580</FILE_START>
<IEN_ROOT_END>14610</IEN_ROOT_END>
<IEN_ROOT_START>14609</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14629</FDA_END>
<FDA_START>14623</FDA_START>
<FILE_START>14614</FILE_START>
<IEN_ROOT_END>14634</IEN_ROOT_END>
<IEN_ROOT_START>14634</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14665</FDA_END>
<FDA_START>14647</FDA_START>
<FILE_START>14638</FILE_START>
<IEN_ROOT_END>14672</IEN_ROOT_END>
<IEN_ROOT_START>14670</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14703</FDA_END>
<FDA_START>14685</FDA_START>
<FILE_START>14676</FILE_START>
<IEN_ROOT_END>14708</IEN_ROOT_END>
<IEN_ROOT_START>14708</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14739</FDA_END>
<FDA_START>14721</FDA_START>
<FILE_START>14712</FILE_START>
<IEN_ROOT_END>14746</IEN_ROOT_END>
<IEN_ROOT_START>14744</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14772</FDA_END>
<FDA_START>14759</FDA_START>
<FILE_START>14750</FILE_START>
<IEN_ROOT_END>14778</IEN_ROOT_END>
<IEN_ROOT_START>14777</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14804</FDA_END>
<FDA_START>14791</FDA_START>
<FILE_START>14782</FILE_START>
<IEN_ROOT_END>14810</IEN_ROOT_END>
<IEN_ROOT_START>14809</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14837</FDA_END>
<FDA_START>14823</FDA_START>
<FILE_START>14814</FILE_START>
<IEN_ROOT_END>14844</IEN_ROOT_END>
<IEN_ROOT_START>14842</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14875</FDA_END>
<FDA_START>14857</FDA_START>
<FILE_START>14848</FILE_START>
<IEN_ROOT_END>14882</IEN_ROOT_END>
<IEN_ROOT_START>14880</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14908</FDA_END>
<FDA_START>14895</FDA_START>
<FILE_START>14886</FILE_START>
<IEN_ROOT_END>14914</IEN_ROOT_END>
<IEN_ROOT_START>14913</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14950</FDA_END>
<FDA_START>14927</FDA_START>
<FILE_START>14918</FILE_START>
<IEN_ROOT_END>14961</IEN_ROOT_END>
<IEN_ROOT_START>14955</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>14991</FDA_END>
<FDA_START>14974</FDA_START>
<FILE_START>14965</FILE_START>
<IEN_ROOT_END>14997</IEN_ROOT_END>
<IEN_ROOT_START>14996</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15027</FDA_END>
<FDA_START>15010</FDA_START>
<FILE_START>15001</FILE_START>
<IEN_ROOT_END>15034</IEN_ROOT_END>
<IEN_ROOT_START>15032</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15065</FDA_END>
<FDA_START>15047</FDA_START>
<FILE_START>15038</FILE_START>
<IEN_ROOT_END>15072</IEN_ROOT_END>
<IEN_ROOT_START>15070</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15103</FDA_END>
<FDA_START>15085</FDA_START>
<FILE_START>15076</FILE_START>
<IEN_ROOT_END>15110</IEN_ROOT_END>
<IEN_ROOT_START>15108</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15136</FDA_END>
<FDA_START>15123</FDA_START>
<FILE_START>15114</FILE_START>
<IEN_ROOT_END>15142</IEN_ROOT_END>
<IEN_ROOT_START>15141</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15168</FDA_END>
<FDA_START>15155</FDA_START>
<FILE_START>15146</FILE_START>
<IEN_ROOT_END>15174</IEN_ROOT_END>
<IEN_ROOT_START>15173</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15201</FDA_END>
<FDA_START>15187</FDA_START>
<FILE_START>15178</FILE_START>
<IEN_ROOT_END>15208</IEN_ROOT_END>
<IEN_ROOT_START>15206</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15239</FDA_END>
<FDA_START>15221</FDA_START>
<FILE_START>15212</FILE_START>
<IEN_ROOT_END>15246</IEN_ROOT_END>
<IEN_ROOT_START>15244</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15272</FDA_END>
<FDA_START>15259</FDA_START>
<FILE_START>15250</FILE_START>
<IEN_ROOT_END>15278</IEN_ROOT_END>
<IEN_ROOT_START>15277</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15316</FDA_END>
<FDA_START>15291</FDA_START>
<FILE_START>15282</FILE_START>
<IEN_ROOT_END>15328</IEN_ROOT_END>
<IEN_ROOT_START>15321</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15359</FDA_END>
<FDA_START>15341</FDA_START>
<FILE_START>15332</FILE_START>
<IEN_ROOT_END>15366</IEN_ROOT_END>
<IEN_ROOT_START>15364</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15397</FDA_END>
<FDA_START>15379</FDA_START>
<FILE_START>15370</FILE_START>
<IEN_ROOT_END>15407</IEN_ROOT_END>
<IEN_ROOT_START>15402</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15454</FDA_END>
<FDA_START>15420</FDA_START>
<FILE_START>15411</FILE_START>
<IEN_ROOT_END>15460</IEN_ROOT_END>
<IEN_ROOT_START>15459</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15482</FDA_END>
<FDA_START>15473</FDA_START>
<FILE_START>15464</FILE_START>
<IEN_ROOT_END>15487</IEN_ROOT_END>
<IEN_ROOT_START>15487</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15511</FDA_END>
<FDA_START>15500</FDA_START>
<FILE_START>15491</FILE_START>
<IEN_ROOT_END>15516</IEN_ROOT_END>
<IEN_ROOT_START>15516</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15540</FDA_END>
<FDA_START>15529</FDA_START>
<FILE_START>15520</FILE_START>
<IEN_ROOT_END>15545</IEN_ROOT_END>
<IEN_ROOT_START>15545</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15599</FDA_END>
<FDA_START>15558</FDA_START>
<FILE_START>15549</FILE_START>
<IEN_ROOT_END>15605</IEN_ROOT_END>
<IEN_ROOT_START>15604</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15641</FDA_END>
<FDA_START>15618</FDA_START>
<FILE_START>15609</FILE_START>
<IEN_ROOT_END>15647</IEN_ROOT_END>
<IEN_ROOT_START>15646</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15741</FDA_END>
<FDA_START>15660</FDA_START>
<FILE_START>15651</FILE_START>
<IEN_ROOT_END>15747</IEN_ROOT_END>
<IEN_ROOT_START>15746</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15769</FDA_END>
<FDA_START>15760</FDA_START>
<FILE_START>15751</FILE_START>
<IEN_ROOT_END>15774</IEN_ROOT_END>
<IEN_ROOT_START>15774</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15809</FDA_END>
<FDA_START>15787</FDA_START>
<FILE_START>15778</FILE_START>
<IEN_ROOT_END>15822</IEN_ROOT_END>
<IEN_ROOT_START>15814</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15847</FDA_END>
<FDA_START>15835</FDA_START>
<FILE_START>15826</FILE_START>
<IEN_ROOT_END>15854</IEN_ROOT_END>
<IEN_ROOT_START>15852</IEN_ROOT_START>
</COMPONENT>
<COMPONENT>
<FDA_END>15874</FDA_END>
<FDA_START>15867</FDA_START>
<FILE_START>15858</FILE_START>
<IEN_ROOT_END>15880</IEN_ROOT_END>
<IEN_ROOT_START>15879</IEN_ROOT_START>
</COMPONENT>
</INDEX>
</REMINDER_EXCHANGE_FILE_ENTRY>
